Novel gene disruptions, compositions and methods relating thereto

专利摘要:

公开号:AU2007351501A1
申请号:U2007351501
申请日:2007-10-01
公开日:2008-10-23
发明作者:Mark Dominic Borromeo；Jaime-Jo Cunningham；Frederic Desauvage；Ellen Filvaroff；Mark Alan Klamer；Laurie Jeanette Minze；Bobby Joe Payne；Carolina Rangel；Zheng-Zheng Shi；Peter Vogel
申请人:Genentech Inc；Lexicon Pharmaceuticals Inc；
IPC主号:A01K67-027

专利说明:
WO 2008/127352 PCT/US2007/080102 NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO FIELD OF THE INVENTION The present invention relates to compositions, including transgenic and knockout 5 animals and methods of using such compositions for the diagnosis and treatment of diseases or disorders. BACKGROUND OF THE INVENTION Extracellular proteins play important roles in, among other things, the formation, 10 differentiation and maintenance of multicellular organisms. The fate of many individual cells, e.g., proliferation, migration, differentiation, or interaction with other cells, is typically governed by information received from other cells and/or the immediate environment. This information is often transmitted by secreted polypeptides (for instance, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones) which 15 are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins. These secreted polypeptides or signaling molecules normallypass through the cellular secretory pathway to reach their site of action in the extracellular environment. Secreted proteins have various industrial applications, including as pharmaceuticals, diagnostics, biosensors and bioreactors. Most protein drugs available at present, such as 20 thrombolytic agents, interferons, interleukins, erythropoietins, colony stimulating factors, and various other cytokines, are secretory proteins. Their receptors, which are membrane proteins, also have potential as therapeutic or diagnostic agents. Efforts are being undertaken by both industry and academia to identify new, native secreted proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for 25 novel secreted proteins. Examples of screening methods and techniques are described in the literature [see, for example, Klein et al., Proc. Natl. Acad. Sci. 93:7108-7113 (1996); U.S. Patent No. 5,536,637)]. Membrane-bound proteins and receptors can play important roles in, among other 1 WO 2008/127352 PCT/US2007/080102 things, the formation, differentiation and maintenance of multicellular organisms. The fate of many individual cells, e.g., proliferation, migration, differentiation, or interaction with other cells, is typically governed by information received from other cells and/or the immediate environment. This information is often transmitted by secreted polypeptides (for instance, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and 5 hormones) which are, in turn, received and interpreted by diverse cell receptors or membrane bound proteins. Such membrane-bound proteins and cell receptors include, but are not limited to, cytokine receptors, receptor kinases, receptor phosphatases, receptors involved in cell-cell interactions, and cellular adhesion molecules like selectins and integrins. For instance, transduction of signals that regulate cell growth and differentiation is regulated in part by 10 phosphorylation of various cellular proteins. Protein tyrosine kinases, enzymes that catalyze that process, can also act as growth factor receptors. Examples include fibroblast growth factor receptor and nerve growth factor receptor. Membrane-bound proteins and receptor molecules have various industrial applications, including as pharmaceutical and diagnostic agents. Receptor immuno-adhesions, for instance, 15 can be employed as therapeutic agents to block receptor-ligand interactions. The membrane bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. Efforts are being undertaken by both industry and academia to identify new, native receptor or membrane-bound proteins. Many efforts are focused on the screening of 20 mammalian recombinant DNA libraries to identify the coding sequences for novel receptor or membrane-bound proteins. Given the importance of secreted and membrane-bound proteins in biological and disease processes, in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction 25 of diseases or dysfunctions. In this regard, genetically engineered mice have proven to be invaluable tools for the functional dissection of biological processes relevant to human disease, including immunology, cancer, neuro-biology, cardiovascular biology, obesity and many others. Gene knockouts can be viewed as modeling the biological mechanism of drug action by presaging the activity of highly specific antagonists in vivo. Knockout mice have been shown 30 to model drug activity; phenotypes of mice deficient for specific pharmaceutical target proteins can resemble the human clinical phenotype caused by the corresponding antagonist drug. Gene 2 WO 2008/127352 PCT/US2007/080102 knockouts enable the discovery of the mechanism of action of the target, the predominant physiological role of the target, and mechanism-based side-effects that might result from inhibition of the target in mammals. Examples of this type include mice deficient in the angiotensin converting enzyme (ACE) [Esther, C.R. et al., Lab. Invest., 74:953-965 (1996)] and cyclooxygenase-1 (COX1) genes [Langenbach, R. et al., Cell, 83:483-492 (1995)]. Conversely, 5 knocking the gene out in the mouse can have an opposite phenotypic effect to that observed in humans after administration of an agonist drug to the corresponding target. Examples include the erythropoietin knockout [Wu, C.S. et al., Cell, 83:59-67 (1996)], in which a consequence of the mutation is deficient red blood cell production, and the GABA(A)-R-P3 knockout [DeLorey, T.M., J. Neurosci., 18:8505-8514 (1998)], in which the mutant mice show 10 hyperactivity and hyper-responsiveness. Both these phenotypes are opposite to the effects of erythropoietin and benzodiazepine administration in humans. A striking example of a target validated using mouse genetics is the ACC2 gene. Although the human ACC2 gene had been identified several years ago, interest in ACC2 as a target for drug development was stimulated only recently after analysis of ACC2 function using a knockout mouse. ACC2 mutant mice eat 15 more than their wild-type littermates, yet burn more fat and store less fat in their adipocytes, making this enzyme a probable target for chemical antagonism in the treatment of obesity [Abu Elheiga, L. et al., Science, 291:2613-2616 (2001)]. In the instant application, mutated gene disruptions have resulted in phenotypic observations related to various disease conditions or dysfunctions including: CNS/neurological 20 disturbances or disorders such as anxiety; eye abnormalities and associated diseases; cardiovascular, endothelial or angiogenic disorders including atherosclerosis; abnormal metabolic disorders including diabetes and dyslipidemias associated with elevated serum triglycerides and cholesterol levels; immunological and inflammatory disorders; oncological disorders; bone metabolic abnormalities or disorders such as arthritis, osteoporosis and 25 osteopetrosis; or a developmental disease such as embryonic lethality. SUMMARY OF THE INVENTION A. Embodiments The invention provides an isolated nucleic acid molecule comprising a nucleotide 30 sequence that encodes a PRO1 105, PRO1279 or PRO1783 polypeptide. In one aspect, the isolated nucleic acid molecule comprises a nucleotide sequence 3 WO 2008/127352 PCT/US2007/080102 having at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% 5 nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91 % nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, 10 alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule encoding a PRO 1105, PRO 1279 or PRO1783 polypeptide having a full-length amino acid sequence as disclosed herein, an 15 amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a). In other aspects, the isolated nucleic acid molecule comprises a nucleotide sequence 20 having at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% 25 nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91 % nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, 30 alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, 4 WO 2008/127352 PCT/US2007/080102 alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule comprising the coding sequence of a full-length PRO 1105, PRO 1279 or PRO 1783 polypeptide cDNA as disclosed herein, the coding sequence of a PRO 1105, PRO 1279 or PRO 1783 polypeptide lacking the signal peptide as disclosed herein, the coding sequence of an extracellular domain of a transmembrane 5 PRO1105, PRO 1279 or PRO 1783 polypeptide, with or without the signal peptide, as disclosed herein or the coding sequence of any other specifically defined fragment of the full-length amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a). In a further aspect, the invention concerns an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively 10 at least about 810% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid 15 sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 910% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively 20 at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule that encodes the same mature polypeptide encoded by any of the human protein cDNAs deposited with the ATCC as disclosed herein, or (b) the complement of the DNA molecule of (a). 25 Another aspect of the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a PRO 1105, PRO1279 or PRO1783 polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated, or is complementary to such encoding nucleotide sequence, wherein the transmembrane domain(s) of such polypeptide are disclosed herein. Therefore, soluble extracellular domains of the herein 30 described polypeptides are contemplated. The invention also provides fragments of a PRO1105, PRO1279 or PRO1783 5 WO 2008/127352 PCT/US2007/080102 polypeptide coding sequence, or the complement thereof, that may find use as, for example, hybridization probes, for encoding fragments of a PRO1105, PRO1279 or PRO1783 polypeptide that may optionally encode a polypeptide comprising a binding site for an anti PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody or as antisense oligonucleotide probes. Such nucleic acid fragments usually are or are at least about 10 nucleotides in length, 5 alternatively are or are at least about 15 nucleotides in length, alternatively are or are at least about 20 nucleotides in length, alternatively are or are at least about 30 nucleotides in length, alternatively are or are at least about 40 nucleotides in length, alternatively are or are at least about 50 nucleotides in length, alternatively are or are at least about 60 nucleotides in length, alternatively are or are at least about 70 nucleotides in length, alternatively are or are at least 10 about 80 nucleotides in length, alternatively are or are at least about 90 nucleotides in length, alternatively are or are at least about 100 nucleotides in length, alternatively are or are at least about 110 nucleotides in length, alternatively are or are at least about 120 nucleotides in length, alternatively are or are at least about 130 nucleotides in length, alternatively are or are at least about 140 nucleotides in length, alternatively are or are at least about 150 nucleotides in length, 15 alternatively are or are at least about 160 nucleotides in length, alternatively are or are at least about 170 nucleotides in length, alternatively are or are at least about 180 nucleotides in length, alternatively are or are at least about 190 nucleotides in length, alternatively are or are at least about 200 nucleotides in length, alternatively are or are at least about 250 nucleotides in length, alternatively are or are at least about 300 nucleotides in length, alternatively are or are at least 20 about 350 nucleotides in length, alternatively are or are at least about 400 nucleotides in length, alternatively are or are at least about 450 nucleotides in length, alternatively are or are at least about 500 nucleotides in length, alternatively are or are at least about 600 nucleotides in length, alternatively are or are at least about 700 nucleotides in length, alternatively are or are at least about 800 nucleotides in length, alternatively are or are at least about 900 nucleotides in length 25 and alternatively are or are at least about 1000 nucleotides in length, wherein in this context the term "about" means the referenced nucleotide sequence length plus or minus 10% of that referenced length. It is noted that novel fragments of a PRO1105, PRO1279 or PRO1783 polypeptide-encoding nucleotide sequence may be determined in a routine manner by aligning the PRO1 105, PRO1279 or PRO1783 polypeptide-encoding nucleotide sequence with other 30 known nucleotide sequences using any of a number of well known sequence alignment programs and determining which PRO 1105, PRO1279 or PRO1783 polypeptide-encoding 6 WO 2008/127352 PCT/US2007/080102 nucleotide sequence fragment(s) are novel. All of such PRO1 105, PRO1279 or PRO1783 polypeptide-encoding nucleotide sequences are contemplated herein. Also contemplated are the PRO1105, PRO 1279 or PRO 1783 polypeptide fragments encoded by these nucleotide molecule fragments, preferably those PRO 1105, PRO 1279 or PRO 1783 polypeptide fragments that comprise a binding site for an anti-PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody. 5 The invention provides isolated PRO1105, PRO1279 or PRO1783 polypeptides encoded by any of the isolated nucleic acid sequences hereinabove identified. In a certain aspect, the invention concerns an isolated PRO1105, PRO1279 or PRO 1783 polypeptide, comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid sequence identity, 10 alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% 15 amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 910% amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, 20 alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to a PRO1 105, PRO1279 or PRO1783 polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as 25 disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein. In a further aspect, the invention concerns an isolated PRO1105, PRO1279 or PRO 1783 polypeptide comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid sequence identity, 30 alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, 7 WO 2008/127352 PCT/US2007/080102 alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91 % amino acid sequence identity, alternatively at least about 92% 5 amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity 10 to an amino acid sequence encoded by any of the human protein cDNAs deposited with the ATCC as disclosed herein. In one aspect, the invention concerns PRO1105, PRO1279 or PRO1783 variant polypeptides which are or are at least about 10 amino acids in length, alternatively are or are at least about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 15 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400,410,420,430,440,450,460,470,480,490,500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600 amino acids in length, or more. Optionally, PRO 1105, PRO1279 or PRO1783 variant polypeptides will have or have no more than one conservative amino acid substitution as compared to the native PRO 1105, PRO1279 or PRO 1783 polypeptide sequence, alternatively 20 will have or will have no more than 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative amino acid substitution as compared to the native PRO 1105, PRO 1279 or PRO 1783 polypeptide sequence. In a specific aspect, the invention provides an isolated PRO1105, PRO1279 or PRO 1783 polypeptide without the N-terminal signal sequence and/or the initiating methionine and is encoded by a nucleotide sequence that encodes such an amino acid sequence as 25 hereinbefore described. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO 1105, PRO1279 or PRO1783 polypeptide and recovering the PRO 1105, PRO1279 or PRO 1783 polypeptide from the cell culture. 30 Another aspect the invention provides an isolated PRO 1105, PRO 1279 or PRO 1783 polypeptide which is either transmembrane domain-deleted or transmembrane domain 8 WO 2008/127352 PCT/US2007/080102 inactivated. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO 1105, PRO1279 or PRO1783 polypeptide and recovering the PRO 1105, PRO1279 or PRO1783 polypeptide from the cell culture. 5 The invention provides agonists and antagonists of a native PRO 1105, PRO 1279 or PRO 1783 polypeptide as defined herein. In particular, the agonist or antagonist is an anti PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody or a small molecule. The invention provides a method of identifying agonists or antagonists to a PRO 1105, PRO 1279 or PRO 1783 polypeptide which comprise contacting the PRO 1105, PRO 1279 or 10 PRO 1783 polypeptide with a candidate molecule and monitoring a biological activity mediated by said PRO 1105, PRO1279 or PRO1783 polypeptide. Preferably, the PRO 1105, PRO1279 or PRO 1783 polypeptide is a native PRO 1105, PRO 1279 or PRO 1783 polypeptide. The invention provides a composition of matter comprising a PRO 1105, PRO1279 or PRO 1783 polypeptide, or an agonist or antagonist of a PRO 1105, PRO 1279 or PRO 1783 15 polypeptide as herein described, or an anti-PRO1105, anti-PRO1279 or anti-PRO1783 antibody, in combination with a carrier. Optionally, the carrier is a pharmaceutically acceptable carter. The invention provides the use of a PRO 1105, PRO 1279 or PRO 1783 polypeptide, or an agonist or antagonist thereof as hereinbefore described, or an anti-PRO 1105, anti-PRO 1279 20 or anti-PRO1783 antibody, for the preparation of a medicament useful in the treatment of a condition which is responsive to the anti-PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody. The invention provides vectors comprising DNA encoding any of the herein described polypeptides. Host cell comprising any such vector are also provided. By way of example, the host cells may be CHO cells, E. coli, or yeast. A process for producing any of the herein 25 described polypeptides is further provided and comprises culturing host cells under conditions suitable for expression of the desired polypeptide and recovering the desired polypeptide from the cell culture. The invention provides chimeric molecules comprising any of the herein described polypeptides fused to a heterologous polypeptide or amino acid sequence. Example of such 30 chimeric molecules comprise any of the herein described polypeptides fused to an epitope tag sequence or a Fc region of an immunoglobulin. 9 WO 2008/127352 PCT/US2007/080102 The invention provides an antibody which binds, preferably specifically, to any of the above or below described polypeptides. Optionally, the antibody is a monoclonal antibody, humanized antibody, antibody fragment or single-chain antibody. The invention provides oligonucleotide probes which may be useful for isolating genomic and cDNA nucleotide sequences, measuring or detecting expression of an associated 5 gene or as antisense probes, wherein those probes may be derived from any of the above or below described nucleotide sequences. Preferred probe lengths are described above. The invention also provides a method of identifying a phenotype associated with a disruption of a gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide, the method comprising: 10 (a) providing a non-human transgenic animal whose genome comprises a disruption of the gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide; (b) measuring a physiological characteristic of the non-human transgenic animal; and (c) comparing the measured physiological characteristic with that of a gender matched wild-type animal, wherein the physiological characteristic of the non-human transgenic animal 15 that differs from the physiological characteristic of the wild-type animal is identified as a phenotype resulting from the gene disruption in the non-human transgenic animal. In one aspect, the non-human transgenic animal is a mammal. In another aspect, the mammal is a rodent. In still another aspect, the mammal is a rat or a mouse. In one aspect, the non-human transgenic animal is heterozygous for the disruption of a gene which encodes for a PRO 1105, 20 PRO1279 or PRO1783 polypeptide. In another aspect, the phenotype exhibited by the non human transgenic animal as compared with gender matched wild-type littermates is at least one of the following: a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality. 25 In yet another aspect, the neurological disorder is an increased anxiety-like response during open field activity testing. In yet another aspect, the neurological disorder is a decreased anxiety-like response during open field activity testing. In yet another aspect, the neurological disorder is an abnormal circadian rhythm during home-cage activity testing. In yet another aspect, the neurological disorder is an enhanced motor coordination during inverted screen 30 testing. In yet another aspect, the neurological disorder is impaired motor coordination during inverted screen testing. In yet another aspect, the neurological disorder includes depression, 10 WO 2008/127352 PCT/US2007/080102 generalized anxiety disorders, attention deficit disorder, sleep disorder, hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia and sensory disorders. Such neurological disorders include the category defined as "anxiety disorders" which include but are not limited to: mild to moderate anxiety, anxiety disorder due to a general medical condition, anxiety disorder not otherwise specified, generalized anxiety disorder, panic 5 attack, panic disorder with agoraphobia, panic disorder without agoraphobia, posttraumatic stress disorder, social phobia, social anxiety, autism, specific phobia, substance-induced anxiety disorder, acute alcohol withdrawal, obsessive compulsive disorder, agoraphobia, monopolar disorders, bipolar disorder I or II, bipolar disorder not otherwise specified, cyclothymic disorder, depressive disorder, major depressive disorder, mood disorder, substance-induced 10 mood disorder, enhancement of cognitive function, loss of cognitive function associated with but not limited to Alzheimer's disease, stroke, or traumatic injury to the brain, seizures resulting from disease or injury including but not limited to epilepsy, learning disorders/disabilities, cerebral palsy. In addition, anxiety disorders may apply to personality disorders including but not limited to the following types: paranoid, antisocial, avoidant behavior, borderline 15 personality disorders, dependent, histronic, narcissistic, obsessive-compulsive, schizoid, and schizotypal. In another aspect, the eye abnormality is a retinal abnormality. In still another aspect, the eye abnormality is consistent with vision problems or blindness. In yet another aspect, the retinal abnormality is consistent with retinitis pigmentosa or is characterized by retinal 20 degeneration or retinal dysplasia. In still another aspect, the retinal abnormalities are consistent with retinal dysplasia, various retinopathies, including retinopathy ofprematurity, retrolental fibroplasia, neovascular glaucoma, age-related macular degeneration, diabetic macular edema, corneal neovascularization, corneal graft neovascularization, corneal graft rejection, retinal/choroidal 25 neovascularization, neovascularization of the angle (rubeosis), ocular neovascular disease, vascular restenosis, arteriovenous malformations (AVM), meningioma, hemangioma, angiofibroma, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, retinal artery obstruction or occlusion; retinal degeneration causing secondary atrophy of the retinal vasculature, retinitis pigmentosa, macular dystrophies, Stargardt's 30 disease, congenital stationary night blindness, choroideremia, gyrate atrophy, Leber's congenital amaurosis, retinoschisis disorders, Wagner's syndrome, Usher syndromes, Zellweger syndrome, 11 WO 2008/127352 PCT/US2007/080102 Saldino-Mainzer syndrome, Senior-Loken syndrome, Bardet-Biedl syndrome, Alport's syndrome, Alstrom's syndrome, Cockayne's syndrome, dysplaisa spondyloepiphysaria congentia, Flynn-Aird syndrome, Friedreich ataxia, Hallgren syndrome, Marshall syndrome, Albers-Schnoberg disease, Refsum's disease, Kearns-Sayre syndrome, Waardenburg's syndrome, Alagile syndrome, myotonic dystrophy, olivopontocerebellar atrophy, Pierre-Marie 5 dunsdrome, Stickler syndrome, carotinemeia, cystinosis, Wolfram syndrome, Bassen-Kornzweig syndrome, abetalipoproteinemia, incontinentia pigmenti, Batten's disease, mucopolysaccharidoses, homocystinuria, or mannosidosis. In still another aspect, the eye abnormality is a cataract. In still yet another aspect, the cataract is a systemic disease such as human Down's syndrome, Hallerman-Streiff syndrome, 10 Lowe syndrome, galactosemia, Marfan syndrome, Trismoy 13-15, Alport syndrome, myotonic dystrophy, Fabry disease, hypoparathroidism or Conradi syndrome. In still another aspect, the developmental abnormality comprises embryonic lethality or reduced viability. In still yet another aspect, the cardiovascular, endothelial or angiogenic disorders are 15 arterial diseases, such as diabetes mellitus; papilledema; optic atrophy; atherosclerosis; angina; myocardial infarctions such as acute myocardial infarctions, cardiac hypertrophy, and heart failure such as congestive heart failure; hypertension; inflammatory vasculitides; Reynaud's disease and Reynaud's phenomenon; aneurysms and arterial restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; peripheral vascular 20 disease; cancer such as vascular tumors, e.g., hemangioma (capillary and cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma, Kaposi's sarcoma, lymphangioma, and lymphangiosarcoma; tumor angiogenesis; trauma such as wounds, burns, and other injured tissue, implant fixation, scarring; ischemia reperfusion injury; rheumatoid arthritis; cerebrovascular disease; renal diseases such 25 as acute renal failure, or osteoporosis. In still another aspect, the immunological disorders are consistent with systemic lupus erythematosis; rheumatoid arthritis; juvenile chronic arthritis; spondyloarthropathies; systemic sclerosis (scleroderma); idiopathic inflammatory myopathies (dermatomyositis, polymyositis); Sj6gren's syndrome; systemic vasculitis; sarcoidosis; autoimmune hemolytic anemia (immune 30 pancytopenia, paroxysmal nocturnal hemoglobinuria); autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia); thyroiditis 12 WO 2008/127352 PCT/US2007/080102 (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis); diabetes mellitus; immune-mediated renal disease (glomerulonephritis, tubulointerstitial nephritis); demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barr6 syndrome, and chronic inflammatory demyelinating polyneuropathy; hepatobiliary diseases such as infectious 5 hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis; inflammatory bowel disease (ulcerative colitis: Crohn's disease); gluten-sensitive enteropathy, and Whipple's disease; autoimmune or immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis; allergic diseases such as 10 asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria; immunologic diseases of the lung such as eosinophilic pneumonia, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis; or transplantation associated diseases including graft rejection and graft -versus-host disease. In still another aspect, the bone metabolic abnormality or disorder is arthritis, 15 osteoporosis, osteopenia or osteopetrosis. In another aspect, the non-human transgenic animal exhibits at least one of the following physiological characteristics compared with gender matched wild-type littermates: a decreased anxiety-like response during open field activity testing; an abnormal habituation response to a novel environment (increased median ambulatory count during home-cage activity 20 testing) during circadian testing; a decreased depressive-like response with decreased median immobility time during tail suspension testing; an increased blood glucose level; impaired glucose tolerance; an increased trabecular bone volume and thickness; decreased percent total body fat mass and percent total body fat; a decreased skin fibroblast proliferation rate; and an increased systolic blood pressure. 25 The invention also provides an isolated cell derived from a non-human transgenic animal whose genome comprises a disruption of the gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide. In one aspect, the isolated cell is a murine cell. In yet another aspect, the murine cell is an embryonic stem cell. In still another aspect, the isolated cell is derived from a non-human transgenic animal which exhibits at least one of the following 30 phenotypes compared with gender matched wild-type littermates: a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological 13 WO 2008/127352 PCT/US2007/080102 disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality. The invention also provides a method of identifying an agent that modulates a phenotype associated with a disruption of a gene which encodes for a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption 5 of the gene which encodes for the PRO 1105, PRO1279 or PRO1783 polypeptide; (b) measuring a physiological characteristic ofthe non-human transgenic animal of(a); (c) comparing the measured physiological characteristic of (b) with that of a gender matched wild-type animal, wherein the physiological characteristic ofthe non-human transgenic animal that differs from the physiological characteristic of the wild-type animal is identified as 10 a phenotype resulting from the gene disruption in the non-human transgenic animal; (d) administering a test agent to the non-human transgenic animal of (a); and (e) determining whether the test agent modulates the identified phenotype associated with gene disruption in the non-human transgenic animal. In one aspect, the phenotype associated with the gene disruption comprises a 15 neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality. In yet another aspect, the neurological disorder is an increased anxiety-like response during open field activity testing. In yet another aspect, the neurological disorder is a decreased 20 anxiety-like response during open field activity testing. In yet another aspect, the neurological disorder is an abnormal circadian rhythm during home-cage activity testing. In yet another aspect, the neurological disorder is an enhanced motor coordination during inverted screen testing. In yet another aspect, the neurological disorder is impaired motor coordination during inverted screen testing. In yet another aspect, the neurological disorder includes depression, 25 generalized anxiety disorders, attention deficit disorder, sleep disorder, hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia and sensory disorders. Such neurological disorders include the category defined as "anxiety disorders" which include but are not limited to: mild to moderate anxiety, anxiety disorder due to a general medical condition, anxiety disorder not otherwise specified, generalized anxiety disorder, panic 30 attack, panic disorder with agoraphobia, panic disorder without agoraphobia, posttraumatic stress disorder, social phobia, social anxiety, autism, specific phobia, substance-induced anxiety 14 WO 2008/127352 PCT/US2007/080102 disorder, acute alcohol withdrawal, obsessive compulsive disorder, agoraphobia, monopolar disorders, bipolar disorder I or II, bipolar disorder not otherwise specified, cyclothymic disorder, depressive disorder, major depressive disorder, mood disorder, substance-induced mood disorder, enhancement of cognitive function, loss of cognitive function associated with but not limited to Alzheimer's disease, stroke, or traumatic injury to the brain, seizures resulting 5 from disease or injury including but not limited to epilepsy, learning disorders/disabilities, cerebral palsy. In addition, anxiety disorders may apply to personality disorders including but not limited to the following types: paranoid, antisocial, avoidant behavior, borderline personality disorders, dependent, histronic, narcissistic, obsessive-compulsive, schizoid, and schizotypal. 10 In yet another aspect, the eye abnormality is a retinal abnormality. In still another aspect, the eye abnormality is consistent with vision problems or blindness. In yet another aspect, the retinal abnormality is consistent with retinitis pigmentosa or is characterized by retinal degeneration or retinal dysplasia. In still another aspect, the retinal abnormalities are consistent with retinal dysplasia, 15 various retinopathies, including retinopathy ofprematurity, retrolental fibroplasia, neovascular glaucoma, age-related macular degeneration, diabetic macular edema, corneal neovascularization, corneal graft neovascularization, corneal graft rejection, retinal/choroidal neovascularization, neovascularization of the angle (rubeosis), ocular neovascular disease, vascular restenosis, arteriovenous malformations (AVM), meningioma, hemangioma, 20 angiofibroma, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, retinal artery obstruction or occlusion; retinal degeneration causing secondary atrophy of the retinal vasculature, retinitis pigmentosa, macular dystrophies, Stargardt's disease, congenital stationarynight blindness, choroideremia, gyrate atrophy, Leber's congenital amaurosis, retinoschisis disorders, Wagner's syndrome, Usher syndromes, Zellweger syndrome, 25 Saldino-Mainzer syndrome, Senior-Loken syndrome, Bardet-Biedl syndrome, Alport's syndrome, Alstrom's syndrome, Cockayne's syndrome, dysplaisa spondyloepiphysaria congentia, Flynn-Aird syndrome, Friedreich ataxia, Hallgren syndrome, Marshall syndrome, Albers-Schnoberg disease, Refsum's disease, Kearns-Sayre syndrome, Waardenburg's syndrome, Alagile syndrome, myotonic dystrophy, olivopontocerebellar atrophy, Pierre-Marie 30 dunsdrome, Stickler syndrome, carotinemeia, cystinosis, Wolfram syndrome, Bassen-Kornzweig syndrome, abetalipoproteinemia, incontinentia pigmenti, Batten's disease, 15 WO 2008/127352 PCT/US2007/080102 mucopolysaccharidoses, homocystinuria, or mannosidosis. In still another aspect, the eye abnormality is a cataract. In still yet another aspect, the cataract is a systemic disease such as human Down's syndrome, Hallerman-Streiff syndrome, Lowe syndrome, galactosemia, Marfan syndrome, Trismoy 13-15, Alport syndrome, myotonic dystrophy, Fabry disease, hypoparathroidism, or Conradi syndrome. 5 In still another aspect, the developmental abnormality comprises embryonic lethality or reduced viability. In still another aspect, the cardiovascular, endothelial or angiogenic disorders are arterial diseases, such as diabetes mellitus; papilledema; optic atrophy; atherosclerosis; angina; myocardial infarctions such as acute myocardial infarctions, cardiac hypertrophy, and heart 10 failure such as congestive heart failure; hypertension; inflammatory vasculitides; Reynaud's disease and Reynaud's phenomenon; aneurysms and arterial restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; peripheral vascular disease; cancer such as vascular tumors, e.g., hemangioma (capillary and cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, 15 haemangiopericytoma, Kaposi's sarcoma, lymphangioma, and lymphangiosarcoma; tumor angiogenesis; trauma such as wounds, burns, and other injured tissue, implant fixation, scarring; ischemia reperfusion injury; rheumatoid arthritis; cerebrovascular disease; renal diseases such as acute renal failure, or osteoporosis. In still another aspect, the immunological disorders are consistent with systemic lupus 20 erythematosis; rheumatoid arthritis; juvenile chronic arthritis; spondyloarthropathies; systemic sclerosis (scleroderma); idiopathic inflammatory myopathies (dermatomyositis, polymyositis); Sj6gren's syndrome; systemic vasculitis; sarcoidosis; autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria); autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia); thyroiditis 25 (Grave's disease, Hashimoto's thyroiditis,juvenile lymphocytic thyroiditis, atrophic thyroiditis); diabetes mellitus; immune-mediated renal disease (glomerulonephritis, tubulointerstitial nephritis); demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barr6 syndrome, and chronic inflammatory demyelinating polyneuropathy; hepatobiliary diseases such as infectious 30 hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis; 16 WO 2008/127352 PCT/US2007/080102 inflammatory bowel disease (ulcerative colitis: Crohn's disease); gluten-sensitive enteropathy, and Whipple's disease; autoimmune or immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis; allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria; immunologic diseases of the lung such as eosinophilic pneumonia, idiopathic pulmonary fibrosis and 5 hypersensitivity pneumonitis; or transplantation associated diseases including graft rejection and graft -versus-host disease. In yet another aspect, the bone metabolic abnormality or disorder is arthritis, osteoporosis, osteopenia or osteopetrosis. In another aspect, the non-human transgenic animal exhibits at least one of the 10 following physiological characteristics compared with gender matched wild-type littermates: a decreased anxiety-like response during open field activity testing; an abnormal habituation response to a novel environment (increased median ambulatory count during home-cage activity testing) during circadian testing; a decreased depressive-like response with decreased median immobility time during tail suspension testing; an increased blood glucose level; impaired 15 glucose tolerance; an increased trabecular bone volume and thickness; decreased percent total body fat mass and percent total body fat; a decreased skin fibroblast proliferation rate; and an increased systolic blood pressure. The invention also provides an agent which modulates the phenotype associated with gene disruption. In one aspect, the agent is an agonist or antagonist of a PRO 1105, PRO1279 20 or PRO1783 polypeptide. In yet another aspect, the agonist agent is an anti-PRO1105, anti PRO 1279 or anti-PRO1783 antibody. In still another aspect, the antagonist agent is an anti PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody. The invention also provides a method of identifying an agent that modulates a physiological characteristic associated with a disruption of the gene which encodes for a 25 PRO 1105, PRO 1279 or PRO 1783 polypeptide, the method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption of the gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide; (b) measuring a physiological characteristic exhibited by the non-human transgenic animal of (a); 30 (c) comparing the measured physiological characteristic of (b) with that of a gender matched wild-type animal, wherein the physiological characteristic exhibited by the non-human 17 WO 2008/127352 PCT/US2007/080102 transgenic animal that differs from the physiological characteristic exhibited by the wild-type animal is identified as a physiological characteristic associated with gene disruption; (d) administering a test agent to the non-human transgenic animal of (a); and (e) determining whether the physiological characteristic associated with gene disruption is modulated. 5 In one aspect, the non-human transgenic animal exhibits at least one of the following physiological characteristics compared with gender matched wild-type littermates: In another aspect, the non-human transgenic animal exhibits at least one of the following physiological characteristics compared with gender matched wild-type littermates: a decreased anxiety-like response during open field activity testing; an abnormal habituation 10 response to a novel environment (increased median ambulatory count during home-cage activity testing) during circadian testing; a decreased depressive-like response with decreased median immobility time during tail suspension testing; an increased blood glucose level; impaired glucose tolerance; an increased trabecular bone volume and thickness; decreased percent total body fat mass and percent total body fat; a decreased skin fibroblast proliferation rate; and an 15 increased systolic blood pressure. The invention also provides an agent that modulates aphysiological characteristic which is associated with gene disruption. In one aspect, the agent is an agonist or antagonist of the phenotype associated with a disruption of a gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide. In yet another aspect, the agent is an agonist or antagonist of a 20 PRO 1105, PRO 1279 or PRO 1783 polypeptide. In yet another aspect, the agonist agent is an anti-PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody. In still another aspect, the antagonist agent is an anti-PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody. The invention also provides a method of identifying an agent which modulates a behavior associated with a disruption of the gene which encodes for a PRO 1105, PRO1279 or 25 PRO 1783 polypeptide, the method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption of the gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide; (b) observing the behavior exhibited by the non-human transgenic animal of (a); (c) comparing the observed behavior of (b) with that of a gender matched wild-type 30 animal, wherein the observed behavior exhibited by the non-human transgenic animal that differs from the observed behavior exhibited by the wild-type animal is identified as a behavior 18 WO 2008/127352 PCT/US2007/080102 associated with gene disruption; (d) administering a test agent to the non-human transgenic animal of (a); and (e) determining whether the agent modulates the behavior associated with gene disruption. In one aspect, the observed behavior is an increased anxiety-like response during open 5 field activity testing. In yet another aspect, the observed behavior is a decreased anxiety-like response during open field activity testing. In yet another aspect, the observed behavior is an abnormal circadian rhythm during home-cage activity testing. In yet another aspect, the observed behavior is an enhanced motor coordination during inverted screen testing. In yet another aspect, the observed behavior is impaired motor coordination during inverted screen 10 testing. In yet another aspect, the observed behavior includes depression, generalized anxiety disorders, attention deficit disorder, sleep disorder, hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia and sensory disorders. Such disorders include the category defined as "anxiety disorders" which include but are not limited to: mild to moderate anxiety, anxiety disorder due to a general medical condition, 15 anxiety disorder not otherwise specified, generalized anxiety disorder, panic attack, panic disorder with agoraphobia, panic disorder without agoraphobia, posttraumatic stress disorder, social phobia, social anxiety, autism, specific phobia, substance-induced anxiety disorder, acute alcohol withdrawal, obsessive compulsive disorder, agoraphobia, monopolar disorders, bipolar disorder I or II, bipolar disorder not otherwise specified, cyclothymic disorder, depressive 20 disorder, major depressive disorder, mood disorder, substance-induced mood disorder, enhancement of cognitive function, loss of cognitive function associated with but not limited to Alzheimer's disease, stroke, or traumatic injury to the brain, seizures resulting from disease or injury including but not limited to epilepsy, learning disorders/disabilities, cerebral palsy. In addition, anxiety disorders may apply to personality disorders including but not limited to 25 the following types: paranoid, antisocial, avoidant behavior, borderline personality disorders, dependent, histronic, narcissistic, obsessive-compulsive, schizoid, and schizotypal. The invention also provides an agent that modulates a behavior which is associated with gene disruption. In one aspect, the agent is an agonist or antagonist of the phenotype associated with a disruption of a gene which encodes for a PRO 1105, PRO 1279 or PRO 1783 polypeptide. 30 In yet another aspect, the agent is an agonist or antagonist of a PRO1105, PRO1279 or PRO 1783 polypeptide. In yet another aspect, the agonist agent is an anti-PRO 1105, anti 19 WO 2008/127352 PCT/US2007/080102 PRO1279 or anti-PR01783 antibody. In still another aspect, the antagonist agent is an anti PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody. The invention also provides a method of identifying an agent that ameliorates or modulates a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality 5 or disorder; a lipid metabolic disorder; or a developmental abnormality associated with a disruption in the gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide, the method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption of the gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide; 10 (b) administering a test agent to said non-human transgenic animal; and (c) determining whether the test agent ameliorates or modulates the neurological disorder; cardiovascular, endothelial or angiogenic disorder; eye abnormality; immunological disorder; oncological disorder; bone metabolic abnormality or disorder; lipid metabolic disorder; or developmental abnormality associated with the gene disruption in the non-human 15 transgenic animal. In yet another aspect, the neurological disorder is an increased anxiety-like response during open field activity testing. In yet another aspect, the neurological disorder is a decreased anxiety-like response during open field activity testing. In yet another aspect, the neurological disorder is an abnormal circadian rhythm during home-cage activity testing. In yet another 20 aspect, the neurological disorder is an enhanced motor coordination during inverted screen testing. In yet another aspect, the neurological disorder is impaired motor coordination during inverted screen testing. In yet another aspect, the neurological disorder includes depression, generalized anxiety disorders, attention deficit disorder, sleep disorder, hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia and sensory 25 disorders. Such neurological disorders include the category defined as "anxiety disorders" which include but are not limited to: mild to moderate anxiety, anxiety disorder due to a general medical condition, anxiety disorder not otherwise specified, generalized anxiety disorder, panic attack, panic disorder with agoraphobia, panic disorder without agoraphobia, posttraumatic stress disorder, social phobia, social anxiety, autism, specific phobia, substance-induced anxiety 30 disorder, acute alcohol withdrawal, obsessive compulsive disorder, agoraphobia, monopolar disorders, bipolar disorder I or II, bipolar disorder not otherwise specified, cyclothymic 20 WO 2008/127352 PCT/US2007/080102 disorder, depressive disorder, major depressive disorder, mood disorder, substance-induced mood disorder, enhancement of cognitive function, loss of cognitive function associated with but not limited to Alzheimer's disease, stroke, or traumatic injury to the brain, seizures resulting from disease or injury including but not limited to epilepsy, learning disorders/disabilities, cerebral palsy. In addition, anxiety disorders may apply to personality disorders including but 5 not limited to the following types: paranoid, antisocial, avoidant behavior, borderline personality disorders, dependent, histronic, narcissistic, obsessive-compulsive, schizoid, and schizotypal. In another aspect, the eye abnormality is a retinal abnormality. In still another aspect, the eye abnormality is consistent with vision problems or blindness. In yet another aspect, the 10 retinal abnormality is consistent with retinitis pigmentosa or is characterized by retinal degeneration or retinal dysplasia. In still another aspect, the retinal abnormalities the retinal abnormalities are consistent with retinal dysplasia, various retinopathies, including retinopathy of prematurity, retrolental fibroplasia, neovascular glaucoma, age-related macular degeneration, diabetic macular edema, 15 corneal neovascularization, corneal graft neovascularization, corneal graft rejection, retinal/choroidal neovascularization, neovascularization of the angle (rubeosis), ocular neovascular disease, vascular restenosis, arteriovenous malformations (AVM), meningioma, hemangioma, angiofibroma, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, retinal artery obstruction or occlusion; retinal degeneration causing 20 secondary atrophy of the retinal vasculature, retinitis pigmentosa, macular dystrophies, Stargardt's disease, congenital stationary night blindness, choroideremia, gyrate atrophy, Leber's congenital amaurosis, retinoschisis disorders, Wagner's syndrome, Usher syndromes, Zellweger syndrome, Saldino-Mainzer syndrome, Senior-Loken syndrome, Bardet-Biedl syndrome, Alport's syndrome, Alstrom's syndrome, Cockayne's syndrome, dysplaisa 25 spondyloepiphysaria congentia, Flynn-Aird syndrome, Friedreich ataxia, Hallgren syndrome, Marshall syndrome, Albers-Schnoberg disease, Refsum's disease, Kearns-Sayre syndrome, Waardenburg's syndrome, Alagile syndrome, myotonic dystrophy, olivopontocerebellar atrophy, Pierre-Marie dunsdrome, Stickler syndrome, carotinemeia, cystinosis, Wolfram syndrome, Bassen-Kornzweig syndrome, abetalipoproteinemia, incontinentia pigmenti, Batten's disease, 30 mucopolysaccharidoses, homocystinuria, or mannosidosis. In still another aspect, the eye abnormality is a cataract. In still yet another aspect, the 21 WO 2008/127352 PCT/US2007/080102 cataract is a systemic disease such as human Down's syndrome, Hallerman-Streiff syndrome, Lowe syndrome, galactosemia, Marfan syndrome, Trismoy 13-15, Alport syndrome, myotonic dystrophy, Fabry disease, hypoparathroidism, or Conradi syndrome. In still another aspect, the developmental abnormality comprises embryonic lethality or reduced viability. 5 In yet another aspect, the cardiovascular, endothelial or angiogenic disorders are arterial diseases, such as diabetes mellitus; papilledema; optic atrophy; atherosclerosis; angina; myocardial infarctions such as acute myocardial infarctions, cardiac hypertrophy, and heart failure such as congestive heart failure; hypertension; inflammatory vasculitides; Reynaud's disease and Reynaud's phenomenon; aneurysms and arterial restenosis; venous and lymphatic 10 disorders such as thrombophlebitis, lymphangitis, and lymphedema; peripheral vascular disease; cancer such as vascular tumors, e.g., hemangioma (capillary and cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma, Kaposi's sarcoma, lymphangioma, and lymphangiosarcoma; tumor angiogenesis; trauma such as wounds, burns, and other injured tissue, implant fixation, scarring; 15 ischemia reperfusion injury; rheumatoid arthritis; cerebrovascular disease; renal diseases such as acute renal failure, or osteoporosis. In still yet another aspect, the immunological disorders are consistent with systemic lupus erythematosis; rheumatoid arthritis; juvenile chronic arthritis; spondyloarthropathies; systemic sclerosis (scleroderma); idiopathic inflammatory myopathies (dermatomyositis, 20 polymyositis); Sj6gren's syndrome; systemic vasculitis; sarcoidosis; autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria); autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia); thyroiditis (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis); diabetes mellitus; immune-mediated renal disease 25 (glomerulonephritis, tubulointerstitial nephritis); demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barr6 syndrome, and chronic inflammatory demyelinating polyneuropathy; hepatobiliary diseases such as infectious hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune chronic active hepatitis, primary biliary cirrhosis, 30 granulomatous hepatitis, and sclerosing cholangitis; inflammatory bowel disease (ulcerative colitis: Crohn's disease); gluten-sensitive enteropathy, and Whipple's disease; autoimmune or 22 WO 2008/127352 PCT/US2007/080102 immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis; allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria; immunologic diseases of the lung such as eosinophilic pneumonia, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis; or transplantation associated diseases including graft rejection and graft -versus-host disease. 5 In yet another aspect, the bone metabolic abnormality or disorder is arthritis, osteoporosis, osteopenia or osteopetrosis. In another aspect, the non-human transgenic animal exhibits at least one of the following physiological characteristics compared with gender matched wild-type littermates: a decreased anxiety-like response during open field activity testing; an abnormal habituation 10 response to a novel environment (increased median ambulatory count during home-cage activity testing) during circadian testing; a decreased depressive-like response with decreased median immobility time during tail suspension testing; an increased blood glucose level; impaired glucose tolerance; an increased trabecular bone volume and thickness; decreased percent total body fat mass and percent total body fat; a decreased skin fibroblast proliferation rate; and an 15 increased systolic blood pressure. The invention also provides an agent that ameliorates or modulates a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality which is associated with gene 20 disruption. In one aspect, the agent is an agonist or antagonist of the phenotype associated with a disruption of a gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide. In yet another aspect, the agent is an agonist or antagonist of a PRO 1105, PRO1279 or PRO1783 polypeptide. In yet another aspect, the agonist agent is an anti-PRO1105, anti-PRO1279 or anti-PRO 1783 antibody. In still another aspect, the antagonist agent is an anti-PRO 1105, anti 25 PRO 1279 or anti-PRO1783 antibody. The invention also provides a therapeutic agent for the treatment of a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality. 30 The invention also provides a method of identifying an agent that modulates the expression of a PRO 1105, PRO1279 or PRO1783 polypeptide, the method comprising: 23 WO 2008/127352 PCT/US2007/080102 (a) contacting a test agent with a host cell expressing a PRO 1105, PRO 1279 or PRO1783 polypeptide; and (b) determining whether the test agent modulates the expression of the PRO 1105, PRO 1279 or PRO 1783 polypeptide by the host cell. The invention also provides an agent that modulates the expression of a PRO 1105, 5 PRO1279 or PRO1783 polypeptide. In one aspect, the agent is an agonist or antagonist of the phenotype associated with a disruption of a gene which encodes for a PRO 1105, PRO 1279 or PRO1783 polypeptide. In yet another aspect, the agent is an agonist or antagonist of a PRO 1105, PRO 1279 or PRO 1783 polypeptide. In yet another aspect, the agonist agent is an anti-PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody. In still another aspect, the antagonist 10 agent is an anti-PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody. The invention also provides a method of evaluating a therapeutic agent capable of affecting a condition associated with a disruption of a gene which encodes for a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption 15 of the gene which encodes for the PRO 1105, PRO1279 or PRO1783 polypeptide; (b) measuring a physiological characteristic ofthe non-human transgenic animal of(a); (c) comparing the measured physiological characteristic of (b) with that of a gender matched wild-type animal, wherein the physiological characteristic ofthe non-human transgenic animal that differs from the physiological characteristic of the wild-type animal is identified as 20 a condition resulting from the gene disruption in the non-human transgenic animal; (d) administering a test agent to the non-human transgenic animal of (a); and (e) evaluating the effects of the test agent on the identified condition associated with gene disruption in the non-human transgenic animal. In one aspect, the condition is a neurological disorder; a cardiovascular, endothelial or 25 angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality. The invention also provides a therapeutic agent which is capable of affecting a condition associated with gene disruption. In one aspect, the agent is an agonist or antagonist of the 30 phenotype associated with a disruption of a gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide. In yet another aspect, the agent is an agonist or antagonist of a 24 WO 2008/127352 PCT/US2007/080102 PRO 1105, PRO 1279 or PRO 1783 polypeptide. In yet another aspect, the agonist agent is an anti-PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody. In still another aspect, the antagonist agent is an anti-PRO 1105, anti-PRO1279 or anti-PRO1783 antibody. The invention also provides a pharmaceutical composition comprising a therapeutic agent capable of affecting the condition associated with gene disruption. 5 The invention also provides a method of treating or preventing or ameliorating a neurological disorder; cardiovascular, endothelial or angiogenic disorder; immunological disorder; oncological disorder; bone metabolic abnormality or disorder, or embryonic lethality associated with the disruption of a gene which encodes for a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the method comprising administering to a subject in need of such treatment whom 10 may already have the disorder, or may be prone to have the disorder or may be in whom the disorder is to be prevented, a therapeutically effective amount of a therapeutic agent, or agonists or antagonists thereof, thereby effectively treating or preventing or ameliorating said disorder or disease. In yet another aspect, the neurological disorder is an increased anxiety-like response 15 during open field activity testing. In yet another aspect, the neurological disorder is a decreased anxiety-like response during open field activity testing. In yet another aspect, the neurological disorder is an abnormal circadian rhythm during home-cage activity testing. In yet another aspect, the neurological disorder is an enhanced motor coordination during inverted screen testing. In yet another aspect, the neurological disorder is impaired motor coordination during 20 inverted screen testing. In yet another aspect, the neurological disorder includes depression, generalized anxiety disorders, attention deficit disorder, sleep disorder, hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia and sensory disorders. Such neurological disorders include the category defined as "anxiety disorders" which include but are not limited to: mild to moderate anxiety, anxiety disorder due to a general 25 medical condition, anxiety disorder not otherwise specified, generalized anxiety disorder, panic attack, panic disorder with agoraphobia, panic disorder without agoraphobia, posttraumatic stress disorder, social phobia, social anxiety, autism, specific phobia, substance-induced anxiety disorder, acute alcohol withdrawal, obsessive compulsive disorder, agoraphobia, monopolar disorders, bipolar disorder I or II, bipolar disorder not otherwise specified, cyclothymic 30 disorder, depressive disorder, major depressive disorder, mood disorder, substance-induced mood disorder, enhancement of cognitive function, loss of cognitive function associated with 25 WO 2008/127352 PCT/US2007/080102 but not limited to Alzheimer's disease, stroke, or traumatic injury to the brain, seizures resulting from disease or injury including but not limited to epilepsy, learning disorders/disabilities, cerebral palsy. In addition, anxiety disorders may apply to personality disorders including but not limited to the following types: paranoid, antisocial, avoidant behavior, borderline personality disorders, dependent, histronic, narcissistic, obsessive-compulsive, schizoid, and 5 schizotypal. In another aspect, the eye abnormality is a retinal abnormality. In still another aspect, the eye abnormality is consistent with vision problems or blindness. In yet another aspect, the retinal abnormality is consistent with retinitis pigmentosa or is characterized by retinal degeneration or retinal dysplasia. 10 In still another aspect, the retinal abnormalities are consistent with retinal dysplasia, various retinopathies, including retinopathy of prematurity, retrolental fibroplasia, neovascular glaucoma, age-related macular degeneration, diabetic macular edema, corneal neovascularization, corneal graft neovascularization, corneal graft rejection, retinal/choroidal neovascularization, neovascularization of the angle (rubeosis), ocular neovascular disease, 15 vascular restenosis, arteriovenous malformations (AVM), meningioma, hemangioma, angiofibroma, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, retinal artery obstruction or occlusion; retinal degeneration causing secondary atrophy of the retinal vasculature, retinitis pigmentosa, macular dystrophies, Stargardt's disease, congenital stationary night blindness, choroideremia, gyrate atrophy, Leber's congenital 20 amaurosis, retinoschisis disorders, Wagner's syndrome, Usher syndromes, Zellweger syndrome, Saldino-Mainzer syndrome, Senior-Loken syndrome, Bardet-Biedl syndrome, Alport's syndrome, Alstrom's syndrome, Cockayne's syndrome, dysplaisa spondyloepiphysaria congentia, Flynn-Aird syndrome, Friedreich ataxia, Hallgren syndrome, Marshall syndrome, Albers-Schnoberg disease, Refsum's disease, Kearns-Sayre syndrome, Waardenburg's 25 syndrome, Alagile syndrome, myotonic dystrophy, olivopontocerebellar atrophy, Pierre-Marie dunsdrome, Stickler syndrome, carotinemeia, cystinosis, Wolfram syndrome, Bassen-Kornzweig syndrome, abetalipoproteinemia, incontinentia pigmenti, Batten's disease, mucopolysaccharidoses, homocystinuria, or mannosidosis. In still another aspect, the eye abnormality is a cataract. In still yet another aspect, the 30 cataract is a systemic disease such as human Down's syndrome, Hallerman-Streiff syndrome, Lowe syndrome, galactosemia, Marfan syndrome, Trismoy 13-15, Alport syndrome, myotonic 26 WO 2008/127352 PCT/US2007/080102 dystrophy, Fabry disease, hypoparathroidism or Conradi syndrome. In still another aspect, the developmental abnormality comprises embryonic lethality or reduced viability. In yet another aspect, the cardiovascular, endothelial or angiogenic disorders are arterial diseases, such as diabetes mellitus; papilledema; optic atrophy; atherosclerosis; angina; 5 myocardial infarctions such as acute myocardial infarctions, cardiac hypertrophy, and heart failure such as congestive heart failure; hypertension; inflammatory vasculitides; Reynaud's disease and Reynaud's phenomenon; aneurysms and arterial restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; peripheral vascular disease; cancer such as vascular tumors, e.g., hemangioma (capillary and cavernous), glomus 10 tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma, Kaposi's sarcoma, lymphangioma, and lymphangiosarcoma; tumor angiogenesis; trauma such as wounds, burns, and other injured tissue, implant fixation, scarring; ischemia reperfusion injury; rheumatoid arthritis; cerebrovascular disease; renal diseases such as acute renal failure, or osteoporosis. 15 In still yet another aspect, the immunological disorders are consistent with systemic lupus erythematosis; rheumatoid arthritis; juvenile chronic arthritis; spondyloarthropathies; systemic sclerosis (scleroderma); idiopathic inflammatory myopathies (dermatomyositis, polymyositis); Sj6gren's syndrome; systemic vasculitis; sarcoidosis; autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria); autoimmune 20 thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia); thyroiditis (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis); diabetes mellitus; immune-mediated renal disease (glomerulonephritis, tubulointerstitial nephritis); demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic demyelinating polyneuropathy 25 or Guillain-Barr6 syndrome, and chronic inflammatory demyelinating polyneuropathy; hepatobiliary diseases such as infectious hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis; inflammatory bowel disease (ulcerative colitis: Crohn's disease); gluten-sensitive enteropathy, and Whipple's disease; autoimmune or 30 immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis; allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, 27 WO 2008/127352 PCT/US2007/080102 food hypersensitivity and urticaria; immunologic diseases of the lung such as eosinophilic pneumonia, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis; or transplantation associated diseases including graft rejection and graft -versus-host disease. In yet another aspect, the bone metabolic abnormality or disorder is arthritis, osteoporosis, osteopenia or osteopetrosis. 5 In another aspect the therapeutic agent is an agonist or antagonist of the phenotype associated with a disruption of a gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide. In yet another aspect, the agent is an agonist or antagonist of a PRO 1105, PRO1279 or PRO1783 polypeptide. In yet another aspect, the agonist agent is an anti PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody. In still another aspect, the antagonist 10 agent is an anti-PRO 1105, anti-PRO1279 or anti-PRO1783 antibody. The invention also provides a method of identifying an agent that ameliorates or modulates a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality associated with a 15 disruption in the gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide, the method comprising: (a) providing a non-human transgenic animal cell culture, each cell of said culture comprising a disruption of the gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide; 20 (b) administering a test agent to said cell culture; and (c) determining whether the test agent ameliorates or modulates the neurological disorder; cardiovascular, endothelial or angiogenic disorder; eye abnormality; immunological disorder; oncological disorder; bone metabolic abnormality or disorder; lipid metabolic disorder; or developmental abnormality in said culture. In yet another aspect, the neurological 25 disorder is an increased anxiety-like response during open field activity testing. In yet another aspect, the neurological disorder is a decreased anxiety-like response during open field activity testing. In yet another aspect, the neurological disorder is an abnormal circadian rhythm during home-cage activity testing. In yet another aspect, the neurological disorder is an enhanced motor coordination during inverted screen testing. In yet another aspect, the neurological 30 disorder is impaired motor coordination during inverted screen testing. In yet another aspect, the neurological disorder includes depression, generalized anxiety disorders, attention deficit 28 WO 2008/127352 PCT/US2007/080102 disorder, sleep disorder, hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia and sensory disorders. Such neurological disorders include the category defined as "anxiety disorders" which include but are not limited to: mild to moderate anxiety, anxiety disorder due to a general medical condition, anxiety disorder not otherwise specified, generalized anxiety disorder, panic attack, panic disorder with agoraphobia, 5 panic disorder without agoraphobia, posttraumatic stress disorder, social phobia, social anxiety, autism, specific phobia, substance-induced anxiety disorder, acute alcohol withdrawal, obsessive compulsive disorder, agoraphobia, monopolar disorders, bipolar disorder I or II, bipolar disorder not otherwise specified, cyclothymic disorder, depressive disorder, major depressive disorder, mood disorder, substance-induced mood disorder, enhancement of 10 cognitive function, loss of cognitive function associated with but not limited to Alzheimer's disease, stroke, or traumatic injury to the brain, seizures resulting from disease or injury including but not limited to epilepsy, learning disorders/disabilities, cerebral palsy. In addition, anxiety disorders may apply to personality disorders including but not limited to the following types: paranoid, antisocial, avoidant behavior, borderline personality disorders, dependent, 15 histronic, narcissistic, obsessive-compulsive, schizoid, and schizotypal. In another aspect, the eye abnormality is a retinal abnormality. In still another aspect, the eye abnormality is consistent with vision problems or blindness. In yet another aspect, the retinal abnormality is consistent with retinitis pigmentosa or is characterized by retinal degeneration or retinal dysplasia. 20 In still another aspect, the retinal abnormalities are consistent with retinal dysplasia, various retinopathies, including retinopathy of prematurity, retrolental fibroplasia, neovascular glaucoma, age-related macular degeneration, diabetic macular edema, corneal neovascularization, corneal graft neovascularization, corneal graft rejection, retinal/choroidal neovascularization, neovascularization of the angle (rubeosis), ocular neovascular disease, 25 vascular restenosis, arteriovenous malformations (AVM), meningioma, hemangioma, angiofibroma, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, retinal artery obstruction or occlusion; retinal degeneration causing secondary atrophy of the retinal vasculature, retinitis pigmentosa, macular dystrophies, Stargardt's disease, congenital stationarynight blindness, choroideremia, gyrate atrophy, Leber's congenital 30 amaurosis, retinoschisis disorders, Wagner's syndrome, Usher syndromes, Zellweger syndrome, Saldino-Mainzer syndrome, Senior-Loken syndrome, Bardet-Biedl syndrome, Alport's 29 WO 2008/127352 PCT/US2007/080102 syndrome, Alstrom's syndrome, Cockayne's syndrome, dysplaisa spondyloepiphysaria congentia, Flynn-Aird syndrome, Friedreich ataxia, Hallgren syndrome, Marshall syndrome, Albers-Schnoberg disease, Refsum's disease, Kearns-Sayre syndrome, Waardenburg's syndrome, Alagile syndrome, myotonic dystrophy, olivopontocerebellar atrophy, Pierre-Marie dunsdrome, Stickler syndrome, carotinemeia, cystinosis, Wolfram syndrome, 5 Bassen-Kornzweig syndrome, abetalipoproteinemia, incontinentia pigmenti, Batten's disease, mucopolysaccharidoses, homocystinuria, or mannosidosis. In still another aspect, the eye abnormality is a cataract. In still yet another aspect, the cataract is a systemic disease such as human Down's syndrome, Hallerman-Streiff syndrome, Lowe syndrome, galactosemia, Marfan syndrome, Trismoy 13-15, Alport syndrome, myotonic 10 dystrophy, Fabry disease, hypoparathroidism or Conradi syndrome. In still another aspect, the developmental abnormality comprises embryonic lethality or reduced viability. In yet another aspect, the cardiovascular, endothelial or angiogenic disorders are arterial diseases, such as diabetes mellitus; papilledema; optic atrophy; atherosclerosis; angina; 15 myocardial infarctions such as acute myocardial infarctions, cardiac hypertrophy, and heart failure such as congestive heart failure; hypertension; inflammatory vasculitides; Reynaud's disease and Reynaud's phenomenon; aneurysms and arterial restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; peripheral vascular disease; cancer such as vascular tumors, e.g., hemangioma (capillary and cavernous), glomus 20 tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma, Kaposi's sarcoma, lymphangioma, and lymphangiosarcoma; tumor angiogenesis; trauma such as wounds, burns, and other injured tissue, implant fixation, scarring; ischemia reperfusion injury; rheumatoid arthritis; cerebrovascular disease; renal diseases such as acute renal failure, or osteoporosis. 25 In still yet another aspect, the immunological disorders are consistent with systemic lupus erythematosis; rheumatoid arthritis; juvenile chronic arthritis; spondyloarthropathies; systemic sclerosis (scleroderma); idiopathic inflammatory myopathies (dermatomyositis, polymyositis); Sj6gren's syndrome; systemic vasculitis; sarcoidosis; autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria); autoimmune 30 thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia); thyroiditis (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic 30 WO 2008/127352 PCT/US2007/080102 thyroiditis, atrophic thyroiditis); diabetes mellitus; immune-mediated renal disease (glomerulonephritis, tubulointerstitial nephritis); demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barr6 syndrome, and chronic inflammatory demyelinating polyneuropathy; hepatobiliary diseases such as infectious hepatitis (hepatitis A, B, C, D, E and other 5 non-hepatotropic viruses), autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis; inflammatory bowel disease (ulcerative colitis: Crohn's disease); gluten-sensitive enteropathy, and Whipple's disease; autoimmune or immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis; allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, 10 food hypersensitivity and urticaria; immunologic diseases of the lung such as eosinophilic pneumonia, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis; or transplantation associated diseases including graft rejection and graft -versus-host disease. In yet another aspect, the bone metabolic abnormality or disorder is arthritis, osteoporosis, osteopenia or osteopetrosis. 15 The invention also provides an agent that ameliorates or modulates a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality which is associated with gene disruption in said culture. In one aspect, the agent is an agonist or antagonist of the phenotype 20 associated with a disruption of a gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide. In yet another aspect, the agent is an agonist or antagonist of a PRO 1105, PRO1279 or PRO1783 polypeptide. In yet another aspect, the agonist agent is an anti PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody. In still another aspect, the antagonist agent is an anti-PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody. 25 The invention also provides a method of modulating a phenotype associated with a disruption of a gene which encodes for a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the method comprising administering to a subject whom may already have the phenotype, or may be prone to have the phenotype or may be in whom the phenotype is to be prevented, an effective amount of an agent identified as modulating said phenotype, or agonists or antagonists 30 thereof, thereby effectively modulating the phenotype. The invention also provides a method of modulating a physiological characteristic 31 WO 2008/127352 PCT/US2007/080102 associated with a disruption of a gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide, the method comprising administering to a subject whom may already exhibit the physiological characteristic, or may be prone to exhibit the physiological characteristic or may be in whom the physiological characteristic is to be prevented, an effective amount of an agent identified as modulating said physiological characteristic, or agonists or antagonists thereof, 5 thereby effectively modulating the physiological characteristic. The invention also provides a method of modulating a behavior associated with a disruption of a gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide, the method comprising administering to a subject whom may already exhibit the behavior, or may be prone to exhibit the behavior or may be in whom the exhibited behavior is to be prevented, 10 an effective amount of an agent identified as modulating said behavior, or agonists or antagonists thereof, thereby effectively modulating the behavior. The invention also provides a method of modulating the expression of a PRO 1105, PRO1279 or PRO1783 polypeptide, the method comprising administering to a host cell expressing said PRO 1105, PRO 1279 or PRO 1783 polypeptide, an effective amount of an agent 15 identified as modulating said expression, or agonists or antagonists thereof, thereby effectively modulating the expression of said polypeptide. The invention also provides a method of modulating a condition associated with a disruption of a gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide, the method comprising administering to a subject whom may have the condition, or may be prone 20 to have the condition or may be in whom the condition is to be prevented, a therapeutically effective amount of a therapeutic agent identified as modulating said condition, or agonists or antagonists thereof, thereby effectively modulating the condition. The invention also provides a method of treating or preventing or ameliorating a neurological disorder; cardiovascular, endothelial or angiogenic disorder; immunological 25 disorder; oncological disorder; bone metabolic abnormality or disorder, or embryonic lethality associated with the disruption of a gene which encodes for a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the method comprising administering to a non-human transgenic animal cell culture, each cell of said culture comprising a disruption of the gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide, an effective amount of an agent identified as 30 treating or preventing or ameliorating said disorder, or agonists or antagonists thereof, thereby effectively treating or preventing or ameliorating said disorder. 32 WO 2008/127352 PCT/US2007/080102 The invention also provides a method of identifying an agent that ameliorates or modulates a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality associated with a disruption in the gene which encodes for a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the 5 method comprising administering to a subject whom may have the neurological disorder; cardiovascular, endothelial or angiogenic disorder; eye abnormality; immunological disorder; oncological disorder; bone metabolic abnormality or disorder; lipid metabolic disorder; or developmental abnormality, a therapeutic agent of identified as ameliorating or modulating a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; 10 an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality, or agonists or antagonists thereof, thereby ameliorating or modulating the disorder. B. Further Embodiments 15 In yet further embodiments, the invention is directed to the following set of potential claims for this application: 1. A method of identifying a phenotype associated with a disruption of a gene which encodes for a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption 20 of the gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide; (b) measuring a physiological characteristic of the non-human transgenic animal; and (c) comparing the measured physiological characteristic with that of a gender matched wild-type animal, wherein the physiological characteristic of the non-human transgenic animal that differs from the physiological characteristic of the wild-type animal is identified as a 25 phenotype resulting from the gene disruption in the non-human transgenic animal. 2. The method of Claim 1, wherein the non-human transgenic animal is heterozygous for the disruption of a gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide. 3. The method of Claim 1, wherein the phenotype exhibited by the non-human transgenic animal as compared with gender matched wild-type littermates is at least one of the following: 30 a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality 33 WO 2008/127352 PCT/US2007/080102 or disorder; a lipid metabolic disorder; or a developmental abnormality. 4. The method of Claim 3, wherein the neurological disorder is an increased anxiety-like response during open field activity testing. 5. The method of Claim 3, wherein the neurological disorder is a decreased anxiety-like response during open field activity testing. 5 6. The method of Claim 3, wherein the neurological disorder is an abnormal circadian rhythm during home-cage activity testing. 7. The method of Claim 3, wherein the neurological disorder is an enhanced motor coordination during inverted screen testing. 8. The method of Claim 3, wherein the neurological disorder is an impaired motor 10 coordination during inverted screen testing. 9. The method of Claim 3, wherein the neurological disorder is depression, generalized anxiety disorders, attention deficit disorder, sleep disorder, hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia or sensory disorders. 10. The method of Claim 3, wherein the eye abnormality is a retinal abnormality. 15 11. The method of Claim 3, wherein the eye abnormality is consistent with vision problems or blindness. 12. The method of Claim 10, wherein the retinal abnormality is consistent with retinitis pigmentosa. 13. The method of Claim 10, wherein the retinal abnormality is characterized by retinal 20 degeneration or retinal dysplasia. 14. The method of Claim 10, wherein the retinal abnormality is consistent with retinal dysplasia, various retinopathies, including retinopathy of prematurity, retrolental fibroplasia, neovascular glaucoma, age-related macular degeneration, diabetic macular edema, corneal neovascularization, corneal graft neovascularization, corneal graft rejection, retinal/choroidal 25 neovascularization, neovascularization of the angle (rubeosis), ocular neovascular disease, vascular restenosis, arteriovenous malformations (AVM), meningioma, hemangioma, angiofibroma, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, retinal artery obstruction or occlusion; retinal degeneration causing secondary atrophy of the retinal vasculature, retinitis pigmentosa, macular dystrophies, Stargardt's 30 disease, congenital stationary night blindness, choroideremia, gyrate atrophy, Leber's congenital amaurosis, retinoschisis disorders, Wagner's syndrome, Usher syndromes, Zellweger syndrome, 34 WO 2008/127352 PCT/US2007/080102 Saldino-Mainzer syndrome, Senior-Loken syndrome, Bardet-Biedl syndrome, Alport's syndrome, Alstrom's syndrome, Cockayne's syndrome, dysplaisa spondyloepiphysaria congentia, Flynn-Aird syndrome, Friedreich ataxia, Hallgren syndrome, Marshall syndrome, Albers-Schnoberg disease, Refsum's disease, Kearns-Sayre syndrome, Waardenburg's syndrome, Alagile syndrome, myotonic dystrophy, olivopontocerebellar atrophy, Pierre-Marie 5 dunsdrome, Stickler syndrome, carotinemeia, cystinosis, Wolfram syndrome, Bassen-Kornzweig syndrome, abetalipoproteinemia, incontinentia pigmenti, Batten's disease, mucopolysaccharidoses, homocystinuria, or mannosidosis. 15. The method of Claim 3, wherein the eye abnormality is a cataract. 16. The method of Claim 15, wherein the cataract is consistent with systemic diseases such 10 as human Down's syndrome, Hallerman-Streiff syndrome, Lowe syndrome, galactosemia, Marfan syndrome, Trismoy 13-15, Alport syndrome, myotonic dystrophy, Fabry disease, hypoparathroidism or Conradi syndrome. 17. The method of Claim 3, wherein the developmental abnormality comprises embryonic lethality or reduced viability. 15 18. The method of Claim 3, wherein the cardiovascular, endothelial or angiogenic disorders are arterial diseases, such as diabetes mellitus; papilledema; optic atrophy; atherosclerosis; angina; myocardial infarctions such as acute myocardial infarctions, cardiac hypertrophy, and heart failure such as congestive heart failure; hypertension; inflammatory vasculitides; Reynaud's disease and Reynaud's phenomenon; aneurysms and arterial restenosis; venous and 20 lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; peripheral vascular disease; cancer such as vascular tumors, e.g., hemangioma (capillary and cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma, Kaposi's sarcoma, lymphangioma, and lymphangiosarcoma; tumor angiogenesis; trauma such as wounds, burns, and other injured tissue, implant fixation, scarring; 25 ischemia reperfusion injury; rheumatoid arthritis; cerebrovascular disease; renal diseases such as acute renal failure, or osteoporosis. 19. The method of Claim 3, wherein the immunological disorders are systemic lupus erythematosis; rheumatoid arthritis; juvenile chronic arthritis; spondyloarthropathies; systemic sclerosis (scleroderma); idiopathic inflammatory myopathies (dermatomyositis, polymyositis); 30 Sj6gren's syndrome; systemic vasculitis; sarcoidosis; autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria); autoimmune thrombocytopenia 35 WO 2008/127352 PCT/US2007/080102 (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia); thyroiditis (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis); diabetes mellitus; immune-mediated renal disease (glomerulonephritis, tubulointerstitial nephritis); demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barr6 syndrome, and 5 chronic inflammatory demyelinating polyneuropathy; hepatobiliary diseases such as infectious hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis; inflammatory bowel disease (ulcerative colitis: Crohn's disease); gluten-sensitive enteropathy, and Whipple's disease; autoimmune or immune-mediated skin diseases including bullous skin 10 diseases, erythema multiforme and contact dermatitis, psoriasis; allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria; immunologic diseases of the lung such as eosinophilic pneumonia, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis; or transplantation associated diseases including graft rejection and graft -versus-host disease. 15 20. The method of Claim 3, wherein the bone metabolic abnormality or disorder is arthritis, osteoporosis or osteopetrosis. 21. The method of Claim 1, wherein the non-human transgenic animal exhibits at least one of the following physiological characteristics compared with gender matched wild-type littermates: a decreased anxiety-like response during open field activity testing; an abnormal 20 habituation response to a novel environment (increased median ambulatory count during home-cage activity testing) during circadian testing; a decreased depressive-like response with decreased median immobility time during tail suspension testing; an increased blood glucose level; impaired glucose tolerance; an increased trabecular bone volume and thickness; decreased percent total body fat mass and percent total body fat; a decreased skin fibroblast 25 proliferation rate; and an increased systolic blood pressure. 22. An isolated cell derived from a non-human transgenic animal whose genome comprises a disruption of the gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide. 23. The isolated cell of Claim 22 which is a murine cell. 24. The isolated cell of Claim 23, wherein the murine cell is an embryonic stem cell. 30 25. The isolated cell of Claim 22, wherein the non-human transgenic animal exhibits at least one of the following phenotypes compared with gender matched wild-type littermates: a 36 WO 2008/127352 PCT/US2007/080102 neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality. 26. A method of identifying an agent that modulates a phenotype associated with a disruption of a gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide, the 5 method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption of the gene which encodes for the PRO 1105, PRO1279 or PRO1783 polypeptide; (b) measuring a physiological characteristic ofthe non-human transgenic animal of(a); (c) comparing the measured physiological characteristic of (b) with that of a gender 10 matched wild-type animal, wherein the physiological characteristic ofthe non-human transgenic animal that differs from the physiological characteristic of the wild-type animal is identified as a phenotype resulting from the gene disruption in the non-human transgenic animal; (d) administering a test agent to the non-human transgenic animal of (a); and (e) determining whether the test agent modulates the identified phenotype associated 15 with gene disruption in the non-human transgenic animal. 27. The method of Claim 26, wherein the phenotype associated with the gene disruption comprises a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality. 20 28. The method of Claim 27, wherein the neurological disorder is an increased anxiety-like response during open field activity testing. 29. The method of Claim 27, wherein the neurological disorder is a decreased anxiety-like response during open field activity testing. 30. The method of Claim 27, wherein the neurological disorder is an abnormal circadian 25 rhythm during home-cage activity testing. 31. The method of Claim 27, wherein the neurological disorder is an enhanced motor coordination during inverted screen testing. 32. The method of Claim 27, wherein the neurological disorder is an impaired motor coordination during inverted screen testing. 30 33. The method of Claim 27, wherein the neurological disorder is depression, generalized anxiety disorders, attention deficit disorder, sleep disorder, hyperactivity disorder, obsessive 37 WO 2008/127352 PCT/US2007/080102 compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia or sensory disorders. 34. The method of Claim 27, wherein the eye abnormality is a retinal abnormality. 35. The method of Claim 27, wherein the eye abnormality is consistent with vision problems or blindness. 36. The method of Claim 34, wherein the retinal abnormality is consistent with retinitis 5 pigmentosa. 37. The method of Claim 34, wherein the retinal abnormality is characterized by retinal degeneration or retinal dysplasia. 38. The method of Claim 34, wherein the retinal abnormality is consistent with retinal dysplasia, various retinopathies, including retinopathy of prematurity, retrolental fibroplasia, 10 neovascular glaucoma, age-related macular degeneration, diabetic macular edema, comeal neovascularization, comeal graft neovascularization, comeal graft rejection, retinal/choroidal neovascularization, neovascularization of the angle (rubeosis), ocular neovascular disease, vascular restenosis, arteriovenous malformations (AVM), meningioma, hemangioma, angiofibroma, thyroid hyperplasias (including Grave's disease), corneal and other tissue 15 transplantation, retinal artery obstruction or occlusion; retinal degeneration causing secondary atrophy of the retinal vasculature, retinitis pigmentosa, macular dystrophies, Stargardt's disease, congenital stationarynight blindness, choroideremia, gyrate atrophy, Leber's congenital amaurosis, retinoschisis disorders, Wagner's syndrome, Usher syndromes, Zellweger syndrome, Saldino-Mainzer syndrome, Senior-Loken syndrome, Bardet-Biedl syndrome, Alport's 20 syndrome, Alstrom's syndrome, Cockayne's syndrome, dysplaisa spondyloepiphysaria congentia, Flynn-Aird syndrome, Friedreich ataxia, Hallgren syndrome, Marshall syndrome, Albers-Schnoberg disease, Refsum's disease, Keams-Sayre syndrome, Waardenburg's syndrome, Alagile syndrome, myotonic dystrophy, olivopontocerebellar atrophy, Pierre-Marie dunsdrome, Stickler syndrome, carotinemeia, cystinosis, Wolfram syndrome, 25 Bassen-Kornzweig syndrome, abetalipoproteinemia, incontinentia pigmenti, Batten's disease, mucopolysaccharidoses, homocystinuria, or mannosidosis. 39. The method of Claim 27, wherein the eye abnormality is a cataract. 40. The method of Claim 39, wherein the cataract is consistent with systemic diseases such as human Down's syndrome, Hallerman-Streiff syndrome, Lowe syndrome, galactosemia, 30 Marfan syndrome, Trismoy 13-15, Alport syndrome, myotonic dystrophy, Fabry disease, hypoparathroidism or Conradi syndrome. 38 WO 2008/127352 PCT/US2007/080102 41. The method of Claim 27, wherein the developmental abnormality comprises embryonic lethality or reduced viability. 42. The method of Claim 27, wherein the cardiovascular, endothelial or angiogenic disorders are arterial diseases, such as diabetes mellitus; papilledema; optic atrophy; atherosclerosis; angina; myocardial infarctions such as acute myocardial infarctions, cardiac 5 hypertrophy, and heart failure such as congestive heart failure; hypertension; inflammatory vasculitides; Reynaud's disease and Reynaud's phenomenon; aneurysms and arterial restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; peripheral vascular disease; cancer such as vascular tumors, e.g., hemangioma (capillary and cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, 10 angiosarcoma, haemangiopericytoma, Kaposi's sarcoma, lymphangioma, and lymphangiosarcoma; tumor angiogenesis; trauma such as wounds, burns, and other injured tissue, implant fixation, scarring; ischemia reperfusion injury; rheumatoid arthritis; cerebrovascular disease; renal diseases such as acute renal failure, or osteoporosis. 43. The method of Claim 27, wherein the immunological disorders are systemic lupus 15 erythematosis; rheumatoid arthritis; juvenile chronic arthritis; spondyloarthropathies; systemic sclerosis (scleroderma); idiopathic inflammatorymyopathies (dermatomyositis, polymyositis); Sj6gren's syndrome; systemic vasculitis; sarcoidosis; autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria); autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia); thyroiditis 20 (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis); diabetes mellitus; immune-mediated renal disease (glomerulonephritis, tubulointerstitial nephritis); demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barr6 syndrome, and chronic inflammatory demyelinating polyneuropathy; hepatobiliary diseases such as infectious 25 hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis; inflammatory bowel disease (ulcerative colitis: Crohn's disease); gluten-sensitive enteropathy, and Whipple's disease; autoimmune or immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis; allergic diseases such as 30 asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria; immunologic diseases of the lung such as eosinophilic pneumonia, idiopathic pulmonary fibrosis and 39 WO 2008/127352 PCT/US2007/080102 hypersensitivity pneumonitis; or transplantation-associated diseases including graft rejection and graft -versus-host disease. 44. The method of Claim 27, wherein said bone metabolic abnormality or disorder is arthritis, osteoporosis or osteopetrosis. 45. The method of Claim 26, wherein the non-human transgenic animal exhibits at least one 5 of the following physiological characteristics compared with gender matched wild-type littermates: a decreased anxiety-like response during open field activity testing; an abnormal habituation response to a novel environment (increased median ambulatory count during home-cage activity testing) during circadian testing; a decreased depressive-like response with decreased median immobility time during tail suspension testing; an increased blood glucose 10 level; impaired glucose tolerance; an increased trabecular bone volume and thickness; decreased percent total body fat mass and percent total body fat; a decreased skin fibroblast proliferation rate; and an increased systolic blood pressure. 46. An agent identified by the method of Claim 26. 47. The agent of Claim 46 which is an agonist or antagonist of a PRO 1105, PRO1279 or 15 PRO1783 polypeptide. 48. The agent of Claim 47, wherein the agonist is an anti-PRO 1105, anti-PRO1279 or anti PRO1783 antibody. 49. The agent of Claim 47, wherein the antagonist is an anti-PRO 1105, anti-PRO1279 or anti-PRO1783 antibody. 20 50. A method of identifying an agent that modulates a physiological characteristic associated with a disruption of the gene which encodes for a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption of the gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide; 25 (b) measuring a physiological characteristic exhibited by the non-human transgenic animal of (a); (c) comparing the measured physiological characteristic of (b) with that of a gender matched wild-type animal, wherein the physiological characteristic exhibited by the non-human transgenic animal that differs from the physiological characteristic exhibited by the wild-type 30 animal is identified as a physiological characteristic associated with gene disruption; (d) administering a test agent to the non-human transgenic animal of (a); and 40 WO 2008/127352 PCT/US2007/080102 (e) determining whether the physiological characteristic associated with gene disruption is modulated. 51. The method of Claim 50, wherein the non-human transgenic animal exhibits at least one of the following physiological characteristics compared with gender matched wild-type littermates: a decreased anxiety-like response during open field activity testing; an abnormal 5 habituation response to a novel environment (increased median ambulatory count during home-cage activity testing) during circadian testing; a decreased depressive-like response with decreased median immobility time during tail suspension testing; an increased blood glucose level; impaired glucose tolerance; an increased trabecular bone volume and thickness; decreased percent total body fat mass and percent total body fat; a decreased skin fibroblast 10 proliferation rate; and an increased systolic blood pressure. 52. An agent identified by the method of Claim 50. 53. The agent of Claim 52 which is an agonist or antagonist of a PRO 1105, PRO1279 or PRO1783 polypeptide. 54. The agent of Claim 53, wherein the agonist is an anti-PRO1105, anti-PRO1279 or anti 15 PRO1783 antibody. 55. The agent of Claim 53, wherein the antagonist is an anti-PRO 1105, anti-PRO1279 or anti-PRO1783 antibody. 56. A method of identifying an agent which modulates a behavior associated with a disruption of the gene which encodes for a PRO1 105, PRO1279 or PRO1783 polypeptide, the 20 method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption of the gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide; (b) observing the behavior exhibited by the non-human transgenic animal of (a); (c) comparing the observed behavior of (b) with that of a gender matched wild-type 25 animal, wherein the observed behavior exhibited by the non-human transgenic animal that differs from the observed behavior exhibited by the wild-type animal is identified as a behavior associated with gene disruption; (d) administering a test agent to the non-human transgenic animal of (a); and (e) determining whether the agent modulates the behavior associated with gene 30 disruption. 57. The method of Claim 56, wherein the behavior is an increased anxiety-like response 41 WO 2008/127352 PCT/US2007/080102 during open field activity testing. 58. The method of Claim 56, wherein the behavior is a decreased anxiety-like response during open field activity testing. 59. The method of Claim 56, wherein the behavior is an abnormal circadian rhythm during home-cage activity testing. 5 60. The method of Claim 56, wherein the behavior is an enhanced motor coordination during inverted screen testing. 61. The method of Claim 56, wherein the behavior is an impaired motor coordination during inverted screen testing. 62. The method of Claim 56, wherein the behavior is depression, generalized anxiety 10 disorders, attention deficit disorder, sleep disorder, hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia or sensory disorders. 63. An agent identified by the method of Claim 56. 64. The agent of Claim 63 which is an agonist or antagonist of a PRO 1105, PRO1279 or PRO1783 polypeptide. 15 65. The agent of Claim 64, wherein the agonist is an anti-PRO 1105, anti-PRO1279 or anti PRO1783 antibody. 66. The agent of Claim 64, wherein the antagonist is an anti-PRO 1105, anti-PRO1279 or anti-PRO1783 antibody. 67. A method of identifying an agent that ameliorates or modulates a neurological disorder; 20 a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality associated with a disruption in the gene which encodes for a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption 25 of the gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide; (b) administering a test agent to said non-human transgenic animal; and (c) determining whether said test agent ameliorates or modulates the neurological disorder; cardiovascular, endothelial or angiogenic disorder; eye abnormality; immunological disorder; oncological disorder; bone metabolic abnormality or disorder; lipid metabolic 30 disorder; or developmental abnormality in the non-human transgenic animal. 68. The method of Claim 67, wherein the neurological disorder is an increased anxiety-like 42 WO 2008/127352 PCT/US2007/080102 response during open field activity testing. 69. The method of Claim 67, wherein the neurological disorder is a decreased anxiety-like response during open field activity testing. 70. The method of Claim 67, wherein the neurological disorder is an abnormal circadian rhythm during home-cage activity testing. 5 71. The method of Claim 67, wherein the neurological disorder is an enhanced motor coordination during inverted screen testing. 72. The method of Claim 67, wherein the neurological disorder is an impaired motor coordination during inverted screen testing. 73. The method of Claim 67, wherein the neurological disorder is depression, generalized 10 anxiety disorders, attention deficit disorder, sleep disorder, hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia or sensory disorders. 74. The method of Claim 67, wherein the eye abnormality is a retinal abnormality. 75. The method of Claim 67, wherein the eye abnormality is consistent with vision problems or blindness. 15 76. The method of Claim 74, wherein the retinal abnormality is consistent with retinitis pigmentosa. 77. The method of Claim 74, wherein the retinal abnormality is characterized by retinal degeneration or retinal dysplasia. 78. The method of Claim 74, wherein the retinal abnormality is consistent with retinal 20 dysplasia, various retinopathies, including retinopathy of prematurity, retrolental fibroplasia, neovascular glaucoma, age-related macular degeneration, diabetic macular edema, comeal neovascularization, corneal graft neovascularization, comeal graft rejection, retinal/choroidal neovascularization, neovascularization of the angle (rubeosis), ocular neovascular disease, vascular restenosis, arteriovenous malformations (AVM), meningioma, hemangioma, 25 angiofibroma, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, retinal artery obstruction or occlusion; retinal degeneration causing secondary atrophy of the retinal vasculature, retinitis pigmentosa, macular dystrophies, Stargardt's disease, congenital stationary night blindness, choroideremia, gyrate atrophy, Leber's congenital amaurosis, retinoschisis disorders, Wagner's syndrome, Usher syndromes, Zellweger syndrome, 30 Saldino-Mainzer syndrome, Senior-Loken syndrome, Bardet-Biedl syndrome, Alport's syndrome, Alstrom's syndrome, Cockayne's syndrome, dysplaisa spondyloepiphysaria 43 WO 2008/127352 PCT/US2007/080102 congentia, Flynn-Aird syndrome, Friedreich ataxia, Hallgren syndrome, Marshall syndrome, Albers-Schnoberg disease, Refsum's disease, Kearns-Sayre syndrome, Waardenburg's syndrome, Alagile syndrome, myotonic dystrophy, olivopontocerebellar atrophy, Pierre-Marie dunsdrome, Stickler syndrome, carotinemeia, cystinosis, Wolfram syndrome, Bassen-Kornzweig syndrome, abetalipoproteinemia, incontinentia pigmenti, Batten's disease, 5 mucopolysaccharidoses, homocystinuria, or mannosidosis. 79. The method of Claim 67, wherein the eye abnormality is a cataract. 80. The method of Claim 79, wherein the cataract is a systemic disease such as human Down's syndrome, Hallerman-Streiff syndrome, Lowe syndrome, galactosemia, Marfan syndrome, Trismoy 13-15, Alport syndrome, myotonic dystrophy, Fabry disease, 10 hypoparathroidism or Conradi syndrome. 81. The method of Claim 67, wherein the developmental abnormality comprises embryonic lethality or reduced viability. 82. The method of Claim 67, wherein the cardiovascular, endothelial or angiogenic disorders are arterial diseases, such as diabetes mellitus; papilledema; optic atrophy; 15 atherosclerosis; angina; myocardial infarctions such as acute myocardial infarctions, cardiac hypertrophy, and heart failure such as congestive heart failure; hypertension; inflammatory vasculitides; Reynaud's disease and Reynaud's phenomenon; aneurysms and arterial restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; peripheral vascular disease; cancer such as vascular tumors, e.g., hemangioma (capillary and 20 cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma, Kaposi's sarcoma, lymphangioma, and lymphangiosarcoma; tumor angiogenesis; trauma such as wounds, burns, and other injured tissue, implant fixation, scarring; ischemia reperfusion injury; rheumatoid arthritis; cerebrovascular disease; renal diseases such as acute renal failure, or osteoporosis. 25 83. The method of Claim 67, wherein the immunological disorders are systemic lupus erythematosis; rheumatoid arthritis; juvenile chronic arthritis; spondyloarthropathies; systemic sclerosis (scleroderma); idiopathic inflammatory myopathies (dermatomyositis, polymyositis); Sj6gren's syndrome; systemic vasculitis; sarcoidosis; autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria); autoimmune thrombocytopenia 30 (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia); thyroiditis (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis); 44 WO 2008/127352 PCT/US2007/080102 diabetes mellitus; immune-mediated renal disease (glomerulonephritis, tubulointerstitial nephritis); demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barr6 syndrome, and chronic inflammatory demyelinating polyneuropathy; hepatobiliary diseases such as infectious hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune chronic 5 active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis; inflammatory bowel disease (ulcerative colitis: Crohn's disease); gluten-sensitive enteropathy, and Whipple's disease; autoimmune or immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis; allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria; immunologic 10 diseases of the lung such as eosinophilic pneumonia, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis; or transplantation associated diseases including graft rejection and graft -versus-host disease. 84. The method of Claim 67, wherein said bone metabolic abnormality or disorder is arthritis, osteoporosis or osteopetrosis. 15 85. The method of Claim 67, wherein the non-human transgenic animal exhibits at least one of the following physiological characteristics compared with gender matched wild-type littermates: a decreased anxiety-like response during open field activity testing; an abnormal habituation response to a novel environment (increased median ambulatory count during home-cage activity testing) during circadian testing; a decreased depressive-like response with 20 decreased median immobility time during tail suspension testing; an increased blood glucose level; impaired glucose tolerance; an increased trabecular bone volume and thickness; decreased percent total body fat mass and percent total body fat; a decreased skin fibroblast proliferation rate; and an increased systolic blood pressure. 86. An agent identified by the method of Claim 67. 25 87. The agent of Claim 86 which is an agonist or antagonist of a PRO 1105, PRO1279 or PRO1783 polypeptide. 88. The agent of Claim 87, wherein the agonist is an anti-PRO 1105, anti-PRO1279 or anti PRO1783 antibody. 89. The agent of Claim 87, wherein the antagonist is an anti-PRO 1105, anti-PRO1279 or 30 anti-PRO1783 antibody. 90. A therapeutic agent identified by the method of Claim 67. 45 WO 2008/127352 PCT/US2007/080102 91. A method of identifying an agent that modulates the expression of a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the method comprising: (a) contacting a test agent with a host cell expressing a PRO 1105, PRO 1279 or PRO1783 polypeptide; and (b) determining whether the test agent modulates the expression of the PRO1 105, 5 PRO 1279 or PRO 1783 polypeptide by the host cell. 92. An agent identified by the method of Claim 91. 93. The agent of Claim 92 which is an agonist or antagonist of a PRO 1105, PRO1279 or PRO1783 polypeptide. 94. The agent of Claim 93, wherein the agonist is an anti-PRO 1105, anti-PRO1279 or anti 10 PRO1783 antibody. 95. The agent of Claim 93, wherein the antagonist is an anti-PRO 1105, anti-PRO 1279 or anti-PRO1783 antibody. 96. A method of evaluating a therapeutic agent capable of affecting a condition associated with a disruption of a gene which encodes for a PRO 1105, PRO 1279 or PRO 1783 polypeptide, 15 the method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption of the gene which encodes for the PRO 1105, PRO1279 or PRO1783 polypeptide; (b) measuring a physiological characteristic ofthe non-human transgenic animal of(a); (c) comparing the measured physiological characteristic of (b) with that of a gender 20 matched wild-type animal, wherein the physiological characteristic ofthe non-human transgenic animal that differs from the physiological characteristic of the wild-type animal is identified as a condition resulting from the gene disruption in the non-human transgenic animal; (d) administering a test agent to the non-human transgenic animal of (a); and (e) evaluating the effects of the test agent on the identified condition associated with 25 gene disruption in the non-human transgenic animal. 97. The method of Claim 96, wherein the condition is a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality. 30 98. A therapeutic agent identified by the method of Claim 96. 99. The therapeutic agent of Claim 98 which is an agonist or antagonist of a PRO 1105, 46 WO 2008/127352 PCT/US2007/080102 PRO 1279 or PRO 1783 polypeptide. 100. The therapeutic agent of Claim 99, wherein the agonist is an anti-PRO1 105, anti PRO 1279 or anti-PRO1783 antibody. 101. The therapeutic agent of Claim 99, wherein the antagonist is an anti-PRO 1105, anti PRO 1279 or anti-PRO1783 antibody. 5 102. A pharmaceutical composition comprising the therapeutic agent of Claim 98. 103. A method of treating or preventing or ameliorating a neurological disorder; cardiovascular, endothelial or angiogenic disorder; immunological disorder; oncological disorder; bone metabolic abnormality or disorder, or embryonic lethality associated with the disruption of a gene which encodes for a PRO1105, PRO1279 or PRO1783 polypeptide, the 10 method comprising administering to a subject in need of such treatment whom may already have the disorder, or may be prone to have the disorder or may be in whom the disorder is to be prevented, a therapeutically effective amount of the therapeutic agent of Claim 98, or agonists or antagonists thereof, thereby effectively treating or preventing or ameliorating said disorder. 15 104. The method of Claim 103, wherein the neurological disorder is an increased anxiety like response during open field activity testing. 105. The method of Claim 103, wherein the neurological disorder is a decreased anxiety-like response during open field activity testing. 106. The method of Claim 103, wherein the neurological disorder is an abnormal circadian 20 rhythm during home-cage activity testing. 107. The method of Claim 103, wherein the neurological disorder is an enhanced motor coordination during inverted screen testing. 108. The method of Claim 103, wherein the neurological disorder is an impaired motor coordination during inverted screen testing. 25 109. The method of Claim 103, wherein the neurological disorder is depression, generalized anxiety disorders, attention deficit disorder, sleep disorder, hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia or sensory disorders. 110. The method of Claim 103, wherein the eye abnormality is a retinal abnormality. 111. The method of Claim 103, wherein the eye abnormality is consistent with vision 30 problems or blindness. 112. The method of Claim 110, wherein the retinal abnormality is consistent with retinitis 47 WO 2008/127352 PCT/US2007/080102 pigmentosa. 113. The method of Claim 110, wherein the retinal abnormality is characterized by retinal degeneration or retinal dysplasia. 114. The method of Claim 110, wherein the retinal abnormality is consistent with retinal dysplasia, various retinopathies, including retinopathy of prematurity, retrolental fibroplasia, 5 neovascular glaucoma, age-related macular degeneration, diabetic macular edema, comeal neovascularization, comeal graft neovascularization, comeal graft rejection, retinal/choroidal neovascularization, neovascularization of the angle (rubeosis), ocular neovascular disease, vascular restenosis, arteriovenous malformations (AVM), meningioma, hemangioma, angiofibroma, thyroid hyperplasias (including Grave's disease), corneal and other tissue 10 transplantation, retinal artery obstruction or occlusion; retinal degeneration causing secondary atrophy of the retinal vasculature, retinitis pigmentosa, macular dystrophies, Stargardt's disease, congenital stationarynight blindness, choroideremia, gyrate atrophy, Leber's congenital amaurosis, retinoschisis disorders, Wagner's syndrome, Usher syndromes, Zellweger syndrome, Saldino-Mainzer syndrome, Senior-Loken syndrome, Bardet-Biedl syndrome, Alport's 15 syndrome, Alstrom's syndrome, Cockayne's syndrome, dysplaisa spondyloepiphysaria congentia, Flynn-Aird syndrome, Friedreich ataxia, Hallgren syndrome, Marshall syndrome, Albers-Schnoberg disease, Refsum's disease, Kearns-Sayre syndrome, Waardenburg's syndrome, Alagile syndrome, myotonic dystrophy, olivopontocerebellar atrophy, Pierre-Marie dunsdrome, Stickler syndrome, carotinemeia, cystinosis, Wolfram syndrome, 20 Bassen-Kornzweig syndrome, abetalipoproteinemia, incontinentia pigmenti, Batten's disease, mucopolysaccharidoses, homocystinuria, or mannosidosis. 115. The method of Claim 103, wherein the eye abnormality is a cataract. 116. The method of Claim 115, wherein the cataract is a systemic disease such as human Down's syndrome, Hallerman-Streiff syndrome, Lowe syndrome, galactosemia, Marfan 25 syndrome, Trismoy 13-15, Alport syndrome, myotonic dystrophy, Fabry disease, hypoparathroidism or Conradi syndrome. 117. The method of Claim 103, wherein the developmental abnormality comprises embryonic lethality or reduced viability. 118. The method of Claim 103, wherein the cardiovascular, endothelial or angiogenic 30 disorders are arterial diseases, such as diabetes mellitus; papilledema; optic atrophy; atherosclerosis; angina; myocardial infarctions such as acute myocardial infarctions, cardiac 48 WO 2008/127352 PCT/US2007/080102 hypertrophy, and heart failure such as congestive heart failure; hypertension; inflammatory vasculitides; Reynaud's disease and Reynaud's phenomenon; aneurysms and arterial restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; peripheral vascular disease; cancer such as vascular tumors, e.g., hemangioma (capillary and cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, 5 angiosarcoma, haemangiopericytoma, Kaposi's sarcoma, lymphangioma, and lymphangiosarcoma; tumor angiogenesis; trauma such as wounds, burns, and other injured tissue, implant fixation, scarring; ischemia reperfusion injury; rheumatoid arthritis; cerebrovascular disease; renal diseases such as acute renal failure, or osteoporosis. 119. The method of Claim 103, wherein the immunological disorders are systemic lupus 10 erythematosis; rheumatoid arthritis; juvenile chronic arthritis; spondyloarthropathies; systemic sclerosis (scleroderma); idiopathic inflammatory myopathies (dermatomyositis, polymyositis); Sj6gren's syndrome; systemic vasculitis; sarcoidosis; autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria); autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia); thyroiditis 15 (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis); diabetes mellitus; immune-mediated renal disease (glomerulonephritis, tubulointerstitial nephritis); demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barr6 syndrome, and chronic inflammatory demyelinating polyneuropathy; hepatobiliary diseases such as infectious 20 hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis; inflammatory bowel disease (ulcerative colitis: Crohn's disease); gluten-sensitive enteropathy, and Whipple's disease; autoimmune or immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis; allergic diseases such as 25 asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria; immunologic diseases of the lung such as eosinophilic pneumonia, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis; or transplantation associated diseases including graft rejection and graft -versus-host disease. 120. The method of Claim 103, wherein said bone metabolic abnormality or disorder is 30 arthritis, osteoporosis or osteopetrosis. 121. A method of identifying an agent that ameliorates or modulates a neurological disorder; 49 WO 2008/127352 PCT/US2007/080102 a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality associated with a disruption in the gene which encodes for a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the method comprising: (a) providing a non-human transgenic animal cell culture, each cell of said culture 5 comprising a disruption of the gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide; (b) administering a test agent to said cell culture; and (c) determining whether said test agent ameliorates or modulates the neurological disorder; cardiovascular, endothelial or angiogenic disorder; eye abnormality; immunological 10 disorder; oncological disorder; bone metabolic abnormality or disorder; lipid metabolic disorder; or developmental abnormality in said cell culture. 122. The method of Claim 121, wherein the neurological disorder is an increased anxiety like response during open field activity testing. 123. The method of Claim 121, wherein the neurological disorder is a decreased anxiety-like 15 response during open field activity testing. 124. The method of Claim 121, wherein the neurological disorder is an abnormal circadian rhythm during home-cage activity testing. 125. The method of Claim 121, wherein the neurological disorder is an enhanced motor coordination during inverted screen testing. 20 126. The method of Claim 121, wherein the neurological disorder is an impaired motor coordination during inverted screen testing. 127. The method of Claim 121, wherein the neurological disorder is depression, generalized anxiety disorders, attention deficit disorder, sleep disorder, hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia or sensory disorders. 25 128. The method of Claim 121, wherein the eye abnormality is a retinal abnormality. 129. The method of Claim 121, wherein the eye abnormality is consistent with vision problems or blindness. 130. The method of Claim 128, wherein the retinal abnormality is consistent with retinitis pigmentosa. 30 131. The method of Claim 128, wherein the retinal abnormality is characterized by retinal degeneration or retinal dysplasia. 50 WO 2008/127352 PCT/US2007/080102 132. The method of Claim 128, wherein the retinal abnormality is consistent with retinal dysplasia, various retinopathies, including retinopathy of prematurity, retrolental fibroplasia, neovascular glaucoma, age-related macular degeneration, diabetic macular edema, comeal neovascularization, comeal graft neovascularization, comeal graft rejection, retinal/choroidal neovascularization, neovascularization of the angle (rubeosis), ocular neovascular disease, 5 vascular restenosis, arteriovenous malformations (AVM), meningioma, hemangioma, angiofibroma, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, retinal artery obstruction or occlusion; retinal degeneration causing secondary atrophy of the retinal vasculature, retinitis pigmentosa, macular dystrophies, Stargardt's disease, congenital stationary night blindness, choroideremia, gyrate atrophy, Leber's congenital 10 amaurosis, retinoschisis disorders, Wagner's syndrome, Usher syndromes, Zellweger syndrome, Saldino-Mainzer syndrome, Senior-Loken syndrome, Bardet-Biedl syndrome, Alport's syndrome, Alstrom's syndrome, Cockayne's syndrome, dysplaisa spondyloepiphysaria congentia, Flynn-Aird syndrome, Friedreich ataxia, Hallgren syndrome, Marshall syndrome, Albers-Schnoberg disease, Refsum's disease, Keams-Sayre syndrome, Waardenburg's 15 syndrome, Alagile syndrome, myotonic dystrophy, olivopontocerebellar atrophy, Pierre-Marie dunsdrome, Stickler syndrome, carotinemeia, cystinosis, Wolfram syndrome, Bassen-Kornzweig syndrome, abetalipoproteinemia, incontinentia pigmenti, Batten's disease, mucopolysaccharidoses, homocystinuria, or mannosidosis. 133. The method of Claim 121, wherein the eye abnormality is a cataract. 20 134. The method of Claim 133, wherein the cataract is a systemic disease such as human Down's syndrome, Hallerman-Streiff syndrome, Lowe syndrome, galactosemia, Marfan syndrome, Trismoy 13-15, Alport syndrome, myotonic dystrophy, Fabry disease, hypoparathroidism or Conradi syndrome. 135. The method of Claim 121, wherein the developmental abnormality comprises 25 embryonic lethality or reduced viability. 136. The method of Claim 121, wherein the cardiovascular, endothelial or angiogenic disorders are arterial diseases, such as diabetes mellitus; papilledema; optic atrophy; atherosclerosis; angina; myocardial infarctions such as acute myocardial infarctions, cardiac hypertrophy, and heart failure such as congestive heart failure; hypertension; inflammatory 30 vasculitides; Reynaud's disease and Reynaud's phenomenon; aneurysms and arterial restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; 51 WO 2008/127352 PCT/US2007/080102 peripheral vascular disease; cancer such as vascular tumors, e.g., hemangioma (capillary and cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma, Kaposi's sarcoma, lymphangioma, and lymphangiosarcoma; tumor angiogenesis; trauma such as wounds, burns, and other injured tissue, implant fixation, scarring; ischemia reperfusion injury; rheumatoid arthritis; 5 cerebrovascular disease; renal diseases such as acute renal failure, or osteoporosis. 137. The method of Claim 121, wherein the immunological disorders are systemic lupus erythematosis; rheumatoid arthritis; juvenile chronic arthritis; spondyloarthropathies; systemic sclerosis (scleroderma); idiopathic inflammatory myopathies (dermatomyositis, polymyositis); Sj6gren's syndrome; systemic vasculitis; sarcoidosis; autoimmune hemolytic anemia (immune 10 pancytopenia, paroxysmal nocturnal hemoglobinuria); autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia); thyroiditis (Grave's disease, Hashimoto's thyroiditis,juvenile lymphocytic thyroiditis, atrophic thyroiditis); diabetes mellitus; immune-mediated renal disease (glomerulonephritis, tubulointerstitial nephritis); demyelinating diseases of the central and peripheral nervous systems such as 15 multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barr6 syndrome, and chronic inflammatory demyelinating polyneuropathy; hepatobiliary diseases such as infectious hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis; inflammatory bowel disease (ulcerative colitis: Crohn's disease); gluten-sensitive enteropathy, 20 and Whipple's disease; autoimmune or immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis; allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria; immunologic diseases of the lung such as eosinophilic pneumonia, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis; or transplantation associated diseases including graft rejection 25 and graft -versus-host disease. 138. The method of Claim 121, wherein said bone metabolic abnormality or disorder is arthritis, osteoporosis or osteopetrosis. 139. An agent identified by the method of Claim 121. 140. The agent of Claim 139 which is an agonist or antagonist of a PRO 1105, PRO1279 or 30 PRO1783 polypeptide. 141. The agent of Claim 140, wherein the agonist is an anti-PRO 1105, anti-PRO1279 or 52 WO 2008/127352 PCT/US2007/080102 anti-PRO1783 antibody. 142. The agent of Claim 140, wherein the antagonist is an anti-PRO 1105, anti-PRO1279 or anti-PRO1783 antibody. 143. A therapeutic agent identified by the method of Claim 121. 144. A method of modulating a phenotype associated with a disruption of a gene which 5 encodes for a PRO1105, PRO1279 or PRO1783 polypeptide, the method comprising administering to a subject whom may already have the phenotype, or maybe prone to have the phenotype or may be in whom the phenotype is to be prevented, an effective amount of the agent of Claim 46, or agonists or antagonists thereof, thereby effectively modulating the phenotype. 10 145. A method of modulating a physiological characteristic associated with a disruption of a gene which encodes for a PRO1105, PRO1279 or PRO1783 polypeptide, the method comprising administering to a subject whom may already exhibit the physiological characteristic, or may be prone to exhibit the physiological characteristic or may be in whom the physiological characteristic is to be prevented, an effective amount of the agent of Claim 15 52, or agonists or antagonists thereof, thereby effectively modulating the physiological characteristic. 146. A method of modulating a behavior associated with a disruption of a gene which encodes for a PRO1105, PRO1279 or PRO1783 polypeptide, the method comprising administering to a subject whom may already exhibit the behavior, or may be prone to exhibit 20 the behavior or maybe in whom the exhibited behavior is to be prevented, an effective amount of the agent of Claim 63, or agonists or antagonists thereof, thereby effectively modulating the behavior. 147. A method of modulating the expression of a PRO1 105, PRO1279 or PRO1783 polypeptide, the method comprising administering to a host cell expressing said PRO 1105, 25 PRO 1279 or PRO 1783 polypeptide, an effective amount of the agent of Claim 92, or agonists or antagonists thereof, thereby effectively modulating the expression of said polypeptide. 148. A method of modulating a condition associated with a disruption of a gene which encodes for a PRO1105, PRO1279 or PRO1783 polypeptide, the method comprising administering to a subject whom may have the condition, or may be prone to have the condition 30 or may be in whom the condition is to be prevented, a therapeutically effective amount of the therapeutic agent of Claim 98, or agonists or antagonists thereof, thereby effectively modulating 53 WO 2008/127352 PCT/US2007/080102 the condition. 149. A method of treating or preventing or ameliorating a neurological disorder; cardiovascular, endothelial or angiogenic disorder; immunological disorder; oncological disorder; bone metabolic abnormality or disorder, or embryonic lethality associated with the disruption of a gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide, the 5 method comprising administering to a non-human transgenic animal cell culture, each cell of said culture comprising a disruption of the gene which encodes for a PRO 1105, PRO1279 or PRO 1783 polypeptide, a therapeutically effective amount ofthe agent of Claim 139, or agonists or antagonists thereof, thereby effectively treating or preventing or ameliorating said disorder. 150. A method of identifying an agent that ameliorates or modulates a neurological disorder; 10 a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality associated with a disruption in the gene which encodes for a PRO1105, PRO1279 or PRO1783 polypeptide, the method comprising administering to a subject whom may have the neurological disorder; cardiovascular, 15 endothelial or angiogenic disorder; eye abnormality; immunological disorder; oncological disorder; bone metabolic abnormality or disorder; lipid metabolic disorder; or developmental abnormality, a therapeutic agent of Claim 90, or agonists or antagonists thereof, thereby ameliorating or modulating the disorder. 20 BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows a nucleotide sequence (SEQ ID NO:1) of a native sequence PRO 1105 cDNA, wherein SEQ ID NO:1 is a clone designated herein as "DNA59612-1466" (UNQ548). Figure 2 shows the amino acid sequence (SEQ ID NO:2) derived from the coding sequence of SEQ ID NO:1 shown in Figure 1. 25 Figure 3 shows a nucleotide sequence (SEQ ID NO:3) of a native sequence PRO1279 cDNA, wherein SEQ ID NO:3 is a clone designated herein as "DNA65405-1547" (UNQ649). Figure 4 shows the amino acid sequence (SEQ ID NO:4) derived from the coding sequence of SEQ ID NO:3 shown in Figure 3. Figure 5 shows a nucleotide sequence (SEQ ID NO:5) of a native sequence PRO1783 30 cDNA, wherein SEQ ID NO:5 is a clone designated herein as "DNA71182" (UNQ845). Figure 6 shows the amino acid sequence (SEQ ID NO:6) derived from the coding 54 WO 2008/127352 PCT/US2007/080102 sequence of SEQ ID NO:5 shown in Figure 5. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS I. Definitions The terms "PRO polypeptide" and "PRO" as used herein and when immediately 5 followed by a numerical designation refer to various polypeptides, wherein the complete designation (i.e., PRO/number) refers to specific polypeptide sequences as described herein. The terms "PRO/number polypeptide" and "PRO/number" wherein the term "number" is provided as an actual numerical designation as used herein encompass native sequence polypeptides and polypeptide variants (which are further defined herein). The PRO 1105, 10 PRO1279 or PRO1783 polypeptides described herein may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods. The term "PRO polypeptide" refers to each individual PRO/number polypeptide disclosed herein. All disclosures in this specification which refer to the "PRO polypeptide" refer to each of the polypeptides individually as well as jointly. For example, 15 descriptions of the preparation of, purification of, derivation of, formation of antibodies to or against, administration of, compositions containing, treatment of a disease with, etc., pertain to each polypeptide of the invention individually. The term "PRO polypeptide" also includes variants of the PRO/number polypeptides disclosed herein. A "native sequence PRO1105, PRO1279 or PRO1783 polypeptide" comprises a 20 polypeptide having the same amino acid sequence as the corresponding PRO 1105, PRO 1279 or PRO1783 polypeptide derived from nature. Such native sequence PRO 1105, PRO1279 or PRO 1783 polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native sequence PRO 1105, PRO 1279 or PRO 1783 polypeptide" specifically encompasses naturally-occurring truncated or secreted forms of the specific 25 PRO1105, PRO1279 or PRO1783 polypeptide (e.g., an extracellular domain sequence), naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants of the polypeptide. The invention provides native sequence PRO 1105, PRO1279 or PRO1783 polypeptides disclosed herein which are mature or full-length native sequence polypeptides comprising the full-length amino acids sequences shown in the 30 accompanying figures. Start and stop codons are shown in bold font and underlined in the figures. However, while the PRO 1105, PRO 1279 or PRO 1783 polypeptide disclosed in the 55 WO 2008/127352 PCT/US2007/080102 accompanying figures are shown to begin with methionine residues designated herein as amino acid position 1 in the figures, it is conceivable and possible that other methionine residues located either upstream or downstream from the amino acid position 1 in the figures may be employed as the starting amino acid residue for the PRO1105, PRO1279 or PRO1783 polypeptides. 5 The PRO 1105, PRO 1279 or PRO 1783 polypeptide "extracellular domain" or "ECD" refers to a form of the PRO 1105, PRO 1279 or PRO 1783 polypeptide which is essentially free of the transmembrane and cytoplasmic domains. Ordinarily, a PRO1105, PRO1279 or PRO 1783 polypeptide ECD will have less than 1% of such transmembrane and/or cytoplasmic domains and preferably, will have less than 0.5% of such domains. It will be understood that 10 any transmembrane domains identified for the PRO 1105, PRO1279 or PRO1783 polypeptides of the present invention are identified pursuant to criteria routinely employed in the art for identifying that type of hydrophobic domain. The exact boundaries of a transmembrane domain may vary but most likely by no more than about 5 amino acids at either end of the domain as initially identified herein. Optionally, therefore, an extracellular domain of a PRO 1105, 15 PRO 1279 or PRO 1783 polypeptide may contain from about 5 or fewer amino acids on either side ofthe transmembrane domain/extracellular domain boundary as identified in the Examples or specification and such polypeptides, with or without the associated signal peptide, and nucleic acid encoding them, are contemplated by the present invention. The approximate location of the "signal peptides" of the various PRO 1105, PRO 1279 20 or PRO 1783 polypeptides disclosed herein are shown in the present specification and/or the accompanying figures. It is noted, however, that the C-terminal boundary of a signal peptide may vary, but most likely by no more than about 5 amino acids on either side of the signal peptide C-terminal boundary as initially identified herein, wherein the C-terminal boundary of the signal peptide may be identified pursuant to criteria routinely employed in the art for 25 identifying that type of amino acid sequence element (e.g., Nielsen et al., Prot. Eng. 10:1-6 (1997) and von Heinje et al., Nucl. Acids. Res. 14:4683-4690 (1986)). Moreover, it is also recognized that, in some cases, cleavage of a signal sequence from a secreted polypeptide is not entirely uniform, resulting in more than one secreted species. These mature polypeptides, where the signal peptide is cleaved within no more than about 5 amino acids on either side of 30 the C-terminal boundary of the signal peptide as identified herein, and the polynucleotides encoding them, are contemplated by the present invention. 56 WO 2008/127352 PCT/US2007/080102 "PRO 1105, PRO1279 or PRO1783 polypeptide variant" means a PRO 1105, PRO1279 or PRO 1783 polypeptide, preferably an active PRO 1105, PRO 1279 or PRO 1783 polypeptide, as defined herein having at least about 80% amino acid sequence identity with a full-length native sequence PRO 1105, PRO 1279 or PRO 1783 polypeptide sequence as disclosed herein, a PRO1105, PRO1279 or PRO1783 polypeptide sequence lacking the signal peptide as 5 disclosed herein, an extracellular domain of a PRO 1105, PRO 1279 or PRO 1783 polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO 1105, PRO1279 or PRO1783 polypeptide sequence as disclosed herein (such as those encoded by a nucleic acid that represents only a portion of the complete coding sequence for a full-length PRO 1105, PRO1279 or PRO1783 polypeptide). Such PRO1105, PRO1279 or 10 PRO1783 polypeptide variants include, for instance, PRO1105, PRO1279 or PRO1783 polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C terminus of the full-length native amino acid sequence. Ordinarily, a PRO 1105, PRO 1279 or PRO 1783 polypeptide variant will have or will have at least about 80% amino acid sequence identity, alternatively will have or will have at least about 81%, 82%, 83%, 84%, 85%, 86%, 15 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity, to a full-length native sequence PRO1105, PRO1279 or PRO1783 polypeptide sequence as disclosed herein, a PRO 1105, PRO 1279 or PRO 1783 polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO 1105, PRO 1279 or PRO 1783 polypeptide, with or without the signal peptide, as disclosed herein or 20 any other specifically defined fragment of a full-length PRO 1105, PRO 1279 or PRO 1783 polypeptide sequence as disclosed herein. Ordinarily, PRO 1105, PRO 1279 or PRO 1783 variant polypeptides are or are at least about 10 amino acids in length, alternatively are or are at least about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200,210,220,230,240,250,260,270,280,290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 25 390, 400,410,420,430,440,450,460,470,480,490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600 amino acids in length, or more. Optionally, PRO 1105, PRO1279 or PRO1783 variant polypeptides will have no more than one conservative amino acid substitution as compared to the native PRO 1105, PRO 1279 or PRO 1783 polypeptide sequence, alternatively will have or will have no more than 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative amino acid 30 substitution as compared to the native PRO 1105, PRO 1279 or PRO 1783 polypeptide sequence. "Percent (%) amino acid sequence identity" with respect to the PRO 1105, PRO 1279 or 57 WO 2008/127352 PCT/US2007/080102 PRO 1783 polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific PRO 1105, PRO 1279 or PRO 1783 polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for 5 purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For 10 purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 15 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN 2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary. 20 In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 25 100 times the fraction X/Y where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total 30 number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence 58 WO 2008/127352 PCT/US2007/080102 identity of A to B will not equal the % amino acid sequence identity of B to A. As examples of % amino acid sequence identity calculations using this method, Tables 2 and 3 demonstrate how to calculate the % amino acid sequence identity of the amino acid sequence designated "Comparison Protein" to the amino acid sequence designated "PRO", wherein "PRO" represents the amino acid sequence of a hypothetical PRO polypeptide of interest, "Comparison 5 Protein" represents the amino acid sequence of a polypeptide against which the "PRO" polypeptide of interest is being compared, and "X, "Y" and "Z" each represent different hypothetical amino acid residues. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program. 10 "PRO 1105, PRO1279 or PRO1783 variant polynucleotide" or "PRO 1105, PRO1279 or PRO 1783 variant nucleic acid sequence" means a nucleic acid molecule which encodes a PRO 1105, PRO1279 or PRO1783 polypeptide, preferably an active PRO 1105, PRO1279 or PRO1783 polypeptide, as defined herein and which has at least about 80% nucleic acid sequence identity with a nucleotide acid sequence encoding a full-length native sequence 15 PRO 1105, PRO 1279 or PRO 1783 polypeptide sequence as disclosed herein, a full-length native sequence PRO 1105, PRO 1279 or PRO 1783 polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO 1105, PRO 1279 or PRO 1783 polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO 1105, PRO 1279 or PRO 1783 polypeptide sequence as disclosed herein (such as those 20 encoded by a nucleic acid that represents only a portion of the complete coding sequence for a full-length PRO1105, PRO1279 or PRO1783 polypeptide). Ordinarily, a PRO1105, PRO 1279 or PRO 1783 variant polynucleotide will have or will have at least about 80%nucleic acid sequence identity, alternatively will have or will have at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 9 3 %, 94%, 95%, 96%, 97%, 98%, or 99% 25 nucleic acid sequence identity with a nucleic acid sequence encoding a full-length native sequence PRO 1105, PRO 1279 or PRO 1783 polypeptide sequence as disclosed herein, a full length native sequence PRO 1105, PRO1279 or PRO1783 polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO1105, PRO1279 or PRO 1783 polypeptide, with or without the signal sequence, as disclosed herein or any other 30 fragment of a full-length PRO 1105, PRO 1279 or PRO 1783 polypeptide sequence as disclosed herein. Variants do not encompass the native nucleotide sequence. 59 WO 2008/127352 PCT/US2007/080102 Ordinarily, PRO 1105, PRO 1279 or PRO 1783 variant polynucleotides are or are at least about 5 nucleotides in length, alternatively are or are at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,35,40,45,50,55,60,65,70,75, 80,85,90,95,100,105,110,115,120,125,130,135,140,145,150,155,160,165,170,175, 180,185,190,195,200,210,220,230,240,250,260,270,280,290,300,310,320,330,340, 5 350,360,370,380,390,400,410,420,430,440,450,460,470,480,490,500,510,520,530, 540,550,560,570,580,590,600,610,620,630,640,650,660,670,680,690,700,710,720, 730,740,750,760,770,780,790,800,810,820,830,840,850,860,870,880,890,900,910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 nucleotides in length, wherein in this context the term "about" means the referenced nucleotide sequence length plus or minus 10% of that 10 referenced length. "Percent (%) nucleic acid sequence identity" with respect to PRO 1105-, PRO1279- or PRO 1783-encoding nucleic acid sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the PRO 1105, PRO1279 or PRO1783 nucleic acid sequence of interest, after aligning the sequences and 15 introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. For purposes herein, however, % nucleic acid sequence identity values are generated using the sequence comparison 20 computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is 25 publicly available through Genentech, Inc., South San Francisco, California or maybe compiled from the source code provided in Table 1 below. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary. In situations where ALIGN-2 is employed for nucleic acid sequence comparisons, the 30 % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence 60 WO 2008/127352 PCT/US2007/080102 C that has or comprises a certain % nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows: 100 times the fraction W/Z 5 where W is the number of nucleotides scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C. As examples of % nucleic acid 10 sequence identity calculations, Tables 4 and 5, demonstrate how to calculate the % nucleic acid sequence identity of the nucleic acid sequence designated "Comparison DNA" to the nucleic acid sequence designated "PRO-DNA", wherein "PRO-DNA" represents a hypothetical PRO encoding nucleic acid sequence of interest, "Comparison DNA" represents the nucleotide sequence of a nucleic acid molecule against which the "PRO-DNA" nucleic acid molecule of 15 interest is being compared, and "N", "L" and "V" each represent different hypothetical nucleotides. Unless specifically stated otherwise, all % nucleic acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program. The invention also provides PRO 1105, PRO 1279 or PRO 1783 variant polynucleotides 20 which are nucleic acid molecules that encode a PRO 1105, PRO 1279 or PRO 1783 polypeptide and which are capable of hybridizing, preferably under stringent hybridization and wash conditions, to nucleotide sequences encoding a full-length PRO 1105, PRO 1279 or PRO 1783 polypeptide as disclosed herein. PRO1 105, PRO1279 or PRO1783 variant polypeptides may be those that are encoded by a PRO 1105, PRO 1279 or PRO 1783 variant polynucleotide. 25 The term "full-length coding region" when used in reference to a nucleic acid encoding a PRO 1105, PRO1279 or PRO1783 polypeptide refers to the sequence of nucleotides which encode the full-length PRO 1105, PRO 1279 or PRO 1783 polypeptide of the invention (which is often shown between start and stop codons, inclusive thereof, in the accompanying figures). The term "full-length coding region" when used in reference to an ATCC deposited nucleic acid 30 refers to the PRO 1105, PRO1279 or PRO1783 polypeptide-encoding portion ofthe cDNA that is inserted into the vector deposited with the ATCC (which is often shown between start and 61 WO 2008/127352 PCT/US2007/080102 stop codons, inclusive thereof, in the accompanying figures). "Isolated," when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may 5 include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. The invention provides that the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide in 10 situ within recombinant cells, since at least one component of the PRO 1105, PRO1279 or PRO 1783 polypeptide natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step. An "isolated" PRO 1105, PRO 1279 or PRO 1783 polypeptide-encoding nucleic acid or other polypeptide-encoding nucleic acid is a nucleic acid molecule that is identified and 15 separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the polypeptide-encoding nucleic acid. An isolated polypeptide-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated polypeptide-encoding nucleic acid molecules therefore are distinguished from the specific polypeptide-encoding nucleic acid molecule as it exists in 20 natural cells. However, an isolated polypeptide-encoding nucleic acid molecule includes polypeptide-encoding nucleic acid molecules contained in cells that ordinarily express the polypeptide where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells. The term "control sequences" refers to DNA sequences necessary for the expression of 25 an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers. Nucleic acid is "operably linked" when it is placed into a functional relationship with 30 another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in 62 WO 2008/127352 PCT/US2007/080102 the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. 5 Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. "Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing 10 temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be 15 used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995). "Stringent conditions" or "high stringency conditions", as defined herein, may be 20 identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50'C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 25 75 mM sodium citrate at 42'C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 [tg/ml), 0.l1% SDS, and 10% dextran sulfate at 42'C, with washes at 42'C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55 0 C, followed by a high-stringency wash consisting of 0.1 x SSC containing 30 EDTA at 55'C. "Moderately stringent conditions" may be identified as described by Sambrook et al., 63 WO 2008/127352 PCT/US2007/080102 Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent that those described above. An example of moderately stringent conditions is overnight incubation at 37 0 C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x 5 Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50'C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like. The term "epitope tagged" when used herein refers to a chimeric polypeptide comprising 10 a PRO1105, PRO1279 or PRO1783 polypeptide fused to a "tag polypeptide". The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused. The tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least 15 six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues). "Active" or "activity" for the purposes herein refers to form(s) of a PRO 1105, PRO 1279 or PRO 1783 polypeptide which retain a biological and/or an immunological activity of native or naturally-occurring PRO 1105, PRO 1279 or PRO 1783 polypeptide, wherein "biological" 20 activity refers to a biological function (either inhibitory or stimulatory) caused by a native or naturally-occurring PRO 1105, PRO 1279 or PRO 1783 polypeptide other than the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring PRO 1105, PRO 1279 or PRO 1783 polypeptide and an "immunological" activity refers to the ability to induce the production of an antibody against an antigenic epitope 25 possessed by a native or naturally-occurring PRO 1105, PRO1279 or PRO1783 polypeptide. The term "antagonist" is used in the broadest sense [unless otherwise qualified], and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native PRO 1105, PRO 1279 or PRO 1783 polypeptide disclosed herein. In a similar manner, the term "agonist" is used in the broadest sense [unless otherwise qualified] and 30 includes any molecule that mimics a biological activity of a native PRO 1105, PRO 1279 or PRO 1783 polypeptide disclosed herein. Suitable agonist or antagonist molecules specifically 64 WO 2008/127352 PCT/US2007/080102 include agonist or antagonist antibodies or antibody fragments, fragments or amino acid sequence variants ofnative PRO 1105, PRO 1279 or PRO 1783 polypeptides, peptides, antisense oligonucleotides, small organic molecules, etc. Methods for identifying agonists or antagonists of a PRO 1105, PRO1279 or PRO1783 polypeptide may comprise contacting a PRO 1105, PRO1279 or PRO1783 polypeptide with a candidate agonist or antagonist molecule and 5 measuring a detectable change in one or more biological activities normally associated with the PRO 1105, PRO 1279 or PRO 1783 polypeptide. "Treating" or "treatment" or "alleviation" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. A subject in need of treatment may already have 10 the disorder, or may be prone to have the disorder or may be in whom the disorder is to be prevented. "Chronic" administration refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time. "Intermittent" administration is treatment that is not consecutively 15 done without interruption, but rather is cyclic in nature. "Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, rodents such as rats or mice, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc. Preferably, the mammal is human. 20 Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order. "Carriers" as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH 25 buffered solution. Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other 30 carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic 65 WO 2008/127352 PCT/US2007/080102 surfactants such as TWEEN
TM
, polyethylene glycol (PEG), and PLURONICS T M . By "solid phase" is meant a non-aqueous matrix to which the antibody of the present invention can adhere. Examples of solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones. Depending on the context, the 5 solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149. A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as a PRO 1105, PRO 1279 or 10 PRO 1783 polypeptide or antibody thereto) to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes. A "small molecule" is defined herein to have a molecular weight below about 500 Daltons. 15 An "effective amount" of a PRO 1105, PRO 1279 or PRO 1783 polypeptide, an anti PRO1105, anti-PRO1279 or anti-PRO1783 antibody, a PRO1105, PRO1279 or PRO1783 binding oligopeptide, a PRO 1105, PRO 1279 or PRO 1783 binding organic molecule or an agonist or antagonist thereof as disclosed herein is an amount sufficient to carry out a specifically stated purpose. An "effective amount" may be determined empirically and in a 20 routine manner, in relation to the stated purpose. The term "therapeutically effective amount" refers to an amount of an anti-PRO 1105, anti-PRO1279 or anti-PRO1783 antibody, a PRO 1105, PRO1279 or PRO1783 polypeptide, a PRO 1105, PRO1279 or PRO1783 binding oligopeptide, a PRO 1105, PRO1279 or PRO1783 binding organic molecule or other drug effective to "treat" a disease or disorder in a subject or 25 mammal. In the case of cancer, the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. See the definition herein of 30 "treating". To the extent the drug may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. 66 WO 2008/127352 PCT/US2007/080102 The phrases "cardiovascular, endothelial and angiogenic disorder", "cardiovascular, endothelial and angiogenic dysfunction", "cardiovascular, endothelial or angiogenic disorder" and "cardiovascular, endothelial or angiogenic dysfunction" are used interchangeably and refer in part to systemic disorders that affect vessels, such as diabetes mellitus, as well as diseases of the vessels themselves, such as of the arteries, capillaries, veins, and/or lymphatics. This 5 would include indications that stimulate angiogenesis and/or cardiovascularization, and those that inhibit angiogenesis and/or cardiovascularization. Such disorders include, for example, arterial disease, such as atherosclerosis, hypertension, inflammatory vasculitides, Reynaud's disease and Reynaud's phenomenon, aneurysms, and arterial restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; and other vascular 10 disorders such as peripheral vascular disease, cancer such as vascular tumors, e.g., hemangioma (capillary and cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma, Kaposi's sarcoma, lymphangioma, and lymphangiosarcoma, tumor angiogenesis, trauma such as wounds, burns, and other injured tissue, implant fixation, scarring, ischemia reperfusion injury, rheumatoid 15 arthritis, cerebrovascular disease, renal diseases such as acute renal failure, or osteoporosis. This would also include angina, myocardial infarctions such as acute myocardial infarctions, cardiac hypertrophy, and heart failure such as CHF. "Hypertrophy", as used herein, is defined as an increase in mass of an organ or structure independent of natural growth that does not involve tumor formation. Hypertrophy of an organ 20 or tissue is due either to an increase in the mass of the individual cells (true hypertrophy), or to an increase in the number of cells making up the tissue (hyperplasia), or both. Certain organs, such as the heart, lose the ability to divide shortly after birth. Accordingly, "cardiac hypertrophy" is defined as an increase in mass of the heart, which, in adults, is characterized by an increase in myocyte cell size and contractile protein content without concomitant cell 25 division. The character of the stress responsible for inciting the hypertrophy, (e.g., increased preload, increased afterload, loss of myocytes, as in myocardial infarction, or primary depression of contractility), appears to play a critical role in determining the nature of the response. The early stage of cardiac hypertrophy is usually characterized morphologically by increases in the size ofmyofibrils and mitochondria, as well as by enlargement of mitochondria 30 and nuclei. At this stage, while muscle cells are larger than normal, cellular organization is largely preserved. At a more advanced stage of cardiac hypertrophy, there are preferential 67 WO 2008/127352 PCT/US2007/080102 increases in the size or number of specific organelles, such as mitochondria, and new contractile elements are added in localized areas of the cells, in an irregular manner. Cells subjected to long-standing hypertrophy show more obvious disruptions in cellular organization, including markedly enlarged nuclei with highly lobulated membranes, which displace adjacent myofibrils and cause breakdown of normal Z-band registration. The phrase "cardiac hypertrophy" is used 5 to include all stages of the progression of this condition, characterized by various degrees of structural damage of the heart muscle, regardless of the underlying cardiac disorder. Hence, the term also includes physiological conditions instrumental in the development of cardiac hypertrophy, such as elevated blood pressure, aortic stenosis, or myocardial infarction. "Heart failure" refers to an abnormality of cardiac function where the heart does not 10 pump blood at the rate needed for the requirements of metabolizing tissues. The heart failure can be caused by a number of factors, including ischemic, congenital, rheumatic, or idiopathic forms. "Congestive heart failure" (CHF) is a progressive pathologic state where the heart is increasingly unable to supply adequate cardiac output (the volume ofblood pumped by the heart 15 over time) to deliver the oxygenated blood to peripheral tissues. As CHF progresses, structural and hemodynamic damages occur. While these damages have a variety of manifestations, one characteristic symptom is ventricular hypertrophy. CHF is a common end result of a number of various cardiac disorders. "Myocardial infarction" generally results from atherosclerosis of the coronary arteries, 20 often with superimposed coronary thrombosis. It may be divided into two major types: transmural infarcts, in which myocardial necrosis involves the full thickness of the ventricular wall, and subendocardial (nontransmural) infarcts, in which the necrosis involves the subendocardium, the intramural myocardium, or both, without extending all the way through the ventricular wall to the epicardium. Myocardial infarction is known to cause both a change 25 in hemodynamic effects and an alteration in structure in the damaged and healthy zones of the heart. Thus, for example, myocardial infarction reduces the maximum cardiac output and the stroke volume of the heart. Also associated with myocardial infarction is a stimulation of the DNA synthesis occurring in the interstice as well as an increase in the formation of collagen in the areas of the heart not affected. 30 As a result of the increased stress or strain placed on the heart in prolonged hypertension due, for example, to the increased total peripheral resistance, cardiac hypertrophy has long been 68 WO 2008/127352 PCT/US2007/080102 associated with "hypertension". A characteristic of the ventricle that becomes hypertrophic as a result of chronic pressure overload is an impaired diastolic performance. Fouad et al., J. Am. Coll. Cardiol., 4: 1500-1506 (1984); Smith et al., J. Am. Coll. Cardiol., 5: 869-874 (1985). A prolonged left ventricular relaxation has been detected in early essential hypertension, in spite of normal or supranormal systolic function. Hartford et al., Hypertension, 6: 329-338 (1984). 5 However, there is no close parallelism between blood pressure levels and cardiac hypertrophy. Although improvement in left ventricular function in response to antihypertensive therapy has been reported in humans, patients variously treated with a diuretic (hydrochlorothiazide), a 1 blocker (propranolol), or a calcium channel blocker (diltiazem), have shown reversal of left ventricular hypertrophy, without improvement in diastolic function. Inouye et al., Am. J. 10 Cardiol., 53: 1583-7 (1984). Another complex cardiac disease associated with cardiac hypertrophy is "hypertrophic cardiomyopathy". This condition is characterized by a great diversity of morphologic, functional, and clinical features (Maron et al., N. Engl. J. Med., 316: 780-789 (1987); Spirito et al., N. Engl. J. Med., 320: 749-755 (1989); Louie and Edwards, Prog. Cardiovasc. Dis., 36: 15 275-308 (1994); Wigle et al., Circulation, 92: 1680-1692 (1995)), the heterogeneity of which is accentuated by the fact that it afflicts patients of all ages. Spirito et al., N. Engl. J. Med., 336: 775-785 (1997). The causative factors of hypertrophic cardiomyopathy are also diverse and little understood. In general, mutations in genes encoding sarcomeric proteins are associated with hypertrophic cardiomyopathy. Recent data suggest that p-myosin heavy chain mutations 20 may account for approximately 30 to 40 percent of cases of familial hypertrophic cardiomyopathy. Watkins et al., N. Engl. J. Med., 326: 1108-1114 (1992); Schwartz et al, Circulation, 91: 532-540 (1995); Marian and Roberts, Circulation, 92: 1336-1347 (1995); Thierfelder et al., Cell, 77: 701-712 (1994); Watkins et al., Nat. Gen., 11: 434-437 (1995). Besides P-myosin heavy chain, other locations of genetic mutations include cardiac troponin 25 T, alpha topomyosin, cardiac myosin binding protein C, essential myosin light chain, and regulatory myosin light chain. See, Malik and Watkins, Curr. Opin. Cardiol., 12: 295-302 (1997). Supravalvular "aortic stenosis" is an inherited vascular disorder characterized by narrowing of the ascending aorta, but other arteries, including the pulmonary arteries, may also 30 be affected. Untreated aortic stenosis may lead to increased intracardiac pressure resulting in myocardial hypertrophy and eventually heart failure and death. The pathogenesis of this 69 WO 2008/127352 PCT/US2007/080102 disorder is not fully understood, but hypertrophy and possibly hyperplasia of medial smooth muscle are prominent features of this disorder. It has been reported that molecular variants of the elastin gene are involved in the development and pathogenesis of aortic stenosis. U.S. Patent No. 5,650,282 issued July 22, 1997. "Valvular regurgitation" occurs as a result of heart diseases resulting in disorders of the 5 cardiac valves. Various diseases, like rheumatic fever, can cause the shrinking or pulling apart of the valve orifice, while other diseases may result in endocarditis, an inflammation of the endocardium or lining membrane of the atrioventricular orifices and operation of the heart. Defects such as the narrowing of the valve stenosis or the defective closing of the valve result in an accumulation of blood in the heart cavity or regurgitation of blood past the valve. If 10 uncorrected, prolonged valvular stenosis or insufficiency may result in cardiac hypertrophy and associated damage to the heart muscle, which may eventually necessitate valve replacement. The term "immune related disease" means a disease in which a component of the immune system of a mammal causes, mediates or otherwise contributes to a morbidity in the mammal. Also included are diseases in which stimulation or intervention of the immune 15 response has an ameliorative effect on progression of the disease. Included within this term are immune-mediated inflammatory diseases, non-immune-mediated inflammatory diseases, infectious diseases, immunodeficiency diseases, neoplasia, etc. The term "T cell mediated disease" means a disease in which T cells directly or indirectly mediate or otherwise contribute to a morbidity in a mammal. The T cell mediated 20 disease may be associated with cell mediated effects, lymphokine mediated effects, etc., and even effects associated with B cells if the B cells are stimulated, for example, by the lymphokines secreted by T cells. Examples of immune-related and inflammatory diseases, some of which are immune or T cell mediated, include systemic lupus erythematosis, rheumatoid arthritis, juvenile chronic 25 arthritis, spondyloarthropathies, systemic sclerosis (scleroderma), idiopathic inflammatory myopathies (dermatomyositis, polymyositis), Sj6gren's syndrome, systemic vasculitis, sarcoidosis, autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria), autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia), thyroiditis (Grave's disease, Hashimoto's thyroiditis, 30 juvenile lymphocytic thyroiditis, atrophic thyroiditis), diabetes mellitus, immune-mediated renal disease (glomerulonephritis, tubulointerstitial nephritis), demyelinating diseases of the central 70 WO 2008/127352 PCT/US2007/080102 and peripheral nervous systems such as multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barr6 syndrome, and chronic inflammatory demyelinating polyneuropathy, hepatobiliary diseases such as infectious hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis, inflammatory bowel disease (ulcerative 5 colitis: Crohn's disease), gluten-sensitive enteropathy, and Whipple's disease, autoimmune or immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis, allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria, immunologic diseases of the lung such as eosinophilic pneumonia, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis, or transplantation 10 associated diseases including graft rejection and graft -versus-host-disease. Infectious diseases including viral diseases such as AIDS (HIV infection), hepatitis A, B, C, D, and E, herpes, etc., bacterial infections, fungal infections, protozoal infections and parasitic infections. An "autoimmune disease" herein is a disease or disorder arising from and directed against an individual's own tissues or organs or a co-segregate or manifestation thereof or 15 resulting condition therefrom. In many of these autoimmune and inflammatory disorders, a number of clinical and laboratory markers may exist, including, but not limited to, hypergammaglobulinemia, high levels of autoantibodies, antigen-antibody complex deposits in tissues, benefit from corticosteroid or immunosuppressive treatments, and lymphoid cell aggregates in affected tissues. Without being limited to any one theory regarding B-cell 20 mediated autoimmune disease, it is believed that B cells demonstrate a pathogenic effect in human autoimmune diseases through a multitude of mechanistic pathways, including autoantibody production, immune complex formation, dendritic and T-cell activation, cytokine synthesis, direct chemokine release, and providing a nidus for ectopic neo-lymphogenesis. Each of these pathways may participate to different degrees in the pathology of autoimmune 25 diseases. "Autoimmune disease" can be an organ-specific disease (i.e., the immune response is specifically directed against an organ system such as the endocrine system, the hematopoietic system, the skin, the cardiopulmonary system, the gastrointestinal and liver systems, the renal system, the thyroid, the ears, the neuromuscular system, the central nervous system, etc.) or a 30 systemic disease which can affect multiple organ systems (for example, systemic lupus erythematosus (SLE), rheumatoid arthritis, polymyositis, etc.). Preferred such diseases include 71 WO 2008/127352 PCT/US2007/080102 autoimmune rheumatologic disorders (such as, for example, rheumatoid arthritis, Sj6gren's syndrome, scleroderma, lupus such as SLE and lupus nephritis, polymyositis/dermatomyositis, cryoglobulinemia, anti-phospholipid antibody syndrome, and psoriatic arthritis), autoimmune gastrointestinal and liver disorders (such as, for example, inflammatory bowel diseases (e.g., ulcerative colitis and Crohn's disease), autoimmune gastritis and pernicious anemia, 5 autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, and celiac disease), vasculitis (such as, for example, ANCA-associated vasculitis, including Churg-Strauss vasculitis, Wegener's granulomatosis, and polyarteriitis), autoimmune neurological disorders (such as, for example, multiple sclerosis, opsoclonus myoclonus syndrome, myasthenia gravis, neuromyelitis optica, Parkinson's disease, Alzheimer's disease, and autoimmune 10 polyneuropathies), renal disorders (such as, for example, glomerulonephritis, Goodpasture's syndrome, and Berger's disease), autoimmune dermatologic disorders (such as, for example, psoriasis, urticaria, hives, pemphigus vulgaris, bullous pemphigoid, and cutaneous lupus erythematosus), hematologic disorders (such as, for example, thrombocytopenic purpura, thrombotic thrombocytopenic purpura, post-transfusion purpura, and autoimmune hemolytic 15 anemia), atherosclerosis, uveitis, autoimmune hearing diseases (such as, for example, inner ear disease and hearing loss), Behcet's disease, Raynaud's syndrome, organ transplant, and autoimmune endocrine disorders (such as, for example, diabetic-related autoimmune diseases such as insulin-dependent diabetes mellitus (IDDM), Addison's disease, and autoimmune thyroid disease (e.g., Graves' disease and thyroiditis)). More preferred such diseases include, 20 for example, rheumatoid arthritis, ulcerative colitis, ANCA-associated vasculitis, lupus, multiple sclerosis, Sj6gren's syndrome, Graves' disease, IDDM, pernicious anemia, thyroiditis, and glomerulonephritis. Specific examples of other autoimmune diseases as defined herein, which in some cases encompass those listed above, include, but are not limited to, arthritis (acute and chronic, 25 rheumatoid arthritis including juvenile-onset rheumatoid arthritis and stages such as rheumatoid synovitis, gout or gouty arthritis, acute immunological arthritis, chronic inflammatory arthritis, degenerative arthritis, type II collagen-induced arthritis, infectious arthritis, Lyme arthritis, proliferative arthritis, psoriatic arthritis, Still's disease, vertebral arthritis, osteoarthritis, arthritis chronica progrediente, arthritis deformans, polyarthritis chronica primaria, reactive arthritis, 30 menopausal arthritis, estrogen-depletion arthritis, and ankylosing spondylitis/rheumatoid spondylitis), autoimmune lymphoproliferative disease, inflammatory hyperproliferative skin 72 WO 2008/127352 PCT/US2007/080102 diseases, psoriasis such as plaque psoriasis, gutatte psoriasis, pustular psoriasis, and psoriasis of the nails, atopy including atopic diseases such as hay fever and Job's syndrome, dermatitis including contact dermatitis, chronic contact dermatitis, exfoliative dermatitis, allergic dermatitis, allergic contact dermatitis, hives, dermatitis herpetiformis, nummular dermatitis, seborrheic dermatitis, non-specific dermatitis, primary irritant contact dermatitis, and atopic 5 dermatitis, x-linked hyper IgM syndrome, allergic intraocular inflammatory diseases, urticaria such as chronic allergic urticaria and chronic idiopathic urticaria, including chronic autoimmune urticaria, myositis, polymyositis/dermatomyositis,juvenile dermatomyositis, toxic epidermal necrolysis, scleroderma (including systemic scleroderma), sclerosis such as systemic sclerosis, multiple sclerosis (MS) such as spino-optical MS, primary progressive MS (PPMS), 10 and relapsing remitting MS (RRMS), progressive systemic sclerosis, atherosclerosis, arteriosclerosis, sclerosis disseminata, ataxic sclerosis, neuromyelitis optica (NMO), inflammatory bowel disease (IBD) (for example, Crohn's disease, autoimmune-mediated gastrointestinal diseases, gastrointestinal inflammation, colitis such as ulcerative colitis, colitis ulcerosa, microscopic colitis, collagenous colitis, colitis polyposa, necrotizing enterocolitis, and 15 transmural colitis, and autoimmune inflammatory bowel disease), bowel inflammation, pyoderma gangrenosum, erythema nodosum, primary sclerosing cholangitis, respiratory distress syndrome, including adult or acute respiratory distress syndrome (ARDS), meningitis, inflammation of all or part of the uvea, iritis, choroiditis, an autoimmune hematological disorder, graft-versus-host disease, angioedema such as hereditary angioedema, cranial nerve 20 damage as in meningitis, herpes gestationis, pemphigoid gestationis, pruritis scroti, autoimmune premature ovarian failure, sudden hearing loss due to an autoimmune condition, IgE-mediated diseases such as anaphylaxis and allergic and atopic rhinitis, encephalitis such as Rasmussen's encephalitis and limbic and/or brainstem encephalitis, uveitis, such as anterior uveitis, acute anterior uveitis, granulomatous uveitis, nongranulomatous uveitis, phacoantigenic uveitis, 25 posterior uveitis, or autoimmune uveitis, glomerulonephritis (GN) with and without nephrotic syndrome such as chronic or acute glomerulonephritis such as primary GN, immune-mediated GN, membranous GN (membranous nephropathy), idiopathic membranous GN or idiopathic membranous nephropathy, membrano- or membranous proliferative GN (MPGN), including Type I and Type II, and rapidly progressive GN (RPGN), proliferative nephritis, autoimmune 30 polyglandular endocrine failure, balanitis including balanitis circumscripta plasmacellularis, balanoposthitis, erythema annulare centrifugum, erythema dyschromicum perstans, eythema 73 WO 2008/127352 PCT/US2007/080102 multiform, granuloma annulare, lichen nitidus, lichen sclerosus et atrophicus, lichen simplex chronicus, lichen spinulosus, lichen planus, lamellar ichthyosis, epidermolytic hyperkeratosis, premalignant keratosis, pyoderma gangrenosum, allergic conditions and responses, food allergies, drug allergies, insect allergies, rare allergic disorders such as mastocytosis, allergic reaction, eczema including allergic or atopic eczema, asteatotic eczema, dyshidrotic eczema, 5 and vesicular palmoplantar eczema, asthma such as asthma bronchiale, bronchial asthma, and auto-immune asthma, conditions involving infiltration of T cells and chronic inflammatory responses, immune reactions against foreign antigens such as fetal A-B-O blood groups during pregnancy, chronic pulmonary inflammatory disease, autoimmune myocarditis, leukocyte adhesion deficiency, lupus, including lupus nephritis, lupus cerebritis, pediatric lupus, non-renal 10 lupus, extra-renal lupus, discoid lupus and discoid lupus erythematosus, alopecia lupus, SLE, such as cutaneous SLE or subacute cutaneous SLE, neonatal lupus syndrome (NLE), and lupus erythematosus disseminatus, juvenile onset (Type I) diabetes mellitus, including pediatric IDDM, adult onset diabetes mellitus (Type II diabetes), autoimmune diabetes, idiopathic diabetes insipidus, diabetic retinopathy, diabetic nephropathy, diabetic colitis, diabetic 15 large-artery disorder, immune responses associated with acute and delayed hypersensitivity mediated by cytokines and T-lymphocytes, tuberculosis, sarcoidosis, granulomatosis including lymphomatoid granulomatosis, Wegener's granulomatosis, agranulocytosis, vasculitides, including vasculitis, large-vessel vasculitis (including polymyalgia rheumatica and giant-cell (Takayasu's) arteritis), medium-vessel vasculitis (including Kawasaki's disease and polyarteritis 20 nodosa/periarteritis nodosa), microscopic polyarteritis, immunovasculitis, CNS vasculitis, cutaneous vasculitis, hypersensitivity vasculitis, necrotizing vasculitis such as systemic necrotizing vasculitis, and ANCA-associated vasculitis, such as Churg-Strauss vasculitis or syndrome (CSS) and ANCA-associated small-vessel vasculitis, temporal arteritis, aplastic anemia, autoimmune aplastic anemia, Coombs positive anemia, Diamond Blackfan anemia, 25 hemolytic anemia or immune hemolytic anemia including autoimmune hemolytic anemia (AIHA), pernicious anemia (anemia perniciosa), Addison's disease, pure red cell anemia or aplasia (PRCA), Factor VIII deficiency, hemophilia A, autoimmune neutropenia(s), cytopenias such as pancytopenia, leukopenia, diseases involving leukocyte diapedesis, CNS inflammatory disorders, Alzheimer's disease, Parkinson's disease, multiple organ injury syndrome such as 30 those secondary to septicemia, trauma or hemorrhage, antigen-antibody complex- mediated diseases, anti-glomerular basement membrane disease, anti-phospholipid antibody syndrome, 74 WO 2008/127352 PCT/US2007/080102 motoneuritis, allergic neuritis, Behget's disease/syndrome, Castleman's syndrome, Goodpasture's syndrome, Reynaud's syndrome, Sj6gren's syndrome, Stevens-Johnson syndrome, pemphigoid such as pemphigoid bullous and skin pemphigoid, pemphigus (including pemphigus vulgaris, pemphigus foliaceus, pemphigus mucus-membrane pemphigoid, and pemphigus erythematosus), autoimmune polyendocrinopathies, Reiter's disease or syndrome, 5 thermal injury due to an autoimmune condition, preeclampsia, an immune complex disorder such as immune complex nephritis, antibody-mediated nephritis, neuroinflammatory disorders, polyneuropathies, chronic neuropathy such as IgM polyneuropathies or IgM-mediated neuropathy, thrombocytopenia (as developed by myocardial infarction patients, for example), including thrombotic thrombocytopenic purpura (TTP), post-transfusion purpura (PTP), 10 heparin-induced thrombocytopenia, and autoimmune or immune-mediated thrombocytopenia including, for example, idiopathic thrombocytopenic purpura (ITP) including chronic or acute ITP, scleritis such as idiopathic cerato-scleritis, episcleritis, autoimmune disease of the testis and ovary including autoimmune orchitis and oophoritis, primary hypothyroidism, hypoparathyroidism, autoimmune endocrine diseases including thyroiditis such as autoimmune 15 thyroiditis, Hashimoto's disease, chronic thyroiditis (Hashimoto's thyroiditis), or subacute thyroiditis, autoimmune thyroid disease, idiopathic hypothyroidism, Grave's disease, polyglandular syndromes such as autoimmune polyglandular syndromes, for example, type I (or polyglandular endocrinopathy syndromes), paraneoplastic syndromes, including neurologic paraneoplastic syndromes such as Lambert-Eaton myasthenic syndrome or Eaton-Lambert 20 syndrome, stiff-man or stiff-person syndrome, encephalomyelitis such as allergic encephalomyelitis or encephalomyelitis allergica and experimental allergic encephalomyelitis (EAE), myasthenia gravis such as thymoma-associated myasthenia gravis, cerebellar degeneration, neuromyotonia, opsoclonus or opsoclonus myoclonus syndrome (OMS), and sensory neuropathy, multifocal motor neuropathy, Sheehan's syndrome, autoimmune hepatitis, 25 chronic hepatitis, lupoid hepatitis, giant-cell hepatitis, chronic active hepatitis or autoimmune chronic active hepatitis, pneumonitis such as lymphoid interstitial pneumonitis (LIP), bronchiolitis obliterans (non-transplant) vs NSIP, Guillain-Barr6 syndrome, Berger's disease (IgA nephropathy), idiopathic IgA nephropathy, linear IgA dermatosis, acute febrile neutrophilic dermatosis, subcomeal pustular dermatosis, transient acantholytic dermatosis, 30 cirrhosis such as primary biliary cirrhosis and pneumonocirrhosis, autoimmune enteropathy syndrome, Celiac or Coeliac disease, celiac sprue (gluten enteropathy), refractory sprue, 75 WO 2008/127352 PCT/US2007/080102 idiopathic sprue, cryoglobulinemia such as mixed cryoglobulinemia, amylotrophic lateral sclerosis (ALS; Lou Gehrig's disease), coronary artery disease, autoimmune ear disease such as autoimmune inner ear disease (AIED), autoimmune hearing loss, polychondritis such as refractory or relapsed or relapsing polychondritis, pulmonary alveolar proteinosis, Cogan's syndrome/nonsyphilitic interstitial keratitis, Bell's palsy, Sweet's disease/syndrome, rosacea 5 autoimmune, zoster-associated pain, amyloidosis, a non-cancerous lymphocytosis, a primary lymphocytosis, which includes monoclonal B cell lymphocytosis (e.g., benign monoclonal gammopathy and monoclonal gammopathy of undetermined significance, MGUS), peripheral neuropathy, paraneoplastic syndrome, channelopathies such as epilepsy, migraine, arrhythmia, muscular disorders, deafness, blindness, periodic paralysis, and channelopathies of the CNS, 10 autism, inflammatory myopathy, focal or segmental or focal segmental glomerulosclerosis (FSGS), endocrine ophthalmopathy, uveoretinitis, chorioretinitis, autoimmune hepatological disorder, fibromyalgia, multiple endocrine failure, Schmidt's syndrome, adrenalitis, gastric atrophy, presenile dementia, demyelinating diseases such as autoimmune demyelinating diseases and chronic inflammatory demyelinating polyneuropathy, Dressler's syndrome, 15 alopecia areata, alopecia totalis, CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia), male and female autoimmune infertility, e.g., due to anti-spermatozoan antibodies, mixed connective tissue disease, Chagas' disease, rheumatic fever, recurrent abortion, farmer's lung, erythema multiforme, post-cardiotomy syndrome, Cushing's syndrome, bird-fancier's lung, allergic granulomatous 20 angiitis, benign lymphocytic angiitis, Alport's syndrome, alveolitis such as allergic alveolitis and fibrosing alveolitis, interstitial lung disease, transfusion reaction, leprosy, malaria, parasitic diseases such as leishmaniasis, kypanosomiasis, schistosomiasis, ascariasis, aspergillosis, Sampter's syndrome, Caplan's syndrome, dengue, endocarditis, endomyocardial fibrosis, diffuse interstitial pulmonary fibrosis, interstitial lung fibrosis, fibrosing mediastinitis, pulmonary 25 fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis, endophthalmitis, erythema elevatum et diutinum, erythroblastosis fetalis, eosinophilic faciitis, Shulman's syndrome, Felty's syndrome, flariasis, cyclitis such as chronic cyclitis, heterochronic cyclitis, iridocyclitis (acute or chronic), or Fuch's cyclitis, Henoch-Schonlein purpura, human immunodeficiency virus (HIV) infection, SCID, acquired immune deficiency syndrome (AIDS), echovirus infection, sepsis (systemic 30 inflammatory response syndrome (SIRS)), endotoxemia, pancreatitis, thyroxicosis, parvovirus infection, rubella virus infection, post-vaccination syndromes, congenital rubella infection, 76 WO 2008/127352 PCT/US2007/080102 Epstein-Barr virus infection, mumps, Evan's syndrome, autoimmune gonadal failure, Sydenham's chorea, post-streptococcal nephritis, thromboangitis ubiterans, thyrotoxicosis, tabes dorsalis, chorioiditis, giant-cell polymyalgia, chronic hypersensitivity pneumonitis, conjunctivitis, such as vernal catarrh, keratoconjunctivitis sicca, and epidemic keratoconjunctivitis, idiopathic nephritic syndrome, minimal change nephropathy, benign 5 familial and ischemia-reperfusion injury, transplant organ reperfusion, retinal autoimmunity, joint inflammation, bronchitis, chronic obstructive airway/pulmonary disease, silicosis, aphthae, aphthous stomatitis, arteriosclerotic disorders (cerebral vascular insufficiency) such as arteriosclerotic encephalopathy and arteriosclerotic retinopathy, aspermiogenese, autoimmune hemolysis, Boeck's disease, cryoglobulinemia, Dupuytren's contracture, endophthalmia 10 phacoanaphylactica, enteritis allergica, erythema nodosum leprosum, idiopathic facial paralysis, chronic fatigue syndrome, febris rheumatica, Hamman-Rich's disease, sensoneural hearing loss, haemoglobinuria paroxysmatica, hypogonadism, ileitis regionalis, leucopenia, mononucleosis infectiosa, traverse myelitis, primary idiopathic myxedema, nephrosis, ophthalmia symphatica, orchitis granulomatosa, pancreatitis, polyradiculitis acuta, pyoderma gangrenosum, Quervain's 15 thyreoiditis, acquired spenic atrophy, non-malignant thymoma, lymphofollicular thymitis, vitiligo, toxic-shock syndrome, food poisoning, conditions involving infiltration of T cells, leukocyte-adhesion deficiency, immune responses associated with acute and delayed hypersensitivity mediated by cytokines and T-lymphocytes, diseases involving leukocyte diapedesis, multiple organ injury syndrome, antigen-antibody complex-mediated diseases, 20 antiglomerular basement membrane disease, autoimmune polyendocrinopathies, oophoritis, primary myxedema, autoimmune atrophic gastritis, sympathetic ophthalmia, rheumatic diseases, mixed connective tissue disease, nephrotic syndrome, insulitis, polyendocrine failure, autoimmune polyglandular syndromes, including polyglandular syndrome type I, adult-onset idiopathic hypoparathyroidism (AOIH), cardiomyopathy such as dilated cardiomyopathy, 25 epidermolisis bullosa acquisita (EBA), hemochromatosis, myocarditis, nephrotic syndrome, primary sclerosing cholangitis, purulent or nonpurulent sinusitis, acute or chronic sinusitis, ethmoid, frontal, maxillary, or sphenoid sinusitis, allergic sinusitis, an eosinophil-related disorder such as eosinophilia, pulmonary infiltration eosinophilia, eosinophilia-myalgia syndrome, Loffler's syndrome, chronic eosinophilic pneumonia, tropical pulmonary 30 eosinophilia, bronchopneumonic aspergillosis, aspergilloma, or granulomas containing eosinophils, anaphylaxis, spondyloarthropathies, seronegative spondyloarthritides, 77 WO 2008/127352 PCT/US2007/080102 polyendocrine autoimmune disease, sclerosing cholangitis, sclera, episclera, chronic mucocutaneous candidiasis, Bruton's syndrome, transient hypogammaglobulinemia of infancy, Wiskott-Aldrich syndrome, ataxia telangiectasia syndrome, angiectasis, autoimmune disorders associated with collagen disease, rheumatism such as chronic arthrorheumatism, lymphadenitis, reduction in blood pressure response, vascular dysfunction, tissue injury, cardiovascular 5 ischemia, hyperalgesia, renal ischemia, cerebral ischemia, and disease accompanying vascularization, allergic hypersensitivity disorders, glomerulonephritides, reperfusion injury, ischemic re-perfusion disorder, reperfusion injury ofmyocardial or other tissues, lymphomatous tracheobronchitis, inflammatory dermatoses, dermatoses with acute inflammatory components, multiple organ failure, bullous diseases, renal cortical necrosis, acute purulent meningitis or 10 other central nervous system inflammatory disorders, ocular and orbital inflammatory disorders, granulocyte transfusion-associated syndromes, cytokine-induced toxicity, narcolepsy, acute serious inflammation, chronic intractable inflammation, pyelitis, endarterial hyperplasia, peptic ulcer, valvulitis, and endometriosis. The phrase "anxiety related disorders" refers to disorders of anxiety, mood, and 15 substance abuse, including but not limited to: depression, generalized anxiety disorders, attention deficit disorder, sleep disorder, hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia and sensory disorders. Such disorders include the mild to moderate anxiety, anxiety disorder due to a general medical condition, anxiety disorder not otherwise specified, generalized anxiety disorder, panic attack, panic disorder with 20 agoraphobia, panic disorder without agoraphobia, posttraumatic stress disorder, social phobia, social anxiety, autism, specific phobia, substance-induced anxiety disorder, acute alcohol withdrawal, obsessive compulsive disorder, agoraphobia, monopolar disorders, bipolar disorder I or II, bipolar disorder not otherwise specified, cyclothymic disorder, depressive disorder, major depressive disorder, mood disorder, substance-induced mood disorder, enhancement of 25 cognitive function, loss of cognitive function associated with but not limited to Alzheimer's disease, stroke, or traumatic injury to the brain, seizures resulting from disease or injury including but not limited to epilepsy, learning disorders/disabilities, cerebral palsy. In addition, anxiety disorders may apply to personality disorders including but not limited to the following types: paranoid, antisocial, avoidant behavior, borderline personality disorders, dependent, 30 histronic, narcissistic, obsessive-compulsive, schizoid, and schizotypal. The term "lipid metabolic disorder" refers to abnormal clinical chemistry levels of 78 WO 2008/127352 PCT/US2007/080102 cholesterol and triglycerides, wherein elevated levels of these lipids is an indication for atherosclerosis. Additionally, abnormal serum lipid levels may be an indication of various cardiovascular diseases including hypertension, stroke, coronary artery diseases, diabetes and/or obesity. The phrase "eye abnormality" refers to such potential disorders of the eye as they may 5 be related to atherosclerosis or various ophthalmological abnormalities. Such disorders include but are not limited to the following: retinal dysplasia, various retinopathies, restenosis, retinal artery obstruction or occlusion; retinal degeneration causing secondary atrophy of the retinal vasculature, retinitis pigmentosa, macular dystrophies, Stargardt's disease, congenital stationary night blindness, choroideremia, gyrate atrophy, Leber's congenital amaurosis, 10 retinoschisis disorders, Wagner's syndrome, Usher syndromes, Zellweger syndrome, Saldino-Mainzer syndrome, Senior-Loken syndrome, Bardet-Biedl syndrome, Alport's syndrome, Alstrom's syndrome, Cockayne's syndrome, dysplaisa spondyloepiphysaria congentia, Flynn-Aird syndrome, Friedreich ataxia, Hallgren syndrome, Marshall syndrome, Albers-Schnoberg disease, Refsum's disease, Keams-Sayre syndrome, Waardenburg's 15 syndrome, Alagile syndrome, myotonic dystrophy, olivopontocerebellar atrophy, Pierre-Marie dunsdrome, Stickler syndrome, carotinemeia, cystinosis, Wolfram syndrome, Bassen-Kornzweig syndrome, abetalipoproteinemia, incontinentia pigmenti, Batten's disease, mucopolysaccharidoses, homocystinuria, or mannosidosis. Cataracts are also considered an eye abnormality and are associated with such systemic diseases as: Human Down's syndrome, 20 Hallerman-Streiff syndrome, Lowe syndrome, galactosemia, Marfan syndrome, Trismoy 13-15 condition, Alport syndrome, myotonic dystrophy, Fabry disease, hypothroidisms, or Conradi syndrome. Other ocular developmental anomalies include: Aniridia, anterior segment and dysgenesis syndrome. Cataracts may also occur as a result of an intraocular infection or inflammation (uveitis). 25 A "growth inhibitory amount" of an anti-PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody, PRO1 105, PRO1279 or PRO1783 polypeptide, PRO1 105, PRO1279 or PRO1783 binding oligopeptide or PRO 1105, PRO 1279 or PRO 1783 binding organic molecule is an amount capable of inhibiting the growth of a cell, especially tumor, e.g., cancer cell, either in vitro or in vivo. A "growth inhibitory amount" of an anti-PRO 1105, anti-PRO 1279 or anti 30 PRO1783 antibody, PRO 1105, PRO1279 or PRO1783 polypeptide, PRO 1105, PRO1279 or PRO 1783 binding oligopeptide or PRO 1105, PRO 1279 or PRO 1783 binding organic molecule 79 WO 2008/127352 PCT/US2007/080102 for purposes of inhibiting neoplastic cell growth may be determined empirically and in a routine manner. A "cytotoxic amount" of an anti-PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody, PRO1105, PRO1279 or PRO1783 polypeptide, PRO1105, PRO1279 or PRO1783 binding oligopeptide or PRO1105, PRO1279 or PRO1783 binding organic molecule is an amount 5 capable of causing the destruction of a cell, especially tumor, e.g., cancer cell, either in vitro or in vivo. A "cytotoxic amount" of an anti-PRO1105, anti-PRO1279 or anti-PRO1783 antibody, PRO 1105, PRO1279 or PRO1783 polypeptide, PRO 1105, PRO1279 or PRO1783 binding oligopeptide or PRO1105, PRO1279 or PRO1783 binding organic molecule for purposes of inhibiting neoplastic cell growth may be determined empirically and in a routine 10 manner. The term "antibody" is used in the broadest sense and specifically covers, for example, single anti-PRO1105, anti-PR01279 or anti-PR01783 antibody monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies), anti-PRO 1105, anti-PRO 1279 or anti-PRO1783 antibody compositions with polyepitopic specificity, polyclonal antibodies, 15 single chain anti-PRO1 105, anti-PR01279 or anti-PR01783 antibodies, and fragments of anti PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibodies (see below) as long as they exhibit the desired biological or immunological activity. The term "immunoglobulin" (Ig) is used interchangeable with antibody herein. An "isolated antibody" is one which has been identified and separated and/or recovered 20 from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. The invention provides that the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% 25 by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, 30 isolated antibody will be prepared by at least one purification step. The basic 4-chain antibody unit is a heterotetrameric glycoprotein composed of two 80 WO 2008/127352 PCT/US2007/080102 identical light (L) chains and two identical heavy (H) chains (an IgM antibody consists of 5 of the basic heterotetramer unit along with an additional polypeptide called J chain, and therefore contain 10 antigen binding sites, while secreted IgA antibodies can polymerize to form polyvalent assemblages comprising 2-5 of the basic 4-chain units along with J chain). In the case of IgGs, the 4-chain unit is generally about 150,000 daltons. Each L chain is linked to a 5 H chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds depending on the H chain isotype. Each H and L chain also has regularly spaced intrachain disulfide bridges. Each H chain has at the N-terminus, a variable domain (VH) followed by three constant domains (CH) for each of the a and y chains and four CH domains for L and E isotypes. Each L chain has at the N-terminus, a variable domain (VL) 10 followed by a constant domain (CL) at its other end. The VL is aligned with the VH and the CL is aligned with the first constant domain of the heavy chain (CH 1). Particular amino acid residues are believed to form an interface between the light chain and heavy chain variable domains. The pairing of a VH and VL together forms a single antigen-binding site. For the structure and properties of the different classes of antibodies, see, e.g., Basic and Clinical 15 Immunologv, 8th edition, Daniel P. Stites, Abba I. Terr and Tristram G. Parslow (eds.), Appleton & Lange, Norwalk, CT, 1994, page 71 and Chapter 6. The L chain from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains. Depending on the amino acid sequence of the constant domain of their heavy chains (CH), 20 immunoglobulins can be assigned to different classes or isotypes. There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, having heavy chains designated a, 8, E, y, and L, respectively. The y and a classes are further divided into subclasses on the basis of relatively minor differences in CH sequence and function, e.g., humans express the following subclasses: IgGI, IgG2, IgG3, IgG4, IgA1, and IgA2. 25 The term "variable" refers to the fact that certain segments ofthe variable domains differ extensively in sequence among antibodies. The V domain mediates antigen binding and define specificity of a particular antibody for its particular antigen. However, the variability is not evenly distributed across the 110-amino acid span of the variable domains. Instead, the V regions consist of relatively invariant stretches called framework regions (FRs) of 15-30 amino 30 acids separated by shorter regions of extreme variability called "hypervariable regions" that are each 9-12 amino acids long. The variable domains of native heavy and light chains each 81 WO 2008/127352 PCT/US2007/080102 comprise four FRs, largely adopting a P -sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases forming part of, the P -sheet structure. The hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological 5 Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody dependent cellular cytotoxicity (ADCC). The term "hypervariable region" when used herein refers to the amino acid residues of 10 an antibody which are responsible for antigen-binding. The hypervariable region generally comprises amino acid residues from a "complementarity determining region" or "CDR" (e.g. around about residues 24-34 (LI), 50-56 (L2) and 89-97 (L3) in the VL, and around about 1-35 (HI), 50-65 (H2) and 95-102 (H3) in the VH; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, 15 MD. (1991)) and/or those residues from a "hypervariable loop" (e.g. residues 26-32 (LI), 50-52 (L2) and 91-96 (L3) in the VL, and 26-32 (HI), 53-55 (H2) and 96-101 (H3) in the VH; Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)). The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising 20 the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, 25 the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier "monoclonal" is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies useful in the present invention may be prepared by the hybridoma methodology first described by Kohler et al., Nature, 256:495 (1975), or may be made using recombinant DNA methods in bacterial, 30 eukaryotic animal or plant cells (see, e.g., U.S. Patent No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described 82 WO 2008/127352 PCT/US2007/080102 in Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597 (1991), for example. The monoclonal antibodies herein include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or 5 subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (see U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). Chimeric antibodies of interest herein include "primatized" antibodies 10 comprising variable domain antigen-binding sequences derived from a non-human primate (e.g. Old World Monkey, Ape etc), and human constant region sequences. An "intact" antibody is one which comprises an antigen-binding site as well as a CL and at least heavy chain constant domains, CH 1, CH 2 and CH 3. The constant domains may be native sequence constant domains (e.g. human native sequence constant domains) or amino acid 15 sequence variant thereof. Preferably, the intact antibody has one or more effector functions. "Antibody fragments" comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab') 2 , and Fv fragments; diabodies; linear antibodies (see U.S. Patent No. 5,641,870, Example 2; Zapata et al., Protein Eng. 8(10): 1057-1062 [1995]); single-chain antibody 20 molecules; and multispecific antibodies formed from antibody fragments. Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, and a residual "Fc" fragment, a designation reflecting the ability to crystallize readily. The Fab fragment consists of an entire L chain along with the variable region domain of the H chain (VH), and the first constant domain of one heavy chain (CH 1). Each Fab 25 fragment is monovalent with respect to antigen binding, i.e., it has a single antigen-binding site. Pepsin treatment of an antibody yields a single large F(ab') 2 fragment which roughly corresponds to two disulfide linked Fab fragments having divalent antigen-binding activity and is still capable of cross-linking antigen. Fab' fragments differ from Fab fragments by having additional few residues at the carboxy terminus of the CH 1 domain including one or more 30 cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab') 2 antibody 83 WO 2008/127352 PCT/US2007/080102 fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known. The Fc fragment comprises the carboxy-terminal portions of both H chains held together by disulfides. The effector functions of antibodies are determined by sequences in the Fc region, which region is also the part recognized by Fc receptors (FcR) found on certain types 5 of cells. "Fv" is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This fragment consists of a dimer of one heavy- and one light-chain variable region domain in tight, non-covalent association. From the folding of these two domains emanate six hypervariable loops (3 loops each from the H and L chain) that contribute the 10 amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site. "Single-chain Fv" also abbreviated as "sFv" or "scFv" are antibody fragments that 15 comprise the VH and VL antibody domains connected into a single polypeptide chain. Preferably, the sFv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv, see Pluckthun in The Pharmacologv of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); Borrebaeck 1995, infra. 20 The term "diabodies" refers to small antibody fragments prepared by constructing sFv fragments (see preceding paragraph) with short linkers (about 5-10 residues) between the VH and VL domains such that inter-chain but not intra-chain pairing of the V domains is achieved, resulting in a bivalent fragment, i.e., fragment having two antigen-binding sites. Bispecific diabodies are heterodimers of two "crossover" sFv fragments in which the VH and VL domains 25 ofthe two antibodies are present on different polypeptide chains. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993). "Humanized" forms ofnon-human (e.g., rodent) antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody. For the most part, humanized 30 antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of 84 WO 2008/127352 PCT/US2007/080102 a non-human species (donor antibody) such as mouse, rat, rabbit or non-human primate having the desired antibody specificity, affinity, and capability. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine 5 antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region 10 (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992). A "species-dependent antibody," e.g., a mammalian anti-human IgE antibody, is an antibody which has a stronger binding affinity for an antigen from a first mammalian species 15 than it has for a homologue of that antigen from a second mammalian species. Normally, the species-dependent antibody "bind specifically" to a human antigen (i.e., has a binding affinity (Kd) value of no more than about 1 x 10-7 M, preferably no more than about 1 x 108 and most preferably no more than about 1 x 10-9 M) but has a binding affinity for a homologue of the antigen from a second non-human mammalian species which is at least about 50 fold, or at least 20 about 500 fold, or at least about 1000 fold, weaker than its binding affinity for the human antigen. The species-dependent antibody can be of any of the various types of antibodies as defined above, but preferably is a humanized or human antibody. A "PRO 1105, PRO 1279 or PRO 1783 binding oligopeptide" is an oligopeptide that binds, preferably specifically, to a PRO 1105, PRO 1279 or PRO 1783 polypeptide as described 25 herein. PRO 1105, PRO 1279 or PRO 1783 binding oligopeptides maybe chemically synthesized using known oligopeptide synthesis methodology or may be prepared and purified using recombinant technology. PRO 1105, PRO 1279 or PRO 1783 binding oligopeptides usually are or are at least about 5 amino acids in length, alternatively are or are at least about 6, 7, 8, 9, 10, 11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35, 30 36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60, 61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85, 85 WO 2008/127352 PCT/US2007/080102 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 amino acids in length or more, wherein such oligopeptides that are capable of binding, preferably specifically, to a PRO 1105, PRO1279 or PRO1783 polypeptide as described herein. PRO1105, PRO1279 or PRO1783 binding oligopeptides may be identified without undue experimentation using well known techniques. In this regard, it is noted that techniques for screening oligopeptide libraries for 5 oligopeptides that are capable of specifically binding to a polypeptide target are well known in the art (see, e.g., U.S. Patent Nos. 5,556,762, 5,750,373, 4,708,871, 4,833,092, 5,223,409, 5,403,484, 5,571,689, 5,663,143; PCT Publication Nos. WO 84/03506 and WO84/03564; Geysen et al., Proc. Natl. Acad. Sci. U.S.A., 81:3998-4002 (1984); Geysen et al., Proc. Natl. Acad. Sci. U.S.A., 82:178-182 (1985); Geysen et al., in Synthetic Peptides as Antigens, 10 130-149 (1986); Geysen et al., J. Immunol. Meth., 102:259-274 (1987); Schoofs et al., J Immunol., 140:611-616 (1988), Cwirla, S. E. et al. (1990) Proc. Natl. Acad. Sci. USA, 87:6378; Lowman, H.B. et al. (1991) Biochemistry, 30:10832; Clackson, T. et al. (1991) Nature, 352: 624; Marks, J. D. et al. (1991), J. Mol. Biol., 222:581; Kang, A.S. et al. (1991) Proc. Natl. Acad. Sci. USA, 88:8363, and Smith, G. P. (1991) Current Opin. Biotechnol., 2:668). 15 A "PRO 1105, PRO 1279 or PRO 1783 binding organic molecule" is an organic molecule other than an oligopeptide or antibody as defined herein that binds, preferably specifically, to a PRO 1105, PRO1279 or PRO1783 polypeptide as described herein. PRO 1105, PRO1279 or PRO1783 binding organic molecules may be identified and chemically synthesized using known methodology (see, e.g., PCT Publication Nos. WOOO/00823 and WOOO/39585). 20 PRO 1105, PRO 1279 or PRO 1783 binding organic molecules are usually less than about 2000 daltons in size, alternatively less than about 1500, 750, 500, 250 or 200 daltons in size, wherein such organic molecules that are capable of binding, preferably specifically, to a PRO 1105, PRO1279 or PRO1783 polypeptide as described herein may be identified without undue experimentation using well known techniques. In this regard, it is noted that techniques for 25 screening organic molecule libraries for molecules that are capable of binding to a polypeptide target are well known in the art (see, e.g., PCT Publication Nos. WOOO/00823 and WOOO/39585). An antibody, oligopeptide or other organic molecule "which binds" an antigen of interest, e.g. a tumor-associated polypeptide antigen target, is one that binds the antigen with 30 sufficient affinity such that the antibody, oligopeptide or other organic molecule is preferably useful as a diagnostic and/or therapeutic agent in targeting a cell or tissue expressing the 86 WO 2008/127352 PCT/US2007/080102 antigen, and does not significantly cross-react with other proteins. The extent of binding of the antibody, oligopeptide or other organic molecule to a "non-target" protein will be less than about 10% of the binding of the antibody, oligopeptide or other organic molecule to its particular target protein as determined by fluorescence activated cell sorting (FACS) analysis or radioimmunoprecipitation (RIA). With regard to the binding of an antibody, oligopeptide 5 or other organic molecule to a target molecule, the term "specific binding" or "specifically binds to" or is "specific for" a particular polypeptide or an epitope on a particular polypeptide target means binding that is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule, which generally is a molecule of similar structure that does not have binding 10 activity. For example, specific binding can be determined by competition with a control molecule that is similar to the target, for example, an excess of non-labeled target. In this case, specific binding is indicated if the binding of the labeled target to a probe is competitively inhibited by excess unlabeled target. The term "specific binding" or "specifically binds to" or is "specific for" a particular polypeptide or an epitope on a particular polypeptide target as used 15 herein can be exhibited, for example, by a molecule having a Kd for the target of at least about 10- M, alternatively at least about 10-5 M, alternatively at least about 106 M, alternatively at least about 10-7 M, alternatively at least about 108 M, alternatively at least about 10-' M, alternatively at least about 10-10 M, alternatively at least about 10-11 M, alternatively at least about 10-12 M, or greater. The term "specific binding" refers to binding where a molecule binds 20 to a particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope. An antibody, oligopeptide or other organic molecule that "inhibits the growth of tumor cells expressing a "PRO1105, PRO1279 or PRO1783" or a "growth inhibitory" antibody, oligopeptide or other organic molecule is one which results in measurable growth inhibition of 25 cancer cells expressing or overexpressing the appropriate PRO 1105, PRO 1279 or PRO 1783 polypeptide. The PRO 1105, PRO 1279 or PRO 1783 polypeptide may be a transmembrane polypeptide expressed on the surface of a cancer cell or may be a polypeptide that is produced and secreted by a cancer cell. Preferred growth inhibitory anti-PRO 1105, anti-PRO1279 or anti-PRO 1783 antibodies, oligopeptides or organic molecules inhibit growth of PRO 1105-, 30 PRO1279- or PRO1783-expressing tumor cells by or by greater than 20%, preferably from about 20% to about 50%, and even more preferably, byorbygreaterthan 50% (e.g., from about 87 WO 2008/127352 PCT/US2007/080102 50% to about 100%) as compared to the appropriate control, the control typically being tumor cells not treated with the antibody, oligopeptide or other organic molecule being tested. Growth inhibition can be measured at an antibody concentration of about 0.1 to 30 Lg/ml or about 0.5 nM to 200 nM in cell culture, where the growth inhibition is determined 1-10 days after exposure of the tumor cells to the antibody. Growth inhibition of tumor cells in vivo can be 5 determined in various ways. The antibody is growth inhibitory in vivo if administration of the anti-PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody at about 1 rig/kg to about 100 mg/kg body weight results in reduction in tumor size or tumor cell proliferation within about 5 days to 3 months from the first administration of the antibody, preferably within about 5 to 30 days. An antibody, oligopeptide or other organic molecule which "induces apoptosis" is one 10 which induces programmed cell death as determined by binding of annexin V, fragmentation of DNA, cell shrinkage, dilation of endoplasmic reticulum, cell fragmentation, and/or formation of membrane vesicles (called apoptotic bodies). The cell is usually one which overexpresses a PRO1105, PRO1279 or PRO1783 polypeptide. Preferably the cell is a tumor cell, e.g., a prostate, breast, ovarian, stomach, endometrial, lung, kidney, colon, bladder cell. Various 15 methods are available for evaluating the cellular events associated with apoptosis. For example, phosphatidyl serine (PS) translocation can be measured by annexin binding; DNA fragmentation can be evaluated through DNA laddering; and nuclear/chromatin condensation along with DNA fragmentation can be evaluated by any increase in hypodiploid cells. Preferably, the antibody, oligopeptide or other organic molecule which induces apoptosis is one 20 which results in or in about 2 to 50 fold, preferably in or in about 5 to 50 fold, and most preferably in or in about 10 to 50 fold, induction of annexin binding relative to untreated cell in an annexin binding assay. Antibody "effector functions" refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody, 25 and vary with the antibody isotype. Examples of antibody effector functions include: Clq binding and complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor); and B cell activation. "Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of 30 cytotoxicity in which secreted Ig bound onto Fc receptors (FcRs) present on certain cytotoxic cells (e.g., Natural Killer (NK) cells, neutrophils, and macrophages) enable these cytotoxic 88 WO 2008/127352 PCT/US2007/080102 effector cells to bind specifically to an antigen-bearing target cell and subsequently kill the target cell with cytotoxins. The antibodies "arm" the cytotoxic cells and are absolutely required for such killing. The primary cells for mediating ADCC, NK cells, express FcyRIII only, whereas monocytes express FcyRI, FcyRII and FcyRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 5 9:457-92 (1991). To assess ADCC activity of a molecule of interest, an in vitro ADCC assay, such as that described in US Patent No. 5,500,362 or 5,821,337 may be performed. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in a animal model such as that disclosed in Clynes et al.Proc. Natl. 10 Acad. Sci. U.S.A. 95:652-656 (1998). "Fc receptor" or "FcR" describes a receptor that binds to the Fc region of an antibody. The preferred FcR is a native sequence human FcR. Moreover, a preferred FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the FcyRI, FcyRII and FcyRIII subclasses, including allelic variants and alternatively spliced forms of these receptors. 15 FcyRII receptors include FcyRIIA (an "activating receptor") and FcyRIIB (an "inhibiting receptor"), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Activating receptor FcyRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcyRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain. (see review 20 M. in Daron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed in Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991); Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including those to be identified in the future, are encompassed by the term "FcR" herein. The term also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus 25 (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)). "Human effector cells" are leukocytes which express one or more FcRs and perform effector functions. Preferably, the cells express at least FcyRIII and perform ADCC effector function. Examples of human leukocytes which mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells and 30 neutrophils; with PBMCs and NK cells being preferred. The effector cells may be isolated from a native source, e.g., from blood. 89 WO 2008/127352 PCT/US2007/080102 "Complement dependent cytotoxicity" or "CDC" refers to the lysis of a target cell in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (Clq) to antibodies (of the appropriate subclass) which are bound to their cognate antigen. To assess complement activation, a CDC assay, e.g., as described in Gazzano-Santoro et al., J. Immunol. Methods 5 202:163 (1996), maybe performed. The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More particular examples of such cancers include squamous cell cancer, lung cancer (including small-cell lung 10 cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung), cancer ofthe peritoneum, hepatocellular cancer, gastric or stomach cancer (including gastrointestinal cancer), pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate 15 cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma (including low grade/follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade/follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; 20 and Waldenstrom's Macroglobulinemia); chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; and post transplant lymphoproliferative disorder (PTLD). Preferably, the cancer comprises a tumor that expresses an IGF receptor, more preferably breast cancer, lung cancer, colorectal cancer, or prostate cancer, and most preferably breast or prostate cancer. 25 A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and CYTOXAN@ cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, 30 triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; 90 WO 2008/127352 PCT/US2007/080102 callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlomaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide 5 hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e. g., calicheamicin, especially calicheamicin gammall and calicheamicin omegall (see, e.g., Agnew, Chem Intl. Ed. Engl., 33: 183-186 (1994)); dynemicin, including dynemicinA; bisphosphonates, such as clodronate; 10 an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN@ doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin 15 and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such 20 as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti- adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; 25 aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2- ethylhydrazide; procarbazine; PSK@ 30 polysaccharide complex (JHS Natural Products, Eugene, OR); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes 91 WO 2008/127352 PCT/US2007/080102 (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, e.g., TAXOL@ paclitaxel (Bristol- Myers Squibb Oncology, Princeton, N.J.), ABRAXANE TM Cremophor-free, albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, Illinois), and 5 TAXOTERE@ doxetaxel (Rh6ne- Poulenc Rorer, Antony, France); chloranbucil; GEMZAR@ gemcitabine; 6- thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; NAVELBINE@ vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; 10 difluorometlhylomithine (DMFO); retinoids such as retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included in this definition are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX® tamoxifen), raloxifene, 15 droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, and FARESTON- toremifene; aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASE@ megestrol acetate, AROMASIN@ exemestane, formestanie, fadrozole, RIVISOR@ vorozole, FEMARA@ letrozole, and ARIMIDEX@ anastrozole; and 2 0 anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; as well as troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); antisense oligonucleotides, particularly those which inhibit expression of genes in signaling pathways implicated in abherant cell proliferation, such as, for example, PKC-alpha, Ralf and H-Ras; ribozymes such as a VEGF expression inhibitor (e.g., ANGIOZYME@ ribozyme) and a HER2 expression 25 inhibitor; vaccines such as gene therapy vaccines, for example, ALLOVECTIN@ vaccine, LEUVECTIN@ vaccine, and VAXID@ vaccine; PROLEUKIN@ rIL-2; LURTOTECAN@ topoisomerase 1 inhibitor; ABARELIX@ rmRH; and pharmaceutically acceptable salts, acids or derivatives of any of the above. The terms "cell proliferative disorder" and "proliferative disorder" refer to disorders that 30 are associated with some degree of abnormal cell proliferation. In one aspect of the invention, the cell proliferative disorder is cancer. 92 WO 2008/127352 PCT/US2007/080102 "Tumor", as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. An antibody, oligopeptide or other organic molecule which "induces cell death" is one which causes a viable cell to become nonviable. The cell is one which expresses a PRO 1105, PRO 1279 or PRO 1783 polypeptide, preferably a cell that overexpresses a PRO 1105, PRO 1279 5 or PRO 1783 polypeptide as compared to a normal cell of the same tissue type. The PRO1105, PRO1279 or PRO1783 polypeptide may be a transmembrane polypeptide expressed on the surface of a cancer cell or may be a polypeptide that is produced and secreted by a cancer cell. Preferably, the cell is a cancer cell, e.g., a breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, thyroid, pancreatic or bladder cell. Cell death in vitro may be determined 10 in the absence of complement and immune effector cells to distinguish cell death induced by antibody-dependent cell-mediated cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC). Thus, the assay for cell death may be performed using heat inactivated serum (i.e., in the absence of complement) and in the absence of immune effector cells. To determine whether the antibody, oligopeptide or other organic molecule is able to induce cell death, loss of 15 membrane integrity as evaluated by uptake of propidium iodide (PI), trypan blue (see Moore et al. Cytotechnology 17:1-11 (1995)) or 7AAD can be assessed relative to untreated cells. Preferred cell death-inducing antibodies, oligopeptides or other organic molecules are those which induce PI uptake in the PI uptake assay in BT474 cells. As used herein, the term "immunoadhesion" designates antibody-like molecules which 20 combine the binding specificity of a heterologous protein (an "adhesion") with the effector functions of immunoglobulin constant domains. Structurally, the immunoadhesions comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is "heterologous"), and an immunoglobulin constant domain sequence. The adhesion part of an immunoadhesion 25 molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand. The immunoglobulin constant domain sequence in the immunoadhesion may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM. The word "label" when used herein refers to a detectable compound or composition 30 which is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody. The label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the 93 WO 2008/127352 PCT/US2007/080102 case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable. "Replication-preventing agent" is an agent wherein replication, function, and/or growth ofthe cells is inhibited or prevented, or cells are destroyed, no matter what the mechanism, such as by apoptosis, angiostasis, cytosis, tumoricide, mytosis inhibition, blocking cell cycle 5 progression, arresting cell growth, binding to tumors, acting as cellular mediators, etc. Such agents include a chemotherapeutic agent, cytotoxic agent, cytokine, growth-inhibitory agent, or anti-hormonal agent, e.g., an anti-estrogen compound such as tamoxifen, an anti-progesterone such as onapristone (see, EP 616 812); or an anti-androgen such as flutamide, as well as aromidase inhibitors, or a hormonal agent such as an androgen. 10 The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes (e.g., At 21 1 , 11, V25, Y 9 0 , Re' 86 , Re 88 , Sm 153 , Bi 21 2 p 32 and radioactive isotopes of Lu), chemotherapeutic agents e.g. methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, 15 daunorubicin or other intercalating agents, enzymes and fragments thereof such as nucleolytic enzymes, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof, and the various antitumor or anticancer agents disclosed below. Other cytotoxic agents are described below. A tumoricidal agent causes destruction of tumor cells. 2 0 Preferred cytotoxic agents herein for the specific tumor types to use in combination with the antagonists herein are as follows: 1. Prostate cancer: androgens, docetaxel, paclitaxel, estramustine, doxorubicin, mitoxantrone, antibodies to ErbB2 domain(s) such as 2C4 (WO 01/00245; hybridoma ATCC HB-12697), which binds to a region in the extracellular domain of ErbB2 (e.g., any one or more residues 25 in the region from about residue 22 to about residue 584 of ErbB2, inclusive), AVASTINTM anti-vascular endothelial growth factor (VEGF), TARCEVAT OSI-774 (erlotinib) (Genenetech and OSI Pharmaceuticals), or other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI's). 2. Stomach cancer: 5-fluorouracil (5FU), XELODATM capecitabine, methotrexate, etoposide, 30 cisplatin/carboplatin, pacliitaxel, docetaxel, gemcitabine, doxorubicin, and CPT-1 1 (camptothcin- 11; irinotecan, USA Brand Name: CAMPTOSAR*). 94 WO 2008/127352 PCT/US2007/080102 3. Pancreatic cancer: gemcitabine, 5FU, XELODATM capecitabine, CPT-11, docetaxel, paclitaxel, cisplatin, carboplatin, TARCEVAT erlotinib, and other EGFR TKI's. 4. Colorectal cancer: 5FU, XELODAT capecitabine, CPT-11, oxaliplatin, AVASTIN T M anti-VEGF, TARCEVA T M erlotinib and other EGFR TKI's, and ERBITUX T M (formerly known as IMC-C225) human:murine-chimerized monoclonal antibodythat binds to EGFR and blocks 5 the ability of EGF to initiate receptor activation and signaling to the tumor. 5. Renal cancer: IL-2, interferon alpha, AVASTIN T M anti-VEGF, MEGACE TM (Megestrol acetate) progestin, vinblastine, TARCEVATM erlotinib, and other EGFR TKI's. A "growth inhibitory agent" when used herein refers to a compound or composition which inhibits growth of a cell, especially a PRO 1105-, PRO 1279- or PRO 1783-expressing 10 cancer cell, either in vitro or in vivo. Thus, the growth inhibitory agent may be one which significantly reduces the percentage of PRO 1105-, PRO 1279- or PRO 1783-expressing cells in S phase. Examples of growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce GI arrest and M-phase arrest. Classical M-phase blockers include the vincas (vincristine and vinblastine), taxanes, and 15 topoisomerase II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest GI also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in The Molecular Basis of Cancer, Mendelsohn and Israel, eds., Chapter 1, entitled "Cell cycle regulation, 20 oncogenes, and antineoplastic drugs" by Murakami et al. (WB Saunders: Philadelphia, 1995), especially p. 13. The taxanes (paclitaxel and docetaxel) are anticancer drugs both derived from the yew tree. Docetaxel (TAXOTERE*, Rhone-Poulenc Rorer), derived from the European yew, is a semisynthetic analogue of paclitaxel (TAXOL*, Bristol-Myers Squibb). Paclitaxel and docetaxel promote the assembly of microtubules from tubulin dimers and stabilize 25 microtubules bypreventing depolymerization, which results in the inhibition ofmitosis in cells. "Doxorubicin" is an anthracycline antibiotic. The full chemical name of doxorubicin is (8 S-cis)- 10- [(3 -amino-2,3,6-trideoxy-a-L-lyxo-hexapyranosyl)oxy] -7,8,9,1 0-tetrahydro 6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione. The term "cytokine" is a generic term for proteins released by one cell population which 30 act on another cell as intercellular mediators. Examples of such cytokines are lymphokines, monokines, and traditional polypeptide hormones. Included among the cytokines are growth 95 WO 2008/127352 PCT/US2007/080102 hormone such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor; fibroblast growth factor; prolactin; placental lactogen; tumor necrosis factor-a and -P; mullerian-inhibiting substance; 5 mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors such as NGF-P; platelet-growth factor; transforming growth factors (TGFs) such as TGF-a and TGF-P; insulin-like growth factor-I and -II; erythropoietin (EPO); osteoinductive factors; interferons such as interferon -a, -P, and -y; colony stimulating factors (CSFs) such as macrophage-CSF (M-CSF); granulocyte 10 macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs) such as IL-I, IL- l a, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12; a tumor necrosis factor such as TNF-a or TNF-B; and other polypeptide factors including LIF and kit ligand (KL). As used herein, the term cytokine includes proteins from natural sources or from recombinant cell culture and biologically active equivalents of the native sequence cytokines. 15 The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products. The term "gene" refers to (a) a gene containing at least one of the DNA sequences 2 0 disclosed herein; (b) any DNA sequence that encodes the amino acid sequence encoded by the DNA sequences disclosed herein and/or; (c) any DNA sequence that hybridizes to the complement of the coding sequences disclosed herein. Preferably, the term includes coding as well as noncoding regions, and preferably includes all sequences necessary for normal gene expression. 25 The term "gene targeting" refers to a type of homologous recombination that occurs when a fragment of genomic DNA is introduced into a mammalian cell and that fragment locates and recombines with endogenous homologous sequences. Gene targeting by homologous recombination employs recombinant DNA technologies to replace specific genomic sequences with exogenous DNA of particular design. 30 The term "homologous recombination" refers to the exchange of DNA fragments between two DNA molecules or chromatids at the site of homologous nucleotide sequences. 96 WO 2008/127352 PCT/US2007/080102 The term "target gene" (alternatively referred to as "target gene sequence" or "target DNA sequence") refers to any nucleic acid molecule, polynucleotide, or gene to be modified by homologous recombination. The target sequence includes an intact gene, an exon or intron, a regulatory sequence or any region between genes. The target gene my comprise a portion of a particular gene or genetic locus in the individual's genomic DNA. 5 "Disruption" of a PRO1105, PRO1279 or PRO1783 gene occurs when a fragment of genomic DNA locates and recombines with an endogenous homologous sequence wherein the disruption is a deletion of the native gene or a portion thereof, or a mutation in the native gene or wherein the disruption is the functional inactivation of the native gene. Alternatively, sequence disruptions maybe generated by nonspecific insertional inactivation using a gene trap 10 vector (i.e. non-human transgenic animals containing and expressing a randomly inserted transgene; see for example U.S. Pat. No. 6,436,707 issued August 20, 2002). These sequence disruptions or modifications may include insertions, missense, frameshift, deletion, or substitutions, or replacements of DNA sequence, or any combination thereof. Insertions include the insertion of entire genes, which maybe of animal, plant, fungal, insect, prokaryotic, 15 or viral origin. Disruption, for example, can alter the normal gene product by inhibiting its production partially or completely or by enhancing the normal gene product's activity. Preferably, the disruption is a null disruption, wherein there is no significant expression of the PRO 1105, PRO1279 or PRO1783 gene. The term "native expression" refers to the expression of the full-length polypeptide 20 encoded by the PRO 1105, PRO 1279 or PRO 1783 gene, at expression levels present in the wild-type mouse. Thus, a disruption in which there is "no native expression" ofthe endogenous PRO1105, PRO1279 or PRO1783 gene refers to a partial or complete reduction of the expression of at least a portion of a polypeptide encoded by an endogenous PRO1105, PRO1279 or PRO1783 gene of a single cell, selected cells, or all of the cells of a mammal. 25 The term "knockout" refers to the disruption of a PRO 1105, PRO1279 or PRO1783 gene wherein the disruption results in: the functional inactivation of the native gene; the deletion of the native gene or a portion thereof; or a mutation in the native gene. The term "knock-in" refers to the replacement of the mouse ortholog (or other mouse gene) with a human cDNA encoding any of the specific human PRO1105-, PRO1279- or 30 PRO 1783-encoding genes or variants thereof (ie. the disruption results in a replacement of a native mouse gene with a native human gene). 97 WO 2008/127352 PCT/US2007/080102 The term "construct" or "targeting construct" refers to an artificially assembled DNA segment to be transferred into a target tissue, cell line or animal. Typically, the targeting construct will include a gene or a nucleic acid sequence ofparticular interest, a marker gene and appropriate control sequences. As provided herein, the targeting construct comprises a PRO 1105, PRO1279 or PRO1783 targeting construct. A "PRO 1105, PRO1279 or PRO1783 5 targeting construct" includes a DNA sequence homologous to at least one portion of a PRO 1105, PRO 1279 or PRO 1783 gene and is capable of producing a disruption in a PRO 1105, PRO 1279 or PRO 1783 gene in a host cell. The term "transgenic cell" refers to a cell containing within its genome a PRO 1105, PRO 1279 or PRO 1783 gene that has been disrupted, modified, altered, or replaced completely 10 or partially by the method of gene targeting. The term "transgenic animal" refers to an animal that contains within its genome a specific gene that has been disrupted or otherwise modified or mutated by the methods described herein or methods otherwise well known in the art. Preferably the non-human transgenic animal is a mammal. More preferably, the mammal is a rodent such as a rat or 15 mouse. In addition, a "transgenic animal" may be a heterozygous animal (i.e., one defective allele and one wild-type allele) or a homozygous animal (i.e., two defective alleles). An embryo is considered to fall within the definition of an animal. The provision of an animal includes the provision of an embryo or foetus in utero, whether by mating or otherwise, and whether or not the embryo goes to term. 20 As used herein, the terms "selective marker" and position selection marker" refer to a gene encoding a product that enables only the cells that carry the gene to survive and/or grow under certain conditions. For example, plant and animal cells that express the introduced neomycin resistance (Neor) gene are resistant to the compound G418. Cells that do not carry the Neor gene marker are killed by G418. Other positive selection markers are known to, or are 25 within the purview of, those of ordinary skill in the art. The term "modulates" or "modulation" as used herein refers to the decrease, inhibition, reduction, amelioration, increase or enhancement of a PRO 1105, PRO1279 or PRO1783 gene function, expression, activity, or alternatively a phenotype associated with PRO 1105, PRO1279 or PRO1783 gene. 30 The term "ameliorates" or "amelioration" as used herein refers to a decrease, reduction or elimination of a condition, disease, disorder, or phenotype, including an abnormality or 98 WO 2008/127352 PCT/US2007/080102 symptom. The term "abnormality" refers to any disease, disorder, condition, or phenotype in which PRO1105, PRO1279 or PRO1783 is implicated, including pathological conditions and behavioral observations. 99 WO 2008/127352 PCT/US2007/080102 Table 1 /* * C-C increased from 12 to 15 * Z is average of EQ 5 * B is average of ND * match with stop is _M; stop-stop = 0; J (joker) match = 0 #define _M -8 /* value of a match with a stop */ 10 int _day[26][26] = { /*A B C D E F G H I J K L M N O P Q R S T U V W X Y Z*/ /* A */ { 2, 0,-2, 0, 0,-4, 1,-1,-1, 0,-1,-2, -1, 0,_M, 1, 0,-2, 1, 1, 0, 0,-6, 0,-3, 0}, /* B */ { 0, 3,-4, 3, 2,-5, 0, 1,-2, 0, 0,-3,-2, 2,_M,-1, 1, 0, 0, 0, 0,-2,-5, 0,-3, 1}, /* C */ {-2,-4,15,-5,-5,-4,-3,-3,-2, 0,-5,-6,-5,-4, M,-3,-5,-4, 0,-2, 0,-2,-8, 0, 0,-5}, 15 /* D */ { 0, 3,-5, 4, 3,-6, 1, 1,-2, 0, 0,-4,-3, 2,_M,-1, 2,-1, 0, 0, 0,-2,-7, 0,-4, 2}, /* E */ { 0, 2,-5, 3, 4,-5, 0, 1,-2, 0, 0,-3,-2, 1,_M,-i, 2,-1, 0, 0, 0,-2,-7, 0,-4, 3}, /* F */ {-4,-5,-4,-6,-5, 9,-5,-2, 1, 0,-5, 2, 0,-4,_M,-5,-5,-4,-3,-3, 0,-1, 0, 0, 7,-5}, /* G */ { i, 0,-3, 1, 0,-5, 5,-2,-3, 0,-2,-4,-3, 0__M,-1,-1,-3, 1, 0, 0,-1,-7, 0,-5, 0}, /* H */ {-1, i,-3, 1, 1,-2,-2, 6,-2, 0, 0,-2,-2 2__M, 0, 3, 2,-1,-1, 0,-2,-3, 0, 0, 2}, 20 /* I */ {-1,-2,-2,-2,-2, 1,-3,-2, 5, 0,-2, 2, 2,-2,_M,-2,-2,-2,-1, 0,0, 4,-5, 0,-1,-2}, /*J*/ { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,0 0 0_M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0}, /* K */ {-1, 0,-5, 0, 0,-5,-2, 0,-2, 0, 5,-3, 0 1,_M,-1, 1, 3, 0, 0, 0,-2,-3, 0,-4, 0}, /* L */ {-2,-3,-6,-4,-3, 2,-4,-2, 2, 0,-3, 6, 4,-3,_M,-3,-2,-3,-3,-1, 0, 2,-2, 0,-1,-2}, /* M */ {-1,-2,-5,-3,-2, 0,-3,-2, 2, 0, 0, 4 6-2_M,-2,-1, 0,-2,-1, 0, 2,-4, 0,-2,-1}, 25 /* N */ { 0, 2,-4, 2, 1,-4, 0, 2,-2, 0, 1,-3 -2, 2_M,-1, 1, 0, 1, 0, 0,-2,-4, 0,-2, 1}, /*O*/ LM,MMMMMMMMMMMMM 0,_M,_M,_M,_M,_M,_M,_M_M_M,_M,_M}, /* P */ { 1,-1,-3,-1,-1,-5,-1, 0,-2, 0,-1,-3,-2,-1,_M 6, 0, 0, 1, 0, 0,-1,-6, 0,-5, 0}, /* Q */ { 0, 1,-5, 2, 2,-5,-1, 3,-2, 0, 1,-2,-1, 1,_M, 0, 4, 1,-1,-1, 0,-2,-5, 0,-4, 3}, 30 /* R */ {-2, 0,-4,-1,-1,-4,-3, 2,-2, 0, 3,-3, 0, 0,_M, 0, 1, 6, 0,-1, 0,-2, 2, 0,-4, 0}, /* S */ { 1, 0, 0, 0, 0,-3, 1,-1,-1, 0, 0,-3,-2 1__M, 1,-1, 0, 2, 1, 0,-1,-2, 0,-3, 0}, /* T */ { 1, 0,-2, 0, 0,-3, 0,- 0, 0, 0,-1,-1 0__M, 0,-1,-1, 1, 3, 0, 0,-5, 0,-3, 0}, /*U*/ { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 0 0M, 0, 0, 0, 0, 0, 0, 0, 0,0,0,0}, /* V */ { 0,-2,-2,-2,-2,-1,-1,-2, 4, 0,-2, 2, 2,-2,_M,-1,-2,-2,-1, 0, 0, 4,-6, 0,-2,-2}, 35 /* W */ {-6,-5,-8,-7,-7, 0,-7,-3,-5, 0,-3,-2,-4,-4_M,-6,-5, 2,-2,-5, 0,-6,17, 0, 0,-6}, /*X*/ { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,0 0 0_M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0}, /* Y */ {-3,-3, 0,-4,-4, 7,-5, 0,-1, 0,-4,-1,-2,-2,_M,-5,-4,-4,-3,-3, 0,-2, 0, 0,10,-4}, /* Z */ { 0, 1,-5, 2, 3,-5, 0, 2,-2, 0, 0,-2-1, 1,_M, 0, 3, 0, 0, 0, 0,-2,-6, 0,-4, 4} }; 40 45 100 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') #include <stdio.h> #include <ctype.h> 5 #define MAXJMP 16 /* max jumps in a diag #define MAXGAP 24 /* don't continue to penalize gaps larger than this #define JMPS 1024 /* max jmps in an path */ #define MX 4 save if there's at least MX-I bases since last jmp 10 #define DMAT 3 /* value of matching bases #define DMIS 0 /* penalty for mismatched bases #define DINSO 8 /* penalty for a gap #define DINS1 1 /* penalty per base 15 #define PINSO 8 /* penalty for a gap #define PINS 1 4 /* penalty per residue gt struct1jmp / short n[MAXJMP]; /* size of jmp (neg for dely) 20 unsigned short x[MAXJMP]; /* base no. ofjmp in seq x 0 ; /* limits seq to 2At16 -1 b struct diag I t score; /* score at last jmp */ 25 long offset; /* offset of prey block */ short i 8mp; /* current jmp index */ strict jmp jp; /* list of jumps iu 30 struct path { int spc; /* number of leading spaces * short n[JMPS]; /* size of jmp (gap) */ int x[JMPS]; /* soc ofjmp (last elem before gap) */ 35 char *ofile; /* output file name char *namex[2]; /* seq names: getseqsO */ char * prog; /* prog name for err msgs * char *seqx[2]; /* seqs: getseqsO * 4 0 st dmax; /* best diag: nwo */ int dmaxO; /* final diag * nt dna; /* set if dna: main */ 5 t endgaps; /* set if penalizing end gaps t gapx, gapy; /* total gaps inex */ 45 t lenO, en; /* seq lens */ t ngapx,ngapy; /* total size of gaps* nt smax; * max score: nwo 101 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') int *xbm; /* bitmap for matching */ long offset; /* current offset in jmp file */ 5 struct diag *dx; /* holds diagonals */ struct path pp[2]; /* holds path for seqs */ char *calloco, *malloco, indexx, *strcpyO; char *getseq(, *gcalloc(; 102 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') /* Needleman-Wunsch alignment program * * usage: progs file file2 * where file and file2 are two dna or two protein sequences. 5 * The sequences can be in upper- or lower-case an may contain ambiguity * Any lines beginning with ';', '>' or '<' are ignored * Max file length is 65535 (limited by unsigned short x in the jmp struct) * A sequence with 1/3 or more of its elements ACGTU is assumed to be DNA * Output is in the file "align.out" 10 * * The program may create a tmp file in /tmp to hold info about traceback. * Original version developed under BSD 4.3 on a vax 8650 #include "nw.h" 15 #include "day.h" static _dbval[26] = { 1,14,2,13,0,0,4,11,0,0,12,0,3,15,0,0,0,5,6,8,8,7,9,0,10,0 20 static _pbval[26] = { 1, 2|(1<<('D'-'A'))|(1<<('N'-'A')), 4, 8, 16, 32, 64, 128, 256, OxFFFFFFF, 1<<10, 1<<11, 1<<12, 1<<13, 1<<14, 1<<15, 1<<16, 1<<17, 1<<18, 1<<19, 1<<20, 1<<21, 1<<22, 25 1<<23, 1<<24, 1<<25|(1<<('E'-'A'))|(1<<('Q'-'A')) }; main(ac, av) main int ac; 30 char *av[]; { prog = av[0]; if (ac != 3) { fprintf(stderr,"usage: %s file file2n", prog); 35 fprintf(stderr,"where file and file2 are two dna or two protein sequences.n"); fprintf(stderr,"The sequences can be in upper- or lower-casen"); fprintf(stderr,"Any lines beginning with ';' or '<' are ignoredn"); fprintf(stderr,"Output is in the file "align.outVn"); exit(1); 40 } namex[0] = av[1]; namex[l] = av[2]; seqx[0] = getseq(namex[0], &lenO); seqx[1] = getseq(namex[1], &len1); 45 xbm = (dna) _dbval : _pbval; endgaps = 0; /* 1 to penalize endgaps */ 103 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') ofile = "align.out"; /* output file */ nw(; /* fill in the matrix, get the possible jmps */ 5 readjmpso; /* get the actual jmps */ print; /* print stats, alignment */ cleanup(O); /* unlink any tmp files */} 104 WO 2008/127352 PCT/US2007/080102 Table 1 count' ) /* do the alignment, return best score: main * dna: values in Fitch and Smith, PNAS, 80, 1382-1386, 1983 * pro: PAM 250 values * When scores are equal, we prefer mismatches to any gap, prefer 5 * a new gap to extending an ongoing gap, and prefer a gap in seqx * to a gap in seq y. nw() w { 10 char *px, *py; /* seqs and ptrs int *ndely, *dely; /* keep track of dely int ndelx, delx; /* keep track of delx int *tmp; /* for swapping rowO, row / int mis; score for each type 15 int insO, insI; /* insertion penalties register id; /* diagonal index register ij; /* jmp index */ register *colO, *coll; /* score for curry, last row register xx, yy; /* index into seqs 20 dx = (struct diag *)g calloc("to get diags", lenO+lenl+1, sizeof(struct diag)); ndely = (ut *)gcalloc to get ndely", len +1, szeof(t)); dely = (jut *)gncallocto get delay , len + , szeof(ut)); colO = (jut *)g calloc("to get colO", lenl+1, sizeof(iut)); 25 coll = (jut *)g calloc(to get coll", lenl+ , sizeof(it)); insO = (dna) DINSO :PINS0; insiI = (dna) DINS l / PINnS 1; smax = -10000; ifj(endgaps);i 30 for (colO[*] = dely[O] = -insO, yy= 1; yy<= len; yy++) colO[yy] = dely[yy] = colO[yy-1] - inse; ndely[yy] = yy; colOc= ] = 0; /* Waterman Bull Math Biol 84*g1 35} else for(yy = 1; yy<= lenl; yy++) dely[yy] = -insO; /* fill in match matrix 40 for (px = seqx[0], xx = 1; xx <= lenO; px++, xx++){ /* initialize first entry in col iff(endgaps) 45 if (xx = 1) colo0y ] = delx = -(insO+insl); else 105 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') col1[0] = deIx = colO[0] - insl; ndelx = xx; 5 } else { coll[0] = 0; deIx = -insO; ndelx = 0; 10 } 106 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') ... nw for (py = seqx[1], yy = 1; yy <= len1; py++, yy++) { mis = colO[yy-1]; if (dna) 5 mis += (xbm[*px-'A']&xbm[*py-'A']) DMAT: DMIS; else mis += _day[*px-'A'][*py-'A']; /* update penalty for del in x seq; 10 * favor new del over ongong del * ignore MAXGAP if weighting endgaps if (endgaps || ndely[yy] < MAXGAP) { if (colO[yy] - insO >= dely[yy]) { 15 dely[yy] = colO[yy] - (insO+ins1); ndely[yy] = 1; } else { dely[yy] -= insl; ndely[yy]++; 20 } } else { if (colO[yy] - (insO+ins1) >= dely[yy]) { dely[yy] = colO[yy] - (insO+insl); ndely[yy] = 1; 25 } else ndely[yy]++; } /* update penalty for del in y seq; 30 * favor new del over ongong del if (endgaps || ndelx < MAXGAP) { if (col 1 [yy- 1] - insO >= delx) { delx = coll[yy-1] - (insO+ins1); 35 ndelx = 1; } else { delx -= ins1; ndelx++; } 40 }else{ if (col1[yy-1] - (insO+ins1) >= delx) { delx = coll[yy-1] - (insO+ins1); ndelx = 1; } else 45 ndelx++; } /* pick the maximum score; we're favoring 107 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') * mis over any del and delx over dely 5 ... nw id = xx - yy + lenl - 1; if (mis >= delx && mis >= dely[yy]) coll[yy] = mis; 10 108 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') else if (delx >= dely[yy]) { coll[yy] = delx; ij = dx[id].ijmp; if (dx[id].jp.n[O] && (!dna || (ndelx >= MAXJMP 5 && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINSO)) { dx[id].ijmp++; if (++ij >= MAXJMP) { writejmps(id); ij = dx[id].ijmp = 0; 10 dx[id].offset = offset; offset += sizeof(struct jmp) + sizeof(offset); } } dx[id].jp.n[ij] = ndelx; 15 dx[id].jp.x[ij] = xx; dx[id].score = delx; else{ coll[yy] = dely[yy]; 20 ij = dx[id].ijmp; if (dx[id].jp.n[O] && (!dna ||(ndely[yy] >= MAXJMP && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINSO)) { dx[id].ijmp++; if (++ij >= MAXJMP) { 25 writejmps(id); ij = dx[id].ijmp = 0; dx[id].offset = offset; offset += sizeof(struct jmp) + sizeof(offset); } 30} dx[id].jp.n[ij] = -ndely[yy]; dx[id].jp.x[ij] = xx; dx[id].score = dely[yy]; } 35 if (xx == lenO && yy < lenl){ /* last col if (endgaps) col l[yy] -= insO+ins1 *(len1-yy); 40 if (col 1[yy] > smax) { smax = coll[yy]; dmax = id; } } 45 } if (endgaps && xx < lenO) col 1[yy-1] -= insO+ins1 *(lenO-xx); if (col1[yy-1] > smax) { 109 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') smax = coll[yy-1]; dmax = id; 5 } tmp = colo; colo = coll; coil = tmp; } (void) free((char *)ndely); (void) free((char *)dely); (void) free((char *)colo); 10 (void) free((char *)coll); } 110 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') /* * print() -- only routine visible outside this module * 5 * static: * getmato -- trace back best path, count matches: print * pr aligno -- print alignment of described in array p[]: print * dumpblocko -- dump a block of lines with numbers, stars: pr align() * numso -- put out a number line: dumpblocko 10 * putlineo -- put out a line (name, [num], seq, [num]): dumpblocko * stars - -put a line of stars: dumpblocko * stripnameo -- strip any path and prefix from a seqname 15 #include "nw.h" #define SPC 3 #define PLINE 256 /* maximum output line */ #define PSPC 3 /* space between name or num and seq */ 20 extern _day[26][26]; int olen; /* set output line length */ FILE *fx; /* output file */ 25 print() print { int lx, ly, firstgap, lastgap; /* overlap */ if ((fx = fopen(ofile, "w")) == 0) { 30 fprintf(stderr,"%s: can't write %sn", prog, ofile); cleanup(1); } fprintf(fx, "<first sequence: %s (length = %d)n", namex[0], lenO); fprintf(fx, "<second sequence: %s (length = %d)n", namex[l], len1); 35 olen = 60; lx = lenO; ly = len1; firstgap = lastgap = 0; if (dmax < len1 - 1) { /* leading gap in x 40 pp[0].spc = firstgap = len1 - dmax - 1; ly -= pp[0].spc; } else if (dmax > len1 - 1) { /* leading gap in y */ pp[1].spc = firstgap = dmax - (len1 - 1); 45 lx -= pp[1].spc; } if (dmaxO < lenO - 1) { /* trailing gap in x lastgap = lenO - dmaxO -1; 111 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') lx -= lastgap; } 5 else if (dmaxO > lenO - 1) { /* trailing gap in y */ lastgap = dmaxO - (lenO - 1); ly -= lastgap; } getmat(lx, ly, firstgap, lastgap); 10 pr aligno; } 112 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') * trace back the best path, count matches static 5 getmat(lx, ly, firstgap, lastgap) getmat int lx, ly; /* "core" (minus endgaps) */ int firstgap, lastgap; /* leading trailing overlap */ { int nm, iO, il, sizO, sizl; 10 char outx[32]; double pct; register n, nl; register char *pO, *pl; /* get total matches, score 15 iO= il = sizo = sizl = 0; p0 = seqx[O] + pp[1].spc; pl = seqx[1] + pp[O].spc; nO =pp[1].spc + 1; 20 nl=pp[O].spc+ 1; nm = 0; while ( *p0 && *pl ) { if (sizO) { p1++; 25 n1++; sizO--; } else if (sizl) { p0++; 30 n0++; sizI--; } else { if (xbm[*p0-'A']&xbm[*p1-'A']) 35 nm++; if (nO++ == pp[O].x[iO]) sizO = pp[O].n[iO++]; if (nl++ == pp[1].x[il]) sizI = pp[1].n[il++]; 40 p0++; p1++; } } 45 /* pct homology: * if penalizing endgaps, base is the shorter seq * else, knock off overhangs and take shorter core 113 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') if (endgaps) lx = (lenO < len1) lenO : len1; 5 else lx = (lx < ly) lx : ly; pet = 100.*(double)nm/(double)lx; fprintf(fx, "n"); fprintf(fx, "<%d matches in an overlap of %d: %.2f percent similarityn", 10 nm, (nm == 1) "" : "es", lx, pet); 114 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') fprintf(fx, "<gaps in first sequence: %d", gapx); ...getmat if (gapx) { (void) sprintf(outx, " (%d %s%s)", ngapx, (dna) "base":"residue", (ngapx == 1) "":"s"); 5 fprintf(fx,"%s", outx); fprintf(fx, ", gaps in second sequence: %d", gapy); if (gapy) { (void) sprintf(outx, " (%d %s%s)", ngapy, (dna) "base":"residue", (ngapy == 1) "":"s"); 10 fprintf(fx,"%s", outx); } if (dna) fprintf(fx, "n<score: %d (match = %d, mismatch = %d, gap penalty = %d + %d per 15 base)n", smax, DMAT, DMIS, DINSO, DINS 1); else fprintf(fx, "n<score: %d (Dayhoff PAM 250 matrix, gap penalty = %d + %d per 20 residue)n", smax, PINSO, PINS 1); if (endgaps) fprintf(fx, "<endgaps penalized. left endgap: %d %s%s, right endgap: %d %s%sn", 25 firstgap, (dna) "base" : "residue", (firstgap == 1) "" : "s", lastgap, (dna) "base" : "residue", (lastgap == 1) "" : s else fprintf(fx, "<endgaps not penalizedn"); } 30 static nm; /* matches in core--for checking static lmax; /* lengths of stripped file names static ij[2]; /* jmp index for a path */ static nc[2]; /* number at start of current line static ni[2]; /* current elem number -- for gaping 35 static siz[2]; static char *ps[2]; /* ptr to current element static char *po[ 2 ]; /* ptr to next output char slot */ static char out[2]j[PLIN]; /* output line*/ static char star[PLINE]; /* set by stars */ 40 /* * print alignment of described in struct path pp[] static pr align() pralign 45 { int nn; /* char count */ int more; register I; 115 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') for (I = 0, imax = 0; I < 2; I++) { nn = stripname(namex[i]); 5 if (nn > Imax) Imax = nn; nc[i] = 1; ni[i] = 1; siz[i] = ij[i] = 0; 10 ps[i] = seqx[i]; po[i]= out[i]; } 116 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') for (nn = nm = 0, more = 1; more; ) { ...pr_align for (I = more = 0; I < 2; I++) { 5 * do we have more of this sequence if (!*ps[i]) continue; more++; 10 if (pp[i].spc) { /* leading space */ * poli]++ = ''; pp[i].spc--; } else if (siz[i]) { /* in a gap */ 15 *po[i]++= '-; siz[i]--; } else { /* we're putting a seq element 20 *po[i] = *ps[i]; if (islower(*ps[i])) *ps[i] = toupper(*ps[i]); poli]++; psli]++; 25 /* * are we at next gap for this seq if (ni[i] pp[i].x[ij[i]]) { 30 * we need to merge all gaps * at this location siz[i] = pp[i].n[ij[i]++]; while (ni[i] == pp[i].x[ij[i]]) 35 siz[i] += pp[i].n[ij[i]++]; } ni[i]++; } } 40 if (++nn ==olen |!more && nn){ dumpblocko; for (I = 0; 1 < 2; I++) po[i] = out[i]; nn=0; 45 } } } 117 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') * dump a block of lines, including numbers, stars: pr align() 5 static dumpblocko dumpblock { register I; for (I= 0; 1 < 2; I++) 10 *po[i]-- =''; 118 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') ...dumpblock (void) putc('n', fx); for (I= 0; I < 2; I++) { if (*out[i] && (*out[i] !='' *(po[i]) != '')) { 5 if(I==0) nums(I); if(I == 0 && *out[1]) starsO; putline(I); 10 if (I ==0 && *out[1]) fprintf(fx, star); if (I== 1) nums(I); } 15 } } * put out a number line: dumpblocko 20 static nums(ix) nums int ix; /* index in out[] holding seq line */ { char nline[PLINE]; 25 register I, j; register char *pn, *px, *py; for (pn = nline, I = 0; I < lmax+PSPC; I++, pn++) *pn = ''V; for (I = nc[ix], py = out[ix]; *py; py++, pn++) { 30 if (*py =='' *pyz=='-') *pn =''; else { if (1%10 == 0 || (I == 1 && nc[ix] != 1)) { j = (I < 0) -I : I; 35 for (px = pn; j; j /= 10, px--) *px =j%10 +'0'; if (I < 0) *px=-'; } 40 else *pn=''; I++; } } 45 *pn ''; nc[ix] = I; for (pn = nline; *pn; pn++) (void) putc(*pn, fx); 119 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') (void) putc('n', fx); } 5 /* * put out a line (name, [num], seq, [num]): dumpblocko static putline(ix) putline 10 int ix; { 120 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') ... putline int I; register char *px; 5 for (px = namex[ix], I = 0; *px && *px != px±±, I) (void) putc(*px, fx); for (; I < lmax+PSPC; I++) (void) putc('', fx); 10 /* these count from 1: * ni[] is current element (from 1) * nc[] is number at start of current line 15 for (px = out[ix]; *px; px++) (void) putc(*px&Ox7F, fx); (void) putc('n', fx); } 20 * put a line of stars (seqs always in out[O], out[1]): dumpblocko static 25 starsO stars { int I; register char *pO, *pl, cx, *px; 30 if (!*out[O] (*out[O]== '' && *(po[O])==) !*out[1] (*out[1]== '' && *(po[l]) return; px = star; for (I = Imax+PSPC; I; I--) 35 *px++=''; for (pO = out[O], p l = out[1]; *p0 && *p1; pO++, pl++) { if (isalpha(*pO) && isalpha(*p 1)) { 40 if (xbm[*pO-'A']&xbm[*p1-'A']) { cx ='*'; nm++; } else if (!dna && _day[*pO-'A'][*p1-'A'] > 0) 45x ='. else cx } 121 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') else cx 5 *px++= cx; } *px++ ='n'; *px =''; } 10 122 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') * strip path or prefix from pn, return len: pr align() static 5 stripname(pn) stripname char *pn; /* file name (may be path) */ { register char *px, *py; 10 py = 0; for (px = pn; *px; px++) if (*px =='/') py = px + 1; if (py) 15 (void) strcpy(pn, py); return(strlen(pn)); } 20 123 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') * cleanup -- cleanup any tmp file * getseqO -- read in seq, set dna, len, maxlen * gcalloco -- calloco with error checkin 5 * readjmpso -- get the good jmps, from tmp file if necessary * writejmps() -- write a filled array ofjmps to a tmp file: nwo #include "nw.h" #include <sys/file.h> 10 char *jname = "/tmp/homgXXXXXX"; /* tmp file for jmps */ FILE *fj; int cleanup; /* cleanup tmp file */ long lseeko; 15 /* * remove any tmp file if we blow cleanup(I) cleanup int I; 20 { if (fj) (void) unlink(jname); exit(I); } 25 /* * read, return ptr to seq, set dna, len, maxlen * skip lines starting with ';', '<', or'>' * seq in upper or lower case 30 char * getseq(file, len) getseq char *file; /* file name int *len; /* seq len */ { 35 char line[1024], *pseq; register char *px, *py; int natgc, tlen; FILE *fp; if ((fp = fopen(file,"r")) == 0) { 4 0 fprintf(stderr,"%s: can't read %sn", prog, file); exit(1); } tlen = natgc = 0; while (fgets(line, 1024, fp)) { 45 if (*line ==';' ll *line-= '<' *line == continue; for (px = line; *px !='n'; px++) if (isupper(*px) islower(*px)) 124 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') tlen++; } 5 if ((pseq = malloc((unsigned)(tlen+6))) == 0) { fprintf(stderr,"%s: malloco failed to get %d bytes for %sn", prog, tlen+6, file); exit(1); } pseq[O] = pseq[] = pseq[2] = pseq[3] ''; 125 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') ...getseq py = pseq + 4; *len = tlen; rewind(fp); 5 while (fgets(line, 1024, fp)) { if (*line ==';' ll *i line == ' continue; for (px = line; *px !='n'; px++) { if (isupper(*px)) 10 *py++ = *px; else if (islower(*px)) *py++ = toupper(*px); if (index("ATGCU",*(py-1))) natgc++; 15 } } *py++ = ''; *py =; (void) fclose(fp); 2 0 dna = natgc > (tlen/3); return(pseq+4); } char * g_calloc(msg, nx, sz) g-calloc 25 char *msg; /* program, calling routine */ int nx, sz; /* number and size of elements */ { char *px, *calloco; if ((px = calloc((unsigned)nx, (unsigned)sz)) == 0) { 30 if (*msg) { fprintf(stderr, "%s: gcalloco failed %s (n=%d, sz=%d)n", prog, msg, nx, sz); exit(1); } 35 } return(px); } 40 * get final jmps from dx[] or tmp file, set pp[], reset dmax: mainO readjmps() readjmps { int fd = -1; 45 int siz, i0, iI; register I, j, xx; if (fj) { (void) fclose(fj); 126 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') if ((fd = open(jname, ORDONLY, 0)) < 0) { fprintf(stderr, "%s: can't open(
%
sn", prog, namee; 5 cleanup(1); } } for (I =0 = il = 0, dmax0 = dmax, xx = lenO; ; I++) { while (1) { 10 for (j = dx[dmax].ijmp; j >= 0 && dx[dmax].jp.xb] >= xx; j--) 127 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') ...readjmps if ( < 0 && dx[dmax].offset && fj) { (void) lseek(fd, dx[dmax].offset, 0); (void) read(fd, (char *)&dx[dmax] .jp, sizeof(struct jmp)); 5 (void) read(fd, (char *)&dx [dmax].offset, sizeof(dx[dmax].offset)); dx[dmax].ijmp = MAXJMP-1; } else break; } 10 if(I>=JMPS){ fprintf(stderr, "%s: too many gaps in alignmentn", prog); cleanup(1); } if (j >= 0) { 15 siz = dx[dmax].jp.nb]; xx = dx[dmax].jp.xrj]; dmax += siz; if (siz < 0) { /* gap in second seq */ pp[1].n[il] = -siz; 20 xx += siz; /* id = xx -yy +1en1 - 1 pp[1].x[il] = xx - dmax + leni - 1; gapy++; ngapy -= siz; 25 /* ignore MAXGAP when doing endgaps */ siz = (-siz < MAXGAP || endgaps) -siz: MAXGAP; il++; } else if (siz > 0) { /* gap in first seq */ 30 pp[O].n[iO] = siz; pp[O].x[iO] = xx; gapx++; ngapx += siz; /* ignore MAXGAP when doing endgaps */ 35 siz = (siz < MAXGAP || endgaps) siz: MAXGAP; 10++; } } else 40 break; } /* reverse the order ofjmps */ for (j = 0, i0--; j <i; j++, i0--) { I = pp[O].nb]; pp[O].nb] = pp[0].n[i0]; pp[0].n[i0] = I; 45 I = pp[O].xj]; pp[O].xj] = pp[0].x[i0]; pp[0].x[i0] = I; } for (j = 0, il--; j < il; j++, il--) { I = pp[1].nb]; pp[1].nb] = pp[1].n[il]; pp[1].n[il] = I; 128 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') I = pp[l].xlj]; pp[1].xj] = pp[1].x[il]; pp[1].x[il] = I; } 5 if (fd >= 0) (void) close(fd); if (fi) { (void) unlink(jname); fj = 0; 10 offset = 0; } } 129 WO 2008/127352 PCT/US2007/080102 Table 1 (cont') * write a filled jmp struct offset of the prev one (if any): nwO 5 writejmps(ix) writejmps int ix; { char *mfktempo; 10 if (!fj) { if (mktemp(jname) < 0) { fprintf(stderr, "%s: can't mktemp() %sn", prog, namee; cleanup(1); } 15 if ((fj = fopen(jname, "w")) == 0) { fprintf(stderr, "%s: can't write %sn", prog, namee; exit(1); } } 20 (void) fwrite((char *)&dx[ix].jp, sizeof(struct jmp), 1, fj); (void) fwrite((char *)&dx[ix].offset, sizeof(dx[ix].offset), 1, fj); } 130 WO 2008/127352 PCT/US2007/080102 Table 2 PRO XXXXXXXXXXXXXXX (Length = 15 amino acids) Comparison Protein XXXXXYYYYYYY (Length = 12 amino acids) 5 % amino acid sequence identity = (the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide)= 10 5 divided by 15 = 33.3% Table 3 PRO XXXXXXXXXX (Length = 10 amino acids) 15 Comparison Protein XXXXXYYYYYYZZYZ (Length = 15 amino acids) % amino acid sequence identity = 20 (the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) = 5 divided by 10 = 50% 25 30 131 WO 2008/127352 PCT/US2007/080102 Table 4 PRO-DNA NNNNNNNNNNNNNN (Length = 14 nucleotides) Comparison DNA NNNNNNLLLLLLLLLL (Length = 16 5 nucleotides) % nucleic acid sequence identity = (the number of identically matching nucleotides between the two nucleic acid sequences as 10 determined by ALIGN-2) divided by (the total number ofnucleotides of the PRO-DNA nucleic acid sequence) = 6 divided by 14 = 42.9% 132 WO 2008/127352 PCT/US2007/080102 Table 5 PRO-DNA NNNNNNNNNNNN (Length = 12 nucleotides) Comparison DNA NNNNLLLVV (Length = 9 nucleotides) 5 % nucleic acid sequence identity = (the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number ofnucleotides of the PRO-DNA nucleic acid sequence)= 10 4 divided by 12 = 33.3% II. Compositions and Methods of the Invention A. Full-Length PRO 1105, PRO 1279 or PRO 1783 Polypeptides 15 The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO1105, PRO1279 or PRO1783 polypeptides. In particular, cDNAs encoding various PRO1105, PRO1279 or PRO 1783 polypeptides have been identified and isolated, as disclosed in further detail in the Examples below. It is noted that proteins produced in separate expression rounds may be given 20 different PRO numbers but the UNQ number is unique for any given DNA and the encoded protein, and will not be changed. However, for sake of simplicity, in the present specification the protein encoded by the full length native nucleic acid molecules disclosed herein as well as all further native homologues and variants included in the foregoing definition of PRO, will be referred to as "PRO/number", regardless of their origin or mode of preparation. 25 As disclosed in the Examples below, various cDNA clones have been deposited with the ATCC. The actual nucleotide sequences of those clones can readily be determined by the skilled artisan by sequencing of the deposited clone using routine methods in the art. The predicted amino acid sequence can be determined from the nucleotide sequence using routine skill. For the PRO 1105, PRO 1279 or PRO 1783 polypeptides and encoding nucleic acids 30 described herein, Applicants have identified what is believed to be the reading frame best identifiable with the sequence information available at the time. 133 WO 2008/127352 PCT/US2007/080102 B. PRO 1105, PRO 1279 or PRO 1783 Polypeptide Variants In addition to the full-length native sequence PRO1105, PRO1279 or PRO1783 polypeptides described herein, it is contemplated that PRO1105, PRO1279 or PRO1783 variants can be prepared. PRO1105, PRO1279 or PRO1783 variants can be prepared by introducing appropriate nucleotide changes into the PRO 1105, PRO 1279 or PRO 1783 DNA, 5 and/or by synthesis ofthe desired PRO 1105, PRO 1279 or PRO 1783 polypeptide. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the PRO 1105, PRO1279 or PRO1783 polypeptide, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics. Variations in the native full-length sequence PRO1105, PRO1279 or PRO1783 10 polypeptide or in various domains of the PRO1105, PRO1279 or PRO1783 polypeptide described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion or insertion of one or more codons encoding the PRO 1105, PRO 1279 or PRO 1783 polypeptide that results in a change in the 15 amino acid sequence of the PRO 1105, PRO1279 or PRO1783 polypeptide as compared with the native sequence PRO 1105, PRO 1279 or PRO 1783 polypeptide. Optionally the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the PRO 1105, PRO 1279 or PRO 1783 polypeptide. Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the 20 desired activity may be found by comparing the sequence of the PRO 1105, PRO 1279 or PRO 1783 polypeptide with that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, 25 i.e., conservative amino acid replacements. Insertions or deletions may optionally be in the range of about I to 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence. PRO 1105, PRO 1279 or PRO 1783 polypeptide fragments are provided herein. Such 30 fragments may be truncated at the N-terminus or C-terminus, or may lack internal residues, for example, when compared with a full length native protein. Certain fragments lack amino acid 134 WO 2008/127352 PCT/US2007/080102 residues that are not essential for a desired biological activity of the PRO 1105, PRO1279 or PRO1783 polypeptide. PRO1105, PRO1279 or PRO1783 fragments may be prepared by any of a number of conventional techniques. Desired peptide fragments may be chemically synthesized. An alternative approach involves generating PRO 1105, PRO 1279 or PRO 1783 fragments by 5 enzymatic digestion, e.g., by treating the protein with an enzyme known to cleave proteins at sites defined by particular amino acid residues, or by digesting the DNA with suitable restriction enzymes and isolating the desired fragment. Yet another suitable technique involves isolating and amplifying a DNA fragment encoding a desired polypeptide fragment, by polymerase chain reaction (PCR). Oligonucleotides that define the desired termini of the DNA 10 fragment are employed at the 5' and 3' primers in the PCR. Preferably, PRO 1105, PRO 1279 or PRO 1783 polypeptide fragments share at least one biological and/or immunological activity with the native PRO 1105, PRO1279 or PRO1783 polypeptide disclosed herein. Conservative substitutions of interest are shown in Table 6 under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more 15 substantial changes, denominated exemplary substitutions in Table 6, or as further described below in reference to amino acid classes, are preferably introduced and the products screened. Table 6 2 0 Origin Exemplary Preferred al Substitutions Substitutions Residu e Ala Val; Leu; Ile Val 25 (A) Arg Lys; Gln; Asn Lys (R) Asn Gln; His; Asp, Lys; Arg Gln (N) 30 Asp Glu; Asn Glu (D) Cys Ser; Ala Ser (C) Gln Asn; Glu Asn 35 (Q) Glu Asp; Gln Asp (E) 135 WO 2008/127352 PCT/US2007/080102 Gly Ala Ala (G) His Asn; Gln; Lys; Arg Arg (H) Ile (I) Leu; Val; Met; Ala; Leu Phe; Norleucine 5 Leu Norleucine; Ile; Val; Ile (L) Met; Ala; Phe Lys Arg; Gln; Asn Arg (K) Met Leu; Phe; Ile Leu 10 (M) Phe (F) Trp; Leu; Val; Ile; Ala; Tyr Tyr Pro (P) Ala Ala Ser (S) Thr Thr Thr (T) Val; Ser Ser 15 Trp Tyr; Phe Tyr (W) Tyr Trp; Phe; Thr; Ser Phe Val Ile; Leu; Met; Phe; Leu 2 0 (V) Ala; Norleucine Substantial modifications in function or immunological identity of the PRO 1105, PRO1279 or PRO1783 polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the 25 area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties: Amino acids may be grouped according to similarities in the properties of their side chains (in A. L. Lehninger, in Biochemistry, second ed., pp. 73-75, Worth Publishers, New York (1975)): 30 (1) non-polar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M) (2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q) (3) acidic: Asp (D), Glu (E) (4) basic: Lys (K), Arg (R), His(H) Alternatively, naturally occurring residues may be divided into groups based on common 35 side-chain properties: (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; 136 WO 2008/127352 PCT/US2007/080102 (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe. 5 Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites. The variations can be made using methods known in the art such as oligonucleotide mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed 10 mutagenesis [Carter et al., Nucl. Acids Res., 13:4331 (1986); Zoller et al., Nucl. Acids Res., 10:6487 (1987)], cassette mutagenesis [Wells et al., Gene, 34:315 (1985)], restriction selection mutagenesis [Wells et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)] or other known techniques can be performed on the cloned DNA to produce the PRO 1105, PRO 1279 or PRO 1783 variant DNA. 15 Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, seine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the 20 variant [Cunningham and Wells, Science, 244: 1081-1085 (1989)]. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins, (W.H. Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)]. If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used. 25 C. Modifications of PRO 1105, PRO1279 or PRO1783 Polypeptides Covalent modifications of PRO 1105, PRO 1279 or PRO 1783 polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a PRO1105, PRO1279 or PRO1783 polypeptide with an organic 30 derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues ofthe PRO 1105, PRO 1279 or PRO 1783 polypeptide. Derivatization with bifunctional 137 WO 2008/127352 PCT/US2007/080102 agents is useful, for instance, for crosslinking PRO 1105, PRO 1279 or PRO 1783 polypeptides to a water-insoluble support matrix or surface for use in the method for purifying anti PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibodies, and vice-versa. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional 5 imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p azidophenyl)dithio]propioimidate. Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation ofproline and lysine, 10 phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the a-amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group. Another type of covalent modification of the PRO1105, PRO1279 or PRO1783 15 polypeptide included within the scope of this invention comprises altering the native glycosylation pattern ofthe polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence PRO 1105, PRO 1279 or PRO 1783 polypeptides (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or 20 adding one or more glycosylation sites that are not present in the native sequence PRO 1105, PRO1279 or PRO1783 polypeptide. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present. Addition of glycosylation sites to the PRO 1105, PRO 1279 or PRO 1783 polypeptide 25 may be accomplished by altering the amino acid sequence. The alteration may be made, for example, by the addition of, or substitution by, one or more seine or threonine residues to the native sequence PRO 1105, PRO 1279 or PRO 1783 (for O-linked glycosylation sites). The PRO 1105, PRO 1279 or PRO 1783 amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the PRO 1105, 30 PRO1279 or PRO1783 polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids. 138 WO 2008/127352 PCT/US2007/080102 Another means of increasing the number of carbohydrate moieties on the PRO 1105, PRO 1279 or PRO 1783 polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981). Removal of carbohydrate moieties present on the PRO 1105, PRO1279 or PRO1783 5 polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 252:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the 10 use of a variety of endo- and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987). Another type of covalent modification of PRO1105, PRO1279 or PRO1783 polypeptides comprises linking the PRO 1105, PRO1279 or PRO1783 polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, 15 or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337. The PRO 1105, PRO 1279 or PRO 1783 polypeptides of the present invention may also be modified in a way to form a chimeric molecule comprising the PRO 1105, PRO 1279 or PRO 1783 polypeptide fused to another, heterologous polypeptide or amino acid sequence. 20 Such a chimeric molecule comprises a fusion of the PRO 1105, PRO1279 or PRO1783 polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl- terminus of the PRO 1105, PRO 1279 or PRO 1783 polypeptide. The presence of such epitope-tagged forms of the PRO 1105, PRO1279 or PRO1783 polypeptide can be detected using an antibody against 25 the tag polypeptide. Also, provision of the epitope tag enables the PRO1105, PRO1279 or PRO 1783 polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 30 12CA5 [Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biology, 139 WO 2008/127352 PCT/US2007/080102 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al., BioTechnologv, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; an a-tubulin epitope peptide [Skinner et al., J Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz 5 Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)]. The chimeric molecule may comprise a fusion of the PRO 1105, PRO 1279 or PRO 1783 polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule (also referred to as an "immunoadhesin"), such a fusion could be to the Fc region of an IgG molecule. The Ig fusions preferably include the substitution 10 of a soluble (transmembrane domain deleted or inactivated) form of a PRO 1105, PRO1279 or PRO1783 polypeptide in place of at least one variable region within an Ig molecule. In a particularly preferred aspect of the invention, the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CHI, CH2 and CH3 regions of an IgGI molecule. For the production of immunoglobulin fusions see also US Patent No. 5,428,130 issued June 27, 1995. 15 D. Preparation of PRO 1105, PRO 1279 or PRO 1783 Polypeptides The description below relates primarily to production of PRO 1105, PRO 1279 or PRO 1783 polypeptides by culturing cells transformed or transfected with a vector containing PRO 1105, PRO 1279 or PRO 1783 nucleic acid. It is, of course, contemplated that alternative 20 methods, which are well known in the art, may be employed to prepare PRO 1105, PRO1279 or PRO 1783 polypeptides. For instance, the PRO 1105, PRO 1279 or PRO 1783 sequence, or portions thereof, maybe produced by direct peptide synthesis using solid-phase techniques [see, e.g., Stewart et al., Solid-Phase Peptide Synthesis, W.H. Freeman Co., San Francisco, CA (1969); Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963)]. In vitro protein synthesis may 25 be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions. Various portions of the PRO1105, PRO1279 or PRO1783 polypeptide may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length PRO 1105, PRO 1279 or PRO 1783 polypeptide. 30 140 WO 2008/127352 PCT/US2007/080102 1. Isolation of DNA Encoding PRO 1105, PRO1279 or PRO1783 Polypeptides DNA encoding PRO 1105, PRO1279 or PRO1783 polypeptides may be obtained from a cDNA library prepared from tissue believed to possess the PRO 1105, PRO 1279 or PRO 1783 mRNA and to express it at a detectable level. Accordingly, human PRO1 105-, PRO1279- or PRO1783-DNA can be conveniently obtained from a cDNA library prepared from human 5 tissue, such as described in the Examples. The PRO 1105-, PRO 1279- or PRO 1783-encoding gene may also be obtained from a genomic library or by known synthetic procedures (e.g., automated nucleic acid synthesis). Libraries can be screened with probes (such as antibodies to the PRO 1105, PRO 1279 or PRO 1783 polypeptide or oligonucleotides of at least about 20-80 bases) designed to identify 10 the gene of interest or the protein encoded by it. Screening the cDNA or genomic library with the selected probe maybe conducted using standard procedures, such as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989). An alternative means to isolate the gene encoding PRO1105, PRO1279 or PRO1783 is to use PCR methodology [Sambrook et al., supra; Dieffenbach et al., PCR Primer: 15 A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1995)]. The Examples below describe techniques for screening a cDNA library. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of 20 labeling are well known in the art, and include the use of radiolabels like 32 P-labeled ATP, biotinylation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al., supra. Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other 25 private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined using methods known in the art and as described herein. Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first 30 time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al., supra, to detect precursors and processing intermediates of mRNA that may 141 WO 2008/127352 PCT/US2007/080102 not have been reverse-transcribed into cDNA. 2. Selection and Transformation of Host Cells Host cells are transfected or transformed with expression or cloning vectors described herein for PRO1105, PRO1279 or PRO1783 polypeptide production and cultured in 5 conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnolov: 10 a Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook et al., supra. Methods of eukaryotic cell transfection and prokaryotic cell transformation are known to the ordinarily skilled artisan, for example, CaCl 2 , CaPO 4 , liposome-mediated and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as 15 described in Sambrook et al., supra, or electroporation is generally used for prokaryotes. Infection with Agrobacterium tumefaciens is used for transformation of certain plant cells, as described by Shaw et al., Gene, 23:315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology, 52:456-457 (1978) can be employed. General aspects of 20 mammalian cell host system transfections have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen et al., J. Bact., 130:946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76:3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene, 25 polyornithine, may also be used. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzymolosv, 185:527-537 (1990) and Mansour et al., Nature, 336:348-352 (1988). Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes include but are not limited 30 to eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as E. coli. Various E. coli strains are publicly available, such as E. coli 142 WO 2008/127352 PCT/US2007/080102 K12 strain MM294 (ATCC 31,446); E. coli X1776 (ATCC 31,537); E. coli strain W3110 (ATCC 27,325) and K5 772 (ATCC 53,635). Other suitable prokaryotic host cells include Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B. subtilis and B. licheniformis (e.g., B. licheniformis 41P 5 disclosed in DD 266,710 published 12 April 1989), Pseudomonas such as P. aeruginosa, and Streptomyces. These examples are illustrative rather than limiting. Strain W3 110 is one particularly preferred host or parent host because it is a common host strain for recombinant DNA product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3 110 may be modified to effect a genetic mutation in the genes 10 encoding proteins endogenous to the host, with examples of such hosts including E. coli W3110 strain 1A2, which has the complete genotype tonA ; E. coli W3 110 strain 9E4, which has the complete genotype tonA ptr3; E. coli W3 110 strain 27C7 (ATCC 55,244), which has the complete genotype tonA ptr3 phoA E15 (argF-lac)169 degP ompT kan'; E. coli W3110 strain 37D6, which has the complete genotype tonAptr3phoA E15 (argF-lac)169 degP ompT rbs7 15 ilvG kan'; E. coli W3 110 strain 40B4, which is strain 37D6 with a non-kanamycin resistant degP deletion mutation; and an E. coli strain having mutant periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990. Alternatively, in vitro methods of cloning, e.g., PCR or other nucleic acid polymerase reactions, are suitable. In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are 20 suitable cloning or expression hosts for PRO 1105-, PRO 1279- or PRO 1783-encoding vectors. Saccharomyces cerevisiae is a commonly used lower eukaryotic host microorganism. Others include Schizosaccharomyces pombe (Beach and Nurse, Nature, 290: 140 [1981]; EP 139,383 published 2 May 1985); Kluyveromyces hosts (U.S. Patent No. 4,943,529; Fleer et al., Bio/Technoloav, 9:968-975 (1991)) such as, e.g., K. lactis (MW98-8C, CBS683, CBS4574; 25 Louvencourt et al., J. Bacteriol., 154(2):737-742 [1983]), K. fragilis (ATCC 12,424), K. bulgaricus (ATCC 16,045), K. wickeramii (ATCC 24,178), K. waltii (ATCC 56,500), K. drosophilarum (ATCC 36,906; Van den Berg et al., Bio/Technologv, 8:135 (1990)), K. thermotolerans, and K. marxianus; yarrowia (EP 402,226); Pichia pastoris (EP 183,070; Sreekrishna et al., J. Basic Microbiol., 28:265-278 [1988]); Candida; Trichoderma reesia (EP 30 244,234); Neurospora crassa (Case et al., Proc. Natl. Acad. Sci. USA, 76:5259-5263 [1979]); Schwanniomyces such as Schwanniomyces occidentalis (EP 394,538 published 31 October 143 WO 2008/127352 PCT/US2007/080102 1990); and filamentous fungi such as, e.g., Neurospora, Penicillium, Tolypocladium (WO 91/00357 published 10 January 1991), and Aspergillus hosts such as A. nidulans (Ballance et al., Biochem. Biophys. Res. Commun., 112:284-289 [1983]; Tilburn et al., Gene, 26:205-221 [1983]; Yelton et al., Proc. Natl. Acad. Sci. USA, 81: 1470-1474 [1984]) and A. niger (Kelly and Hynes, EMBO J., 4:475-479 [1985]). Methylotropic yeasts are suitable herein and include, 5 but are not limited to, yeast capable of growth on methanol selected from the genera consisting of Hansenula, Candida, Kloeckera, Pichia, Saccharomyces, Torulopsis, and Rhodotorula. A list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, The Biochemistry of Methvlotrophs, 269 (1982). Suitable host cells for the expression of glycosylated PRO 1105, PRO1279 or PRO1783 10 polypeptides are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as Drosophila S2 and Spodoptera Sf9, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension 15 culture, Graham et al., J. Gen Virol., 36:59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL5 1). The selection of the appropriate host cell is deemed to be within the skill in the art. 20 3. Selection and Use of a Replicable Vector The nucleic acid (e.g., cDNA or genomic DNA) encoding PRO 1105, PRO 1279 or PRO 1783 polypeptides may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for 25 example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a 30 transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled 144 WO 2008/127352 PCT/US2007/080102 artisan. The PRO1105, PRO 1279 or PRO 1783 polypeptide may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the 5 vector, or it may be a part of the PRO 1105-, PRO1279- or PRO1783-encoding DNA that is inserted into the vector. The signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including Saccharomyces and Kluyveromyces a-factor leaders, the 10 latter described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the C. albicans glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In mammalian cell expression, mammalian signal sequences maybe used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders. 15 Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors 20 in mammalian cells. Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from 25 complex media, e.g., the gene encoding D-alanine racemase for Bacilli. An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the PRO1105-, PRO1279- or PRO1783 encoding nucleic acid, such as DHFR or thymidine kinase. An appropriate host cell when wild type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and 30 propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77:4216 (1980). A suitable selection gene for use in yeast is the trpl gene present in the yeast plasmid YRp7 145 WO 2008/127352 PCT/US2007/080102 [Stinchcomb et al., Nature, 282:39 (1979); Kingsman et al., Gene, 7:141 (1979); Tschemper et al., Gene, 10:157 (1980)]. The trpl gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 [Jones, Genetics, 85:12 (1977)]. Expression and cloning vectors usually contain a promoter operably linked to the 5 PRO1105-, PRO 1279- or PRO 1783-encoding nucleic acid sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the p-lactamase and lactose promoter systems [Chang et al., Nature, 275:615 (1978); Goeddel et al., Nature, 281:544 (1979)], alkaline phosphatase, a tryptophan (trp) promoter system [Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776], 10 and hybrid promoters such as the tac promoter [deBoer et al., Proc. Natl. Acad. Sci. USA, 80:21-25 (1983)]. Promoters for use in bacterial systems also will contain a Shine-Dalgamo (S.D.) sequence operably linked to the DNA encoding PRO 1105, PRO1279 or PRO1783 polypeptides. Examples of suitable promoting sequences for use with yeast hosts include the 15 promoters for 3-phosphoglycerate kinase [Hitzeman et al., J. Biol. Chem., 255:2073 (1980)] or other glycolytic enzymes [Hess et al., J. Adv. Enzyme Reg., 7:149 (1968); Holland, Biochemistry, 17:4900 (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3 phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose 20 isomerase, and glucokinase. Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3 -phosphate dehydrogenase, and 25 enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657. PRO 1105, PRO 1279 or PRO 1783 transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes ofviruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 30 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter 146 WO 2008/127352 PCT/US2007/080102 or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems. Transcription of a DNA encoding the PRO 1105, PRO 1279 or PRO 1783 polypeptide by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a 5 promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, a-fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus 10 enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the PRO 1105, PRO 1279 or PRO1783 coding sequence, but is preferably located at a site 5' from the promoter. Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences 15 are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding PRO 1105, PRO 1279 or PRO 1783 polypeptides. Still other methods, vectors, and host cells suitable for adaptation to the synthesis of 20 PRO 1105, PRO 1279 or PRO 1783 polypeptides in recombinant vertebrate cell culture are described in Gething et al., Nature, 293:620-625 (1981); Mantei et al., Nature, 281:40-46 (1979); EP 117,060; and EP 117,058. 4. Detecting Gene Amplification/Expression 25 Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)], dot blotting (DNA analysis), or in situ hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific 30 duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn maybe labeled and the assay maybe carried out 147 WO 2008/127352 PCT/US2007/080102 where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected. Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for 5 immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence PRO 1105, PRO 1279 or PRO 1783 polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to PRO 1105-, PRO 1279- or PRO 1783-DNA and encoding a specific antibody 10 epitope. 5. Purification of Polypeptide Forms ofPRO1 105, PRO1279 orPRO1783 polypeptides maybe recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane 15 using a suitable detergent solution (e.g. Triton-X 100) or by enzymatic cleavage. Cells employed in expression of PRO 1105, PRO 1279 or PRO 1783 polypeptides can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents. It may be desired to purify PRO 1105, PRO 1279 or PRO 1783 polypeptides from 2 0 recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; 25 and metal chelating columns to bind epitope-tagged forms of the PRO 1105, PRO 1279 or PRO 1783 polypeptide. Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, Methods in Enzymology, 182 (1990); Scopes, Protein Purification: Principles and Practice, Springer-Verlag, New York (1982). The purification step(s) selected will depend, for example, on the nature of the 30 production process used and the particular PRO 1105, PRO 1279 or PRO 1783 polypeptide produced. 148 WO 2008/127352 PCT/US2007/080102 E. Uses for PRO 1105, PRO 1279 or PRO 1783 Polypeptides Nucleotide sequences (or their complement) encoding PRO1105, PRO1279 or PRO 1783 polypeptides have various applications in the art ofmolecular biology, including uses as hybridization probes, in chromosome and gene mapping and in the generation of anti-sense RNA and DNA. PRO 1105, PRO1279 or PRO1783 nucleic acid will also be useful for the 5 preparation of PRO 1105, PRO1279 or PRO1783 polypeptides by the recombinant techniques described herein. The full-length native sequence PRO 1105, PRO1279 or PRO1783 gene, or portions thereof, may be used as hybridization probes for a cDNA library to isolate the full-length PRO 1105, PRO 1279 or PRO 1783 cDNA or to isolate still other cDNAs (for instance, those 10 encoding naturally-occurring variants of PRO 1105, PRO1279 or PRO1783 polypeptides or PRO 1105, PRO 1279 or PRO 1783 polypeptides from other species) which have a desired sequence identity to the native PRO 1105, PRO 1279 or PRO 1783 sequence disclosed herein. Optionally, the length of the probes will be about 20 to about 50 bases. The hybridization probes may be derived from at least partially novel regions of the full length native nucleotide 15 sequence wherein those regions may be determined without undue experimentation or from genomic sequences including promoters, enhancer elements and introns of native sequence PRO1105, PRO1279 or PRO1783. By way of example, a screening method will comprise isolating the coding region of the PRO1105, PRO1279 or PRO1783 gene using the known DNA sequence to synthesize a selected probe of about 40 bases. Hybridization probes may be 2 0 labeled by a variety of labels, including radionucleotides such as 32 P or 35 S, or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems. Labeled probes having a sequence complementary to that of the PRO 1105, PRO 1279 or PRO 1783 gene of the present invention can be used to screen libraries of human cDNA, genomic DNA or mRNA to determine which members of such libraries the probe hybridizes to. Hybridization 25 techniques are described in further detail in the Examples below. Any EST sequences disclosed in the present application may similarly be employed as probes, using the methods disclosed herein. Other useful fragments of the PRO 1105, PRO1279 or PRO1783 nucleic acids include antisense or sense oligonucleotides comprising a singe-stranded nucleic acid sequence (either 30 RNA or DNA) capable of binding to target PRO 1105, PRO 1279 or PRO 1783 mRNA (sense) or PRO1105-, PRO1279- or PRO1783-DNA (antisense) sequences. Antisense or sense 149 WO 2008/127352 PCT/US2007/080102 oligonucleotides, according to the present invention, comprise a fragment of the coding region of PRO1105-, PRO1279- or PRO1783-DNA. Such a fragment generally comprises at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, for example, Stein and Cohen (Cancer Res. 48:2659, 1988) and van der Krol 5 et al. (BioTechniques 6:958, 1988). Binding of antisense or sense oligonucleotides to target nucleic acid sequences results in the formation of duplexes that block transcription or translation of the target sequence by one of several means, including enhanced degradation of the duplexes, premature termination of transcription or translation, or by other means. The antisense oligonucleotides thus may be used 10 to block expression of PRO 1105, PRO 1279 or PRO 1783. Antisense or sense oligonucleotides further comprise oligonucleotides having modified sugar-phosphodiester backbones (or other sugar linkages, such as those described in WO 91/06629) and wherein such sugar linkages are resistant to endogenous nucleases. Such oligonucleotides with resistant sugar linkages are stable in vivo (i.e., capable of resisting enzymatic degradation) but retain sequence specificity 15 to be able to bind to target nucleotide sequences. Other examples of sense or antisense oligonucleotides include those oligonucleotides which are covalently linked to organic moieties, such as those described in WO 90/10048, and other moieties that increases affinity of the oligonucleotide for a target nucleic acid sequence, such as poly-(L-lysine). Further still, intercalating agents, such as ellipticine, and alkylating 20 agents or metal complexes may be attached to sense or antisense oligonucleotides to modify binding specificities ofthe antisense or sense oligonucleotide for the target nucleotide sequence. Antisense or sense oligonucleotides may be introduced into a cell containing the target nucleic acid sequence by any gene transfer method, including, for example, CaPO 4 -mediated DNA transfection, electroporation, or by using gene transfer vectors such as Epstein-Barr virus. 25 In a preferred procedure, an antisense or sense oligonucleotide is inserted into a suitable retroviral vector. A cell containing the target nucleic acid sequence is contacted with the recombinant retroviral vector, either in vivo or ex vivo. Suitable retroviral vectors include, but are not limited to, those derived from the murine retrovirus M-MuLV, N2 (a retrovirus derived from M-MuLV), or the double copy vectors designated DCT5A, DCT5B and DCT5C (see WO 30 90/13641). Sense or antisense oligonucleotides also may be introduced into a cell containing the 150 WO 2008/127352 PCT/US2007/080102 target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule 5 or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a sense or an antisense oligonucleotide may be introduced into a cell containing the target nucleic acid sequence by formation of an oligonucleotide-lipid complex, as described in WO 90/10448. The sense or antisense oligonucleotide-lipid complex is 10 preferably dissociated within the cell by an endogenous lipase. Antisense or sense RNA or DNA molecules are generally at least about 5 bases in length, about 10 bases in length, about 15 bases in length, about 20 bases in length, about 25 bases in length, about 30 bases in length, about 35 bases in length, about 40 bases in length, about 45 bases in length, about 50 bases in length, about 55 bases in length, about 60 bases in 15 length, about 65 bases in length, about 70 bases in length, about 75 bases in length, about 80 bases in length, about 85 bases in length, about 90 bases in length, about 95 bases in length, about 100 bases in length, or more. The probes may also be employed in PCR techniques to generate a pool of sequences for identification of closely related PRO 1105, PRO1279 or PRO1783 coding sequences. 20 Nucleotide sequences encoding a PRO 1105, PRO 1279 or PRO 1783 polypeptide can also be used to construct hybridization probes for mapping the gene which encodes that PRO 1105, PRO 1279 or PRO 1783 polypeptide and for the genetic analysis of individuals with genetic disorders. The nucleotide sequences provided herein maybe mapped to a chromosome and specific regions of a chromosome using known techniques, such as in situ hybridization, 25 linkage analysis against known chromosomal markers, and hybridization screening with libraries. When the coding sequences for PRO 1105, PRO 1279 or PRO 1783 encode a protein which binds to another protein (for example, where the PRO 1105, PRO 1279 or PRO 1783 is a receptor), the PRO 1105, PRO 1279 or PRO 1783 polypeptide can be used in assays to identify 30 the other proteins or molecules involved in the binding interaction. By such methods, inhibitors of the receptor/ligand binding interaction can be identified. Proteins involved in such binding 151 WO 2008/127352 PCT/US2007/080102 interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction. Also, the receptor PRO 1105, PRO 1279 or PRO 1783 can be used to isolate correlative ligand(s). Screening assays can be designed to find lead compounds that mimic the biological activity of a native PRO 1105, PRO 1279 or PRO 1783 polypeptide or a receptor for PRO 1105, PRO 1279 or PRO 1783 polypeptides. Such screening assays will 5 include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates. Small molecules contemplated include synthetic organic or inorganic compounds. The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays and cell based assays, which are well characterized in the art. 10 Nucleic acids which encode PRO 1105, PRO 1279 or PRO 1783 polypeptides or its modified forms can also be used to generate either transgenic animals or "knock out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A transgenic animal (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., 15 an embryonic stage. A transgene is a DNA which is integrated into the genome of a cell from which a transgenic animal develops. The invention provides cDNA encoding a PRO 1105, PRO1279 or PRO1783 polypeptide which can be used to clone genomic DNA encoding a PRO 1105, PRO 1279 or PRO 1783 polypeptide in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express 20 DNA encoding PRO 1105, PRO 1279 or PRO 1783 polypeptides. Any technique known in the art may be used to introduce a target gene transgene into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to pronuclear microinjection (U.S. Pat. Nos. 4,873,191, 4,736,866 and 4,870,009); retrovirus mediated gene transfer into germ lines (Van der Putten, et al., Proc. Natl. Acad. Sci.,USA, 82:6148-6152 25 (1985)); gene targeting in embryonic stem cells (Thompson, et al., Cell, 56:313-321 (1989)); nonspecific insertional inactivation using a gene trap vector (U.S. Pat. No. 6,436,707); electroporation of embryos (Lo, Mol. Cell. Biol., 3:1803-1814 (1983)); and sperm-mediated gene transfer (Lavitrano, et al., Cell, 57:717-723 (1989)); etc. Typically, particular cells would be targeted for a PRO 1105, PRO 1279 or PRO 1783 transgene incorporation with tissue-specific 30 enhancers. Transgenic animals that include a copy of a transgene encoding a PRO1105, PRO 1279 or PRO 1783 polypeptide introduced into the germ line ofthe animal at an embryonic 152 WO 2008/127352 PCT/US2007/080102 stage can be used to examine the effect of increased expression of DNA encoding PRO 1105, PRO1279 or PRO1783 polypeptides. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this facet of the invention, an animal is treated with the reagent and a reduced incidence of the pathological condition, compared to untreated animals 5 bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition. Alternatively, non-human homologues of PRO1105, PRO1279 or PRO1783 polypeptides can be used to construct a PRO1105, PRO1279 or PRO1783 "knockout" animal which has a defective or altered gene encoding PRO 1105, PRO 1279 or PRO 1783 proteins as a result of homologous recombination between the endogenous gene encoding PRO 1105, 10 PRO 1279 or PRO 1783 polypeptides and altered genomic DNA encoding PRO 1105, PRO 1279 or PRO1783 polypeptides introduced into an embryonic stem cell of the animal. Preferablythe knock out animal is a mammal. More preferably, the mammal is a rodent such as a rat or mouse. For example, cDNA encoding PRO 1105, PRO 1279 or PRO 1783 polypeptides can be used to clone genomic DNA encoding PRO 1105, PRO 1279 or PRO 1783 polypeptides in 15 accordance with established techniques. A portion of the genomic DNA encoding the PRO 1105, PRO 1279 or PRO 1783 polypeptide can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see e.g., Thomas and Capecchi, Cell, 51:503 (1987) for a description of 20 homologous recombination vectors]. The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected [see e.g., Li et al., Cell, 69:915 (1992)]. The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras [see e.g., Bradley, in Teratocarcinomas and Embryonic Stem Cells: A Practical 25 Approach, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152]. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knockout animals can be 30 characterized for instance, for their ability to defend against certain pathological conditions and for their development of pathological conditions due to absence of the gene encoding the 153 WO 2008/127352 PCT/US2007/080102 PRO 1105, PRO 1279 or PRO 1783 polypeptide. In addition, knockout mice can be highly informative in the discovery of gene function and pharmaceutical utility for a drug target, as well as in the determination of the potential on target side effects associated with a given target. Gene function and physiology are so well conserved between mice and humans., since they are both mammals and contain similar 5 numbers of genes, which are highly conserved between the species. It has recently been well documented, for example, that 98% of genes on mouse chromosome 16 have a human ortholog (Mural et al., Science 296:1661-71 (2002)). Although gene targeting in embryonic stem (ES) cells has enabled the construction of mice with null mutations in many genes associated with human disease, not all genetic diseases 10 are attributable to null mutations. One can design valuable mouse models of human diseases by establishing a method for gene replacement (knock-in) which will disrupt the mouse locus and introduce a human counterpart with mutation, Subsequently one can conduct in vivo drug studies targeting the human protein (Kitamoto et. Al., Biochemical and Biophysical Res. Commun., 222:742-47 (1996)). 15 Nucleic acid encoding the PRO 1105, PRO 1279 or PRO 1783 polypeptides may also be used in gene therapy. In gene therapy applications, genes are introduced into cells in order to achieve in vivo synthesis of a therapeutically effective genetic product, for example for replacement of a defective gene. "Gene therapy" includes both conventional gene therapy where a lasting effect is achieved by a single treatment, and the administration of gene 2 0 therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or mRNA. Antisense RNAs and DNAs can be used as therapeutic agents for blocking the expression of certain genes in vivo. It has already been shown that short antisense oligonucleotides can be imported into cells where they act as inhibitors, despite their low intracellular concentrations caused by their restricted uptake by the cell membrane. (Zamecnik 25 etal., Proc. Natl. Acad. Sci. USA 83:4143-4146 [1986]). The oligonucleotides can be modified to enhance their uptake, e.g. by substituting their negatively charged phosphodiester groups by uncharged groups. There are a variety of techniques available for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells 30 in vitro, or in vivo in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into mammalian cells in vitro include the use of liposomes, electroporation, 154 WO 2008/127352 PCT/US2007/080102 microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. The currently preferred in vivo gene transfer techniques include transfection with viral (typically retroviral) vectors and viral coat protein-liposome mediated transfection (Dzau et al., Trends in Biotechnology 11, 205-210 [1993]). In some situations it is desirable to provide the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell 5 surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc. Where liposomes are employed, proteins which bind to a cell surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, e.g. capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular 10 half-life. The technique of receptor-mediated endocytosis is described, for example, by Wu et al., J. Biol. Chem. 262, 4429-4432 (1987); and Wagner et al., Proc. Natl. Acad. Sci. USA 87, 3410-3414 (1990). For review of gene marking and gene therapy protocols see Anderson et al., Science 256, 808-813 (1992). The PRO 1105, PRO 1279 or PRO 1783 polypeptides described herein may also be 15 employed as molecular weight markers for protein electrophoresis purposes and the isolated nucleic acid sequences may be used for recombinantly expressing those markers. The nucleic acid molecules encoding the PRO1105, PRO1279 or PRO1783 polypeptides or fragments thereof described herein are useful for chromosome identification. In this regard, there exists an ongoing need to identify new chromosome markers, since 20 relatively few chromosome marking reagents, based upon actual sequence data are presently available. Each PRO 1105, PRO 1279 or PRO 1783 nucleic acid molecule of the present invention can be used as a chromosome marker. The PRO 1105, PRO 1279 or PRO 1783 polypeptides and nucleic acid molecules of the present invention may also be used diagnostically for tissue typing, wherein the PRO1 105, 25 PRO 1279 or PRO 1783 polypeptides of the present invention may be differentially expressed in one tissue as compared to another, preferably in a diseased tissue as compared to a normal tissue of the same tissue type. PRO1 105, PRO1279 or PRO1783 nucleic acid molecules will find use for generating probes for PCR, Northern analysis, Southern analysis and Western analysis. 30 The PRO1105, PRO1279 or PRO1783 polypeptides described herein may also be employed as therapeutic agents. The PRO 1105, PRO1279 or PRO1783 polypeptides of the 155 WO 2008/127352 PCT/US2007/080102 present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the PRO1105, PRO1279 or PRO1783 product hereof is combined in admixture with a pharmaceutically acceptable carrier vehicle. Therapeutic formulations are prepared for storage by mixing the active ingredient having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers 5 (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or 10 immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEENm, PLURONICSm or PEG. 15 The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution. Therapeutic compositions herein generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a 20 hypodermic injection needle. The route of administration is in accord with known methods, e.g. injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial or intralesional routes, topical administration, or by sustained release systems. Dosages and desired drug concentrations of pharmaceutical compositions ofthe present 25 invention may vary depending on the particular use envisioned. The determination of the appropriate dosage or route of administration is well within the skill of an ordinary physician. Animal experiments provide reliable guidance for the determination of effective doses for human therapy. Interspecies scaling of effective doses can be performed following the principles laid down by Mordenti, J. and Chappell, W. "The use of interspecies scaling in 30 toxicokinetics" In Toxicokinetics and New Drug Development, Yacobi et al., Eds., Pergamon Press, New York 1989, pp. 42-96. 156 WO 2008/127352 PCT/US2007/080102 When in vivo administration of a PRO 1105, PRO 1279 or PRO 1783 polypeptide or agonist or antagonist thereof is employed, normal dosage amounts may vary from about 10 ng/kg to up to 100 mg/kg of mammal body weight or more per day, preferably about 1 rig/kg/day to 10 mg/kg/day, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature; see, for example, U.S. 5 Pat. Nos. 4,657,760; 5,206,344; or 5,225,212. It is anticipated that different formulations will be effective for different treatment compounds and different disorders, that administration targeting one organ or tissue, for example, may necessitate delivery in a manner different from that to another organ or tissue. Where sustained-release administration of a PRO1105, PRO1279 or PRO1783 10 polypeptide is desired in a formulation with release characteristics suitable for the treatment of any disease or disorder requiring administration of the PRO 1105, PRO 1279 or PRO 1783 polypeptide, microencapsulation of the PRO1105, PRO1279 or PRO1783 polypeptide is contemplated. Microencapsulation of recombinant proteins for sustained release has been successfully performed with human growth hormone (rhGH), interferon- (rhIFN-), interleukin 15 2, and MN rgp120. Johnson et al., Nat. Med., 2:795-799 (1996); Yasuda, Biomed. Ther., 27:1221-1223 (1993); Hora et al., Bio/Technoloav, 8:755-758 (1990); Cleland, "Design and Production of Single Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems," in Vaccine Design: The Subunit and Adjuvant Approach, Powell and Newman, eds, (Plenum Press: New York, 1995), pp. 439-462; WO 97/03692, WO 96/40072, WO 96/07399; 20 and U.S. Pat. No. 5,654,010. The sustained-release formulations of these proteins were developed using poly-lactic coglycolic acid (PLGA) polymer due to its biocompatibility and wide range of biodegradable properties. The degradation products of PLGA, lactic and glycolic acids, can be cleared quickly within the human body. Moreover, the degradability of this polymer can be adjusted from 25 months to years depending on its molecular weight and composition. Lewis, "Controlled release ofbioactive agents from lactide/glycolide polymer," in: M. Chasin and R. Langer (Eds.), Biodegradable Polymers as Drug Delivery Systems (Marcel Dekker: New York, 1990), pp. 1 41. This invention encompasses methods of screening compounds to identify those that 30 mimic the PRO 1105, PRO1279 or PRO1783 polypeptide (agonists) or prevent the effect of the PRO 1105, PRO 1279 or PRO 1783 polypeptide (antagonists). Agonists that mimic a PRO 1105, 157 WO 2008/127352 PCT/US2007/080102 PRO1279 or PRO1783 polypeptide would be especially valuable therapeutically in those instances where a negative phenotype is observed based on findings with the non-human transgenic animal whose genome comprises a disruption of the gene which encodes for the PRO1105, PRO1279 or PRO1783 polypeptide. Antagonists that prevent the effects of a PRO 1105, PRO 1279 or PRO 1783 polypeptide would be especially valuable therapeutically in 5 those instances where a positive phenotype is observed based upon observations with the non human transgenic knockout animal. Screening assays for antagonist drug candidates are designed to identify compounds that bind or complex with the PRO1105, PRO1279 or PRO 1783 polypeptide encoded by the genes identified herein, or otherwise interfere with the interaction of the encoded polypeptide with other cellular proteins. Such screening assays will 10 include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates. The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays, and cell-based assays, which are well characterized in the art. 15 All assays for antagonists are common in that they call for contacting the drug candidate with a PRO 1105, PRO 1279 or PRO 1783 polypeptide encoded by a nucleic acid identified herein under conditions and for a time sufficient to allow these two components to interact. In binding assays, the interaction is binding and the complex formed can be isolated or detected in the reaction mixture. The PRO 1105, PRO 1279 or PRO 1783 polypeptide encoded 20 by the gene identified herein or the drug candidate is immobilized on a solid phase, e.g., on a microtiter plate, by covalent or non-covalent attachments. Non-covalent attachment generally is accomplished by coating the solid surface with a solution of the PRO 1105, PRO1279 or PRO1783 polypeptide and drying. Alternatively, an immobilized antibody, e.g., a monoclonal antibody, specific for the PRO 1105, PRO 1279 or PRO 1783 polypeptide to be immobilized can 25 be used to anchor it to a solid surface. The assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, e.g., the coated surface containing the anchored component. When the reaction is complete, the non reacted components are removed, e.g., by washing, and complexes anchored on the solid surface are detected. When the originally non-immobilized component carries a detectable 30 label, the detection of label immobilized on the surface indicates that complexing occurred. Where the originally non-immobilized component does not carry a label, complexing can be 158 WO 2008/127352 PCT/US2007/080102 detected, for example, by using a labeled antibody specifically binding the immobilized complex. If the candidate compound interacts with but does not bind to a particular PRO 1105, PRO 1279 or PRO 1783 polypeptide encoded by a gene identified herein, its interaction with that polypeptide can be assayed by methods well known for detecting protein-protein interactions. 5 Such assays include traditional approaches, such as, e.g., cross-linking, co immunoprecipitation, and co-purification through gradients or chromatographic columns. In addition, protein-protein interactions can be monitored by using a yeast-based genetic system described by Fields and co-workers (Fields and Song, Nature (London), 340:245-246 (1989); Chien et al., Proc. Natl. Acad. Sci. USA, 88:9578-9582 (1991)) as disclosed by Chevray and 10 Nathans, Proc. Natl. Acad. Sci. USA, 89: 5789-5793 (1991). Many transcriptional activators, such as yeast GAL4, consist of two physically discrete modular domains, one acting as the DNA-binding domain, the other one functioning as the transcription-activation domain. The yeast expression system described in the foregoing publications (generally referred to as the "two-hybrid system") takes advantage of this property, and employs two hybrid proteins, one 15 in which the target protein is fused to the DNA-binding domain of GAL4, and another, in which candidate activating proteins are fused to the activation domain. The expression of a GALl lacZ reporter gene under control of a GAL4-activated promoter depends on reconstitution of GAL4 activity via protein-protein interaction. Colonies containing interacting polypeptides are detected with a chromogenic substrate for p-galactosidase. A complete kit 20 (MATCHMAKERm) for identifying protein-protein interactions between two specific proteins using the two-hybrid technique is commercially available from Clontech. This system can also be extended to map protein domains involved in specific protein interactions as well as to pinpoint amino acid residues that are crucial for these interactions. Compounds that interfere with the interaction of a gene encoding a PRO 1105, 25 PRO1279 or PRO1783 polypeptide identified herein and other intra- or extracellular components can be tested as follows: usually a reaction mixture is prepared containing the product of the gene and the intra- or extracellular component under conditions and for a time allowing for the interaction and binding of the two products. To test the ability of a candidate compound to inhibit binding, the reaction is run in the absence and in the presence of the test 30 compound. In addition, a placebo may be added to a third reaction mixture, to serve as positive control. The binding (complex formation) between the test compound and the intra- or 159 WO 2008/127352 PCT/US2007/080102 extracellular component present in the mixture is monitored as described hereinabove. The formation of a complex in the control reaction(s) but not in the reaction mixture containing the test compound indicates that the test compound interferes with the interaction of the test compound and its reaction partner. To assay for antagonists, the PRO 1105, PRO 1279 or PRO 1783 polypeptide may be 5 added to a cell along with the compound to be screened for a particular activity and the ability of the compound to inhibit the activity of interest in the presence of the PRO 1105, PRO1279 or PRO 1783 polypeptide indicates that the compound is an antagonist to the PRO 1105, PRO 1279 or PRO 1783 polypeptide. Alternatively, antagonists may be detected by combining the PRO 1105, PRO 1279 or PRO 1783 polypeptide and a potential antagonist with membrane 10 bound PRO 1105, PRO 1279 or PRO 1783 polypeptide receptors or recombinant receptors under appropriate conditions for a competitive inhibition assay. The PRO1105, PRO1279 or PRO1783 polypeptide can be labeled, such as by radioactivity, such that the number of PRO 1105, PRO 1279 or PRO 1783 polypeptide molecules bound to the receptor can be used to determine the effectiveness of the potential antagonist. The gene encoding the receptor can be 15 identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting. Coligan et al., Current Protocols in Immun., 1(2): Chapter 5 (1991). Preferably, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the PRO 1105, PRO 1279 or PRO 1783 polypeptide and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that 20 are not responsive to the PRO 1105, PRO1279 or PRO1783 polypeptide. Transfected cells that are grown on glass slides are exposed to labeled PRO 1105, PRO 1279 or PRO 1783 polypeptide. The PRO1105, PRO1279 or PRO1783 polypeptide can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase. Following fixation and incubation, the slides are subjected to autoradiographic analysis. 25 Positive pools are identified and sub-pools are prepared and re-transfected using an interactive sub-pooling and re-screening process, eventually yielding a single clone that encodes the putative receptor. As an alternative approach for receptor identification, the labeled PRO 1105, PRO 1279 or PRO1783 polypeptide can be photoaffinity-linked with cell membrane or extract 30 preparations that express the receptor molecule. Cross-linked material is resolved by PAGE and exposed to X-ray film. The labeled complex containing the receptor can be excised, 160 WO 2008/127352 PCT/US2007/080102 resolved into peptide fragments, and subjected to protein micro-sequencing. The amino acid sequence obtained from micro- sequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the gene encoding the putative receptor. Another approach in assessing the effect of an antagonist to a PRO 1105, PRO 1279 or 5 PRO 1783 polypeptide, would be administering a PRO 1105, PRO 1279 or PRO 1783 antagonist to a wild-type mouse in order to mimic a known knockout phenotype. Thus, one would initially knockout the PRO 1105, PRO 1279 or PRO 1783 gene of interest and observe the resultant phenotype as a consequence of knocking out or disrupting the PRO1105, PRO1279 or PRO 1783 gene. Subsequently, one could then assess the effectiveness of an antagonist to the 10 PRO 1105, PRO 1279 or PRO 1783 polypeptide by administering an antagonist to the PRO 1105, PRO1279 or PRO1783 polypeptide to a wild-type mouse. An effective antagonist would be expected to mimic the phenotypic effect that was initially observed in the knockout animal. Likewise, one could assess the effect of an agonist to a PRO 1105, PRO 1279 or PRO1783 polypeptide, by administering a PRO 1105, PRO1279 or PRO1783 agonist to a non 15 human transgenic mouse in order to ameliorate a known negative knockout phenotype. Thus, one would initially knockout the PRO 1105, PRO 1279 or PRO 1783 gene of interest and observe the resultant phenotype as a consequence of knocking out or disrupting the PRO 1105, PRO1279 or PRO1783 gene. Subsequently, one could then assess the effectiveness of an agonist to the PRO 1105, PRO 1279 or PRO 1783 polypeptide by administering an agonist to the 20 PRO1105, PRO1279 or PRO1783 polypeptide to a the non-human transgenic mouse. An effective agonist would be expected to ameliorate the negative phenotypic effect that was initially observed in the knockout animal. In another assay for antagonists, mammalian cells or a membrane preparation expressing the receptor would be incubated with a labeled PRO 1105, PRO1279 or PRO1783 polypeptide 25 in the presence of the candidate compound. The ability of the compound to enhance or block this interaction could then be measured. More specific examples of potential antagonists include an oligonucleotide that binds to the fusions of immunoglobulin with the PRO 1105, PRO 1279 or PRO 1783 polypeptide, and, in particular, antibodies including, without limitation, poly- and monoclonal antibodies and 30 antibody fragments, single-chain antibodies, anti-idiotypic antibodies, and chimeric or humanized versions of such antibodies or fragments, as well as human antibodies and antibody 161 WO 2008/127352 PCT/US2007/080102 fragments. Alternatively, a potential antagonist may be a closely related protein, for example, a mutated form of the PRO 1105, PRO 1279 or PRO 1783 polypeptide that recognizes the receptor but imparts no effect, thereby competitively inhibiting the action of the PRO 1105, PRO 1279 or PRO 1783 polypeptide. Another potential PRO 1105, PRO 1279 or PRO 1783 polypeptide antagonist is an 5 antisense RNA or DNA construct prepared using antisense technology, where, e.g., an antisense RNA or DNA molecule acts to block directly the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding 10 portion of the polynucleotide sequence, which encodes the mature PRO 1105, PRO 1279 or PRO 1783 polypeptides herein, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res., 6:3073 (1979); Cooney et al., Science, 241: 456 (1988); Dervan et al., Science, 251:1360 15 (1991)), thereby preventing transcription and the production of the PRO 1105, PRO1279 or PRO1783 polypeptide. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into the PRO 1105, PRO 1279 or PRO 1783 polypeptide (antisense - Okano, Neurochem., 56:560 (1991); Oligodeoxvnucleotides as Antisense Inhibitors of Gene Expression (CRC Press: Boca Raton, FL, 1988). The 2 0 oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed in vivo to inhibit production of the PRO 1105, PRO1279 or PRO1783 polypeptide. When antisense DNA is used, oligodeoxyribonucleotides derived from the translation-initiation site, e.g., between about -10 and +10 positions of the target gene nucleotide sequence, are preferred. 25 Potential antagonists include small molecules that bind to the active site, the receptor binding site, or growth factor or other relevant binding site of the PRO 1105, PRO1279 or PRO 1783 polypeptide, thereby blocking the normal biological activity of the PRO 1105, PRO 1279 or PRO 1783 polypeptide. Examples of small molecules include, but are not limited to, small peptides or peptide-like molecules, preferably soluble peptides, and synthetic non 30 peptidyl organic or inorganic compounds. Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage 162 WO 2008/127352 PCT/US2007/080102 ofRNA. Ribozymes act by sequence-specific hybridization to the complementary target RNA, followed by endonucleolytic cleavage. Specific ribozyme cleavage sites within a potential RNA target can be identified by known techniques. For further details see, e.g., Rossi, Current Biologv, 4:469-471 (1994), and PCT publication No. WO 97/33551 (published September 18, 1997). 5 Nucleic acid molecules in triple-helix formation used to inhibit transcription should be single-stranded and composed of deoxynucleotides. The base composition of these oligonucleotides is designed such that it promotes triple-helix formation via Hoogsteen base pairing rules, which generally require sizeable stretches ofpurines or pyrimidines on one strand of a duplex. For further details see, e.g., PCT publication No. WO 97/3355 1, supra. 10 These small molecules can be identified by any one or more of the screening assays discussed hereinabove and/or by any other screening techniques well known for those skilled in the art. Diagnostic and therapeutic uses of the herein disclosed molecules may also be based upon the positive functional assay hits disclosed and described below. 15 F. Anti-PRO 1105, Anti-PRO 1279 or Anti-PRO 1783 Antibodies The present invention provides anti-PRO1105, anti-PRO1279 or anti-PRO1783 antibodies which may find use herein as therapeutic and/or diagnostic agents. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate 20 antibodies. 1. Polyclonal Antibodies Polyclonal antibodies are preferably raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and an adjuvant. It may be useful to 25 conjugate the relevant antigen (especially when synthetic peptides are used) to a protein that is immunogenic in the species to be immunized. For example, the antigen can be conjugated to keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor, using a bifunctional or derivatizing agent, e.g., maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), 30 glutaraldehyde, succinic anhydride, SOCl 2 , or R 1 N=C=NR, where R and R 1 are different alkyl groups. 163 WO 2008/127352 PCT/US2007/080102 Animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining, e.g., 100 Lg or 5 Lg of the protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later, the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple 5 sites. Seven to 14 days later, the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response. 10 2. Monoclonal Antibodies Monoclonal antibodies may be made using the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or may be made by recombinant DNA methods (U.S. Patent No. 4,816,567). In the hybridoma method, a mouse or other appropriate host animal, such as a hamster, 15 is immunized as described above to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized in vitro. After immunization, lymphocytes are isolated and then fused with a myeloma cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 20 (Academic Press, 1986)). The hybridoma cells thus prepared are seeded and grown in a suitable culture medium which medium preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells (also referred to as fusion partner). For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase 25 (HGPRT or HPRT), the selective culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells. Preferred fusion partner myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive 30 to a selective medium that selects against the unfused parental cells. Preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-1 1 mouse 164 WO 2008/127352 PCT/US2007/080102 tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 and derivatives e.g., X63-Ag8-653 cells available from the American Type Culture Collection, Manassas, Virginia, USA. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J Immunol., 133:3001 (1984); and Brodeur et al., Monoclonal Antibody Production Techniques 5 and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)). Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked 10 immunosorbent assay (ELISA). The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis described in Munson et al., Anal. Biochem., 107:220 (1980). Once hybridoma cells that produce antibodies of the desired specificity, affinity, and/or activity are identified, the clones may be subcloned by limiting dilution procedures and grown 15 by standard methods (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal e.g,, by i.p. injection of the cells into mice. The monoclonal antibodies secreted by the subclones are suitably separated from the 20 culture medium, ascites fluid, or serum by conventional antibody purification procedures such as, for example, affinity chromatography (e.g., using protein A or protein G-Sepharose) or ion exchange chromatography, hydroxylapatite chromatography, gel electrophoresis, dialysis, etc. DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding 25 specifically to genes encoding the heavy and light chains ofmurine antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese Hamster Ovary (CHO) cells, or myeloma cells that do not otherwise produce antibody protein, to obtain the synthesis ofmonoclonal antibodies in the recombinant host cells. 30 Review articles on recombinant expression in bacteria of DNA encoding the antibody include Skerra et al., Curr. Opinion in Immunol., 5:256-262 (1993) and Plickthun, Immunol. Revs. 165 WO 2008/127352 PCT/US2007/080102 130:151-188 (1992). Monoclonal antibodies or antibody fragments can be isolated from antibody phage libraries generated using the techniques described in McCafferty et al., Nature, 348:552-554 (1990). Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581 597 (1991) describe the isolation of murine and human antibodies, respectively, using phage 5 libraries. Subsequent publications describe the production of high affinity (nM range) human antibodies by chain shuffling (Marks et al., Bio/Technologv, 10:779-783 (1992)), as well as combinatorial infection and in vivo recombination as a strategy for constructing very large phage libraries (Waterhouse et al., Nuc. Acids. Res. 21:2265-2266 (1993)). Thus, these techniques are viable alternatives to traditional monoclonal antibody hybridoma techniques for 10 isolation of monoclonal antibodies. The DNA that encodes the antibody may be modified to produce chimeric or fusion antibody polypeptides, for example, by substituting human heavy chain and light chain constant domain (CH and CL) sequences for the homologous murine sequences (U.S. Patent No. 4,816,567; and Morrison, et al., Proc. Natl Acad. Sci. USA, 81:6851 (1984)), or by fusing the 15 immunoglobulin coding sequence with all or part of the coding sequence for a non immunoglobulin polypeptide (heterologous polypeptide). The non-immunoglobulin polypeptide sequences can substitute for the constant domains of an antibody, or they are substituted for the variable domains of one antigen-combining site of an antibody to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for an 20 antigen and another antigen-combining site having specificity for a different antigen. 3. Human and Humanized Antibodies The anti-PRO 1105, anti-PRO1279 or anti-PRO1783 antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms ofnon-human 25 (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab') 2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) ofthe recipient are replaced by residues from a CDR 30 of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human 166 WO 2008/127352 PCT/US2007/080102 immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or 5 substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522 525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)]. 10 Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 15 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In 20 practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies. The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity and HAMA response (human 25 anti-mouse antibody) when the antibody is intended for human therapeutic use. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable domain sequences. The human V domain sequence which is closest to that of the rodent is identified and the human framework region (FR) within it accepted for the humanized antibody (Sims et al., J. Immunol. 151:2296 30 (1993); Chothia et al., J. Mol. Biol., 196:901 (1987)). Another method uses a particular framework region derived from the consensus sequence of all human antibodies of a particular 167 WO 2008/127352 PCT/US2007/080102 subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); Presta et al., J. Immunol. 151:2623 (1993)). It is further important that antibodies be humanized with retention of high binding affinity for the antigen and other favorable biological properties. To achieve this goal, 5 according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of 10 selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the 15 target antigen(s), is achieved. In general, the hypervariable region residues are directly and most substantially involved in influencing antigen binding. Various forms of a humanized anti-PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody are contemplated. For example, the humanized antibody may be an antibody fragment, such as a Fab, which is optionally conjugated with one or more cytotoxic agent(s) in order to 20 generate an immunoconjugate. Alternatively, the humanized antibody may be an intact antibody, such as an intact IgGI antibody. As an alternative to humanization, human antibodies can be generated. For example, it is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous 25 immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region (JH) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer ofthe human germ line immunoglobulin gene array into such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. 30 USA, 90:2551 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggemann et al., Year in Immuno. 7:33 (1993); U.S. Patent Nos. 5,545,806, 5,569,825, 5,591,669 (all of GenPharm); 168 WO 2008/127352 PCT/US2007/080102 5,545,807; and WO 97/17852. Alternatively, phage display technology (McCafferty et al., Nature 348:552-553 [1990]) can be used to produce human antibodies and antibody fragments in vitro, from immunoglobulin variable (V) domain gene repertoires from unimmunized donors. According to this technique, antibody V domain genes are cloned in-frame into either a major or minor 5 coat protein gene of a filamentous bacteriophage, such as M13 or fd, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties. Thus, the phage mimics some of the properties of the B-cell. 10 Phage display canbe performed in a varietyof formats, reviewed in, e.g., Johnson, Kevin S. and Chiswell, David J., Current Opinion in Structural Biology 3:564-571 (1993). Several sources ofV-gene segments can be used for phage display. Clackson et al., Nature, 352:624-628 (1991) isolated a diverse array of anti-oxazolone antibodies from a small random combinatorial library of V genes derived from the spleens of immunized mice. A repertoire of V genes from 15 unimmunized human donors can be constructed and antibodies to a diverse array of antigens (including self-antigens) can be isolated essentially following the techniques described by Marks et al., J. Mol. Biol. 222:581-597 (1991), or Griffith et al., EMBO J. 12:725-734 (1993). See, also, U.S. Patent Nos. 5,565,332 and 5,573,905. As discussed above, human antibodies may also be generated by in vitro activated B 20 cells (see U.S. Patents 5,567,610 and 5,229,275). 4. Antibody fragments In certain circumstances there are advantages of using antibody fragments, rather than whole antibodies. The smaller size of the fragments allows for rapid clearance, and may lead 25 to improved access to solid tumors. Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117 (1992); and Brennan et al., Science, 229:81 (1985)). However, these fragments can now be produced 30 directly by recombinant host cells. Fab, Fv and ScFv antibody fragments can all be expressed in and secreted from E. coli, thus allowing the facile production of large amounts of these 169 WO 2008/127352 PCT/US2007/080102 fragments. Antibody fragments can be isolated from the antibody phage libraries discussed above. Alternatively, Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab') 2 fragments (Carter et al., Bio/Technoloav 10:163-167 (1992)). According to another approach, F(ab') 2 fragments can be isolated directly from recombinant host cell culture. Fab and F(ab') 2 fragment with increased in vivo half-life comprising a salvage 5 receptor binding epitope residues are described in U.S. Patent No. 5,869,046. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner. The antibody of choice is a single chain Fv fragment (scFv). See WO 93/16185; U.S. Patent No. 5,571,894; and U.S. Patent No. 5,587,458. Fv and sFv are the only species with intact combining sites that are devoid of constant regions; thus, they are suitable for reduced 10 nonspecific binding during in vivo use. sFv fusion proteins may be constructed to yield fusion of an effector protein at either the amino or the carboxy terminus of an sFv. See Antibody Engineerin , ed. Borrebaeck, supra. The antibody fragment may also be a "linear antibody", e.g., as described in U.S. Patent 5,641,870 for example. Such linear antibody fragments may be monospecific or bispecific. 15 5. Bispecific Antibodies Bispecific antibodies are antibodies that have binding specificities for at least two different epitopes. Exemplary bispecific antibodies may bind to two different epitopes of a PRO1105, PRO 1279 or PRO 1783 protein as described herein. Other such antibodies may 20 combine a PRO 1105, PRO 1279 or PRO 1783 binding site with a binding site for another protein. Alternatively, an anti-PRO1105, anti-PRO1279 or anti-PRO1783 arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD3), or Fc receptors for IgG (FcyR), such as FcyRI (CD64), FcyRII (CD32) and FcyRIII (CD16), so as to focus and localize cellular defense mechanisms to the 25 PRO1105-, PRO 1279- or PRO 1783-expressing cell. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express a PRO1105, PRO1279 or PRO1783 polypeptide. These antibodies possess a PRO 1105-, PRO1279- or PRO1783-binding arm and an arm which binds the cytotoxic agent (e.g., saporin, anti-interferon-a, vinca alkaloid, ricin A chain, methotrexate or radioactive isotope hapten). Bispecific antibodies can be prepared as 30 full length antibodies or antibody fragments (e.g., F(ab') 2 bispecific antibodies). WO 96/16673 describes a bispecific anti-ErbB2/anti-FcyRlII antibody and U.S. Patent 170 WO 2008/127352 PCT/US2007/080102 No. 5,837,234 discloses a bispecific anti-ErbB2/anti-FcyRI antibody. A bispecific anti ErbB2/Fca antibody is shown in W098/02463. U.S. Patent No. 5,821,337 teaches a bispecific anti-ErbB2/anti-CD3 antibody. Methods for making bispecific antibodies are known in the art. Traditional production of full length bispecific antibodies is based on the co-expression of two immunoglobulin heavy 5 chain-light chain pairs, where the two chains have different specificities (Millstein et al., Nature 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and 10 the product yields are low. Similar procedures are disclosed in WO 93/08829, and in Traunecker et al., EMBO J. 10:3655-3659 (1991). According to a different approach, antibody variable domains with the desired binding specificity (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences. Preferably, the fusion is with an Ig heavy chain constant domain, comprising at least 15 part of the hinge, CH 2 , and CH 3 regions. It is preferred to have the first heavy-chain constant region (CHl) containing the site necessary for light chain bonding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co transfected into a suitable host cell. This provides for greater flexibility in adjusting the mutual 20 proportions of the three polypeptide fragments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yield of the desired bispecific antibody. It is, however, possible to insert the coding sequences for two or all three polypeptide chains into a single expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios have no significant affect on the yield of the 25 desired chain combination. The invention provides bispecific antibodies which are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired 30 bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile 171 WO 2008/127352 PCT/US2007/080102 way of separation. This approach is disclosed in WO 94/04690. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology 121:210 (1986). According to another approach described in U.S. Patent No. 5,731,168, the interface between a pair of antibody molecules can be engineered to maximize the percentage of 5 heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH 3 domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large 10 amino acid side chains with smaller ones (e.g., alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers. Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, the other to 15 biotin. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360, WO 92/200373, and EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Patent No. 4,676,980, along with a number of cross-linking techniques. 2 0 Techniques for generating bispecific antibodies from antibody fragments have also been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab') 2 fragments. These fragments are reduced in the presence of the dithiol complexing agent, sodium arsenite, to stabilize vicinal dithiols and 25 prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes. 30 Recent progress has facilitated the direct recovery of Fab'-SH fragments from E. coli, which can be chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 172 WO 2008/127352 PCT/US2007/080102 175: 217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab') 2 molecule. Each Fab' fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets. 5 Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge 10 region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a VH connected to a VL by a linked which is too short to allow pairing between the two domains 15 on the same chain. Accordingly, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen binding sites. Another strategy for making bispecific antibody fragments by the use of single chain Fv (sFv) dimers has also been reported. See Gruber et al., J. Immunol., 152:5368 (1994). Antibodies with more than two valencies are contemplated. For example, trispecific 20 antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991). 6. Heteroconjugate Antibodies Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalentlyjoined antibodies. Such antibodies 25 have, for example, been proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and for treatment of HIV infection [WO 91/00360; WO 92/200373; EP 03089]. It is contemplated that the antibodies may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins maybe constructed using a disulfide exchange reaction orby forming a thioether 30 bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4 mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980. 173 WO 2008/127352 PCT/US2007/080102 7. Multivalent Antibodies A multivalent antibody may be internalized (and/or catabolized) faster than a bivalent antibody by a cell expressing an antigen to which the antibodies bind. The antibodies of the present invention can be multivalent antibodies (which are other than of the IgM class) with three or more antigen binding sites (e.g. tetravalent antibodies), which can be readily produced 5 by recombinant expression of nucleic acid encoding the polypeptide chains of the antibody. The multivalent antibody can comprise a dimerization domain and three or more antigen binding sites. The preferred dimerization domain comprises (or consists of) an Fc region or a hinge region. In this scenario, the antibody will comprise an Fc region and three or more antigen binding sites amino-terminal to the Fc region. The preferred multivalent antibody herein 10 comprises (or consists of) three to about eight, but preferably four, antigen binding sites. The multivalent antibody comprises at least one polypeptide chain (and preferably two polypeptide chains), wherein the polypeptide chain(s) comprise two or more variable domains. For instance, the polypeptide chain(s) may comprise VD1-(X1),-VD2-(X2),-Fc, wherein VD1 is a first variable domain, VD2 is a second variable domain, Fc is one polypeptide chain of an Fc 15 region, X1 and X2 represent an amino acid or polypeptide, and n is 0 or 1. For instance, the polypeptide chain(s) may comprise: VH-CH1-flexible linker-VH-CH1 -Fc region chain; or VH CH1-VH-CH1-Fc region chain. The multivalent antibody herein preferably further comprises at least two (and preferably four) light chain variable domain polypeptides. The multivalent antibody herein may, for instance, comprise from about two to about eight light chain variable 20 domain polypeptides. The light chain variable domain polypeptides contemplated here comprise a light chain variable domain and, optionally, further comprise a CL domain. 8. Effector Function Engineering It may be desirable to modify the antibody of the invention with respect to effector 25 function, e.g., so as to enhance antigen-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) of the antibody. This may be achieved by introducing one or more amino acid substitutions in an Fc region of the antibody. Alternatively or additionally, cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated 30 may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med. 174 WO 2008/127352 PCT/US2007/080102 176:1191-1195 (1992) and Shopes, B. J. Immunol. 148:2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al., Cancer Research 53:2560-2565 (1993). Alternatively, an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design 5 3:219-230 (1989). To increase the serum half life of the antibody, one may incorporate a salvage receptor binding epitope into the antibody (especially an antibody fragment) as described in U.S. Patent 5,739,277, for example. As used herein, the term "salvage receptor binding epitope" refers to an epitope of the Fc region of an IgG molecule (e.g., IgG 1 , IgG 2 , IgG 3 , or IgG 4 ) that is responsible for increasing the in vivo serum half-life of the IgG molecule. 10 9. Immunoconjugates The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, a growth inhibitory agent, a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), 15 or a radioactive isotope (i.e., a radioconjugate). Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, 20 Aleuritesfordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production ofradioconjugated antibodies. Examples include 212 Bi, 1311 131 1n, 9 0 Y, and 186 Re. Conjugates of the antibody and cytotoxic agent are made using 25 a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such 30 as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4 dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et 175 WO 2008/127352 PCT/US2007/080102 al., Science, 238: 1098 (1987). Carbon- 14-labeled 1 -isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026. Conjugates of an antibody and one or more small molecule toxins, such as a calicheamicin, maytansinoids, a trichothene, and CC 1065, and the derivatives of these toxins 5 that have toxin activity, are also contemplated herein. Maytansine and mavtansinoids The invention provides an anti-PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody (full length or fragments) which is conjugated to one or more maytansinoid molecules. 10 Maytansinoids are mitototic inhibitors which act by inhibiting tubulin polymerization. Maytansine was first isolated from the east African shrub Maytenus serrata (U.S. Patent No. 3,896,111). Subsequently, it was discovered that certain microbes also produce maytansinoids, such as maytansinol and C-3 maytansinol esters (U.S. Patent No. 4,151,042). Synthetic maytansinol and derivatives and analogues thereof are disclosed, for example, in U.S. Patent 15 Nos. 4,137,230; 4,248,870; 4,256,746; 4,260,608; 4,265,814; 4,294,757; 4,307,016; 4,308,268; 4,308,269; 4,309,428; 4,313,946; 4,315,929; 4,317,821; 4,322,348; 4,331,598; 4,361,650; 4,364,866; 4,424,219; 4,450,254; 4,362,663; and 4,371,533, the disclosures of which are hereby expressly incorporated by reference. 20 Maytansinoid-antibody conjugates In an attempt to improve their therapeutic index, maytansine and maytansinoids have been conjugated to antibodies specifically binding to tumor cell antigens. Immunoconjugates containing maytansinoids and their therapeutic use are disclosed, for example, in U.S. Patent Nos. 5,208,020, 5,416,064 and European Patent EP 0 425 235 BI, the disclosures of which are 25 hereby expressly incorporated by reference. Liu et al., Proc. Natl. Acad. Sci. USA 93:8618 8623 (1996) described immunoconjugates comprising a maytansinoid designated DM1 linked to the monoclonal antibody C242 directed against human colorectal cancer. The conjugate was found to be highly cytotoxic towards cultured colon cancer cells, and showed antitumor activity in an in vivo tumor growth assay. Chari et al., Cancer Research 52:127-131 (1992) describe 30 immunoconjugates in which a maytansinoid was conjugated via a disulfide linker to the murine antibody A7 binding to an antigen on human colon cancer cell lines, or to another murine 176 WO 2008/127352 PCT/US2007/080102 monoclonal antibody TA. 1 that binds the HER-2/neu oncogene. The cytotoxicity of the TA. 1 maytansonoid conjugate was tested in vitro on the human breast cancer cell line SK-BR-3, which expresses 3 x 10 HER-2 surface antigens per cell. The drug conjugate achieved a degree of cytotoxicity similar to the free maytansonid drug, which could be increased by increasing the number of maytansinoid molecules per antibody molecule. The A7-maytansinoid conjugate 5 showed low systemic cytotoxicity in mice. Anti-PRO1105, Anti-PRO1279 or Anti-PRO1783 Antibody-Maytansinoid Conjugates (Immunoconjugates) Anti-PRO 1105, anti-PRO1279 or anti-PRO1783 antibody-maytansinoid conjugates are 10 prepared by chemically linking an anti-PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibody to a maytansinoid molecule without significantly diminishing the biological activity of either the antibody or the maytansinoid molecule. An average of 3-4 maytansinoid molecules conjugated per antibody molecule has shown efficacy in enhancing cytotoxicity of target cells without negatively affecting the function or solubility of the antibody, although even one molecule of 15 toxin/antibody would be expected to enhance cytotoxicity over the use of naked antibody. Maytansinoids are well known in the art and can be synthesized by known techniques or isolated from natural sources. Suitable maytansinoids are disclosed, for example, in U.S. Patent No. 5,208,020 and in the other patents and nonpatent publications referred to hereinabove. Preferred maytansinoids are maytansinol and maytansinol analogues modified in the aromatic 2 0 ring or at other positions of the maytansinol molecule, such as various maytansinol esters. There are many linking groups known in the art for making antibody-maytansinoid conjugates, including, for example, those disclosed in U.S. Patent No. 5,208,020 or EP Patent 0 425 235 BI, and Chari et al., Cancer Research 52:127-131 (1992). The linking groups include disufide groups, thioether groups, acid labile groups, photolabile groups, peptidase 25 labile groups, or esterase labile groups, as disclosed in the above-identified patents, disulfide and thioether groups being preferred. Conjugates of the antibody and maytansinoid may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane- 1 -carboxylate, iminothiolane (IT), 30 bifunctional derivatives ofimidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such 177 WO 2008/127352 PCT/US2007/080102 as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). Particularly preferred coupling agents include N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) (Carlsson et al., Biochem. J. 173:723-737 [1978]) and N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP) to 5 provide for a disulfide linkage. The linker may be attached to the maytansinoid molecule at various positions, depending on the type of the link. For example, an ester linkage may be formed by reaction with a hydroxyl group using conventional coupling techniques. The reaction may occur at the C-3 position having a hydroxyl group, the C-14 position modified with hyrdoxymethyl, the C 10 15 position modified with a hydroxyl group, and the C-20 position having a hydroxyl group. The linkage is formed at the C-3 position of maytansinol or a maytansinol analogue. Calicheamicin Another immunoconjugate of interest comprises an anti-PRO 1105, anti-PRO1279 or 15 anti-PRO 1783 antibody conjugated to one or more calicheamicin molecules. The calicheamicin family of antibiotics are capable of producing double-stranded DNA breaks at sub-picomolar concentrations. For the preparation of conjugates of the calicheamicin family, see U.S. patents 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, 5,877,296 (all to American Cyanamid Company). Structural analogues of calicheamicin which may be used 20 include, but are not limited to, y 1 , a 2 , a,', N-acetyl-yl 1 , PSAG and 0', (Hinman et al., Cancer Research 53:3336-3342 (1993), Lode et al., Cancer Research 58:2925-2928 (1998) and the aforementioned U.S. patents to American Cyanamid). Another anti-tumor drug that the antibody can be conjugated is QFA which is an antifolate. Both calicheamicin and QFA have intracellular sites of action and do not readily cross the plasma membrane. Therefore, cellular 25 uptake of these agents through antibody mediated internalization greatly enhances their cytotoxic effects. Other cytotoxic agents Other antitumor agents that can be conjugated to the anti-PRO 1105, anti-PRO 1279 or 30 anti-PRO1783 antibodies of the invention include BCNU, streptozoicin, vincristine and 5 fluorouracil, the family of agents known collectively LL-E33288 complex described in U.S. 178 WO 2008/127352 PCT/US2007/080102 patents 5,053,394, 5,770,710, as well as esperamicins (U.S. patent 5,877,296). Enzymatically active toxins and fragments thereof which can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleuritesfordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and 5 PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes. See, for example, WO 93/21232 published October 28, 1993. The present invention further contemplates an immunoconjugate formed between an antibody and a compound with nucleolytic activity (e.g., a ribonuclease or a DNA endonuclease 10 such as a deoxyribonuclease; DNase). For selective destruction of the tumor, the antibody may comprise a highly radioactive atom. A variety of radioactive isotopes are available for the production ofradioconjugated anti PRO1 105, anti-PR01279 or anti-PR01783 antibodies. Examples include At 2 11 , 1131, 125, y 90 5 Re 1 86 , Re 88 , Sm 1 53 , Bi 21 2 p 32 , Pb 21 2 and radioactive isotopes of Lu. When the conjugate is used 15 for diagnosis, it may comprise a radioactive atom for scintigraphic studies, for example tc 9 9 m or I123, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, mri), such as iodine-123 again, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron. The radio- or other labels may be incorporated in the conjugate in known ways. For 20 example, the peptide may be biosynthesized or may be synthesized by chemical amino acid synthesis using suitable amino acid precursors involving, for example, fluorine- 19 in place of hydrogen. Labels such as tc 99 m or I123 .Re' 86 , Re 88 and In" 1 can be attached via a cysteine residue in the peptide. Yttrium-90 can be attached via a lysine residue. The IODOGEN method (Fraker et al (1978) Biochem. Biophys. Res. Commun. 80: 49-57 can be used to incorporate 25 iodine-123. "Monoclonal Antibodies in Immunoscintigraphy" (Chatal,CRC Press 1989) describes other methods in detail. Conjugates of the antibody and cytotoxic agent may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane- 1 -carboxylate, iminothiolane (IT), 30 bifunctional derivatives ofimidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such 179 WO 2008/127352 PCT/US2007/080102 as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science 238:1098 (1987). Carbon 14-labeled 1 -isothiocyanatobenzyl-3 -methyldiethylene triaminepentaacetic acid (MX-DTPA) 5 is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See W094/11026. The linker may be a "cleavable linker" facilitating release of the cytotoxic drug in the cell. For example, an acid-labile linker, peptidase-sensitive linker, photolabile linker, dimethyl linker or disulfide-containing linker (Chari et al., Cancer Research 52:127-131 (1992); U.S. Patent No. 5,208,020) may be used. 10 Alternatively, a fusion protein comprising the anti-PRO 1105, anti-PRO 1279 or anti PRO1783 antibody and cytotoxic agent may be made, e.g., by recombinant techniques or peptide synthesis. The length of DNA may comprise respective regions encoding the two portions of the conjugate either adjacent one another or separated by a region encoding a linker peptide which does not destroy the desired properties of the conjugate. 15 The invention provides that the antibody may be conjugated to a "receptor" (such streptavidin) for utilization in tumor pre-targeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) which is conjugated to a cytotoxic agent (e.g., a radionucleotide). 20 10. Immunoliposomes The anti-PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibodies disclosed herein may also be formulated as immunoliposomes. A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug to a 25 mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA 77:4030 (1980); U.S. Pat. Nos. 4,485,045 and 4,544,545; and W097/38731 published October 23, 1997. Liposomes with 30 enhanced circulation time are disclosed in U.S. Patent No. 5,013,556. Particularly useful liposomes can be generated by the reverse phase evaporation method 180 WO 2008/127352 PCT/US2007/080102 with a lipid composition comprising phosphatidylcholine, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem. 257:286-288 (1982) via a disulfide interchange reaction. A chemotherapeutic agent is 5 optionally contained within the liposome. See Gabizon et al., J. National Cancer Inst. 81(19):1484 (1989). 11. Pharmaceutical Compositions of Antibodies Antibodies specifically binding a PRO1105, PRO1279 or PRO1783 polypeptide 10 identified herein, as well as other molecules identified by the screening assays disclosed hereinbefore, can be administered for the treatment of various disorders in the form of pharmaceutical compositions. If the PRO1105, PRO1279 or PRO1783 polypeptide is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, lipofections 15 or liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced 20 by recombinant DNA technology. See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition may comprise an agent that enhances its function, such as, for example, a cytotoxic agent, 25 cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended. The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, 30 respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions. Such techniques are 181 WO 2008/127352 PCT/US2007/080102 disclosed in Remington's Pharmaceutical Sciences, supra. The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes. Sustained-release preparations maybe prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the 5 antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2 hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and y ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT ' (injectable 10 microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37 0 C, resulting in 15 a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, 20 and developing specific polymer matrix compositions. G. Uses for Anti-PRO 1105, Anti-PRO1279 or Anti-PRO1783 Antibodies The anti-PRO 1105, anti-PRO1279 or anti-PRO1783 antibodies of the invention have various therapeutic and/or diagnostic utilities for a neurological disorder; a cardiovascular, 25 endothelial or angiogenic disorder; an immunological disorder; an oncological disorder ; an embryonic developmental disorder or lethality, or a metabolic abnormality. For example, anti PRO 1105, anti- PRO 1279 or anti-PRO 1783 antibodies may be used in diagnostic assays for PRO 1105, PRO 1279 or PRO 1783, e.g., detecting its expression (and in some cases, differential expression) in specific cells, tissues, or serum. Various diagnostic assay techniques known in 30 the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either heterogeneous or homogeneous phases [Zola, 182 WO 2008/127352 PCT/US2007/080102 Monoclonal Antibodies: A Manual of Techniques, CRC Press, Inc. (1987) pp. 147-158]. The antibodies used in the diagnostic assays can be labeled with a detectable moiety. The detectable moiety should be capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as 3 H, 14 C, 32 P, 35S, or 125, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or 5 luciferin, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter et al., Nature, 144:945 (1962); David et al., Biochemistry, 13:1014 (1974); Pain et al., J. Immunol. Meth., 40:219 (1981); and Nygren, J. Histochem. and Cytochem., 30:407 (1982). 10 Anti-PRO 1105, anti-PRO 1279 or anti-PRO 1783 antibodies also are useful for the affinity purification of PRO 1105, PRO1279 or PRO1783 polypeptides from recombinant cell culture or natural sources. In this process, the antibodies against PRO 1105, PRO 1279 or PRO 1783 polypeptides are immobilized on a suitable support, such a Sephadex resin or filter paper, using methods well known in the art. The immobilized antibody then is contacted with 15 a sample containing the PRO1105, PRO1279 or PRO1783 polypeptide to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the PRO 1105, PRO 1279 or PRO 1783 polypeptide, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent that will release the PRO 1105, PRO1279 or PRO1783 polypeptide from the antibody. 20 The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety. 25 EXAMPLES Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Manassas, VA. 30 183 WO 2008/127352 PCT/US2007/080102 EXAMPLE 1: Extracellular Domain Homology Screening to Identify Novel Polypeptides and cDNA Encoding Therefor The extracellular domain (ECD) sequences (including the secretion signal sequence, if any) from about 950 known secreted proteins from the Swiss-Prot public database were used to search EST databases. The EST databases included public databases (e.g., Dayhoff, 5 GenBank), and proprietary databases (e.g. LIFESEQm, Incyte Pharmaceuticals, Palo Alto, CA). The search was performed using the computer program BLAST or BLAST-2 (Altschul et al., Methods in Enzymoloav, 266:460-480 (1996)) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequences. Those comparisons with a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and 10 assembled into consensus DNA sequences with the program "phrap" (Phil Green, University of Washington, Seattle, WA). Using this extracellular domain homology screen, consensus DNA sequences were assembled relative to the other identified EST sequences using phrap. In addition, the consensus DNA sequences obtained were often (but not always) extended using repeated cycles 15 of BLAST or BLAST-2 and phrap to extend the consensus sequence as far as possible using the sources of EST sequences discussed above. Based upon the consensus sequences obtained as described above, oligonucleotides were then synthesized and used to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for a PRO 20 polypeptide. Forward and reverse PCR primers generally range from 20 to 30 nucleotides and are often designed to give a PCR product of about 100-1000 bp in length. The probe sequences are typically 40-55 bp in length. In some cases, additional oligonucleotides are synthesized when the consensus sequence is greater than about 1-1. 5kbp. In order to screen several libraries for a full-length clone, DNA from the libraries was screened by PCR amplification, as per 25 Ausubel et al., Current Protocols in Molecular Biologv, with the PCR primer pair. A positive library was then used to isolate clones encoding the gene of interest using the probe oligonucleotide and one of the primer pairs. The cDNA libraries used to isolate the cDNA clones were constructed by standard methods using commercially available reagents such as those from Invitrogen, San Diego, CA. 30 The cDNA was primed with oligo dT containing a NotI site, linked with blunt to SalI hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned 184 WO 2008/127352 PCT/US2007/080102 in a defined orientation into a suitable cloning vector (such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the SfiI site; see, Holmes et al., Science, 253:1278 1280 (1991)) in the unique XhoI and NotI sites. EXAMPLE 2: Isolation of cDNA clones by Amylase Screening 5 1. Preparation of oligo dT primed cDNA library mRNA was isolated from a human tissue of interest using reagents and protocols from Invitrogen, San Diego, CA (Fast Track 2). This RNA was used to generate an oligo dT primed cDNA library in the vector pRK5D using reagents and protocols from Life Technologies, Gaithersburg, MD (Super Script Plasmid System). In this procedure, the double stranded 10 cDNA was sized to greater than 1000 bp and the SalI/NotI linkered cDNA was cloned into XhoI/NotI cleaved vector. pRK5D is a cloning vector that has an sp6 transcription initiation site followed by an SfiI restriction enzyme site preceding the XhoI/NotI cDNA cloning sites. 2. Preparation of random primed cDNA library 15 A secondary cDNA library was generated in order to preferentially represent the 5' ends of the primary cDNA clones. Sp6 RNA was generated from the primary library (described above), and this RNA was used to generate a random primed cDNA library in the vector pSST AMY.0 using reagents and protocols from Life Technologies (Super Script Plasmid System, referenced above). In this procedure the double stranded cDNA was sized to 500-1000 bp, 2 0 linkered with blunt to NotI adaptors, cleaved with SfiI, and cloned into SfiI/NotI cleaved vector. pSST-AMY.0 is a cloning vector that has a yeast alcohol dehydrogenase promoter preceding the cDNA cloning sites and the mouse amylase sequence (the mature sequence without the secretion signal) followed by the yeast alcohol dehydrogenase terminator, after the cloning sites. Thus, cDNAs cloned into this vector that are fused in frame with amylase sequence will lead 25 to the secretion of amylase from appropriately transfected yeast colonies. 3. Transformation and Detection DNA from the library described in paragraph 2 above was chilled on ice to which was added electrocompetent DH1OB bacteria (Life Technologies, 20 ml). The bacteria and vector 30 mixture was then electroporated as recommended by the manufacturer. Subsequently, SOC media (Life Technologies, 1 ml) was added and the mixture was incubated at 37'C for 30 185 WO 2008/127352 PCT/US2007/080102 minutes. The transformants were then plated onto 20 standard 150 mm LB plates containing ampicillin and incubated for 16 hours (37 0 C). Positive colonies were scraped off the plates and the DNA was isolated from the bacterial pellet using standard protocols, e.g. CsCl-gradient. The purified DNA was then carried on to the yeast protocols below. The yeast methods were divided into three categories: (1) Transformation of yeast with 5 the plasmid/cDNA combined vector; (2) Detection and isolation of yeast clones secreting amylase; and (3) PCR amplification of the insert directly from the yeast colony and purification of the DNA for sequencing and further analysis. The yeast strain used was HD56-5A (ATCC-90785). This strain has the following genotype: MAT alpha, ura3-52, leu2-3, leu2-112, his3-1 1, his3-15, MAL', SUC, GAL. 10 Preferably, yeast mutants can be employed that have deficient post-translational pathways. Such mutants may have translocation deficient alleles in sec7 1, sec72, sec62, with truncated sec71 being most preferred. Alternatively, antagonists (including antisense nucleotides and/or ligands) which interfere with the normal operation of these genes, other proteins implicated in this post translation pathway (e.g., SEC6 1p, SEC72p, SEC62p, SEC63p, TDJip or SSAlp-4p) 15 or the complex formation of these proteins may also be preferably employed in combination with the amylase-expressing yeast. Transformation was performed based on the protocol outlined by Gietz et al., Nucl. Acid. Res., 20:1425 (1992). Transformed cells were then inoculated from agar into YEPD complex media broth (100 ml) and grown overnight at 30'C. The YEPD broth was prepared 20 as described in Kaiser et al., Methods in Yeast Genetics, Cold Spring Harbor Press, Cold Spring Harbor, NY, p. 207 (1994). The overnight culture was then diluted to about 2 x 106 cells/ml (approx. OD 600 =0. 1) into fresh YEPD broth (500 ml) and regrown to 1 x 107 cells/ml (approx. OD 600 =0.4-0.5). The cells were then harvested and prepared for transformation by transfer into GS3 rotor 25 bottles in a Sorval GS3 rotor at 5,000 rpm for 5 minutes, the supernatant discarded, and then resuspended into sterile water, and centrifuged again in 50 ml falcon tubes at 3,500 rpm in a Beckman GS-6KR centrifuge. The supernatant was discarded and the cells were subsequently washed with LiAc/TE (10 ml, 10 mM Tris-HCl, 1 mM EDTA pH 7.5, 100 mM Li 2 00CCH 3 ), and resuspended into LiAc/TE (2.5 ml). 30 Transformation took place by mixing the prepared cells (100 [l) with freshly denatured single stranded salmon testes DNA (Lofstrand Labs, Gaithersburg, MD) and transforming DNA 186 WO 2008/127352 PCT/US2007/080102 (1 rig, vol. < 10 pl) in microfuge tubes. The mixture was mixed briefly by vortexing, then 40% PEG/TE (600 p1, 40% polyethylene glycol-4000, 10 mM Tris-HCl, 1 mM EDTA, 100 mM Li 2 00CCH 3 , pH 7.5) was added. This mixture was gently mixed and incubated at 30'C while agitating for 30 minutes. The cells were then heat shocked at 42'C for 15 minutes, and the reaction vessel centrifuged in a microfuge at 12,000 rpm for 5-10 seconds, decanted and 5 resuspended into TE (500 [L1, 10 mM Tris-HCl, 1 mM EDTA pH 7.5) followed by recentrifugation. The cells were then diluted into TE (1 ml) and aliquots (200 pl) were spread onto the selective media previously prepared in 150 mm growth plates (VWR). Alternatively, instead of multiple small reactions, the transformation was performed using a single, large scale reaction, wherein reagent amounts were scaled up accordingly. 10 The selective media used was a synthetic complete dextrose agar lacking uracil (SCD Ura) prepared as described in Kaiser et al., Methods in Yeast Genetics, Cold Spring Harbor Press, Cold Spring Harbor, NY, p. 208-210 (1994). Transformants were grown at 30'C for 2-3 days. The detection of colonies secreting amylase was performed by including red starch in 15 the selective growth media. Starch was coupled to the red dye (Reactive Red-120, Sigma) as per the procedure described by Biely et al., Anal. Biochem., 172:176-179 (1988). The coupled starch was incorporated into the SCD-Ura agar plates at a final concentration of 0.15% (w/v), and was buffered with potassium phosphate to a pH of 7.0 (50-100 mM final concentration). The positive colonies were picked and streaked across fresh selective media (onto 150 20 mm plates) in order to obtain well isolated and identifiable single colonies. Well isolated single colonies positive for amylase secretion were detected by direct incorporation of red starch into buffered SCD-Ura agar. Positive colonies were determined by their ability to break down starch resulting in a clear halo around the positive colony visualized directly. 25 4. Isolation of DNA by PCR Amplification When a positive colony was isolated, a portion of it was picked by a toothpick and diluted into sterile water (30 pl) in a 96 well plate. At this time, the positive colonies were either frozen and stored for subsequent analysis or immediately amplified. An aliquot of cells (5 pl) was used as a template for the PCR reaction in a 25 pl volume containing: 0.5 pl Klentaq 30 (Clontech, Palo Alto, CA); 4.0 p1 10 mM dNTP's (Perkin Elmer-Cetus); 2.5 pl Kentaq buffer (Clontech); 0.25 p1 forward oligo 1; 0.25 p1 reverse oligo 2; 12.5 p1 distilled water. The 187 WO 2008/127352 PCT/US2007/080102 sequence of the forward oligonucleotide 1 was: 5'-TGTAAAACGACGGCCAGTTAAATAGACCTGCAATTATTAATCT-3' (SEQ ID NO:7) The sequence of reverse oligonucleotide 2 was: 5'-CAGGAAACAGCTATGACCACCTGCACACCTGCAAATCCATT-3' (SEQ ID 5 NO:8) PCR was then performed as follows: a. Denature 92'C, 5 minutes b. 3 cycles of: Denature 92'C, 30 seconds 10 Anneal 59'C, 30 seconds Extend 72'C, 60 seconds c. 3 cycles of: Denature 92'C, 30 seconds Anneal 57'C, 30 seconds 15 Extend 72'C, 60 seconds d. 25 cycles of: Denature 92'C, 30 seconds Anneal 55'C, 30 seconds Extend 72'C, 60 seconds 20 e. Hold 4 0 C The underlined regions of the oligonucleotides annealed to the ADH promoter region and the amylase region, respectively, and amplified a 307 bp region from vector pSST-AMY.0 25 when no insert was present. Typically, the first 18 nucleotides of the 5' end of these oligonucleotides contained annealing sites for the sequencing primers. Thus, the total product of the PCR reaction from an empty vector was 343 bp. However, signal sequence-fused cDNA resulted in considerably longer nucleotide sequences. Following the PCR, an aliquot of the reaction (5 pl) was examined by agarose gel 30 electrophoresis in a 1% agarose gel using a Tris-Borate-EDTA (TBE) buffering system as described by Sambrook et al., supra. Clones resulting in a single strong PCR product larger than 400 bp were further analyzed by DNA sequencing after purification with a 96 Qiaquick PCR clean-up column (Qiagen Inc., Chatsworth, CA). 35 EXAMPLE 3: Isolation of cDNA Clones Using Signal Algorithm Analysis Various polypeptide-encoding nucleic acid sequences were identified by applying a 188 WO 2008/127352 PCT/US2007/080102 proprietary signal sequence finding algorithm developed by Genentech, Inc. (South San Francisco, CA) upon ESTs as well as clustered and assembled EST fragments from public (e.g., GenBank) and/or private (LIFESEQ@, Incyte Pharmaceuticals, Inc., Palo Alto, CA) databases. The signal sequence algorithm computes a secretion signal score based on the character of the DNA nucleotides surrounding the first and optionally the second methionine codon(s) (ATG) 5 at the 5'-end of the sequence or sequence fragment under consideration. The nucleotides following the first ATG must code for at least 35 unambiguous amino acids without any stop codons. If the first ATG has the required amino acids, the second is not examined. If neither meets the requirement, the candidate sequence is not scored. In order to determine whether the EST sequence contains an authentic signal sequence, the DNA and corresponding amino acid 10 sequences surrounding the ATG codon are scored using a set of seven sensors (evaluation parameters) known to be associated with secretion signals. Use of this algorithm resulted in the identification of numerous polypeptide-encoding nucleic acid sequences. Using the techniques described in Examples 1 to 3 above, numerous full-length cDNA clones were identified as encoding PRO 1105, PRO 1279 or PRO 1783 polypeptides as disclosed 15 herein. In addition, the sequence of DNA71182 encoding PRO1783 polypeptides was identified from GenBank accession no.: NM_012206. These cDNAs were then deposited under the terms of the Budapest Treaty with the American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209, USA (ATCC) as shown in Table 7 below. Table 7 20 Material ATCC Dep. No. Deposit Date DNA59612-1466 209947 June 9, 1998 DNA65405-1547 203476 November 17, 1998 These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent 25 Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture of the deposit for 30 years from the date of deposit. The deposits will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the culture of the deposit to the public upon issuance of the pertinent U.S. patent 30 or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of 189 WO 2008/127352 PCT/US2007/080102 Patents and Trademarks to be entitled thereto according to 35 USC § 122 and the Commissioner's rules pursuant thereto (including 37 CFR § 1.14 with particular reference to 886 OG 638). The assignee of the present application has agreed that if a culture of the materials on deposit should die or be lost or destroyed when cultivated under suitable conditions, the 5 materials will be promptly replaced on notification with another of the same. Availability of the deposited material is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws. 10 EXAMPLE 4: Isolation of cDNA clones Encoding Human PRO 1105 Polypeptides [UNQ5481 Use of the signal sequence algorithm described in Example 3 above allowed identification of an EST cluster sequence from the Incyte database. This EST cluster sequence was then compared to a variety of expressed sequence tag (EST) databases which included public EST databases (e.g., GenBank) and a proprietary EST DNA database (Lifeseq@, Incyte 15 Pharmaceuticals, Palo Alto, CA) to identify existing homologies. The homology search was performed using the computer program BLAST or BLAST2 (Altshul et al., Methods in Enzymology 266:460-480 (1996)). Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into a consensus DNA sequence with the program "phrap" (Phil Green, University of 20 Washington, Seattle, Washington). The consensus sequence obtained therefrom is herein designated DNA56430. In light of an observed sequence homology between the DNA56430 sequence and an EST sequence encompassed within the Incyte EST clone no. 1853047, the Incyte EST clone 1853047 was purchased and the cDNA insert was obtained and sequenced. It was found that 25 this insert encoded a full-length protein. The sequence of this cDNA insert is shown in Figure 1 and is herein designated as DNA59612-1466. The entire nucleotide sequence of DNA59612-1466 is shown in Figure 1 (SEQ ID NO: 1). Clone DNA59612-1466 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 28-30 and ending at the stop codon at 30 nucleotide positions 568-570 of SEQ ID NO: 1 (Figure 1). The predicted polypeptide precursor is 180 amino acids long (Figure 2; SEQ ID NO.:2). The full-length PRO 1105 protein shown 190 WO 2008/127352 PCT/US2007/080102 in Figure 2 has an estimated molecular weight of about 20,040 daltons and a pI of about 8.35. Clone DNA59612-1466 has been deposited with the ATCC on June 9, 1998 with ATCC No.: 209947. It is understood that the deposited clone has the actual nucleic acid sequence and that the sequences provided herein are based on known sequencing techniques. Analyzing Figure 2, a signal peptide is at about amino acids 1-19 of SEQ ID NO:2 and 5 transmembrane domains are shown at about amino acids 80-99 and 145-162 of SEQ ID NO:2. It is understood that the skilled artisan could form a polypeptide with all of or any combination or individual selection of these regions. It is also understood that the corresponding nucleic acids can be routinely identified and prepared based on the information provided herein. 10 EXAMPLE 5: Isolation of cDNA clones Encoding Human PRO 1279 Polypeptides [UNQ6491 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA30856. Based on the DNA30856 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to 15 isolate a clone of the full-length coding sequence for PRO 1279. PCR primers (forward and reverse) were synthesized: forward PCRprimer (30856.fl) 5'-GGCTGCGGGACTGGAAGTCATCGGG-3' (SEQ ID NO:9) forward PCR primer (30856.fi 1) 5'-CTCCAGGCCATGAGGATTCTGCAG-3' (SEQ ID 20 NO:10) forward PCR primer (30856.fl2) 5'-CCTCTGGTCTGTAACCAG-3' (SEQ ID NO:11) reverse PCR primer (30856.rl) 5'-TCTGTGATGTTGCCGGGGTAGGCG-3' (SEQ ID NO:12) reverse PCR primer (30856.rl 1) 5'-CGTGTAGACACCAGGCTTTCGGGTG-3' (SEQ 25 ID NO:13) reverse PCR primer (30856.r12) 5'-CCCTTGATGATCCTGGTC-3' (SEQ ID NO:14) Additionally, synthetic oligonucleotide hybridization probes were constructed from the consensus DNA30856 sequence which had the following nucleotide sequences hybridization probe (30856.pl) 30 5'-AGGCCATGAGGATTCTGCAGTTAATCCTGCTTGCTCTGGCAACAGGGCTT-3'(SEQ ID NO:15) 191 WO 2008/127352 PCT/US2007/080102 hybridization probe (30856.p11) 5'-GAGAGACCAGGATCATCAAGGGGTTCGAGTGCAAGCCTCACTC-3' (SEQ ID NO:16) In order to screen several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A 5 positive library was then used to isolate clones encoding the PRO 1279 gene using the probe oligonucleotide and one of the PCR primers. RNA for construction of the cDNA libraries was isolated from human lung tumor tissue. DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO1279 (designated herein as DNA65405-1547 [Figure 3, SEQ ID NO:3]; and 10 the derived protein sequence for PRO 1279. The entire nucleotide sequence of DNA65405-1547 is shown in Figure 3 (SEQ ID NO:3). Clone DNA65405-1547 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 106-108 and ending at the stop codon at nucleotide positions 856-858 (Figure 3). The predicted polypeptide precursor is 250 amino 15 acids long (Figure 4). The full-length PRO 1279 protein shown in Figure 4 has an estimated molecular weight of about 27,466 daltons and a pI of about 8.87. Analysis of the full-length PRO 1279 sequence shown in Figure 4 (SEQ ID NO:4) evidences the presence ofthe following: a signal peptide from about amino acid 1 to about amino acid 18, a serine protease, trypsin family, histidine active site from about amino acid 58 to about amino acid 63, potential 20 N-glycosylation sites from about amino acid 99 to about amino acid 102, from about amino acid 165 to about amino acid 168, from about amino acid 181 to about amino acid 184 and from about amino acid 210 to about amino acid 213, a glycosaminoglycan attachment site from about amino acid 145 to about amino acid 148, amino acid sequence blocks present in kringle domain proteins from about amino acid 197 to about amino acid 209 and from about amino acid 47 to 25 about amino acid 64, amino acid sequence blocks having homology to serine protease, trypsin family, histidine proteins from about amino acid 199 to about amino acid 209, from about amino acid 47 to about amino acid 63 and from about amino acid 220 to about amino acid 243 and amino acid sequence blocks having homology to apple domain proteins from about amino acid 222 to about amino acid 249 and from about amino acid 189 to about amino acid 222. 30 Clone DNA65405-1547 has been deposited with ATCC on November 17, 1998 and is assigned ATCC deposit no. 203476. 192 WO 2008/127352 PCT/US2007/080102 An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence alignment analysis ofthe full-length sequence shown in Figure 4 (SEQ ID NO:4), evidenced significant homology between the PRO 1279 amino acid sequence and the following Dayhoff sequences: 156559, S55066, KLK7_RAT, KLK1_RAT, KLKB_RAT, KLK3_MOUSE, KLK8_RAT, AF0139881, D78203_1 and HSU62801_1. 5 Additionally, DNA65405-1547 was obtained by purchasing the Incyte EST clone no. 2723646 and sequencing the insert of that clone, thereby giving the DNA65405-1547 sequence shown in Figure 3 (SEQ ID NO:3). EXAMPLE 6: Generation and Analysis of Mice Comprising PRO 1105, PRO 1279 or PRO 1783 10 Gene Disruptions To investigate the role of PRO 1105, PRO 1279 or PRO 1783 polypeptides, disruptions in PRO1 105,PRO 1279 or PRO 1783 genes were produced by homologous recombination or retroviral insertion techniques. Specifically, transgenic mice comprising disruptions in PRO1 105,PRO1279 or PRO1783 genes (i.e., knockout mice) were created by either gene 15 targeting or gene trapping. Mutations were confirmed by southern blot analysis to confirm correct targeting on both the 5' and 3' ends. Gene-specific genotyping was also performed by genomic PCR to confirm the loss of the endogenous native transcript as demonstrated by RT PCR using primers that anneal to exons flanking the site of insertion. Targeting vectors were electroporated into 129 strain ES cells and targeted clones were identified. Targeted clones 20 were microinjected into host blastocysts to produce chimeras. Chimeras were bred with C57 animals to produce F 1 heterozygotes. Heterozygotes were intercrossed to produce F2 wildtype, heterozygote and homozygote cohorts which were used for phenotypic analysis. Rarely, if not enough F1 heterozygotes were produced, the F1 hets were bred to wildtype C57 mice to produce sufficient heterozygotes to breed for cohorts to be analyzed for a phenotype. All 25 phenotypic analysis was performed from 12-16 weeks after birth. Overall Summary of Phenotypic Results: 6.1. Generation and Analysis of Mice Comprising DNA59612-1466 (U1NQ548) Gene Disruptions 30 In these knockout experiments, the gene encoding PRO 1105 polypeptides (designated as DNA59612-1466) (UNQ548) was disrupted. The gene specific information for these studies 193 WO 2008/127352 PCT/US2007/080102 is as follows: the mutated mouse gene corresponds to nucleotide reference: NM_029748 ACCESSION:NM_029748 NID: gi 22267453 refNM_029748.1 Mus musculus RIKEN cDNA 2510006D 16 gene (2510006D 1 6Rik); protein reference: Q8R1E7 ACCESSION:Q8R1E7 NID: Mus musculus (Mouse). RIKEN cDNA 2510006D16 gene (Weakly similar to PP 1065); the human gene sequence reference: NM_019118 ACCESSION:NM_019118 NID: gi 21361813 5 ref NM_019118.2 Homo sapiens hypothetical protein RP4-622L5 (RP4-622L5); the human protein sequence corresponds to reference: Q8WY98 ACCESSION:Q8WY98 NID: Homo sapiens (Human). PP 1065 (Similar to hypothetical protein RP4-622L5). The gene of interest is mouse RIKEN cDNA 2510006D16 gene, ortholog of human Clorf9l (chromosome 1 open reading frame 91). Aliases include 2510006D16Rik, 10 1500002D1 IRik; 4933407D05Rik, AASL548; PRO1 105; FLJ90779; RP4-622L5; dJ622L5.7; RP4-622L5.3. Cl orf91 is a hypothetical integral plasma membrane protein (Clark e al, Genome Res 13:2265-70 (2003)), containing a signal peptide and two transmembrane segments. Targeted or gene trap mutations are generated in strain 129SvEvBrd-derived embryonic 15 stem (ES) cells. The chimeric mice are bred to C57BL/6J albino mice to generate Fl heterozygous animals. These progeny are intercrossed to generate F2 wild type, heterozygous, and homozygous mutant progeny. On rare occasions, for example when very few Fl mice are obtained from the chimera, Fl heterozygous mice are crossed to 129SvEvBrd /C57 hybrid mice to yield additional heterozygous animals for the intercross to generate the F2 mice. Level I 2 0 phenotypic analysis is performed on mice from this generation wt het hom Total Observed 12 26 22 60 Expected 15 30 15 60 Chi-Sq.= 0.29 Significance= 0.8650223 (hom/n)= 0.26 Avg. Litter Size= 7 25 Mutation Type: Homologous Recombination (standard) Description: The gene consists of 5 exons, with the start codon located in exon 1 (NCBI accession NM_029748.1). Exons 4 and 5 were targeted. 1. Wild-type Expression Panel: Expression of the target gene was detected in embryonic stem (ES) cells and in all 13 adult tissue samples tested by RT-PCR, except skeletal muscle. 30 2. QC Expression: Disruption of the target gene was confirmed by Southern hybridization analysis. 194 WO 2008/127352 PCT/US2007/080102 6.1.1. PHENOTYPIC ANALYSIS (for disrupted gene: DNA59612-1466 (U1NQ548) (a) OVERALL PHENOTYPIC SUMMARY: Mutation of the gene encoding the ortholog of human chromosome 1 open reading frame 91 (C lorf9 1) resulted in decreased total body fat mass and % total body fat in (-/-) mice. In addition, the mutant (-/-) mice also exhibited an increased trabecular bone volume and 5 thickness. Gene disruption was confirmed by Southern blot. (b) Bone Metabolism & Body Diagnostics In the area of bone metabolism, targets were identified herein for the treatment of arthritis, osteoporosis, osteopenia and osteopetrosis as well as identifying targets that promote bone healing. Tests included: 10 DEXA for measurement of bone mineral density on femur and vertebra MicroCT for very high resolution and very high sensitivity measurements of bone mineral density for both trabecular and cortical bone. Dexa Analysis - Test Description: Procedure: A cohort of 4 wild type, 4 heterozygous and 8 homozygous mice were 15 tested in this assay. Dual Energy X-ray Absorptiometry (DEXA) has been used successfully to identify changes in bone. Anesthetized animals were examined and bone mineral content (BMC), BMC/LBM ratios, volumetric bone mineral density (vBMD), total body BMD, femur BMD and vertebra BMD were measured. The mouse was anesthetized by intraperitoneal injection of Avertin (1.25% 20 2,2,2,-tribromoethanol, 20 ml/kg body weight ), body length and weight were measured, and then the mouse was placed in a prone position on the platform of the PIXImusTM Densitometer (Lunar Inc.) for a DEXA scan. Using Lunar PIXImus software, the bone mineral density (BMD) and fat composition (% fat) and total tissue mass (TTM) were determined in the regions of interest (ROI) [ i.e., whole body, vertebrae, and both femurs]. 25 Bone microCT Analysis: Procedure: MicroCT was also used to get very sensitive measurements of BMD. One vertebra and 1 femur were taken from a cohort of 4 wild type and 8 homozygous mice. Measurements were taken of lumbar 5 veterbra traebecular bone volume, traebecular thickness, connectivity density and midshaft femur total bone area and cortical thickness. The LCT40 30 scans provided detailed information on bone mass and architecture. Multiple bones were placed into sample holders and scanned automatically. Instrument software was used to select 195 WO 2008/127352 PCT/US2007/080102 regions of interest for analysis. Trabecular bone parameters were analyzed in the fifth lumbar vertebrae (LV5) at 16 micrometer resolution and cortical bone parameters were analyzed in the femur midshaft at a resolution of 20 micrometers. Results: Micro CT: The (-/-) mice exhibited increased mean trabecular bone volume and thickness 5 when compared with their gender-matched (+/+) littermates and the historical mean. The male (-/-) mice exhibited increased mean trabecular bone volume and thickness when compared with their gender-matched (+/+) littermates. These results indicate that the knockout mutant phenotype may be associated with such bone abnormalities as osteopetrosis. Osteopetrosis is a condition characterized by abnormal thickening and hardening of bone and 10 abnormal fragility of the bones. As such, PRO 1105 polypeptides or agonists thereof would be beneficial for the treatment of osteopetrosis. A phenotype associated with an increased bone mineral content, and total body and femoral bone mineral density suggests that agents which mimic these effects (e.g. antagonists of PRO 1105 polypeptides)would be useful in bone healing. 15 Results: DEXA: The (-/-) mice exhibited decreased mean percent total body fat and total fat mass when compared with their gender-matched (+/+) littermates and the historical means. The difference was more notable in the males. The mutant (-/-) mice exhibit depleted total body fat and fat mass suggestive of tissue 20 wasting diseases. Decreased body weight and length measurements in (-/-) mice substantiates a growth retardation phenotype. Thus antagonists (or inhibitors) of PRO 1105 polypeptides would be expected to mimic this negative phenotype. PRO 1105 polypeptides or agonists thereof would be useful in maintaining normal fat metabolism and associated growth related metabolism. 25 (c) Blood Chemistry/Glucose Tolerance In the area ofmetabolism, targets may be identified for the treatment of diabetes. Blood chemistry phenotypic analysis includes blood glucose measurements. The COBAS Integra 400 (mfr: Roche) was used for running blood chemistry tests on the mice. In the area of metabolism, targets may be identified for the treatment of diabetes. Blood chemistry 30 phenotypic analysis includes glucose tolerance tests to measure insulin sensitivity and changes in glucose metabolism. Abnormal glucose tolerance test results may indicate but may not be 196 WO 2008/127352 PCT/US2007/080102 limited to the following disorders or conditions: Diabetes Type 1 and Type 2, Syndrome X, various cardiovascular diseases and/or obesity. Procedure: A cohort of 2 wild type and 4 homozygous mice were used in this assay. The glucose tolerance test is the standard for defining impaired glucose homeostasis in mammals. Glucose tolerance tests were performed using a Lifescan glucometer. Animals were 5 injected IP at 2g/kg with D-glucose delivered as a 20% solution and blood glucose levels were measured at 0, 30, 60 and 90 minutes after injection. Results: Oral Glucose Tolerance: The (-/-) mice exhibited an impaired glucose tolerance when compared with that of their gender-matched (+/+) littermates and the historical mean. 10 These studies indicated that (-/-) mice exhibit a decreased or impaired glucose tolerance in the presence of normal fasting glucose at all 3 intervals tested when compared with their gender-matched (+/+) littermates and the historical means. Thus, knockout mutant mice exhibited the phenotypic pattern of an impaired glucose homeostasis, and therefor PRO 1105 polypeptides (or agonists thereof) or its encoding gene would be useful in the treatment of 15 conditions associated with an impaired glucose homeostasis and/or various cardiovascular diseases, including diabetes. 6.2. Generation and Analysis of Mice Comprising DNA65405-1547 (U1NQ649) Gene Disruptions 20 In these knockout experiments, the gene encoding PRO1279 polypeptides (designated as DNA65405-1547) (UN649) was disrupted. The gene specific information for these studies is as follows: the mutated mouse gene corresponds to nucleotide reference: NM_019974 ACCESSION:NM_019974 NID: gi 9910297 refNM_019974.1 Mus musculus RIKEN cDNA 2310015108 gene (2310015I08Rik); protein reference: Q9QYN3 ACCESSION:Q9QYN3 NID: 25 Mus musculus (Mouse). Hippostasin prostate type (Adult male tongue cDNA, RIKEN full-length enriched library, clone:23 10015108 product:protease, serine, 20, full insert sequence) (Adult male tongue cDNA, RIKEN full-length enriched library, clone:23 10040F07 product:protease, serine, 20, full insert sequence); the human gene sequence reference: NM_144947 ACCESSION:NM_144947 NID: gi 21618356 ref NM_144947.1 Homo sapiens 30 kallikrein 11 (KLK1 1), transcript variant 2; the human protein sequence corresponds to reference: Q9UBX7 ACCESSION:Q9UBX7 NID: Homo sapiens (Human). Kallikrein 11 197 WO 2008/127352 PCT/US2007/080102 precursor (EC 3.4.2 1.-) (Hippostasin) (Trypsin-like protease). The gene of interest is mouse Klk 11 (kallikrein 11), ortholog of human KLK1 1. Aliases include TLSP, PRSS20, 2310015108Rik, and MGC33060. KLK1 1 is a secreted serine protease expressed primarily in brain and prostate. This protease is upregulated in ovarian, prostate, and neuroendocrine cancers and is likely to have 5 clinical value as a biomarker for the diagnosis and monitoring of prostate and ovarian cancers (Yoshida et al, Biochim Biophys Acta 1399:225-8 (1998); Mitsui et al, Biochim Biophys Acta 1494:206-10 (2000); Yousef et al, Genomics 63:88-96 (2000); Borgono et al, Mol Cancer Res 2:257-80 (2004); Stavropoulou et al, Clin Chim Acta 357:190-5 (2005)). Targeted or gene trap mutations are generated in strain 129SvEvBrd-derived embryonic 10 stem (ES) cells. The chimeric mice are bred to C57BL/6J albino mice to generate F1 heterozygous animals. These progeny are intercrossed to generate F2 wild type, heterozygous, and homozygous mutant progeny. On rare occasions, for example when very few F1 mice are obtained from the chimera, F1 heterozygous mice are crossed to 129SvEvBrd /C57 hybrid mice to yield additional heterozygous animals for the intercross to generate the F2 mice. Level I 15 phenotypic analysis is performed on mice from this generation wt het hom Total Observed 19 24 16 59 Expected 14.75 29.5 14.75 59 Chi-Sq.= 0.4 Significance= 0.8187308 (hom/n)= 0.24 Avg. Litter Size= 9 20 Mutation Information Mutation Type: Homologous Recombination (standard) Description: The gene consists of 6 exons, with the start codon located in exon 2 (NCBI accession NM_019974.1). Exons 2 through 5 were targeted. 1. Wild-type Expression Panel: Expression of the target gene was detected in all 13 adult tissue 25 samples tested by RT-PCR, except skeletal muscle and bone. 2. QC Expression: Disruption of the target gene was confirmed by Southern hybridization analysis. 6.2.1. PHENOTYPIC ANALYSIS (for disrupted gene: DNA65405-1547 (UNQ649) 30 (a) OVERALL PHENOTYPIC SUMMARY: Mutation of the gene encoding the ortholog of human kallikrein 11 (KLK1 1) resulted 198 WO 2008/127352 PCT/US2007/080102 in increased systolic blood pressure in (-/-) mice. Male (-/-) mice exhibited a decreased anxiety-like response. Gene disruption was confirmed by Southern blot. (b) Phenotypic Analysis: CNS/Neurology In the area of neurology, analysis focused herein on identifying in vivo validated targets for the treatment of neurological and psychiatric disorders including depression, generalized 5 anxiety disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia and sensory disorders. Neurological disorders include the category defined as "anxiety disorders" which include but are not limited to: mild to moderate anxiety, anxiety disorder due to a general medical condition, anxiety disorder not otherwise specified, generalized anxiety disorder, panic attack, panic disorder with agoraphobia, 10 panic disorder without agoraphobia, posttraumatic stress disorder, social phobia, specific phobia, substance-induced anxiety disorder, acute alcohol withdrawal, obsessive compulsive disorder, agoraphobia, bipolar disorder I or II, bipolar disorder not otherwise specified, cyclothymic disorder, depressive disorder, major depressive disorder, mood disorder, substance induced mood disorder. In addition, anxiety disorders may apply to personality disorders 15 including but not limited to the following types: paranoid, antisocial, avoidant behavior, borderline personality disorders, dependent, histronic, narcissistic, obsessive-compulsive, schizoid, and schizotypal. Procedure: Behavioral screens were performed on a cohort of 4 wild type, 4 heterozygous and 8 20 homozygous mice. All behavioral tests were done between 12 and 16 weeks of age unless reduced viability necessitates earlier testing. These tests included open field to measure anxiety, activity levels and exploration. Open field test: Several targets of known drugs have exhibited phenotypes in the open field test. These 25 include knockouts of the seratonin transporter, the dopamine transporter (Giros et al., Nature. 1996 Feb 15;379(6566):606-12), and the GABA receptor (Homanics et al., Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4143-8). An automated open-field assay was customized to address changes related to affective state and exploratory patterns related to learning. First, the field (40 X 40 cm) was selected to be relatively large for a mouse, thus designed to pick up changes 30 in locomotor activity associated with exploration. In addition, there were 4 holes in the floor to allow for nose-poking, an activity specifically related to exploration. Several factors were 199 WO 2008/127352 PCT/US2007/080102 also designed to heighten the affective state associated with this test. The open-field test is the first experimental procedure in which the mice are tested, and the measurements that were taken were the subjects' first experience with the chamber. In addition, the open-field was brightly lit. All these factors will heighten the natural anxiety associated with novel and open spaces. The pattern and extent of exploratory activity, and especially the center-to-total distance 5 traveled ratio, may then be able to discern changes related to susceptibility to anxiety or depression. A large arena (40 cm x 40 cm, VersaMax animal activity monitoring system from AccuScan Instruments) with infrared beams at three different levels was used to record rearing, hole poke, and locomotor activity. The animal was placed in the center and its activity was measured for 20 minutes. Data from this test was analyzed in five, 4-minute intervals. The total 10 distance traveled (cm), vertical movement number (rearing), number of hole pokes, and the center to total distance ratio were recorded. The propensity for mice to exhibit normal habituation responses to a novel environment is assessed by determining the overall change in their horizontal locomotor activity across the 5 time intervals. This calculated slope of the change in activity over time is determined using 15 normalized, rather than absolute, total distance traveled. The slope is determined from the regression line through the normalized activity at each of the 5 time intervals. Normal habituation is represented by a negative slope value. Results: The male (-/-) mice exhibited an increased median sum time-in-center when compared 20 with their gender-matched (+/+) littermates and the historical mean, suggesting a decreased anxiety-like response in the mutants. A notable difference was observed during open field activity testing. The male (-/-) mice exhibited an increased median sum time in the center area when compared with their gender-matched (+/+) littermates, which is indicative of a decreased anxiety-like response in 25 the mutants. Thus, knockout mice demonstrated a phenotype consistent with depression, generalized anxiety disorders, cognitive disorders, hyperalgesia and sensory disorders and/or bipolar disorders. Thus, PRO 1279 polypeptides and agonists thereof would be useful for the treatment or amelioration of the symptoms associated with depressive disorders. (c) Cardiology/Diagnostics -Blood Pressure 30 Description: Systolic blood pressure is measured via a noninvasive tail-cuff method for four days on 200 WO 2008/127352 PCT/US2007/080102 the Visitech BP-2000 Blood Pressure Analysis System. The blood pressure is measured ten times each day for four days. The four days are then averaged to obtain a mouse's conscious systolic blood pressure. Results: Blood Pressure: The (-/-) mice exhibited a decreased systolic blood pressure (1 SD below) 5 when compared with that of their gender-matched (+/+) littermates and the historical mean. 6.3. Generation and Analysis of Mice Comprising DNA71182 (UNQ845) Gene Disruptions In these knockout experiments, the gene encoding PRO 1783 polypeptides (designated as DNA71182) (UNQ845) was disrupted. The gene specific information for these studies is 10 as follows: the mutated mouse gene corresponds to nucleotide reference: NM_134248 ACCESSION:NM_134248 NID:19527409 Mus musculus Mus musculus T-cell immunoglobulin and mucin domain containing 1 (Timd1); protein reference: Q8VIM2 ACCESSION:Q8VIM2 NID: Mus musculus (Mouse). TIMI; the human gene sequence reference: NM_012206 ACCESSION:NM_012206 NID: gi 6912407 refNM_012206.1 Homo 15 sapiens hepatitis A virus cellular receptor 1 (HAVCRI); the human protein sequence corresponds to reference: 043656 ACCESSION:043656 NID: Homo sapiens (Human). HEPATITIS A VIRUS CELLULAR RECEPTOR 1. The gene of interest is mouse Havcri (hepatitis A virus cellular receptor 1), ortholog of human HAVCRI. Aliases include A1503787, KIMI, TIMI, HAVCR, KIM-1, TIM-1, 20 TIMD1, and HAVCR-1. HAVCRI is an integral plasma membrane protein expressed primarily on subsets of T cells that functions as a receptor for hepatitis A virus (HAV) and for TIMD4 (T-cell immunoglobulin and mucin domain containing 4), an integral plasma membrane protein expressed on antigen-presenting cells. HAVCRi plays a costimulatory role in T cell activation 25 and is associated with atopic diseases, such as asthma, allergic rhinitis, and atopic dermatitis (Meyers et al, Nat Immunol 6:455-64 (2005); McIntire et al, Nature 425:576 (2003); Umetsu et al, Nat Immunol 6:447-54 (2005); de Souza et al, Proc Natl Acad Sci U S A 102:17113-8 (2005)). Targeted or gene trap mutations are generated in strain 129SvEvBrd-derived embryonic 30 stem (ES) cells. The chimeric mice are bred to C57BL/6J albino mice to generate F1 heterozygous animals. These progeny are intercrossed to generate F2 wild type, heterozygous, 201 WO 2008/127352 PCT/US2007/080102 and homozygous mutant progeny. On rare occasions, for example when very few F1 mice are obtained from the chimera, F1 heterozygous mice are crossed to 129SvEvBrd /C57 hybrid mice to yield additional heterozygous animals for the intercross to generate the F2 mice. Level I phenotypic analysis is performed on mice from this generation wt het hom Total 5 Observed 13 44 13 70 Expected 17.5 35 17.5 70 Chi-Sq.= 1.87 Significance= 0.39258587 (hom/n)= 0.24 Avg. Litter Size= 8 Mutation Information Mutation Type: Homologous Recombination (standard) 10 Description: The gene consists of 8 exons, with the start codon located in exon 2 (NCBI accession BC053400.1). Exons 2 and 3 were targeted. 1. Wild-type Expression Panel: Expression of the target gene was detected in embryonic stem (ES) cells and in all 13 adult tissue samples tested by RT-PCR, except brain, skeletal muscle, heart, and adipose. 15 2. QC Expression: Disruption of the target gene was confirmed by Southern hybridization analysis. 6.3.1. PHENOTYPIC ANALYSIS (for disrupted gene: DNA71182 (UNQ845) (a) OVERALL PHENOTYPIC SUMMARY: 20 Mutation of the gene encoding the ortholog of human hepatitis A virus cellular receptor 1 (HAVCRI) resulted in male (-/-) mice exhibiting a decreased depressive-like response in the tail suspension testing and an abnormal habituation response to a novel environment. Female (-/-) mice exhibited a decreased skin fibroblast proliferation rate. Gene disruption was confirmed by Southern blot. 25 (b) Adult skin cell proliferation: Procedure: Skin cells were isolated from 16 week old animals (2 wild type and 4 homozygous mice). These were developed into primary fibroblast cultures and the fibroblast proliferation rates were measured in a strictly controlled protocol. The ability of this assay to detect hyper-proliferative and hypo-proliferative phenotypes has been demonstrated with p53 30 and Ku8O. Proliferation was measured using Brdu incorporation. Specifically, in these studies the skin fibroblast proliferation assay was used. An 202 WO 2008/127352 PCT/US2007/080102 increase in the number of cells in a standardized culture was used as a measure of relative proliferative capacity. Primary fibroblasts were established from skin biopsies taken from wild type and mutant mice. Duplicate or triplicate cultures of 0.05 million cells were plated and allowed to grow for six days. At the end of the culture period, the number of cells present in the culture was determined using a electronic particle counter. 5 Results: Skin Proliferation: The female (-/-) mice exhibited a decreased mean skin fibroblast proliferation rate when compared with that of their gender-matched (+/+) littermates and the historical mean. Thus, homozygous mutant mice demonstrated a hypo-proliferative phenotype. As 10 suggested by these observations, antagonists or inhibitors of PRO 1783 polypeptides would mimic this hypo-proliferative phenotype and could function as tumor suppressors and would be useful in decreasing abnormal cell proliferation. (c) Phenotypic Analysis: CNS/Neurology In the area of neurology, analysis focused herein on identifying in vivo validated targets 15 for the treatment of neurological and psychiatric disorders including depression, generalized anxiety disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia and sensory disorders. Neurological disorders include the category defined as "anxiety disorders" which include but are not limited to: mild to moderate anxiety, anxiety disorder due to a general medical condition, anxiety disorder not 2 0 otherwise specified, generalized anxiety disorder, panic attack, panic disorder with agoraphobia, panic disorder without agoraphobia, posttraumatic stress disorder, social phobia, specific phobia, substance-induced anxiety disorder, acute alcohol withdrawal, obsessive compulsive disorder, agoraphobia, bipolar disorder I or II, bipolar disorder not otherwise specified, cyclothymic disorder, depressive disorder, major depressive disorder, mood disorder, substance 25 induced mood disorder. In addition, anxiety disorders may apply to personality disorders including but not limited to the following types: paranoid, antisocial, avoidant behavior, borderline personality disorders, dependent, histronic, narcissistic, obsessive-compulsive, schizoid, and schizotypal. Procedure: 30 Behavioral screens were performed on a cohort of 4 wild type, 4 heterozygous and 8 homozygous mice. All behavioral tests were done between 12 and 16 weeks of age unless 203 WO 2008/127352 PCT/US2007/080102 reduced viability necessitates earlier testing. These tests included open field to measure anxiety, activity levels and exploration. Functional Observational Battery (FOB) Test - Tail Suspension Testing: The FOB is a series of situations applied to the animal to determine gross sensory and motor deficits. A subset of tests from the Irwin neurological screen that evaluates gross 5 neurological function is used. In general, short-duration, tactile, olfactory, and visual stimuli are applied to the animal to determine their ability to detect and respond normally. These simple tests take approximately 10 minutes and the mouse is returned to its home cage at the end of testing. Tail Suspension Testing: 10 The tail suspension test is a procedure that has been developed as a model for depressive-like behavior in rodents. In this particular setup, a mouse is suspended by its tail for 6 minutes, and in response the mouse will struggle to escape from this position. After a certain period of time the struggling of the mouse decreases and this is interpreted as a type of learned helplessness paradigm. Animals with invalid data (i.e. climbed their tail during the testing 15 period) are excluded from analysis. Results: Tail Suspension2: The male (-/-) mice exhibited decreased median immobility time when compared with that of their gender-matched (+/+) littermates and the historical mean, suggesting a decreased depressive-like response in the mutants. 20 In summary, the tail suspension testing revealed a phenotype associated with increased anxiety which could be associated with mild to moderate anxiety, anxiety due to a general medical condition, and/or bipolar disorders; hyperactivity; sensory disorders; obsessive compulsive disorders, schizophrenia or a paranoid personality. Thus, PRO 1783 polypeptides or agonists thereof would be useful in the treatment of such neurological disorders. 25 Circadian Test Description: Female mice are individually housed at 4 pm on the first day of testing in 48.2 cm x 26.5 cm home cages and administered food and water ad libitum. Animals are exposed to a 12-hour light/dark cycle with lights turning on at 7 am and turning off at 7 pm. The system software records the number of beam interruptions caused by the animal's movements, with 30 beam breaks automatically divided into ambulations. Activity is recorded in 60, one-hour intervals during the three-day test. Data generated are displayed by median activity levels 204 WO 2008/127352 PCT/US2007/080102 recorded for each hour (circadian rhythm) and median total activity during each light/dark cycle (locomotor activity) over the three-day testing period. Results: Circadian: The female (-/-) mice exhibited an increased median ambulatory count during the 1-hour habituation period when compared with that of their gender-matched (+/+) littermates 5 and the historical mean. Thus, the (-/-) mice exhibited increased ambulatory counts during home-cage activity testing resulting in a hyperactive behavior pattern or abnormal habituation response to a novel environment when compared with their gender-matched (+/+) littermates and the historical means. 10 EXAMPLE 7: Use of PRO 1105, PRO 1279 or PRO 1783 as a hybridization probe The following method describes use of a nucleotide sequence encoding a PRO 1105, PRO 1279 or PRO 1783 polypeptide as a hybridization probe. DNA comprising the coding sequence of full-length or mature PRO 1105, PRO1279 or 15 PRO 1783 polypeptides as disclosed herein is employed as a probe to screen for homologous DNAs (such as those encoding naturally-occurring variants of PRO 1105, PRO 1279 or PRO 1783 polypeptides) in human tissue cDNA libraries or human tissue genomic libraries. Hybridization and washing of filters containing either library DNAs is performed under the following high stringency conditions. Hybridization ofradiolabeled PRO 1105-, PRO 1279 20 or PRO 1783-derived probe to the filters is performed in a solution of 50% formamide, 5x SSC, 0.1% SDS, 0.1% sodium pyrophosphate, 50 mM sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42 0 C for 20 hours. Washing of the filters is performed in an aqueous solution of 0.1x SSC and 0. 1% SDS at 42 0 C. DNAs having a desired sequence identity with the DNA encoding full-length native 25 sequence PRO 1105, PRO 1279 or PRO 1783 polypeptides can then be identified using standard techniques known in the art. EXAMPLE 9: Expression of PRO 1105, PRO 1279 or PRO 1783 in E. coli This example illustrates preparation of an unglycosylated form of PRO 1105, PRO 1279 30 or PRO 1783 polypeptides by recombinant expression in E. coli. The DNA sequence encoding a PRO 1105, PRO1279 or PRO1783 polypeptide is 205 WO 2008/127352 PCT/US2007/080102 initially amplified using selected PCR primers. The primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector. A variety of expression vectors may be employed. An example of a suitable vector is pBR322 (derived from E. coli; see Bolivar et al., Gene, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and 5 dephosphorylated. The PCR amplified sequences are then ligated into the vector. The vector will preferably include sequences which encode for an antibiotic resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage site), the PRO 1105, PRO 1279 or PRO 1783 coding region, lambda transcriptional terminator, and an argU gene. 10 The ligation mixture is then used to transform a selected E. coli strain using the methods described in Sambrook et al., supra. Transformants are identified by their ability to grow on LB plates and antibiotic resistant colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing. Selected clones can be grown overnight in liquid culture medium such as LB broth 15 supplemented with antibiotics. The overnight culture may subsequently be used to inoculate a larger scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on. After culturing the cells for several more hours, the cells can be harvested by centrifugation. The cell pellet obtained by the centrifugation can be solubilized using various 20 agents known in the art, and the solubilized PRO 1105, PRO 1279 or PRO 1783 protein can then be purified using a metal chelating column under conditions that allow tight binding of the protein. PRO 1105, PRO 1279 or PRO 1783 may be expressed in E. coli in a poly-His tagged form, using the following procedure. The DNA encoding PRO 1105, PRO 1279 or PRO 1783 25 is initially amplified using selected PCR primers. The primers will contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector, and other useful sequences providing for efficient and reliable translation initiation, rapid purification on a metal chelation column, and proteolytic removal with enterokinase. The PCR-amplified, poly-His tagged sequences are then ligated into an expression vector, which 30 is used to transform an E. coli host based on strain 52 (W3110 fuhA(tonA) lon galE rpoHts(htpRts) clpP(laclq). Transformants are first grown in LB containing 50 mg/ml 206 WO 2008/127352 PCT/US2007/080102 carbenicillin at 30'C with shaking until an O.D.600 of 3-5 is reached. Cultures are then diluted 50-100 fold into CRAP media (prepared by mixing 3.57 g (NH 4
)
2
SO
4 , 0.71 g sodium citrate-2H20, 1.07 g KCl, 5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 mL water, as well as 110 mM MPOS, pH 7.3, 0.55% (w/v) glucose and 7 mM MgSO 4 ) and grown for approximately 20-30 hours at 30'C with shaking. Samples are removed to verify expression 5 by SDS-PAGE analysis, and the bulk culture is centrifuged to pellet the cells. Cell pellets are frozen until purification and refolding. E. coli paste from 0.5 to 1 L fermentations (6-10 g pellets) is resuspended in 10 volumes (w/v) in 7 M guanidine, 20 mM Tris, pH 8 buffer. Solid sodium sulfite and sodium tetrathionate is added to make final concentrations of 0. 1M and 0.02 M, respectively, and the 10 solution is stirred overnight at 4'C. This step results in a denatured protein with all cysteine residues blocked by sulfitolization. The solution is centrifuged at 40,000 rpm in a Beckman Ultracentifuge for 30 min. The supernatant is diluted with 3-5 volumes of metal chelate column buffer (6 M guanidine, 20 mM Tris, pH 7.4) and filtered through 0.22 micron filters to clarify. The clarified extract is loaded onto a 5 ml Qiagen Ni-NTA metal chelate column equilibrated 15 in the metal chelate column buffer. The column is washed with additional buffer containing 50 mM imidazole (Calbiochem, Utrol grade), pH 7.4. The protein is eluted with buffer containing 250 mM imidazole. Fractions containing the desired protein are pooled and stored at 4'C. Protein concentration is estimated by its absorbance at 280 nm using the calculated extinction coefficient based on its amino acid sequence. 20 The proteins are refolded by diluting the sample slowly into freshly prepared refolding buffer consisting of: 20 mM Tris, pH 8.6, 0.3 M NaCl, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM EDTA. Refolding volumes are chosen so that the final protein concentration is between 50 to 100 micrograms/ml. The refolding solution is stirred gently at 4'C for 12-36 hours. The refolding reaction is quenched by the addition of TFA to a final concentration of 25 0.4% (pH of approximately 3). Before further purification of the protein, the solution is filtered through a 0.22 micron filter and acetonitrile is added to 2-10% final concentration. The refolded protein is chromatographed on a Poros RI/H reversed phase column using a mobile buffer of 0.1% TFA with elution with a gradient of acetonitrile from 10 to 80%. Aliquots of fractions with A280 absorbance are analyzed on SDS polyacrylamide gels and fractions 30 containing homogeneous refolded protein are pooled. Generally, the properly refolded species of most proteins are eluted at the lowest concentrations of acetonitrile since those species are 207 WO 2008/127352 PCT/US2007/080102 the most compact with their hydrophobic interiors shielded from interaction with the reversed phase resin. Aggregated species are usually eluted at higher acetonitrile concentrations. In addition to resolving misfolded forms of proteins from the desired form, the reversed phase step also removes endotoxin from the samples. Fractions containing the desired folded PRO 1105, PRO1279 or PRO1783 polypeptide 5 are pooled and the acetonitrile removed using a gentle stream of nitrogen directed at the solution. Proteins are formulated into 20 mM Hepes, pH 6.8 with 0.14 M sodium chloride and 4% mannitol by dialysis or by gel filtration using G25 Superfine (Pharmacia) resins equilibrated in the formulation buffer and sterile filtered. 10 EXAMPLE 10: Expression of PRO 1105, PRO 1279 or PRO 1783 in mammalian cells This example illustrates preparation of a potentially glycosylated form of a PRO 1105, PRO 1279 or PRO 1783 polypeptide by recombinant expression in mammalian cells. The vector, pRK5 (see EP 307,247, published March 15, 1989), is employed as the expression vector. Optionally, the PRO 1105-, PRO 1279- or PRO 1783-DNA is ligated into 15 pRK5 with selected restriction enzymes to allow insertion of the PRO 1105-, PRO 1279- or PRO1783-DNA using ligation methods such as described in Sambrook et al., supra. The resulting vector is called pRK5-PRO 1105, pRK5-PRO 1279 or pRK5-PRO 1783. The selected host cells may be 293 cells. Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal 20 calf serum and optionally, nutrient components and/or antibiotics. About 10 [ig pRK5 PRO 1105, pRK5-PRO 1279 or pRK5-PRO 1783 DNA is mixed with about 1 [g DNA encoding the VA RNA gene [Thimmappaya et al., Cell, 31:543 (1982)] and dissolved in 500 [1 of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M CaCl 2 . To this mixture is added, dropwise, 500 pl of 50 mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mM NaPO 4 , and a precipitate is allowed to form for 25 10 minutes at 25 0 C. The precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 37 0 C. The culture medium is aspirated off and 2 ml of 20% glycerol in PBS is added for 30 seconds. The 293 cells are then washed with serum free medium, fresh medium is added and the cells are incubated for about 5 days. Approximately 24 hours after the transfections, the culture medium is removed and 30 replaced with culture medium (alone) or culture medium containing 200 CWi/ml 1 5 S-cysteine and 200 pCi/ml 1 5 S-methionine. After a 12 hour incubation, the conditioned medium is 208 WO 2008/127352 PCT/US2007/080102 collected, concentrated on a spin filter, and loaded onto a 15% SDS gel. The processed gel may be dried and exposed to film for a selected period of time to reveal the presence of PRO 1105, PRO1279 or PRO1783 polypeptides. The cultures containing transfected cells may undergo further incubation (in serum free medium) and the medium is tested in selected bioassays. In an alternative technique, PRO 1105, PRO 1279 or PRO 1783 may be introduced into 5 293 cells transiently using the dextran sulfate method described by Somparyrac et al., Proc. Natl. Acad. Sci., 12:7575 (1981). 293 cells are grown to maximal density in a spinner flask and 700 Lg pRK5-PRO1 105, pRK5-PRO1279 or pRK5-PRO1783 DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% 10 glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5 Lg/ml bovine insulin and 0.1 Lg/ml bovine transferrin. After about four days, the conditioned media is centrifuged and filtered to remove cells and debris. The sample containing expressed PRO 1105, PRO 1279 or PRO 1783 can then be concentrated and purified by any selected method, such as dialysis and/or column 15 chromatography. PRO1105, PRO1279 or PRO1783 can be expressed in CHO cells. The pRK5 PRO 1105, pRK5-PRO 1279 or pRK5-PRO 1783 can be transfected into CHO cells using known reagents such as CaPO 4 or DEAE-dextran. As described above, the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a 20 radiolabel such as 1 5 S-methionine. After determining the presence of PRO 1105, PRO1279 or PRO1783 polypeptide, the culture medium may be replaced with serum free medium. Preferably, the cultures are incubated for about 6 days, and then the conditioned medium is harvested. The medium containing the expressed PRO 1105, PRO1279 or PRO1783 can then be concentrated and purified by any selected method. 25 Epitope-tagged PRO 1105, PRO 1279 or PRO 1783 may also be expressed in host CHO cells. The PRO1 105, PRO1279 or PRO1783 maybe subcloned out of the pRK5 vector. The subclone insert can undergo PCR to fuse in frame with a selected epitope tag such as a poly-his tag into a Baculovirus expression vector. The poly-his tagged PRO 1105, PRO 1279 or PRO 1783 insert can then be subcloned into a SV40 driven vector containing a selection marker 30 such as DHFR for selection of stable clones. Finally, the CHO cells can be transfected (as described above) with the SV40 driven vector. Labeling maybe performed, as described above, 209 WO 2008/127352 PCT/US2007/080102 to verify expression. The culture medium containing the expressed poly-His tagged PRO 1105, PRO 1279 or PRO 1783 can then be concentrated and purified by any selected method, such as by Ni 2 -chelate affinity chromatography. PRO 1105, PRO 1279 or PRO 1783 may also be expressed in CHO and/or COS cells by a transient expression procedure or in CHO cells by another stable expression procedure. 5 Stable expression in CHO cells is performed using the following procedure. The proteins are expressed as an IgG construct (immunoadhesin), in which the coding sequences for the soluble forms (e.g. extracellular domains) of the respective proteins are fused to an IgGI constant region sequence containing the hinge, CH2 and CH2 domains and/or is a poly-His tagged form. 10 Following PCR amplification, the respective DNAs are subcloned in a CHO expression vector using standard techniques as described in Ausubel et al., Current Protocols of Molecular Biologv, Unit 3.16, John Wiley and Sons (1997). CHO expression vectors are constructed to have compatible restriction sites 5' and 3' of the DNA of interest to allow the convenient shuttling of cDNA's. The vector used expression in CHO cells is as described in Lucas et al., 15 Nucl. Acids Res. 24:9 (1774-1779 (1996), and uses the SV40 early promoter/enhancer to drive expression of the cDNA of interest and dihydrofolate reductase (DHFR). DHFR expression permits selection for stable maintenance of the plasmid following transfection. Twelve micrograms of the desired plasmid DNA is introduced into approximately 10 million CHO cells using commercially available transfection reagents Superfect* (Qiagen), 20 Dosper* or Fugene* (Boehringer Mannheim). The cells are grown as described in Lucas et al., supra. Approximately 3 x 107 cells are frozen in an ampule for further growth and production as described below. The ampules containing the plasmid DNA are thawed by placement into water bath and mixed by vortexing. The contents are pipetted into a centrifuge tube containing 10 mLs of 25 media and centrifuged at 1000 rpm for 5 minutes. The supernatant is aspirated and the cells are resuspended in 10 mL of selective media (0.2 gm filtered PS20 with 50% 0.2 gm diafiltered fetal bovine serum). The cells are then aliquoted into a 100 mL spinner containing 90 mL of selective media. After 1-2 days, the cells are transferred into a 250 mL spinner filled with 150 mL selective growth medium and incubated at 37 0 C. After another 2-3 days, 250 mL, 500 mL 30 and 2000 mL spinners are seeded with 3 x 105 cells/mL. The cell media is exchanged with fresh media by centrifugation and resuspension in production medium. Although any suitable 210 WO 2008/127352 PCT/US2007/080102 CHO media may be employed, a production medium described in U.S. Patent No. 5,122,469, issued June 16, 1992 may actually be used. A 3L production spinner is seeded at 1.2 x 106 cells/mL. On day 0, the cell number pH ie determined. On day 1, the spinner is sampled and sparging with filtered air is commenced. On day 2, the spinner is sampled, the temperature shifted to 33 0 C, and 30 mL of 500 g/L glucose and 0.6 mL of 10% antifoam (e.g., 35% 5 polydimethylsiloxane emulsion, Dow Coming 365 Medical Grade Emulsion) taken. Throughout the production, the pH is adjusted as necessary to keep it at around 7.2. After 10 days, or until the viability dropped below 70%, the cell culture is harvested by centrifugation and filtering through a 0.22 gm filter. The filtrate was either stored at 4 0 C or immediately loaded onto columns for purification. 10 For the poly-His tagged constructs, the proteins are purified using a Ni-NTA column (Qiagen). Before purification, imidazole is added to the conditioned media to a concentration of 5 mM. The conditioned media is pumped onto a 6 ml Ni-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min. at 4 0 C. After loading, the column is washed with additional equilibration buffer and 15 the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein is subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80 0 C. Immunoadhesin (Fc-containing) constructs are purified from the conditioned media as follows. The conditioned medium is pumped onto a 5 ml Protein A column (Pharmacia) which 20 had been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column is washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5. The eluted protein is immediately neutralized by collecting 1 ml fractions into tubes containing 275 gL of 1 M Tris buffer, pH 9. The highly purified protein is subsequently desalted into storage buffer as described above for the poly-His tagged proteins. The homogeneity is assessed 25 by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation. EXAMPLE 11: Expression of PRO 1105, PRO 1279 or PRO 1783 in Yeast The following method describes recombinant expression of PRO 1105, PRO 1279 or PRO1783 in yeast. 30 First, yeast expression vectors are constructed for intracellular production or secretion of PRO1105, PRO1279 or PRO1783 from the ADH2/GAPDH promoter. DNA encoding 211 WO 2008/127352 PCT/US2007/080102 PRO 1105, PRO 1279 or PRO 1783 and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression of PRO 1105, PRO 1279 or PRO 1783. For secretion, DNA encoding PRO 1105, PRO 1279 or PRO 1783 can be cloned into the selected plasmid, together with DNA encoding the ADH2/GAPDH promoter, a native PRO 1105, PRO1279 or PRO1783 signal peptide or other mammalian signal peptide, or, for 5 example, a yeast alpha-factor or invertase secretory signal/leader sequence, and linker sequences (if needed) for expression of PRO 1105, PRO1279 or PRO1783. Yeast cells, such as yeast strain AB1 10, can then be transformed with the expression plasmids described above and cultured in selected fermentation media. The transformed yeast supernatants can be analyzed by precipitation with 10% trichloroacetic acid and separation by 10 SDS-PAGE, followed by staining of the gels with Coomassie Blue stain. Recombinant PRO 1105, PRO 1279 or PRO 1783 can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters. The concentrate containing PRO 1105, PRO1279 or PRO1783 may further be purified using selected column chromatography resins. 15 EXAMPLE 12: Expression of PRO 1105, PRO 1279 or PRO 1783 in Baculovirus-Infected Insect Cells The following method describes recombinant expression of PRO 1105, PRO 1279 or PRO 1783 in Baculovirus-infected insect cells. 20 The sequence coding for PRO 1105, PRO 1279 or PRO 1783 is fused upstream of an epitope tag contained within a baculovirus expression vector. Such epitope tags include poly his tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen). Briefly, the sequence encoding PRO 1105, PRO 1279 or PRO 1783 or the desired 25 portion of the coding sequence of PRO1105, PRO1279 or PRO1783 such as the sequence encoding the extracellular domain of a transmembrane protein or the sequence encoding the mature protein if the protein is extracellular is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected restriction enzymes and subcloned into 30 the expression vector. Recombinant baculovirus is generated by co-transfecting the above plasmid and 212 WO 2008/127352 PCT/US2007/080102 BaculoGold T M virus DNA (Pharmingen) into Spodopterafrugiperda ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from GIBCO-BRL). After 4 - 5 days of incubation at 28 0 C, the released viruses are harvested and used for further amplifications. Viral infection and protein expression are performed as described by O'Reilley et al., Baculovirus expression vectors: A Laboratory Manual, Oxford: Oxford University Press (1994). 5 Expressed poly-his tagged PRO 1105, PRO 1279 or PRO 1783 can then be purified, for example, by Ni 2 +-chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert et al., Nature, 362:175-179 (1993). Briefly, Sf9 cells are washed, resuspended in sonication buffer (25 mL Hepes, pH 7.9; 12.5 mM MgCl 2 ; 0-1 mM EDTA; 10% glycerol; 0.l1% NP-40; 0.4 M KCl), and sonicated twice for 20 10 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted 50 fold in loading buffer (50 mM phosphate, 300 mM NaCl, 10% glycerol, pH 7.8) and filtered through a 0.45 gm filter. A Ni 2 l-NTA agarose column (commercially available from Qiagen) is prepared with a bed volume of 5 mL, washed with 25 mL of water and equilibrated with 25 mL of loading buffer. The filtered cell extract is loaded onto the column at 0.5 mL per minute. 15 The column is washed to baseline A 2 80 with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% glycerol, pH 6.0), which elutes nonspecifically bound protein. After reaching
A
28 0 baseline again, the column is developed with a 0 to 500 mM Imidazole gradient in the secondary wash buffer. One mL fractions are collected and analyzed by SDS-PAGE and silver 2 0 staining or Western blot with Ni 2 l-NTA-conjugated to alkaline phosphatase (Qiagen). Fractions containing the eluted Hisio-tagged PRO 1105, PRO 1279 or PRO 1783 are pooled and dialyzed against loading buffer. Alternatively, purification of the IgG tagged (or Fc tagged) PRO 1105, PRO 1279 or PRO 1783 can be performed using known chromatography techniques, including for instance, 25 Protein A or protein G column chromatography. EXAMPLE 13: In situ Hybridization In situ hybridization is a powerful and versatile technique for the detection and localization of nucleic acid sequences within cell or tissue preparations. It may be useful, for 30 example, to identify sites of gene expression, analyze the tissue distribution of transcription, identify and localize viral infection, follow changes in specific mRNA synthesis and aid in 213 WO 2008/127352 PCT/US2007/080102 chromosome mapping. In situ hybridization was performed following an optimized version of the protocol by Lu and Gillett, Cell Vision 1:169-176 (1994), using PCR-generated 33 P-labeled riboprobes. Briefly, formalin-fixed, paraffin-embedded human tissues were sectioned, deparaffinized, deproteinated inproteinase K (20 g/ml) for 15 minutes at 37'C, and further processed for in situ 5 hybridization as described by Lu and Gillett, supra. A [ 33 -P] UTP-labeled antisense riboprobe was generated from a PCR product and hybridized at 55'C overnight. The slides were dipped in Kodak NTB2 nuclear track emulsion and exposed for 4 weeks. 33 P-Riboprobe synthesis 10 6.0 p1(125 mCi) of 33 P-UTP (Amersham BF 1002, SA<2000 Ci/mmol) were speed vac dried. To each tube containing dried 33 P-UTP, the following ingredients were added: 2.0 p1 5x transcription buffer 1.0 p1 DTT (100 mM) 2.0 p1 NTP mix (2.5 mM : 10 i'; each of 10 mM GTP, CTP & ATP + 10 pl H 2 0) 15 1.0 1 UTP (50 M) 1.0 1 Rnasin 1.0 p1 DNA template (1 rig) 1.0 l H 2 0 1.0 p1 RNA polymerase (for PCR products T3 = AS, T7 = S, usually) 20 The tubes were incubated at 37'C for one hour. 1.0 p1 RQl DNase were added, followed by incubation at 37'C for 15 minutes. 90 pl TE (10 mM Tris pH 7.6/1mM EDTA pH 8.0) were added, and the mixture was pipetted onto DE81 paper. The remaining solution was loaded in a Microcon-50 ultrafiltration unit, and spun using program 10 (6 minutes). The filtration unit was inverted over a second tube and spun using program 2 (3 minutes). After the 25 final recovery spin, 100 p1 TE were added. 1 p1 of the final product was pipetted on DE81 paper and counted in 6 ml of Biofluor II. The probe was run on a TBE/urea gel. 1-3 p1 of the probe or 5 p1 of RNA Mrk III were added to 3 p1 of loading buffer. After heating on a 95'C heat block for three minutes, the probe was immediately placed on ice. The wells of gel were flushed, the sample loaded, and run at 30 180-250 volts for 45 minutes. The gel was wrapped in saran wrap and exposed to XAR film with an intensifying screen in -70'C freezer one hour to overnight. 214 WO 2008/127352 PCT/US2007/080102 33 P-Hybridization A. Pretreatment of frozen sections The slides were removed from the freezer, placed on aluminium trays and thawed at room temperature for 5 minutes. The trays were placed in 55'C incubator for five minutes to reduce condensation. The slides were fixed for 10 minutes in 4% paraformaldehyde on ice in 5 the fume hood, and washed in 0.5 x SSC for 5 minutes, at room temperature (25 ml 20 x SSC + 975 ml SQ H 2 0). After deproteination in 0.5 Lg/ml proteinase K for 10 minutes at 37'C (12.5 p1 of 10 mg/ml stock in 250 ml prewarmed RNase-free RNAse buffer), the sections were washed in 0.5 x SSC for 10 minutes at room temperature. The sections were dehydrated in 70%, 95 %, 100% ethanol, 2 minutes each. 10 B. Pretreatment of paraffin-embedded sections The slides were deparaffinized, placed in SQ H 2 0, and rinsed twice in 2 x SSC at room temperature, for 5 minutes each time. The sections were deproteinated in 20 Lg/ml proteinase K (500 pl of 10 mg/ml in 250 ml RNase-free RNase buffer; 37'C, 15 minutes) - human embryo, or 8 x proteinase K (100 pl in 250 ml Rnase buffer, 37'C, 30 minutes) - formalin 15 tissues. Subsequent rinsing in 0.5 x SSC and dehydration were performed as described above. C. Prehybridization The slides were laid out in a plastic box lined with Box buffer (4 x SSC, 50% formamide) - saturated filter paper. D. Hybridization 20 1.0 x 106 cpm probe and 1.0 p1 tRNA (50 mg/ml stock) per slide were heated at 95'C for 3 minutes. The slides were cooled on ice, and 48 p1 hybridization buffer were added per slide. After vortexing, 50 p1 33 P mix were added to 50 p1 prehybridization on slide. The slides were incubated overnight at 55 0 C. E. Washes 25 Washing was done 2 x 10 minutes with 2xSSC, EDTA at room temperature (400 ml 20 x SSC + 16 ml 0.25M EDTA, Vf=4L), followed by RNaseA treatment at 37'C for 30 minutes (500 pl of 10 mg/ml in 250 ml Rnase buffer = 20 Lg/ml), The slides were washed 2 x 10 minutes with 2 x SSC, EDTA at room temperature. The stringency wash conditions were as follows: 2 hours at 55 0 C, 0.1 x SSC, EDTA (20 ml 20 x SSC + 16 ml EDTA, Vf=4L). 30 F. Olisonucleotides In situ analysis was performed on a variety of DNA sequences disclosed herein. The 215 WO 2008/127352 PCT/US2007/080102 oligonucleotides employed for these analyses were obtained so as to be complementary to the nucleic acids (or the complements thereof) as shown in the accompanying figures. EXAMPLE 14: Preparation of Antibodies that Bind PRO 1105, PRO1279 or PRO1783 This example illustrates preparation of monoclonal antibodies which can specifically 5 bind PRO 1105, PRO1279 or PRO1783. Techniques for producing the monoclonal antibodies are known in the art and are described, for instance, in Goding, supra. Immunogens that may be employed include purified PRO1105, PRO1279 or PRO1783 polypeptides, fusion proteins containing PRO1105, PRO1279 or PRO1783 polypeptides, and cells expressing recombinant PRO 1105, PRO1279 10 or PRO 1783 polypeptides on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation. Mice, such as Balb/c, are immunized with the PRO 1105, PRO 1279 or PRO 1783 immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1-100 micrograms. Alternatively, the immunogen is 15 emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice by retro-orbital bleeding for testing in ELISA 20 assays to detect anti-PRO 1105, anti-PRO1279 or anti-PRO1783 antibodies. After a suitable antibody titer has been detected, the animals "positive" for antibodies can be injected with a final intravenous injection of PRO 1105, PRO1279 or PRO1783. Three to four days later, the mice are sacrificed and the spleen cells are harvested. The spleen cells are then fused (using 35% polyethylene glycol) to a selected murine myeloma cell line such as 25 P3X63AgU. 1, available from ATCC, No. CRL 1597. The fusions generate hybridoma cells which can then be plated in 96 well tissue culture plates containing HAT (hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids. The hybridoma cells will be screened in an ELISA for reactivity against PRO 1105, 30 PRO1279 or PRO1783. Determination of "positive" hybridoma cells secreting the desired monoclonal antibodies against PRO1 105, PRO1279 or PRO1783 is within the skill in the art. 216 WO 2008/127352 PCT/US2007/080102 The positive hybridoma cells can be injected intraperitoneally into syngeneic Balb/c mice to produce ascites containing the anti-PRO1105, anti-PR01279 or anti-PR01783 monoclonal antibodies. Alternatively, the hybridoma cells can be grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel exclusion 5 chromatography. Alternatively, affinity chromatography based upon binding of antibody to protein A or protein G can be employed. EXAMPLE 15: Purification of PRO 1105, PRO 1279 or PRO 1783 Polypeptides Using Specific Antibodies 10 Native or recombinant PRO 1105, PRO 1279 or PRO 1783 polypeptides may be purified by a variety of standard techniques in the art of protein purification. For example, pro PRO1105, pro-PRO1279 or pro-PRO1783 polypeptide, mature PRO1105, PRO1279 or PRO 1783 polypeptide, or pre-PRO 1105, pre-PRO 1279 or pre-PRO 1783 polypeptide is purified by immunoaffinity chromatography using antibodies specific for the PRO 1105, PRO 1279 or 15 PRO1783 polypeptide of interest. In general, an immunoaffinity column is constructed by covalently coupling the anti-PRO 1105, anti-PRO 1279 or anti-PRO 1783 polypeptide antibody to an activated chromatographic resin. Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB 2 0 Biotechnology, Piscataway, N.J.). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated SEPHAROSEm (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's 25 instructions. Such an immunoaffinity column is utilized in the purification of PRO 1105, PRO 1279 or PRO1783 polypeptide by preparing a fraction from cells containing PRO 1105, PRO1279 or PRO 1783 polypeptide in a soluble form. This preparation is derived by solubilization of the whole cell or of a subcellular fraction obtained via differential centrifugation by the addition 30 of detergent or by other methods well known in the art. Alternatively, soluble polypeptide containing a signal sequence may be secreted in useful quantity into the medium in which the 217 WO 2008/127352 PCT/US2007/080102 cells are grown. A soluble PRO1105, PRO1279 or PRO1783 polypeptide-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PRO 1105, PRO1279 or PRO1783 polypeptide (e.g., high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions that 5 disrupt antibody/PRO 1105, antibody/PRO 1279 or antibody/PRO 1783 polypeptide binding (e.g., a low pH buffer such as approximately pH 2-3, or a high concentration of a chaotrope such as urea or thiocyanate ion), and PRO1105, PRO1279 or PRO1783 polypeptide is collected. 10 EXAMPLE 16: Drug Screening This invention is particularly useful for screening compounds by using PRO 1105, PRO 1279 or PRO 1783 polypeptides or binding fragment thereof in any of a variety of drug screening techniques. The PRO1105, PRO1279 or PRO1783 polypeptide or fragment employed in such a test may either be free in solution, affixed to a solid support, borne on a cell 15 surface, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the PRO 1105, PRO 1279 or PRO 1783 polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of 20 complexes between PRO 1105, PRO 1279 or PRO 1783 polypeptide or a fragment and the agent being tested. Alternatively, one can examine the diminution in complex formation between the PRO 1105, PRO 1279 or PRO 1783 polypeptide and its target cell or target receptors caused by the agent being tested. Thus, the present invention provides methods of screening for drugs or any other agents 25 which can affect a PRO1105, PRO1279 or PRO1783 polypeptide-associated disease or disorder. These methods comprise contacting such an agent with an PRO1105, PRO1279 or PRO1783 polypeptide or fragment thereof and assaying (I) for the presence of a complex between the agent and the PRO 1105, PRO 1279 or PRO 1783 polypeptide or fragment, or (ii) for the presence of a complex between the PRO 1105, PRO1279 or PRO1783 polypeptide or 30 fragment and the cell, by methods well known in the art. In such competitive binding assays, the PRO1105, PRO1279 or PRO1783 polypeptide or fragment is typically labeled. After 218 WO 2008/127352 PCT/US2007/080102 suitable incubation, free PRO 1105, PRO 1279 or PRO 1783 polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to PRO 1105, PRO1279 or PRO1783 polypeptide or to interfere with the PRO 1105, PRO 1279 or PRO 1783 polypeptide/cell complex. Another technique for drug screening provides high throughput screening for 5 compounds having suitable binding affinity to a polypeptide and is described in detail in WO 84/03564, published on September 13, 1984. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. As applied to a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the peptide test compounds are reacted with PRO 1105, PRO 1279 or PRO 1783 polypeptide and washed. Bound 10 PRO 1105, PRO 1279 or PRO 1783 polypeptide is detected by methods well known in the art. Purified PRO 1105, PRO 1279 or PRO 1783 polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies can be used to capture the peptide and immobilize it on the solid support. This invention also contemplates the use of competitive drug screening assays in which 15 neutralizing antibodies capable of binding PRO 1105, PRO 1279 or PRO 1783 polypeptide specifically compete with a test compound for binding to PRO1 105, PRO1279 or PRO1783 polypeptide or fragments thereof. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PRO 1105, PRO 1279 or PRO 1783 polypeptide. 20 EXAMPLE 17: Rational Drug Design The goal of rational drug design is to produce structural analogs of biologically active polypeptide of interest (i.e., a PRO 1105, PRO1279 or PRO1783 polypeptide) or of small molecules with which they interact, e.g., agonists, antagonists, or inhibitors. Any of these 25 examples can be used to fashion drugs which are more active or stable forms of the PRO 1105, PRO1279 or PRO1783 polypeptide or which enhance or interfere with the function of the PRO 1105, PRO 1279 or PRO 1783 polypeptide in vivo (cf, Hodgson, Bio/Technoloav, 2: 19-21 (1991)). In one approach, the three-dimensional structure of the PRO1105, PRO1279 or 30 PRO1783 polypeptide, or of a PRO1105, PRO1279 or PRO1783 polypeptide-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by 219 WO 2008/127352 PCT/US2007/080102 a combination of the two approaches. Both the shape and charges of the PRO 1105, PRO 1279 or PRO 1783 polypeptide must be ascertained to elucidate the structure and to determine active site(s) of the molecule. Less often, useful information regarding the structure of the PRO 1105, PRO1279 or PRO1783 polypeptide may be gained by modeling based on the structure of homologous proteins. In both cases, relevant structural information is used to design analogous 5 PRO1105, PRO 1279 or PRO 1783 polypeptide-like molecules or to identify efficient inhibitors. Useful examples of rational drug design may include molecules which have improved activity or stability as shown by Braxton and Wells, Biochemistry, 31:7796-7801 (1992) or which act as inhibitors, agonists, or antagonists of native peptides as shown by Athauda et al., J Biochem., 113:742-746 (1993). 10 It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the 15 anti-ids would be expected to be an analog of the original receptor. The anti-id could then be used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides would then act as the pharmacore. By virtue of the present invention, sufficient amounts of the PRO 1105, PRO 1279 or PRO1783 polypeptide may be made available to perform such analytical studies as X-ray 20 crystallography. In addition, knowledge of the PRO 1105, PRO 1279 or PRO 1783 polypeptide amino acid sequence provided herein will provide guidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography. 220

权利要求:
Claims (141)
[1] 1. A method of identifying a phenotype associated with a disruption of a gene which encodes for a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption 5 of a gene which is an ortholog of a human gene that encodes for a PRO1 105,PRO 1279 or PRO1783 polypeptide; (b) measuring a physiological characteristic of the non-human transgenic animal; and (c) comparing the measured physiological characteristic with that of a gender matched wild-type animal, wherein the physiological characteristic of the non-human transgenic animal 10 that differs from the physiological characteristic of the wild-type animal is identified as a phenotype resulting from the gene disruption in the non-human transgenic animal.
[2] 2. The method of Claim 1, wherein the non-human transgenic animal is heterozygous for the disruption of a gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide. 15
[3] 3. The method of Claim 1, wherein the phenotype exhibited by the non-human transgenic animal as compared with gender matched wild-type littermates is at least one of the following: a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality 20 or disorder; a lipid metabolic disorder; or a developmental abnormality.
[4] 4. The method of Claim 3, wherein the neurological disorder is an increased anxiety-like response during open field activity testing. 25
[5] 5. The method of Claim 3, wherein the neurological disorder is a decreased anxiety-like response during open field activity testing.
[6] 6. The method of Claim 3, wherein the neurological disorder is an abnormal circadian rhythm during home-cage activity testing. 30
[7] 7. The method of Claim 3, wherein the neurological disorder is an enhanced motor 221 WO 2008/127352 PCT/US2007/080102 coordination during inverted screen testing.
[8] 8. The method of Claim 3, wherein the neurological disorder is an impaired motor coordination during inverted screen testing. 5
[9] 9. The method of Claim 3, wherein the neurological disorder is depression, generalized anxiety disorders, attention deficit disorder, sleep disorder, hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia or sensory disorders.
[10] 10. The method of Claim 3, wherein the eye abnormality is a retinal abnormality. 10
[11] 11. The method of Claim 3, wherein the eye abnormality is consistent with vision problems or blindness.
[12] 12. The method of Claim 10, wherein the retinal abnormality is consistent with retinitis 15 pigmentosa.
[13] 13. The method of Claim 10, wherein the retinal abnormality is characterized by retinal degeneration or retinal dysplasia. 2 0
[14] 14. The method of Claim 10, wherein the retinal abnormality is consistent with retinal dysplasia, various retinopathies, including retinopathy of prematurity, retrolental fibroplasia, neovascular glaucoma, age-related macular degeneration, diabetic macular edema, comeal neovascularization, corneal graft neovascularization, comeal graft rejection, retinal/choroidal neovascularization, neovascularization of the angle (rubeosis), ocular neovascular disease, 25 vascular restenosis, arteriovenous malformations (AVM), meningioma, hemangioma, angiofibroma, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, retinal artery obstruction or occlusion; retinal degeneration causing secondary atrophy of the retinal vasculature, retinitis pigmentosa, macular dystrophies, Stargardt's disease, congenital stationarynight blindness, choroideremia, gyrate atrophy, Leber's congenital 30 amaurosis, retinoschisis disorders, Wagner's syndrome, Usher syndromes, Zellweger syndrome, Saldino-Mainzer syndrome, Senior-Loken syndrome, Bardet-Biedl syndrome, Alport's 222 WO 2008/127352 PCT/US2007/080102 syndrome, Alstrom's syndrome, Cockayne's syndrome, dysplaisa spondyloepiphysaria congentia, Flynn-Aird syndrome, Friedreich ataxia, Hallgren syndrome, Marshall syndrome, Albers-Schnoberg disease, Refsum's disease, Kearns-Sayre syndrome, Waardenburg's syndrome, Alagile syndrome, myotonic dystrophy, olivopontocerebellar atrophy, Pierre-Marie dunsdrome, Stickler syndrome, carotinemeia, cystinosis, Wolfram syndrome, 5 Bassen-Kornzweig syndrome, abetalipoproteinemia, incontinentia pigmenti, Batten's disease, mucopolysaccharidoses, homocystinuria, or mannosidosis.
[15] 15. The method of Claim 3, wherein the eye abnormality is a cataract. 10
[16] 16. The method of Claim 15, wherein the cataract is consistent with systemic diseases such as human Down's syndrome, Hallerman-Streiff syndrome, Lowe syndrome, galactosemia, Marfan syndrome, Trismoy 13-15, Alport syndrome, myotonic dystrophy, Fabry disease, hypoparathroidism or Conradi syndrome. 15
[17] 17. The method of Claim 3, wherein the developmental abnormality comprises embryonic lethality or reduced viability.
[18] 18. The method of Claim 3, wherein the cardiovascular, endothelial or angiogenic disorders are arterial diseases, such as diabetes mellitus; papilledema; optic atrophy; atherosclerosis; 2 0 angina; myocardial infarctions such as acute myocardial infarctions, cardiac hypertrophy, and heart failure such as congestive heart failure; hypertension; inflammatory vasculitides; Reynaud's disease and Reynaud's phenomenon; aneurysms and arterial restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; peripheral vascular disease; cancer such as vascular tumors, e.g., hemangioma (capillary and cavernous), 25 glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma, Kaposi's sarcoma, lymphangioma, and lymphangiosarcoma; tumor angiogenesis; trauma such as wounds, burns, and other injured tissue, implant fixation, scarring; ischemia reperfusion injury; rheumatoid arthritis; cerebrovascular disease; renal diseases such as acute renal failure, or osteoporosis. 30 223 WO 2008/127352 PCT/US2007/080102
[19] 19. The method of Claim 3, wherein the immunological disorders are systemic lupus erythematosis; rheumatoid arthritis; juvenile chronic arthritis; spondyloarthropathies; systemic sclerosis (scleroderma); idiopathic inflammatory myopathies (dermatomyositis, polymyositis); Sj6gren's syndrome; systemic vasculitis; sarcoidosis; autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria); autoimmune thrombocytopenia 5 (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia); thyroiditis (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis); diabetes mellitus; immune-mediated renal disease (glomerulonephritis, tubulointerstitial nephritis); demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barr6 syndrome, and 10 chronic inflammatory demyelinating polyneuropathy; hepatobiliary diseases such as infectious hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis; inflammatory bowel disease (ulcerative colitis: Crohn's disease); gluten-sensitive enteropathy, and Whipple's disease; autoimmune or immune-mediated skin diseases including bullous skin 15 diseases, erythema multiforme and contact dermatitis, psoriasis; allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria; immunologic diseases of the lung such as eosinophilic pneumonias, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis; or transplantation associated diseases including graft rejection and graft -versus-host disease. 20
[20] 20. The method of Claim 3, wherein the bone metabolic abnormality or disorder is arthritis, osteoporosis or osteopetrosis.
[21] 21. The method of Claim 1, wherein the non-human transgenic animal exhibits at least one 25 of the following physiological characteristics compared with gender matched wild-type littermates: a decreased anxiety-like response during open field activity testing; an abnormal habituation response to a novel environment (increased median ambulatory count during home-cage activity testing) during circadian testing; a decreased depressive-like response with decreased median immobility time during tail suspension testing; an increased blood glucose 30 level; impaired glucose tolerance; an increased trabecular bone volume and thickness; decreased percent total body fat mass and percent total body fat; a decreased skin fibroblast 224 WO 2008/127352 PCT/US2007/080102 proliferation rate; and an increased systolic blood pressure.
[22] 22. An isolated cell derived from a non-human transgenic animal whose genome comprises a disruption of a gene which is an ortholog of a human gene that encodes for a PRO 1105, PRO 1279 or PRO 1783 polypeptide. 5
[23] 23. The isolated cell of Claim 22 which is a murine cell.
[24] 24. The isolated cell of Claim 23, wherein the murine cell is an embryonic stem cell. 10
[25] 25. The isolated cell of Claim 22, wherein the non-human transgenic animal exhibits at least one of the following phenotypes compared with gender matched wild-type littermates: a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality. 15
[26] 26. A method of identifying an agent that modulates a phenotype associated with a disruption of a gene which encodes for a PRO1105,PRO1279 or PRO1783 polypeptide, the method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption 20 of a gene which is an ortholog of a human gene that encodes for the PRO 1105, PRO1279 or PRO1783 polypeptide; (b) measuring a physiological characteristic of the non-human transgenic animal of(a); (c) comparing the measured physiological characteristic of (b) with that of a gender matched wild-type animal, wherein the physiological characteristic ofthe non-human transgenic 25 animal that differs from the physiological characteristic of the wild-type animal is identified as a phenotype resulting from the gene disruption in the non-human transgenic animal; (d) administering a test agent to the non-human transgenic animal of (a); and (e) determining whether the test agent modulates the identified phenotype associated with gene disruption in the non-human transgenic animal. 30 225 WO 2008/127352 PCT/US2007/080102
[27] 27. The method of Claim 26, wherein the phenotype associated with the gene disruption comprises a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality. 5
[28] 28. The method of Claim 27, wherein the neurological disorder is an increased anxiety-like response during open field activity testing.
[29] 29. The method of Claim 27, wherein the neurological disorder is a decreased anxiety-like response during open field activity testing. 10
[30] 30. The method of Claim 27, wherein the neurological disorder is an abnormal circadian rhythm during home-cage activity testing.
[31] 31. The method of Claim 27, wherein the neurological disorder is an enhanced motor 15 coordination during inverted screen testing.
[32] 32. The method of Claim 27, wherein the neurological disorder is an impaired motor coordination during inverted screen testing. 20
[33] 33. The method of Claim 27, wherein the neurological disorder is depression, generalized anxiety disorders, attention deficit disorder, sleep disorder, hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia or sensory disorders.
[34] 34. The method of Claim 27, wherein the eye abnormality is a retinal abnormality. 25
[35] 35. The method of Claim 27, wherein the eye abnormality is consistent with vision problems or blindness.
[36] 36. The method of Claim 34, wherein the retinal abnormality is consistent with retinitis 30 pigmentosa. 226 WO 2008/127352 PCT/US2007/080102
[37] 37. The method of Claim 34, wherein the retinal abnormality is characterized by retinal degeneration or retinal dysplasia.
[38] 38. The method of Claim 34, wherein the retinal abnormality is consistent with retinal dysplasia, various retinopathies, including retinopathy of prematurity, retrolental fibroplasia, 5 neovascular glaucoma, age-related macular degeneration, diabetic macular edema, comeal neovascularization, comeal graft neovascularization, comeal graft rejection, retinal/choroidal neovascularization, neovascularization of the angle (rubeosis), ocular neovascular disease, vascular restenosis, arteriovenous malformations (AVM), meningioma, hemangioma, angiofibroma, thyroid hyperplasias (including Grave's disease), corneal and other tissue 10 transplantation, retinal artery obstruction or occlusion; retinal degeneration causing secondary atrophy of the retinal vasculature, retinitis pigmentosa, macular dystrophies, Stargardt's disease, congenital stationarynight blindness, choroideremia, gyrate atrophy, Leber's congenital amaurosis, retinoschisis disorders, Wagner's syndrome, Usher syndromes, Zellweger syndrome, Saldino-Mainzer syndrome, Senior-Loken syndrome, Bardet-Biedl syndrome, Alport's 15 syndrome, Alstrom's syndrome, Cockayne's syndrome, dysplaisa spondyloepiphysaria congentia, Flynn-Aird syndrome, Friedreich ataxia, Hallgren syndrome, Marshall syndrome, Albers-Schnoberg disease, Refsum's disease, Kearns-Sayre syndrome, Waardenburg's syndrome, Alagile syndrome, myotonic dystrophy, olivopontocerebellar atrophy, Pierre-Marie dunsdrome, Stickler syndrome, carotinemeia, cystinosis, Wolfram syndrome, 2 0 Bassen-Kornzweig syndrome, abetalipoproteinemia, incontinentia pigmenti, Batten's disease, mucopolysaccharidoses, homocystinuria, or mannosidosis.
[39] 39. The method of Claim 27, wherein the eye abnormality is a cataract. 25
[40] 40. The method of Claim 39, wherein the cataract is consistent with systemic diseases such as human Down's syndrome, Hallerman-Streiff syndrome, Lowe syndrome, galactosemia, Marfan syndrome, Trismoy 13-15, Alport syndrome, myotonic dystrophy, Fabry disease, hypoparathroidism or Conradi syndrome. 30
[41] 41. The method of Claim 27, wherein the developmental abnormality comprises embryonic lethality or reduced viability. 227 WO 2008/127352 PCT/US2007/080102
[42] 42. The method of Claim 27, wherein the cardiovascular, endothelial or angiogenic disorders are arterial diseases, such as diabetes mellitus; papilledema; optic atrophy; atherosclerosis; angina; myocardial infarctions such as acute myocardial infarctions, cardiac hypertrophy, and heart failure such as congestive heart failure; hypertension; inflammatory vasculitides; Reynaud's disease and Reynaud's phenomenon; aneurysms and arterial restenosis; 5 venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; peripheral vascular disease; cancer such as vascular tumors, e.g., hemangioma (capillary and cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma, Kaposi's sarcoma, lymphangioma, and lymphangiosarcoma; tumor angiogenesis; trauma such as wounds, burns, and other injured 10 tissue, implant fixation, scarring; ischemia reperfusion injury; rheumatoid arthritis; cerebrovascular disease; renal diseases such as acute renal failure, or osteoporosis.
[43] 43. The method of Claim 27, wherein the immunological disorders are systemic lupus erythematosis; rheumatoid arthritis; juvenile chronic arthritis; spondyloarthropathies; systemic 15 sclerosis (scleroderma); idiopathic inflammatory myopathies (dermatomyositis, polymyositis); Sj6gren's syndrome; systemic vasculitis; sarcoidosis; autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria); autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia); thyroiditis (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis); 20 diabetes mellitus; immune-mediated renal disease (glomerulonephritis, tubulointerstitial nephritis); demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barr6 syndrome, and chronic inflammatory demyelinating polyneuropathy; hepatobiliary diseases such as infectious hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune chronic 25 active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis; inflammatory bowel disease (ulcerative colitis: Crohn's disease); gluten-sensitive enteropathy, and Whipple's disease; autoimmune or immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis; allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria; immunologic 30 diseases of the lung such as eosinophilic pneumonia, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis; or transplantation-associated diseases including graft rejection 228 WO 2008/127352 PCT/US2007/080102 and graft -versus-host disease.
[44] 44. The method of Claim 27, wherein said bone metabolic abnormality or disorder is arthritis, osteoporosis or osteopetrosis. 5
[45] 45. The method of Claim 26, wherein the non-human transgenic animal exhibits at least one of the following physiological characteristics compared with gender matched wild-type littermates: a decreased anxiety-like response during open field activity testing; an abnormal habituation response to a novel environment (increased median ambulatory count during home-cage activity testing) during circadian testing; a decreased depressive-like response with 10 decreased median immobility time during tail suspension testing; an increased blood glucose level; impaired glucose tolerance; an increased trabecular bone volume and thickness; decreased percent total body fat mass and percent total body fat; a decreased skin fibroblast proliferation rate; and an increased systolic blood pressure. 15
[46] 46. An agent identified by the method of Claim 26.
[47] 47. The agent of Claim 46 which is an agonist or antagonist of a PRO 1105, PRO1279 or PRO1783 polypeptide. 20
[48] 48. The agent of Claim 47, wherein the agonist is an anti-PRO 1105, anti-PRO1279 or anti PRO1783 antibody.
[49] 49. The agent of Claim 47, wherein the antagonist is an anti-PRO 1105, anti-PRO1279 or anti-PRO1783 antibody. 25
[50] 50. A method of identifying an agent that modulates a physiological characteristic associated with a disruption of a gene which encodes for a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption 30 of a gene which is an ortholog of a human gene that encodes for a PRO 1105, PRO 1279 or PRO1783 polypeptide; 229 WO 2008/127352 PCT/US2007/080102 (b) measuring a physiological characteristic exhibited by the non-human transgenic animal of (a); (c) comparing the measured physiological characteristic of (b) with that of a gender matched wild-type animal, wherein the physiological characteristic exhibited by the non-human transgenic animal that differs from the physiological characteristic exhibited by the wild-type 5 animal is identified as a physiological characteristic associated with gene disruption; (d) administering a test agent to the non-human transgenic animal of (a); and (e) determining whether the physiological characteristic associated with gene disruption is modulated. 10
[51] 51. The method of Claim 50, wherein the non-human transgenic animal exhibits at least one of the following physiological characteristics compared with gender matched wild-type littermates: a decreased anxiety-like response during open field activity testing; an abnormal habituation response to a novel environment (increased median ambulatory count during home-cage activity testing) during circadian testing; a decreased depressive-like response with 15 decreased median immobility time during tail suspension testing; an increased blood glucose level; impaired glucose tolerance; an increased trabecular bone volume and thickness; decreased percent total body fat mass and percent total body fat; a decreased skin fibroblast proliferation rate; and an increased systolic blood pressure. 20
[52] 52. An agent identified by the method of Claim 50.
[53] 53. The agent of Claim 52 which is an agonist or antagonist of a PRO 1105, PRO1279 or PRO1783 polypeptide. 25
[54] 54. The agent of Claim 53, wherein the agonist is an anti-PRO1105, anti-PRO1279 or anti PRO1783 antibody.
[55] 55. The agent of Claim 53, wherein the antagonist is an anti-PRO 1105, anti-PRO1279 or anti-PRO1783 antibody. 30
[56] 56. A method of identifying an agent which modulates a behavior associated with a 230 WO 2008/127352 PCT/US2007/080102 disruption of a gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide, the method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption of a gene which is an ortholog of a human gene that encodes for a PRO 1105, PRO 1279 or PRO1783 polypeptide; 5 (b) observing the behavior exhibited by the non-human transgenic animal of (a); (c) comparing the observed behavior of (b) with that of a gender matched wild-type animal, wherein the observed behavior exhibited by the non-human transgenic animal that differs from the observed behavior exhibited by the wild-type animal is identified as a behavior associated with gene disruption; 10 (d) administering a test agent to the non-human transgenic animal of (a); and (e) determining whether the agent modulates the behavior associated with gene disruption.
[57] 57. The method of Claim 56, wherein the behavior is an increased anxiety-like response 15 during open field activity testing.
[58] 58. The method of Claim 56, wherein the behavior is a decreased anxiety-like response during open field activity testing. 20
[59] 59. The method of Claim 56, wherein the behavior is an abnormal circadian rhythm during home-cage activity testing.
[60] 60. The method of Claim 56, wherein the behavior is an enhanced motor coordination during inverted screen testing. 25
[61] 61. The method of Claim 56, wherein the behavior is an impaired motor coordination during inverted screen testing.
[62] 62. The method of Claim 56, wherein the behavior is depression, generalized anxiety 30 disorders, attention deficit disorder, sleep disorder, hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia or sensory disorders. 231 WO 2008/127352 PCT/US2007/080102
[63] 63. An agent identified by the method of Claim 56.
[64] 64. The agent of Claim 63 which is an agonist or antagonist of a PRO 1105, PRO1279 or PRO1783 polypeptide. 5
[65] 65. The agent of Claim 64, wherein the agonist is an anti-PRO 1105, anti-PRO1279 or anti PRO1783 antibody.
[66] 66. The agent of Claim 64, wherein the antagonist is an anti-PRO 1105, anti-PRO 1279 or anti-PRO1783 antibody. 10
[67] 67. A method of identifying an agent that ameliorates or modulates a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality associated with a disruption in a gene which encodes 15 for a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption of a gene which is an ortholog of a human gene that encodes for a PRO 1105, PRO 1279 or PRO1783 polypeptide; (b) administering a test agent to said non-human transgenic animal; and 20 (c) determining whether said test agent ameliorates or modulates the neurological disorder; cardiovascular, endothelial or angiogenic disorder; eye abnormality; immunological disorder; oncological disorder; bone metabolic abnormality or disorder; lipid metabolic disorder; or developmental abnormality in the non-human transgenic animal. 25
[68] 68. The method of Claim 67, wherein the neurological disorder is an increased anxiety-like response during open field activity testing.
[69] 69. The method of Claim 67, wherein the neurological disorder is a decreased anxiety-like response during open field activity testing. 30 232 WO 2008/127352 PCT/US2007/080102
[70] 70. The method of Claim 67, wherein the neurological disorder is an abnormal circadian rhythm during home-cage activity testing.
[71] 71. The method of Claim 67, wherein the neurological disorder is an enhanced motor coordination during inverted screen testing. 5
[72] 72. The method of Claim 67, wherein the neurological disorder is an impaired motor coordination during inverted screen testing.
[73] 73. The method of Claim 67, wherein the neurological disorder is depression, generalized 10 anxiety disorders, attention deficit disorder, sleep disorder, hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia or sensory disorders.
[74] 74. The method of Claim 67, wherein the eye abnormality is a retinal abnormality. 15
[75] 75. The method of Claim 67, wherein the eye abnormality is consistent with vision problems or blindness.
[76] 76. The method of Claim 74, wherein the retinal abnormality is consistent with retinitis pigmentosa. 20
[77] 77. The method of Claim 74, wherein the retinal abnormality is characterized by retinal degeneration or retinal dysplasia.
[78] 78. The method of Claim 74, wherein the retinal abnormality is consistent with retinal 25 dysplasia, various retinopathies, including retinopathy of prematurity, retrolental fibroplasia, neovascular glaucoma, age-related macular degeneration, diabetic macular edema, comeal neovascularization, comeal graft neovascularization, corneal graft rejection, retinal/choroidal neovascularization, neovascularization of the angle (rubeosis), ocular neovascular disease, vascular restenosis, arteriovenous malformations (AVM), meningioma, hemangioma, 30 angiofibroma, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, retinal artery obstruction or occlusion; retinal degeneration causing secondary 233 WO 2008/127352 PCT/US2007/080102 atrophy of the retinal vasculature, retinitis pigmentosa, macular dystrophies, Stargardt's disease, congenital stationarynight blindness, choroideremia, gyrate atrophy, Leber's congenital amaurosis, retinoschisis disorders, Wagner's syndrome, Usher syndromes, Zellweger syndrome, Saldino-Mainzer syndrome, Senior-Loken syndrome, Bardet-Biedl syndrome, Alport's syndrome, Alstrom's syndrome, Cockayne's syndrome, dysplaisa spondyloepiphysaria 5 congentia, Flynn-Aird syndrome, Friedreich ataxia, Hallgren syndrome, Marshall syndrome, Albers-Schnoberg disease, Refsum's disease, Kearns-Sayre syndrome, Waardenburg's syndrome, Alagile syndrome, myotonic dystrophy, olivopontocerebellar atrophy, Pierre-Marie dunsdrome, Stickler syndrome, carotinemeia, cystinosis, Wolfram syndrome, Bassen-Kornzweig syndrome, abetalipoproteinemia, incontinentia pigmenti, Batten's disease, 10 mucopolysaccharidoses, homocystinuria, or mannosidosis.
[79] 79. The method of Claim 67, wherein the eye abnormality is a cataract.
[80] 80. The method of Claim 79, wherein the cataract is a systemic disease such as human 15 Down's syndrome, Hallerman-Streiff syndrome, Lowe syndrome, galactosemia, Marfan syndrome, Trismoy 13-15, Alport syndrome, myotonic dystrophy, Fabry disease, hypoparathroidism or Conradi syndrome.
[81] 81. The method of Claim 67, wherein the developmental abnormality comprises embryonic 20 lethality or reduced viability.
[82] 82. The method of Claim 67, wherein the cardiovascular, endothelial or angiogenic disorders are arterial diseases, such as diabetes mellitus; papilledema; optic atrophy; atherosclerosis; angina; myocardial infarctions such as acute myocardial infarctions, cardiac 25 hypertrophy, and heart failure such as congestive heart failure; hypertension; inflammatory vasculitides; Reynaud's disease and Reynaud's phenomenon; aneurysms and arterial restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; peripheral vascular disease; cancer such as vascular tumors, e.g., hemangioma (capillary and cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, 30 angiosarcoma, haemangiopericytoma, Kaposi's sarcoma, lymphangioma, and lymphangiosarcoma; tumor angiogenesis; trauma such as wounds, burns, and other injured 234 WO 2008/127352 PCT/US2007/080102 tissue, implant fixation, scarring; ischemia reperfusion injury; rheumatoid arthritis; cerebrovascular disease; renal diseases such as acute renal failure, or osteoporosis.
[83] 83. The method of Claim 67, wherein the immunological disorders are systemic lupus erythematosis; rheumatoid arthritis; juvenile chronic arthritis; spondyloarthropathies; systemic 5 sclerosis (scleroderma); idiopathic inflammatory myopathies (dermatomyositis, polymyositis); Sj6gren's syndrome; systemic vasculitis; sarcoidosis; autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria); autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia); thyroiditis (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis); 10 diabetes mellitus; immune-mediated renal disease (glomerulonephritis, tubulointerstitial nephritis); demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barr6 syndrome, and chronic inflammatory demyelinating polyneuropathy; hepatobiliary diseases such as infectious hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune chronic 15 active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis; inflammatory bowel disease (ulcerative colitis: Crohn's disease); gluten-sensitive enteropathy, and Whipple's disease; autoimmune or immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis; allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria; immunologic 20 diseases of the lung such as eosinophilic pneumonia, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis; or transplantation associated diseases including graft rejection and graft -versus-host disease.
[84] 84. The method of Claim 67, wherein said bone metabolic abnormality or disorder is 25 arthritis, osteoporosis or osteopetrosis.
[85] 85. The method of Claim 67, wherein the non-human transgenic animal exhibits at least one of the following physiological characteristics compared with gender matched wild-type littermates: a decreased anxiety-like response during open field activity testing; an abnormal 30 habituation response to a novel environment (increased median ambulatory count during home-cage activity testing) during circadian testing; a decreased depressive-like response with 235 WO 2008/127352 PCT/US2007/080102 decreased median immobility time during tail suspension testing; an increased blood glucose level; impaired glucose tolerance; an increased trabecular bone volume and thickness; decreased percent total body fat mass and percent total body fat; a decreased skin fibroblast proliferation rate; and an increased systolic blood pressure. 5
[86] 86. An agent identified by the method of Claim 67.
[87] 87. The agent of Claim 86 which is an agonist or antagonist of a PRO 1105, PRO1279 or PRO1783 polypeptide. 10
[88] 88. The agent of Claim 87, wherein the agonist is an anti-PRO 1105, anti-PRO1279 or anti PRO1783 antibody.
[89] 89. The agent of Claim 87, wherein the antagonist is an anti-PRO 1105, anti-PRO1279 or anti-PRO1783 antibody. 15
[90] 90. A therapeutic agent identified by the method of Claim 67.
[91] 91. A method of identifying an agent that modulates the expression of a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the method comprising: 20 (a) contacting a test agent with a host cell expressing a PRO 1105, PRO 1279 or PRO1783 polypeptide; and (b) determining whether the test agent modulates the expression of the PRO 1105, PRO 1279 or PRO 1783 polypeptide by the host cell. 25
[92] 92. An agent identified by the method of Claim 91.
[93] 93. The agent of Claim 92 which is an agonist or antagonist of a PRO 1105, PRO1279 or PRO1783 polypeptide. 30
[94] 94. The agent of Claim 93, wherein the agonist is an anti-PRO 1105, anti-PRO 1279 or anti PRO1783 antibody. 236 WO 2008/127352 PCT/US2007/080102
[95] 95. The agent of Claim 93, wherein the antagonist is an anti-PRO 1105, anti-PRO1279 or anti-PRO1783 antibody.
[96] 96. A method of evaluating a therapeutic agent capable of affecting a condition associated with a disruption of a gene which encodes for a PRO 1105, PRO 1279 or PRO 1783 polypeptide, 5 the method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption of a gene which is an ortholog of a human gene that encodes for the PRO 1105, PRO 1279 or PRO1783 polypeptide; (b) measuring a physiological characteristic of the non-human transgenic animal of(a); 10 (c) comparing the measured physiological characteristic of (b) with that of a gender matched wild-type animal, wherein the physiological characteristic ofthe non-human transgenic animal that differs from the physiological characteristic of the wild-type animal is identified as a condition resulting from the gene disruption in the non-human transgenic animal; (d) administering a test agent to the non-human transgenic animal of (a); and 15 (e) evaluating the effects of the test agent on the identified condition associated with gene disruption in the non-human transgenic animal.
[97] 97. The method of Claim 96, wherein the condition is a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological 2 0 disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality.
[98] 98. A therapeutic agent identified by the method of Claim 96. 25
[99] 99. The therapeutic agent of Claim 98 which is an agonist or antagonist of a PRO 1105, PRO 1279 or PRO 1783 polypeptide.
[100] 100. The therapeutic agent of Claim 99, wherein the agonist is an anti-PRO 1105, anti PRO 1279 or anti-PRO1783 antibody. 30 237 WO 2008/127352 PCT/US2007/080102
[101] 101. The therapeutic agent of Claim 99, wherein the antagonist is an anti-PRO 1105, anti PRO 1279 or anti-PRO1783 antibody.
[102] 102. A pharmaceutical composition comprising the therapeutic agent of Claim 98. 5
[103] 103. A method of treating or preventing or ameliorating a neurological disorder; cardiovascular, endothelial or angiogenic disorder; immunological disorder; oncological disorder; bone metabolic abnormality or disorder, or embryonic lethality associated with the disruption of a gene which encodes for a PRO 1105, PRO1279 or PRO1783 polypeptide, the method comprising administering to a subject in need of such treatment whom may already 10 have the disorder, or may be prone to have the disorder or may be in whom the disorder is to be prevented, a therapeutically effective amount of the therapeutic agent of Claim 90, or agonists or antagonists thereof, thereby effectively treating or preventing or ameliorating said disorder. 15
[104] 104. The method of Claim 103, wherein the neurological disorder is an increased anxiety like response during open field activity testing.
[105] 105. The method of Claim 103, wherein the neurological disorder is a decreased anxiety-like response during open field activity testing. 20
[106] 106. The method of Claim 103, wherein the neurological disorder is an abnormal circadian rhythm during home-cage activity testing.
[107] 107. The method of Claim 103, wherein the neurological disorder is an enhanced motor 25 coordination during inverted screen testing.
[108] 108. The method of Claim 103, wherein the neurological disorder is an impaired motor coordination during inverted screen testing. 30 238 WO 2008/127352 PCT/US2007/080102
[109] 109. The method of Claim 103, wherein the neurological disorder is depression, generalized anxiety disorders, attention deficit disorder, sleep disorder, hyperactivity disorder, obsessive compulsive disorder, schizophrenia, cognitive disorders, hyperalgesia or sensory disorders.
[110] 110. The method of Claim 103, wherein the eye abnormality is a retinal abnormality. 5
[111] 111. The method of Claim 103, wherein the eye abnormality is consistent with vision problems or blindness.
[112] 112. The method of Claim 110, wherein the retinal abnormality is consistent with retinitis 10 pigmentosa.
[113] 113. The method of Claim 110, wherein the retinal abnormality is characterized by retinal degeneration or retinal dysplasia. 15
[114] 114. The method of Claim 110, wherein the retinal abnormality is consistent with retinal dysplasia, various retinopathies, including retinopathy of prematurity, retrolental fibroplasia, neovascular glaucoma, age-related macular degeneration, diabetic macular edema, comeal neovascularization, comeal graft neovascularization, comeal graft rejection, retinal/choroidal neovascularization, neovascularization of the angle (rubeosis), ocular neovascular disease, 20 vascular restenosis, arteriovenous malformations (AVM), meningioma, hemangioma, angiofibroma, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, retinal artery obstruction or occlusion; retinal degeneration causing secondary atrophy of the retinal vasculature, retinitis pigmentosa, macular dystrophies, Stargardt's disease, congenital stationarynight blindness, choroideremia, gyrate atrophy, Leber's congenital 25 amaurosis, retinoschisis disorders, Wagner's syndrome, Usher syndromes, Zellweger syndrome, Saldino-Mainzer syndrome, Senior-Loken syndrome, Bardet-Biedl syndrome, Alport's syndrome, Alstrom's syndrome, Cockayne's syndrome, dysplaisa spondyloepiphysaria congentia, Flynn-Aird syndrome, Friedreich ataxia, Hallgren syndrome, Marshall syndrome, Albers-Schnoberg disease, Refsum's disease, Kearns-Sayre syndrome, Waardenburg's 30 syndrome, Alagile syndrome, myotonic dystrophy, olivopontocerebellar atrophy, Pierre-Marie dunsdrome, Stickler syndrome, carotinemeia, cystinosis, Wolfram syndrome, 239 WO 2008/127352 PCT/US2007/080102 Bassen-Kornzweig syndrome, abetalipoproteinemia, incontinentia pigmenti, Batten's disease, mucopolysaccharidoses, homocystinuria, or mannosidosis.
[115] 115. The method of Claim 103, wherein the eye abnormality is a cataract. 5
[116] 116. The method of Claim 115, wherein the cataract is a systemic disease such as human Down's syndrome, Hallerman-Streiff syndrome, Lowe syndrome, galactosemia, Marfan syndrome, Trismoy 13-15, Alport syndrome, myotonic dystrophy, Fabry disease, hypoparathroidism or Conradi syndrome. 10
[117] 117. The method of Claim 103, wherein the developmental abnormality comprises embryonic lethality or reduced viability.
[118] 118. The method of Claim 103, wherein the cardiovascular, endothelial or angiogenic disorders are arterial diseases, such as diabetes mellitus; papilledema; optic atrophy; 15 atherosclerosis; angina; myocardial infarctions such as acute myocardial infarctions, cardiac hypertrophy, and heart failure such as congestive heart failure; hypertension; inflammatory vasculitides; Reynaud's disease and Reynaud's phenomenon; aneurysms and arterial restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; peripheral vascular disease; cancer such as vascular tumors, e.g., hemangioma (capillary and 20 cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma, Kaposi's sarcoma, lymphangioma, and lymphangiosarcoma; tumor angiogenesis; trauma such as wounds, burns, and other injured tissue, implant fixation, scarring; ischemia reperfusion injury; rheumatoid arthritis; cerebrovascular disease; renal diseases such as acute renal failure, or osteoporosis. 25
[119] 119. The method of Claim 103, wherein the immunological disorders are systemic lupus erythematosis; rheumatoid arthritis; juvenile chronic arthritis; spondyloarthropathies; systemic sclerosis (scleroderma); idiopathic inflammatory myopathies (dermatomyositis, polymyositis); Sj6gren's syndrome; systemic vasculitis; sarcoidosis; autoimmune hemolytic anemia (immune 30 pancytopenia, paroxysmal nocturnal hemoglobinuria); autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia); thyroiditis 240 WO 2008/127352 PCT/US2007/080102 (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis); diabetes mellitus; immune-mediated renal disease (glomerulonephritis, tubulointerstitial nephritis); demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barr6 syndrome, and chronic inflammatory demyelinating polyneuropathy; hepatobiliary diseases such as infectious 5 hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis; inflammatory bowel disease (ulcerative colitis: Crohn's disease); gluten-sensitive enteropathy, and Whipple's disease; autoimmune or immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis; allergic diseases such as 10 asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria; immunologic diseases of the lung such as eosinophilic pneumonia, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis; or transplantation associated diseases including graft rejection and graft -versus-host disease. 15
[120] 120. The method of Claim 103, wherein said bone metabolic abnormality or disorder is arthritis, osteoporosis or osteopetrosis.
[121] 121. A method of modulating a phenotype associated with a disruption of a gene which encodes for a PRO1105, PRO1279 or PRO1783 polypeptide, the method comprising 20 administering to a subject whom may already have the phenotype, or maybe prone to have the phenotype or may be in whom the phenotype is to be prevented, an effective amount of the agent of Claim 46, or agonists or antagonists thereof, thereby effectively modulating the phenotype. 25
[122] 122. A method of modulating a physiological characteristic associated with a disruption of a gene which encodes for a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the method comprising administering to a subject whom may already exhibit the physiological characteristic, or may be prone to exhibit the physiological characteristic or may be in whom the physiological characteristic is to be prevented, an effective amount of the agent of Claim 30 52, or agonists or antagonists thereof, thereby effectively modulating the physiological characteristic. 241 WO 2008/127352 PCT/US2007/080102
[123] 123. A method of modulating a behavior associated with a disruption of a gene which encodes for a PRO1105, PRO1279 or PRO1783 polypeptide, the method comprising administering to a subject whom may already exhibit the behavior, or may be prone to exhibit the behavior or maybe in whom the exhibited behavior is to be prevented, an effective amount of the agent of Claim 63, or agonists or antagonists thereof, thereby effectively modulating the 5 behavior.
[124] 124. A method of modulating the expression of a PRO1 105, PRO1279 or PRO1783 polypeptide, the method comprising administering to a host cell expressing said PRO 1105, PRO 1279 or PRO 1783 polypeptide, an effective amount of the agent of Claim 92, or agonists 10 or antagonists thereof, thereby effectively modulating the expression of said polypeptide.
[125] 125. A method of modulating a condition associated with a disruption of a gene which encodes for a PRO1105, PRO1279 or PRO1783 polypeptide, the method comprising administering to a subject whom may have the condition, or may be prone to have the condition 15 or may be in whom the condition is to be prevented, a therapeutically effective amount of the therapeutic agent of Claim 98, or agonists or antagonists thereof, thereby effectively modulating the condition.
[126] 126. A method of identifying an agent that mimics a condition or phenotype associated with 20 a disruption in a gene which encodes a PRO 1105, PRO 1279 or PRO 1783 polypeptide, the method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption of a gene which is an ortholog of a human gene that encodes a PRO 1105, PRO 1279 or PRO1783 polypeptide; 25 (b) measuring a physiological characteristic ofthe non-human transgenic animal of(a); (c) comparing the measured physiological characteristic of (b) with that of a gender matched wild-type animal, wherein the physiological characteristic ofthe non-human transgenic animal that differs from the physiological characteristic ofthe gender matched wild-type animal is identified as a condition or phenotype resulting from the gene disruption in the non-human 30 transgenic animal; (d) administering a test agent to said gender matched wild-type animal; and 242 WO 2008/127352 PCT/US2007/080102 (e) determining whether said test agent mimics the condition or phenotype initially observed in the non-human transgenic animal.
[127] 127. The method of Claim 126, wherein the condition or phenotype associated with the disruption of the gene which is an ortholog of a human gene that encodes a PRO 1105, 5 PRO 1279 or PRO 1783 polypeptide is enhanced glucose tolerance.
[128] 128. The method of Claim 126, wherein the condition or phenotype associated with the disruption of the gene which is an ortholog of a human gene that encodes a PRO 1105, PRO 1279 or PRO 1783 polypeptide is increased insulin sensitivity. 10
[129] 129. An agent identified by the method of Claim 126.
[130] 130. The agent of Claim 129 which is an antagonist of a PRO 1105, PRO1279 or PRO1783 polypeptide. 15
[131] 131. The agent of Claim 130, wherein the antagonist is an anti-PRO 1105, anti-PRO1279 or anti-PRO1783 antibody.
[132] 132. A method of mimicking a condition or phenotype associated with a disruption of a gene 20 which encodes a PRO1105, PRO1279 or PRO1783 polypeptide, the method comprising administering to a subject in whom the condition or phenotype is to be mimicked, an effective amount of the agent of Claim 129 or an antagonist of a PRO 1105, PRO1279 or PRO1783 polypeptide, thereby effectively mimicking the condition or phenotype. 25
[133] 133. The method of Claim 132, wherein the condition or phenotype associated with the disruption of the gene which is an ortholog of a human gene that encodes a PRO 1105, PRO 1279 or PRO 1783 polypeptide is enhanced glucose tolerance.
[134] 134. The method of Claim 132, wherein the condition or phenotype associated with the 30 disruption of the gene which is an ortholog of a human gene that encodes a PRO 1105, PRO 1279 or PRO 1783 polypeptide is increased insulin sensitivity. 243 WO 2008/127352 PCT/US2007/080102
[135] 135. A method of evaluating a therapeutic agent capable of mimicking a condition or phenotype associated with a disruption of a gene which encodes a PRO 1105, PRO1279 or PRO 1783 polypeptide, the method comprising: (a) providing a non-human transgenic animal whose genome comprises a disruption of a gene which is an ortholog of a human gene that encodes a PRO 1105, PRO 1279 or 5 PRO1783 polypeptide; (b) measuring a physiological characteristic ofthe non-human transgenic animal of(a); (c) comparing the measured physiological characteristic of (b) with that of a gender matched wild-type animal, wherein the physiological characteristic ofthe non-human transgenic animal that differs from the physiological characteristic ofthe gender matched wild-type animal 10 is identified as a condition or phenotype resulting from the gene disruption in the non-human transgenic animal; (d) administering a test agent to said gender matched wild-type animal of (c); and (e) evaluating the ability of the test agent to mimic the condition or phenotype associated with gene disruption in the non-human transgenic animal. 15
[136] 136. A therapeutic agent identified by the method of Claim 135.
[137] 137. The therapeutic agent of Claim 136 which is an antagonist of a PRO1 105, PRO1279 or PRO1783 polypeptide. 20
[138] 138. The therapeutic agent of Claim 137, wherein the antagonist is an anti-PRO 1105, anti PRO 1279 or anti-PRO1783 antibody.
[139] 139. A pharmaceutical composition comprising the therapeutic agent of Claim 136. 25
[140] 140. A method of mimicking a condition or phenotype associated with a disruption of a gene which encodes a PRO1105, PRO1279 or PRO1783 polypeptide, the method comprising administering to a subject in whom the condition or phenotype disorder is to be mimicked, a therapeutically effective amount of the therapeutic agent of Claim 136, or an antagonist of a 30 PRO 1105, PRO1279 or PRO1783 polypeptide, thereby effectively mimicking the condition or phenotype. 244 WO 2008/127352 PCT/US2007/080102
[141] 141. A method of identifying an agent that ameliorates or modulates a neurological disorder; a cardiovascular, endothelial or angiogenic disorder; an eye abnormality; an immunological disorder; an oncological disorder; a bone metabolic abnormality or disorder; a lipid metabolic disorder; or a developmental abnormality associated with a disruption in the gene which encodes for a PRO1105, PRO1279 or PRO1783 polypeptide, the method comprising 5 administering to a subject whom may have the neurological disorder; cardiovascular, endothelial or angiogenic disorder; eye abnormality; immunological disorder; oncological disorder; bone metabolic abnormality or disorder; lipid metabolic disorder; or developmental abnormality, a therapeutic agent of Claim 90, or agonists or antagonists thereof, thereby ameliorating or modulating the disorder. 245

类似技术:

---

公开号 | 公开日 | 专利标题

---

US7947866B2|2011-05-24|Gene disruptions, compositions and methods relating thereto

---

AU2005213965B2|2009-11-19|Gene disruptions, compositions and methods relating thereto

---

US20120005766A1|2012-01-05|Methods of identifying agents that modulate phenotypes related to disruptions, of a gene encoding PRO235 polypeptide

---

EP2186402A1|2010-05-19|Knock-out animal models for novel genes and methods of use

---

US8227661B2|2012-07-24|Methods of identifying agents that ameliorate or modulate effects of PRO1328 gene disruptions

---

US20110182883A1|2011-07-28|Novel gene disruptions, compositions and methods relating thereto

---

US20090288176A1|2009-11-19|Novel Gene Disruptions, Compositions and Methods Relating Thereto

---

US20110252485A1|2011-10-13|Novel gene disruptions, compositions and methods relating thereto

---

US20110200579A1|2011-08-18|Novel gene disruptions, compositions and methods relating thereto

---

US20100233153A1|2010-09-16|Novel gene disruptions, compositions and the methods relating thereto

同族专利:

---

公开号 | 公开日

---

WO2008127352A2|2008-10-23|

---

EP2082052A2|2009-07-29|

---

CA2663523A1|2008-10-23|

---

WO2008127352A3|2009-05-14|

---

JP2010515428A|2010-05-13|

---

US20100233153A1|2010-09-16|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

US5536637A|1993-04-07|1996-07-16|Genetics Institute, Inc.|Method of screening for cDNA encoding novel secreted mammalian proteins in yeast|

---

US20020137890A1|1997-03-31|2002-09-26|Genentech, Inc.|Secreted and transmembrane polypeptides and nucleic acids encoding the same|

---

US7339033B2|1998-06-26|2008-03-04|Genentech, Inc.|Pro1481|

---

US6051690A|1998-04-23|2000-04-18|Genentech, Inc.|NSP molecules|

---

AU3953802A|2000-12-06|2002-06-18|Deltagen Inc|Transgenic mice containing glucagon receptor gene disruptions|

---

US7164055B2|2001-06-26|2007-01-16|Deltagen, Inc.|HSPC150-like gene disruptions, compositions and methods related thereto|

---

EP1863340A2|2005-03-11|2007-12-12|Genentech, Inc.|Gene disruptions, compositions and methods relating thereto|WO2013033513A1|2011-08-31|2013-03-07|University Of Georgia Research Foundation, Inc.|Apoptosis-targeting nanoparticles|

---

JP6356614B2|2012-02-17|2018-07-11|ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド|Nanoparticles for mitochondrial transport of drugs|

---

US10398663B2|2014-03-14|2019-09-03|University Of Georgia Research Foundation, Inc.|Mitochondrial delivery of 3-bromopyruvate|

法律状态:
2011-10-06| MK1| Application lapsed section 142(2)(a) - no request for examination in relevant period|

优先权:

---

申请号 | 申请日 | 专利标题

---

US86577706P| true| 2006-11-14|2006-11-14||

---

US60/865,777||2006-11-14||

---

PCT/US2007/080102|WO2008127352A2|2006-11-14|2007-10-01|Knockout mice for pr01105, pro1279 or pro1783 coding genes|

---